Baxter International (BAX) 10-K 17 Mar 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Feb. 29, 2020	Jun. 28, 2019
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	1-4448
Entity Registrant Name	Baxter International Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-0781620
Entity Address, Address Line One	One Baxter Parkway,
Entity Address, City or Town	Deerfield,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	224
Local Phone Number	948.2000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 42
Entity Common Stock, Shares Outstanding		507,263,731
Documents Incorporated by Reference	Portions of the registrant’s definitive 2020 proxy statement for use in connection with its Annual Meeting of Stockholders expected to be held on May 5, 2020 are incorporated by reference into Part III of this report.
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0000010456
Document Fiscal Period Focus	FY
Amendment Flag	false
Document Fiscal Year Focus	2019
CHICAGO STOCK EXCHANGE, INC. | Common Stock, $1.00 per Value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $1.00 par value
Trading Symbol	BAX (NYSE)
Security Exchange Name	CHX
NEW YORK STOCK EXCHANGE, INC. | Common Stock, $1.00 per Value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $1.00 par value
Trading Symbol	BAX (NYSE)
Security Exchange Name	NYSE
NEW YORK STOCK EXCHANGE, INC. | Global Notes 0.4% due 2024 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.4% Global Notes due 2024
Trading Symbol	BAX 24
Security Exchange Name	NYSE
NEW YORK STOCK EXCHANGE, INC. | Global Notes 1.3% due 2025 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.3% Global Notes due 2025
Trading Symbol	BAX 25
Security Exchange Name	NYSE
NEW YORK STOCK EXCHANGE, INC. | Global Notes 1.3% due 2029 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.3% Global Notes due 2029
Trading Symbol	BAX 29
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,335	$ 1,838
Accounts receivable, net	1,896	1,840
Inventory, Net	1,653	1,667
Prepaid expenses and other current assets	619	614
Total current assets	7,503	5,959
Property, Plant and Equipment, Net	4,512	4,530
Goodwill	3,030	3,002
Intangible Assets, Net (Excluding Goodwill)	1,471	1,410
Operating lease right-of-use assets	608
Other non-current assets	1,069	819
Total assets	18,193	15,720
Current liabilities:
Short-term debt	226	2
Current maturities of long-term debt and finance lease obligations	315	2
Accounts payable and accrued liabilities	2,689	2,810
Total current liabilities	3,230	2,814
Long-term debt and finance lease obligations	4,809	3,481
Operating lease liabilities	510
Other non-current liabilities	1,732	1,559
Total liabilities	10,281	7,854
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2019 and 2018	683	683
Common stock in treasury, at cost, 177,340,358 shares in 2019 and 170,495,859 shares in 2018	(10,764)	(9,989)
Additional contributed capital	5,955	5,898
Retained earnings	15,718	15,075
Accumulated other comprehensive (loss) income	(3,710)	(3,823)
Total Baxter stockholders’ equity	7,882	7,844
Noncontrolling interests	30	22
Total equity	7,912	7,866
Total liabilities and equity	$ 18,193	$ 15,720

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Common stock, authorized (in shares)	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000
Common stock, issued (in shares)	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944
Treasury stock, shares (in shares)	177,340,358	173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net sales	$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Cost of sales			1,681	1,558	1,650		1,590	1,571	3,239	3,161	6,601	6,340	6,110
Gross margin	1,298	1,230	1,153	1,080	1,183	1,232	1,223	1,121	2,233	2,344	4,761	4,759	4,474
Selling, general and administrative expenses			641	601	627		676	633	1,242	1,309	2,535	2,620	2,627
Research and development expenses			166	129	175		172	141	295	313	595	654	615
Other operating income (expense), net											141	99	56
Operating income			350	383	391		377	434	733	811	1,772	1,584	1,288
Interest expense, net			20	18	11		11	12	38	23	71	45	55
Other (income) expense, net			4	(21)	(33)		(38)	(6)	(17)	(44)	731	(78)	133
Income from continuing operations before income taxes			326	386	413		404	428	712	832	970	1,617	1,100
Income tax expense (benefit)			(13)	(44)	(102)		(63)	(46)	(57)	(109)	41	(65)	(491)
Income from continuing operations			313	342	311		341	382	655	723	1,011	1,552	609
Loss from discontinued operations, net of tax					(6)	0	0	0		0	0	(6)	(7)
Net income			313	342	305		341	382	655	723	1,011	1,546	602
Less: Net income attributable to noncontrolling interests											10	0	0
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Earnings per share from continuing operations
Basic (in dollars per share)					$ 0.59	$ 0.97	$ 0.64	$ 0.71		$ 1.35	$ 1.97	$ 2.91	$ 1.12
Diluted (in dollars per share)					0.58	0.95	0.62	0.69		1.32	1.93	2.84	1.10
Loss per share from discontinued operations
Basic (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.01)
Diluted (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.02)
Earnings per share
Basic (in dollars per share)	$ (0.05)	$ 0.72	$ 0.61	$ 0.67	0.58	0.97	0.64	0.71	$ 1.28	1.35	1.97	2.90	1.11
Diluted (in dollars per share)	$ (0.05)	$ 0.71	$ 0.60	$ 0.66	$ 0.57	$ 0.95	$ 0.62	$ 0.69	$ 1.26	$ 1.32	$ 1.93	$ 2.83	$ 1.08
Weighted-average number of shares outstanding
Basic (in shares)			510	512	528		535	539	511	537	509	534	543
Diluted (in shares)			519	522	538		547	551	520	549	519	546	555

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 1,011	$ 1,546	$ 602
Other comprehensive income (loss), net of tax:
Currency translation adjustments, net of tax expense (benefit) of ($5) in 2019, ($52) in 2018 and $89 in 2017	(95)	(323)	599
Pension and other postretirement benefit plans, net of tax expense of $130 in 2019, $10 in 2018, and $60 in 2017	408	33	134
Hedging activities, net of tax expense (benefit) of ($11) in 2019, $3 in 2018, and ($6) in 2017	(39)
Hedging activities, net of tax expense (benefit) of ($11) in 2019, $3 in 2018, and ($6) in 2017		9	(13)
Available-for-sale securities, net of tax expense of zero in 2019, 2018 and 2017, respectively	0	0	2
Total other comprehensive (loss) income, net of tax	274	(281)	722
Comprehensive income	1,285	1,265	1,324
Less: Comprehensive income attributable to noncontrolling interests	(10)	0	0
Comprehensive income attributable to Baxter stockholders	$ 1,275	$ 1,265	$ 1,324

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Tax (benefit) expense on currency translation adjustments	$ (5)	$ (52)	$ 89
Tax expense (benefit) on pension and other employee benefits	130	10	60
Tax (benefit) expense on hedging activities	(11)
Tax (benefit) expense on hedging activities		3	(6)
Tax expense on available-for-sale securities	$ 0	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Millions	Total	Common stock	Common stock in treasury	Additional contributed capital	Retained earnings	Accumulated other comprehensive income (loss)	Total Baxter stockholders' equity	Noncontrolling interests
Beginning of year (in shares) at Dec. 31, 2016		683,000,000
Beginning of year at Dec. 31, 2016	$ 8,221	$ 683	$ (7,995)	$ 5,958	$ 13,846	$ (4,261)	$ 8,231	$ (10)
Beginning of year (in shares) at Dec. 31, 2016			144,000,000
Net income attributable to Baxter stockholders	602				602		602
Net income	602
Other comprehensive income (loss)	$ 722					722	722
Purchases of common stock (in shares)	9,200,000		9,000,000
Purchases of common stock	$ (564)		$ (564)				(564)
Stock issued under employee benefit plans and other (in shares)			11,000,000
Stock issued under employee benefit plans and other	426		$ 578	(18)	(134)		426
Dividends declared on common stock	(334)				(334)		(334)
Distribution	34				34		34
Changes in noncontrolling interests	2							2
End of year at Dec. 31, 2017	9,109	$ 683	$ (7,981)	5,940	14,014	(3,539)	9,117	(8)
End of year (in shares) at Dec. 31, 2017		683,000,000
End of year (in shares) at Dec. 31, 2017			142,000,000
Net income	602
Adoption of new accounting standards	(23)				(20)	(3)	(23)
Net income attributable to Baxter stockholders	382				382		382
Net income	382
Other comprehensive income (loss)	115					115	115
Purchases of common stock (in shares)			8,000,000
Purchases of common stock	(522)		$ (522)				(522)
Stock issued under employee benefit plans and other (in shares)			(3,000,000)
Stock issued under employee benefit plans and other	85		$ 149	(28)	(36)		85
Dividends declared on common stock	(86)				(86)		(86)
Changes in noncontrolling interests	2							2
End of year at Mar. 31, 2018	$ 9,062	$ 683	$ (8,354)	5,912	14,254	(3,427)	9,068	(6)
End of year (in shares) at Mar. 31, 2018	683,494,944	683,000,000
End of year (in shares) at Mar. 31, 2018	146,993,164		147,000,000
Net income	$ 382
Beginning of year (in shares) at Dec. 31, 2017		683,000,000
Beginning of year at Dec. 31, 2017	9,109	$ 683	$ (7,981)	5,940	14,014	(3,539)	9,117	(8)
Beginning of year (in shares) at Dec. 31, 2017			142,000,000
Adoption of new accounting standards	(23)				(20)	(3)	(23)
Net income attributable to Baxter stockholders	723				723		723
Net income	723
Other comprehensive income (loss)	(214)					(214)	(214)
Purchases of common stock (in shares)			11,000,000
Purchases of common stock	(781)		$ (781)				(781)
Stock issued under employee benefit plans and other (in shares)			(5,000,000)
Stock issued under employee benefit plans and other	208		$ 277	(24)	(45)		208
Dividends declared on common stock	(188)				(188)		(188)
Changes in noncontrolling interests	(4)							(4)
End of year at Jun. 30, 2018	$ 8,830	$ 683	$ (8,485)	5,916	14,484	(3,756)	8,842	(12)
End of year (in shares) at Jun. 30, 2018	683,494,944	683,000,000
End of year (in shares) at Jun. 30, 2018	148,485,202		148,000,000
Net income	$ 723
Beginning of year (in shares) at Dec. 31, 2017		683,000,000
Beginning of year at Dec. 31, 2017	9,109	$ 683	$ (7,981)	5,940	14,014	(3,539)	9,117	(8)
Beginning of year (in shares) at Dec. 31, 2017			142,000,000
Adoption of new accounting standards	(25)				(22)	(3)	(25)
Net income attributable to Baxter stockholders	1,546				1,546		1,546
Net income	1,546
Other comprehensive income (loss)	$ (281)					(281)	(281)
Purchases of common stock (in shares)	35,800,000		36,000,000
Purchases of common stock	$ (2,475)		$ (2,415)	(60)			(2,475)
Stock issued under employee benefit plans and other (in shares)			8,000,000
Stock issued under employee benefit plans and other	354		$ 407	18	(71)		354
Dividends declared on common stock	(392)				(392)		(392)
Changes in noncontrolling interests	30							30
End of year at Dec. 31, 2018	$ 7,866	$ 683	$ (9,989)	5,898	15,075	(3,823)	7,844	22
End of year (in shares) at Dec. 31, 2018	683,494,944	683,000,000
End of year (in shares) at Dec. 31, 2018	170,495,859		170,000,000
Net income	$ 1,546
Beginning of year (in shares) at Mar. 31, 2018	683,494,944	683,000,000
Beginning of year at Mar. 31, 2018	$ 9,062	$ 683	$ (8,354)	5,912	14,254	(3,427)	9,068	(6)
Beginning of year (in shares) at Mar. 31, 2018	146,993,164		147,000,000
Net income attributable to Baxter stockholders	$ 341				341		341
Net income	341
Other comprehensive income (loss)	(329)					(329)	(329)
Purchases of common stock (in shares)			3,000,000
Purchases of common stock	(259)		$ (259)				(259)
Stock issued under employee benefit plans and other (in shares)			(2,000,000)
Stock issued under employee benefit plans and other	123		$ 128	4	(9)		123
Dividends declared on common stock	(102)				(102)		(102)
Changes in noncontrolling interests	(6)							(6)
End of year at Jun. 30, 2018	$ 8,830	$ 683	$ (8,485)	5,916	14,484	(3,756)	8,842	(12)
End of year (in shares) at Jun. 30, 2018	683,494,944	683,000,000
End of year (in shares) at Jun. 30, 2018	148,485,202		148,000,000
Net income	$ 341
Net income attributable to Baxter stockholders	518
End of year at Sep. 30, 2018	$ 9,090
End of year (in shares) at Sep. 30, 2018	683,494,944
End of year (in shares) at Sep. 30, 2018	150,213,621
Net income attributable to Baxter stockholders	$ 305
Net income	305
End of year at Dec. 31, 2018	$ 7,866	$ 683	$ (9,989)	5,898	15,075	(3,823)	7,844	22
End of year (in shares) at Dec. 31, 2018	683,494,944	683,000,000
End of year (in shares) at Dec. 31, 2018	170,495,859		170,000,000
Net income	$ 305
Adoption of new accounting standards	0				161	(161)
Net income attributable to Baxter stockholders	342				342		342
Net income	342
Other comprehensive income (loss)	(98)					(98)	(98)
Purchases of common stock (in shares)			8,000,000
Purchases of common stock	(586)		$ (586)				(586)
Stock issued under employee benefit plans and other (in shares)			(5,000,000)
Stock issued under employee benefit plans and other	166		$ 291	(59)	(66)		166
Dividends declared on common stock	(98)				(98)		(98)
Changes in noncontrolling interests	1							1
End of year at Mar. 31, 2019	$ 7,593	$ 683	$ (10,284)	5,839	15,414	(4,082)	7,570	23
End of year (in shares) at Mar. 31, 2019	683,494,944	683,000,000
End of year (in shares) at Mar. 31, 2019	173,447,198		173,000,000
Net income	$ 342
Beginning of year (in shares) at Dec. 31, 2018	683,494,944	683,000,000
Beginning of year at Dec. 31, 2018	$ 7,866	$ 683	$ (9,989)	5,898	15,075	(3,823)	7,844	22
Beginning of year (in shares) at Dec. 31, 2018	170,495,859		170,000,000
Adoption of new accounting standards	$ 0				161	(161)
Net income attributable to Baxter stockholders	655				655		655
Net income	655
Other comprehensive income (loss)	(102)					(102)	(102)
Purchases of common stock (in shares)			10,000,000
Purchases of common stock	(697)		$ (743)	46			(697)
Stock issued under employee benefit plans and other (in shares)			(7,000,000)
Stock issued under employee benefit plans and other	289		$ 410	(38)	(83)		289
Dividends declared on common stock	(210)				(210)		(210)
Changes in noncontrolling interests	2							2
End of year at Jun. 30, 2019	$ 7,803	$ 683	$ (10,322)	5,906	15,598	(4,086)	7,779	24
End of year (in shares) at Jun. 30, 2019	683,494,944	683,000,000
End of year (in shares) at Jun. 30, 2019	173,275,586		173,000,000
Net income	$ 655
Beginning of year (in shares) at Dec. 31, 2018	683,494,944	683,000,000
Beginning of year at Dec. 31, 2018	$ 7,866	$ 683	$ (9,989)	5,898	15,075	(3,823)	7,844	22
Beginning of year (in shares) at Dec. 31, 2018	170,495,859		170,000,000
Adoption of new accounting standards	$ 0				161	(161)
Net income attributable to Baxter stockholders	1,001				1,001		1,001	10
Net income	1,011
Other comprehensive income (loss)	$ 274					274	274
Purchases of common stock (in shares)	16,500,000		16,000,000
Purchases of common stock	$ (1,247)		$ (1,293)	46			(1,247)
Stock issued under employee benefit plans and other (in shares)			9,000,000
Stock issued under employee benefit plans and other	445		$ 518	11	(84)		445
Dividends declared on common stock	(435)				(435)		(435)
Changes in noncontrolling interests	(2)							(2)
End of year at Dec. 31, 2019	$ 7,912	$ 683	$ (10,764)	5,955	15,718	(3,710)	7,882	30
End of year (in shares) at Dec. 31, 2019	683,494,944	683,000,000
End of year (in shares) at Dec. 31, 2019	177,340,358		177,000,000
Net income	$ 1,011
Beginning of year (in shares) at Mar. 31, 2019	683,494,944	683,000,000
Beginning of year at Mar. 31, 2019	$ 7,593	$ 683	$ (10,284)	5,839	15,414	(4,082)	7,570	23
Beginning of year (in shares) at Mar. 31, 2019	173,447,198		173,000,000
Net income attributable to Baxter stockholders	$ 313				313		313
Net income	313
Other comprehensive income (loss)	(4)					(4)	(4)
Purchases of common stock (in shares)			2,000,000
Purchases of common stock	(111)		$ (157)	46			(111)
Stock issued under employee benefit plans and other (in shares)			(2,000,000)
Stock issued under employee benefit plans and other	123		$ 119	21	(17)		123
Dividends declared on common stock	(112)				(112)		(112)
Changes in noncontrolling interests	1							1
End of year at Jun. 30, 2019	$ 7,803	$ 683	$ (10,322)	$ 5,906	$ 15,598	$ (4,086)	$ 7,779	$ 24
End of year (in shares) at Jun. 30, 2019	683,494,944	683,000,000
End of year (in shares) at Jun. 30, 2019	173,275,586		173,000,000
Net income	$ 313

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operations
Net income	$ 1,011	$ 1,546	$ 602
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Loss from discontinued operations, net of tax	0	6	7
Depreciation and amortization	789	771	750
Pension settlement charges	755	1	2
Deferred income taxes	(310)	(263)	211
Stock compensation	122	115	107
Net periodic pension benefit and other postretirement costs	22	39	123
Impairment of intangible assets	31	0	0
Other	115	50	38
Changes in balance sheet items:
Accounts receivable, net	(65)	(12)	30
Inventories	4	(197)	76
Accounts payable and accrued liabilities	(212)	60	11
Other	(152)	(99)	(227)
Cash flows from operations – continuing operations	2,110	2,017	1,730
Cash flows from operations - discontinued operations	(6)	0	(16)
Cash flows from operations	2,104	2,017	1,714
Cash flows from investing activities
Capital expenditures	(696)	(659)	(616)
Acquisitions and investments, net of cash acquired	(418)	(268)	(686)
Other investing activities, net	14	11	10
Cash flows from investing activities	(1,100)	(916)	(1,292)
Cash flows from financing activities
Issuances of debt	1,661	0	665
Borrowings under revolving credit facility	222	0	0
Cash dividends on common stock	(423)	(376)	(315)
Proceeds from stock issued under employee benefit plans	356	258	347
Purchases of treasury stock	(1,270)	(2,452)	(564)
Other financing activities, net	(48)	(33)	(40)
Cash flows from financing activities	498	(2,603)	93
Effect of foreign exchange rate changes on cash and cash equivalents	(5)	(63)	102
Increase (decrease) in cash and cash equivalents	1,497	(1,565)	617
Cash and cash equivalents at beginning of year	1,838	3,403	2,786
Cash and cash equivalents at end of year	3,335	1,838	3,403
Other supplemental information
Interest paid, net of portion capitalized	103	94	80
Income taxes paid	$ 294	$ 301	$ 253

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Baxter International Inc., through our subsidiaries (collectively, Baxter, we, our or us), provides a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and patients at home under physician supervision. We operate in three segments: Americas, EMEA and APAC, which are described in Note 18. Use of Estimates The preparation of the financial statements in conformity with U.S. Generally Accepted Accounting Principles (U.S. GAAP) requires us to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those estimates. Basis of Presentation The consolidated financial statements include the accounts of Baxter and our majority-owned subsidiaries that we control, after elimination of intra-company transactions. Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation. On October 25, 2019, we acquired 100 percent of Cheetah Medical, Inc. (Cheetah) for total upfront cash consideration of $195 million, net of cash acquired, with the potential for additional cash consideration, up to $40 million, based on clinical and commercial milestones for which the acquisition date fair value was $18 million. Beginning October 25, 2019, our financial statements include the assets, liabilities and operating results of Cheetah. Refer to Note 4 for additional information. On November 18, 2018, we acquired a controlling financial interest in our joint venture in Saudi Arabia. The acquisition allows us to increase manufacturing output and utilize the facilities for additional capacity for certain products in the region. Beginning November 18, 2018, we consolidated the financial statements of the joint venture with our consolidated financial statements. Refer to Note 4 for additional information. On March 16, 2018, we acquired two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant for total consideration of $184 million. Beginning March 16, 2018, our financial statements include the assets, liabilities and operating results of RECOTHROM and PREVELEAK. Refer to Note 4 for additional information. On July 27, 2017, we acquired 100 percent of Claris Injectables Limited (Claris), a wholly owned subsidiary of Claris Lifesciences Limited, for total cash consideration of approximately $629 million, net of cash acquired. Beginning July 27, 2017, our financial statements include the assets, liabilities and operating results of Claris. Refer to Note 4 for additional information. Currency restrictions enacted in Venezuela require approval from the Venezuelan government to exchange Venezuelan bolivars for U.S. dollars. Due to a decline in transactions to exchange Venezuelan bolivars for U.S. dollars, and limitations on our ability to repatriate funds generated by our Venezuela operations, we concluded in the second quarter of 2017 that we no longer met the accounting criteria for control over our business in Venezuela and we deconsolidated our Venezuelan operations on June 30, 2017. As a result of deconsolidating the Venezuelan operations, we recorded a pre-tax charge of $33 million in other (income) expense, net in 2017. This charge included the write-off of our investment in our Venezuelan operations, related cumulative translation adjustments and elimination of intra-company amounts. Beginning in the third quarter of 2017, we no longer included the results of our Venezuelan business in our consolidated financial statements. In 2018, we liquidated our subsidiary in Venezuela and currently sell direct to distributors in that country through legal entities outside of Venezuela. The distributors purchase our products in U.S. dollars and are responsible for importing those products into Venezuela. Revenue Recognition We adopted Accounting Standards Update (ASU) No. 2014-9, Revenue from Contracts with Customers (Topic 606) as of January 1, 2018. Results for the years ended December 31, 2019 and 2018 are presented under Topic 606, while the 2017 period is presented under previous guidance. See further discussion of the impact of Topic 606 below under the header “New Accounting Standards.” Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days. The majority of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our geographic segments, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. For a majority of these sales, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. To a lesser extent, in all of our segments, we enter into other types of contracts, including contract manufacturing arrangements, equipment leases, and certain subscription software and licensing arrangements. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or when our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed. As of December 31, 2019, we had $8.6 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more, which are primarily included in the Americas segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue in each of 2020 and 2021, 20% in each of 2022 and 2023, 5% in 2024, and the remaining balance thereafter. Significant Judgments Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration related to rebates, product returns, sales discounts and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accounts receivable, net and accounts payable and accrued liabilities on the consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized in years ended December 31, 2019 and 2018 related to performance obligations satisfied in prior periods was not material. Contract Balances The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets, and customer advances and deposits (contract liabilities) on our consolidated balance sheets. Net trade accounts receivable was $1.8 billion as of December 31, 2019 and 2018. For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are provided and billed, generally over one to seven years. Our contract asset balances totaled $131 million as of December 31, 2019, of which $36 million related to contract manufacturing services, $43 million related to software sales and $52 million related to bundled equipment and consumable medical products contracts. Our contract asset balances totaled $80 million as of December 31, 2018, of which $33 million related to contract manufacturing services and $47 million related to software sales. Contract assets are presented within accounts receivable, net ($63 million and $50 million as of December 31, 2019 and 2018, respectively) and other non-current assets ($68 million and $30 million as of December 31, 2019 and 2018, respectively) on the consolidated balance sheets. Contract liabilities were $12 million as of December 31, 2019 and were included in other non-current liabilities on the consolidated balance sheet. Contract liabilities as of December 31, 2018 were not significant. Practical Expedients We apply a practical expedient to expense as incurred costs to obtain a contract with a customer when the amortization period would have been one year or less. We do not disclose the value of the transaction price that is allocated to unsatisfied performance obligations for contracts with an original expected length of one year or less. We have elected to use the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component if it is expected, at contract inception, that the period between when we transfer a promised good or service to a customer and when the customer pays for that good or service will be one year or less. Additionally, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected from a customer are excluded from revenue. Disaggregation of Net Sales The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international: As Restated 2019 2018 2017 years ended December 31 (in millions) U.S. International Total U.S. International Total U.S. International Total Renal Care 1 $ 791 $ 2,848 $ 3,639 $ 816 $ 2,835 $ 3,651 $ 754 $ 2,737 $ 3,491 Medication Delivery 2 1,822 977 2,799 1,690 974 2,664 1,698 1,002 2,700 Pharmaceuticals 3 940 1,215 2,155 996 1,091 2,087 892 994 1,886 Clinical Nutrition 4 320 552 872 321 554 875 359 526 885 Advanced Surgery 5 535 342 877 466 332 798 403 305 708 Acute Therapies 6 184 351 535 174 341 515 147 310 457 Other 7 234 251 485 260 249 509 257 200 457 Total Baxter $ 4,826 $ 6,536 $ 11,362 $ 4,723 $ 6,376 $ 11,099 $ 4,510 $ 6,074 $ 10,584 1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business. Accounts Receivable and Allowance for Doubtful Accounts In the normal course of business, we provide credit to our customers, perform credit evaluations of these customers and maintain reserves for potential credit losses. In determining the amount of the allowance for doubtful accounts, we consider, among other items, historical credit losses, the past-due status of receivables, payment histories and other customer-specific information. Receivables are written off when we determine they are uncollectible. The allowance for doubtful accounts was $112 million and $110 million as of December 31, 2019 and 2018, respectively. Shipping and Handling Costs Shipping costs, which are costs incurred to physically move product from our premises to the customer’s premises, are classified as selling, general and administrative (SG&A) expenses. Handling costs, which are costs incurred to store, move and prepare products for shipment, are classified as cost of sales. Approximately $324 million in 2019, $329 million in 2018 and $292 million in 2017 of shipping costs were classified in SG&A expenses. Cash and Cash Equivalents Cash and cash equivalents include cash, certificates of deposit and money market and other short-term funds with original maturities of three months or less. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. We review inventories on hand at least quarterly and record provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. Property, Plant and Equipment, Net Property, plant and equipment are stated at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the related assets, which range from 20 to 50 years for buildings and improvements and from three three Research and Development Research and development (R&D) costs, including R&D acquired in transactions that are not business combinations, are expensed as incurred. Pre-regulatory approval contingent milestone obligations to counterparties in collaborative arrangements, which include acquired R&D, are expensed when the milestone is achieved. Contingent milestone payments made to such counterparties on or after regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangible assets, net. Acquired in-process R&D (IPR&D) is the value assigned to technology or products under development acquired in a business combination which have not received regulatory approval and have no alternative future use. Acquired IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and amortized on a straight-line basis over the estimated economic life of the related technology or product, subject to annual impairment reviews as discussed below. If the R&D project is abandoned, the indefinite-lived asset is charged to expense. Collaborative Arrangements We enter into collaborative arrangements in the normal course of business. These collaborative arrangements take a number of forms and structures and are designed to enhance and expedite long-term sales and profitability growth. These arrangements may provide for us to obtain commercialization rights to a product under development, and require us to make upfront payments, contingent milestone payments, profit-sharing, and/or royalty payments. We may be responsible for ongoing costs associated with the arrangements, including R&D cost reimbursements to the counterparty. See the R&D section of this note regarding the accounting treatment of upfront and contingent milestone payments. Any royalty and profit-sharing payments during the commercialization phase are expensed as cost of sales when they become due and payable. Restructuring Charges We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are primarily recorded when actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Refer to the discussion below regarding the accounting for asset impairment charges. Goodwill, Intangible Assets, and Other Long-Lived Assets Goodwill is the excess of the purchase price over the fair value of acquired assets and liabilities in a business combination. Goodwill is not amortized but is subject to an impairment review annually and whenever indicators of impairment exist. We have the option to assess goodwill for impairment by initially performing a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then the two-step goodwill impairment test is not required to be performed. If we determine that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, or if we do not elect the option to perform an initial qualitative assessment, we perform the two-step goodwill impairment test. In the first step, the fair value of the reporting unit is compared with its book value including goodwill. If the fair value of the reporting unit is in excess of its book value, the related goodwill is not impaired and no further analysis is necessary. If the fair value of the reporting unit is less than its book value, there is an indication of potential impairment and a second step is performed. When required, the second step of testing involves calculating the implied fair value of goodwill for the reporting unit. The implied fair value of goodwill is determined in the same manner as goodwill recognized in a business combination, which is the excess of the fair value of the reporting unit determined in step one over the fair value of its net assets, including identifiable intangible assets, as if the reporting unit had been acquired. If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. Indefinite-lived intangible assets, such as IPR&D acquired in business combinations and certain trademarks with indefinite lives, are subject to an impairment review annually and whenever indicators of impairment exist. We have the option to assess indefinite-lived intangible assets for impairment by first performing qualitative assessments to determine whether it is more-likely-than-not that the fair values of its indefinite-lived intangible assets are less than the carrying amounts. If we determine that it is more-likely-than-not that an indefinite-lived intangible asset is impaired, or if we elect not to perform an initial qualitative assessment, we then perform the quantitative impairment test by comparing the fair value of the indefinite-lived intangible asset with its carrying amount. If the carrying amount exceeds the fair value of the indefinite-lived intangible asset, we write the carrying amount down to the fair value. We review the carrying amounts of long-lived assets, other than goodwill and intangible assets not subject to amortization, for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating recoverability, we group assets and liabilities at the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows of other assets and liabilities. We then compare the carrying amounts of the assets or asset groups with the related estimated undiscounted future cash flows. In the event impairment exists, an impairment charge is recorded as the amount by which the carrying amount of the asset or asset group exceeds the fair value. Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We maintain valuation allowances unless it is more-likely-than-not that the deferred tax asset will be realized. With respect to uncertain tax positions, we determine whether the position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. Any tax position that meets the more-likely-than-not recognition threshold is measured and recognized in the consolidated financial statements at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The liability relating to uncertain tax positions is classified as current in the consolidated balance sheets to the extent that we anticipate making a payment within one year. Interest and penalties associated with income taxes are classified in the income tax expense line in the consolidated statements of income. Refer to the Recently Adopted Accounting Pronouncements section of this note and Note 14 for additional information related to the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Foreign Currency Translation Currency translation adjustments (CTA) related to foreign operations are included in other comprehensive income (OCI). For foreign operations in highly inflationary economies, translation gains and losses are included in other (income) expense, net, and were not material in 2019, 2018 and 2017. Derivatives and Hedging Activities All derivative instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt instruments as hedging instruments in cash flow, fair value or net investment hedges. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to OCI over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intra-company sales denominated in foreign currencies and anticipated issuances of debt, respectively. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt. We have designated our Euro-denominated senior notes as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. For derivative instruments that are not designated as hedges, the change in fair value is recorded directly to other (income) expense, net. If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. If we remove a net investment hedge designation, any gains or losses recognized in AOCI are not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. Derivatives, including those that are not designated as a hedge, are principally classified in the operating section of the consolidated statements of cash flows. Refer to Note 16 for further information regarding our derivative and hedging activities. New Accounting Standards Recently adopted accounting pronouncements As of January 1, 2019, we adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under this guidance, lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all operating leases, other than those that meet the definition of a short-term lease. We adopted Topic 842 using the modified retrospective method. We elected the following practical expedients when assessing the transition impact: i) not to reassess whether any expired or existing contracts as of the adoption date are or contain leases; ii) not to reassess the lease classification for any expired or existing leases as of the adoption date; and iii) not to reassess initial direct costs for any existing leases as of the adoption date. The adjustment to record operating lease right-of-use assets and operating lease liabilities was $502 million as of January 1, 2019. The impact to the consolidated statements of income was not material and there was no net impact to the consolidated statements of cash flows. As of January 1, 2019, we adopted ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities. The purpose of this ASU is to better align a company’s risk management activities and financial reporting for hedging relationships, simplify the hedge accounting requirements, and improve the disclosures of hedging arrangements. The adoption of this standard did not have a material impact on our consolidated financial statements. As of January 1, 2019, we adopted ASU No. 2018-02, Reclassification of Certain Tax Effects from AOCI. As a result of the enactment of the U.S. Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), this guidance provides for a reclassification of certain tax effects from AOCI to retained earnings. The impact of the adoption of this standard was a $161 million increase to retained earnings. As of January 1, 2018, we adopted ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory (ASU No. 2016-16) using the modified retrospective method. ASU No. 2016-16 generally accelerates the recognition of income tax consequences for intra-company asset transfers other than inventory. We recorded a $70 million reduction to retained earnings upon adoption of the standard on January 1, 2018 related to the unrecognized income tax effects of asset transfers that occurred prior to adoption. Net income increased $14 million for the year ended December 31, 2018 as a result of the adoption of the standard. As of January 1, 2018, we adopted ASU No. 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in earnings. For privately-held securities, we elected the measurement alternative approach for our investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of this standard did not have a material impact on our consolidated financial statements. As of January 1, 2018, we adopted Topic 606, which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. The primary impact of the new standard relates to our contract manufacturing operations and software arrangements. Certain contract manufacturing arrangements require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This results in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under prior accounting literature. The new guidance also impacts our arrangements subject to previous software revenue recognition guidance, as we are required to recognize as revenue a significant portion of the contract consideration upon delivery of the software compared to the previous practice of recognizing the contract consideration ratably over time for certain arrangements. We adopted Topic 606 using the modified retrospective method. The adjustment upon adoption increased our opening balance of retained earnings by approximately $45 million, net of tax, on January 1, 2018. The impact to net sales as a result of the adoption was an increase of $7 million for the year ended December 31, 2018. The impact to cost of sales was not material for the year ended December 31, 2018. In December 2017, the SEC issued guidance for situations where the accounting for certain elements of the 2017 Tax Act could not be completed prior to the release of a company's financial statements. For specific elements of the 2017 Tax Act, we determined a reasonable estimate for certain effects and recorded that estimate as a provisional amount in 2017. The guidance provided a measurement period to allow a company to account for these specific elements, which began in the reporting period that included the enactment of the 2017 Tax Act and ended when we obtained, prepared and analyzed the information needed in order to complete its accounting assessments or one year, whichever occu

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS We have restated herein our consolidated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and 2017. We have also restated impacted amounts within the accompanying notes to the consolidated financial statements, as applicable. Restatement Background On October 24, 2019, we reported that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. Our internal investigation, as it pertains to the evaluation of related financial statement impacts, is complete. We previously had applied a longstanding convention for the initial measurement of foreign currency transactions and the subsequent remeasurement of foreign currency denominated monetary assets and liabilities (collectively, our historical exchange rate convention) that was not consistent with U.S. GAAP. U.S. GAAP requires that foreign currency transactions be initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction and it requires that foreign currency denominated monetary assets and liabilities be remeasured at the end of each reporting period using the exchange rate at that date. Under our historical exchange rate convention, all foreign currency transactions in a given month were initially measured using exchange rates from a specified date near the middle of the previous month. Additionally, all foreign currency denominated monetary assets and liabilities were subsequently remeasured at the end of each month using exchange rates from a specified date near the middle of the then current month. Beginning years after the adoption of our historical exchange rate convention, certain intra-company transactions were undertaken, after the related exchange rates were already known, solely for the purpose of generating non-operating foreign exchange gains or avoiding foreign exchange losses. We identified misstatements relating to foreign currency denominated monetary assets and liabilities and foreign currency derivative contracts that caused our Other income (expense), net and Income from continuing operations before income taxes to be overstated by $59 million and $113 million, respectively, for the years ended December 31, 2018 and 2017. Our quantification of those misstatements to our previously reported foreign exchange gains and losses was not limited to intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses after the related exchange rates were already known. Rather, we identified every legal entity within our consolidated group that had foreign exchange gains or losses above an immaterial threshold and, for those entities, we remeasured all foreign exchange gains and losses from foreign currency denominated cash balances and intra-company loan receivables and payables using the exchange rates required by U.S. GAAP. For those entities, we also quantified misstatements to our previously reported gains and losses on foreign currency derivative contracts, which had used foreign exchange rates determined under our historical exchange rate convention as inputs to the fair value measurements of those contracts. Our quantification of misstatements to the consolidated financial statements did not include foreign currency gains or losses from short-term third-party and intra-company trade receivables and trade payables denominated in foreign currencies. We determined that any potential misstatements relating to such balances that arise in the ordinary course of business and are ultimately settled for cash within a short period of time, generally thirty to sixty days, would not be material to our consolidated financial statements. In order to correct our previously issued financial statements, we have restated herein our consolidated financial statements as of December 31, 2018 and for the years ended December 31, 2018 and 2017, in accordance with Accounting Standards Codification (ASC) Topic 250, Accounting Changes and Error Corrections . In addition to the misstatements described above relating to foreign exchange gains and losses, we corrected additional misstatements that were not material, individually or in the aggregate, to our previously issued consolidated financial statements. Those other immaterial misstatements relate to equipment leased to customers under operating leases, classification of foreign currency gains and losses on cash balances and intra-company loan receivables and payables in our consolidated statements of cash flows, translation of the financial position and results of operations of our foreign operations into U.S. dollars, income statement classification of transition services income related to the separation of Baxalta in 2015, other miscellaneous adjustments, and the income tax effects of those items. We believe that the use of our historical exchange rate convention to generate non-operating foreign exchange gains and avoid losses had occurred for at least ten years. The cumulative impact of misstatements related to non-operating foreign exchange gains and losses that we corrected for periods earlier than 2017, as well as the cumulative impact of correcting other immaterial misstatements relating to those earlier periods, have been recorded as a reduction to our opening retained earnings as of January 1, 2017. Restated interim financial information for the quarterly periods ended June 30, 2019, March 31, 2019, December 31, 2018, June 30, 2018, and March 31, 2018 is included in Note 19, Quarterly Financial Results (Unaudited) . The categories of misstatements and their impact on our previously issued consolidated financial statements are described in more detail below. Description of Misstatements Misstatements of Foreign Exchange Gains and Losses (a) Foreign Currency Denominated Monetary Assets and Liabilities As discussed above, we recorded adjustments to correct foreign exchange gains and losses on monetary assets and liabilities denominated in a foreign currency to reflect the gains and losses resulting from application of the exchange rates required by U.S. GAAP. The impacts of the foreign currency gain or loss misstatements on each period are discussed in restatement reference (a) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . (b) Foreign Currency Derivative Contracts As discussed above, we recorded adjustments to correct gains and losses on foreign currency derivative contracts by using current exchange rates at the applicable measurement dates as inputs to the related fair value measurements. The impacts of the foreign currency derivative contract gain or loss misstatements on each period are discussed in restatement reference (b) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . Additional Misstatements (c) Equipment Leased to Customers under Operating Leases Our manufacturing subsidiaries often sell products to commercial subsidiaries within our consolidated group which then sell or lease those products to third-party customers. Under U.S. GAAP, intra-company sales, intra-company cost of sales, and any step-ups in the carrying amount of inventory from intra-company transactions are eliminated in consolidation. If we subsequently sell the products to a third-party customer, the related intra-company profit previously eliminated in consolidation is recognized in our consolidated statements of income. For transactions in which we lease, rather than sell, our products to customers under operating lease arrangements, no profit or loss should be recognized at inception of the arrangement and any intra-company profit previously eliminated in consolidation should be recognized as a reduction to the carrying amount of the related leased assets. Prior to the third quarter of 2019, our international operations incorrectly recognized intra-company profit previously eliminated in consolidation as a reduction of cost of sales, rather than as a reduction of leased assets, at inception of operating lease arrangements. Accordingly, we have recorded adjustments to increase cost of sales and decrease property, plant, and equipment, net in our consolidated financial statements. Those adjustments include corrections of depreciation expense and accumulated depreciation resulting from the decreases to the carrying amounts of the related leased equipment. The impacts of the operating lease misstatements on each period are discussed in restatement reference (c) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . (d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows We previously included foreign exchange gains and losses related to intra-company receivables and payables and cash balances within our cash flows from operations. In the accompanying consolidated statements of cash flows, foreign exchange gains and losses, as restated, related to intra-company receivables and payables and cash balances are presented as reconciling items between income from continuing operations and cash flows from operations. The impacts of those misclassifications on our operating cash flows for each period are discussed in restatement reference (d) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars U.S. GAAP specifies that the income statement of a foreign operation should be translated into the reporting currency using the exchange rates on the dates the income or expense was recognized and indicates that the use of weighted-average exchange rates during the period is generally appropriate. Similar to our convention for the initial measurement of foreign currency transactions, we historically translated the results of operations of our foreign operations for a given month into U.S. dollars using exchange rates from a specified date near the middle of the previous month. Accordingly, we have recorded adjustments to translate the income statements of our foreign operations into U.S. dollars using the applicable average foreign exchange rates for each month. U.S. GAAP specifies that the assets and liabilities of foreign operations be translated into the reporting currency at the end of each reporting period using the exchange rate at that date. Similar to our convention for the subsequent remeasurement of foreign currency denominated monetary assets and liabilities, our financial reporting systems were previously configured to translate assets and liabilities at the end of each month using exchange rates from a specified date near the middle of the current month. In recent years, we separately computed the impact of translating assets and liabilities at period-end exchange rates and adjusted our consolidated balance sheets to reflect that difference. However, due to an incorrect input in those manual calculations as of December 31, 2018, our balance sheet was misstated as of that date. The impacts of misstatements related to the translation of the financial position and results of operations of our foreign operations on each period are discussed in restatement reference (e) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . (f) Income Statement Classification of Transition Services Income We entered into a transition services agreement (TSA) with Baxalta in connection with the July 1, 2015 separation transaction. Services we provided under the TSA included, among others, finance, information technology, human resources, quality, supply chain, and certain other administrative services. Those services generally commenced on July 1, 2015 and concluded on July 1, 2018. As previously disclosed, we recognized income of approximately $9 million and $56 million, respectively, under the TSA for the years ended December 31, 2018 and 2017. The amounts earned for those services were previously presented as a reduction of Selling, general, and administrative expenses (which we previously referred to as “Marketing and administrative expenses”) in our consolidated statements of income. The accompanying restated consolidated statements of income for the years ended December 31, 2018 and 2017 present the amounts earned for those services within Other operating income, net, rather than as a reduction of Selling, general, and administrative expenses. The impacts of the income statement misclassification of TSA income on each period are discussed in restatement reference (f) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . (g) Other Miscellaneous Adjustments We recorded adjustments to correct other out-of-period items and previously uncorrected misstatements that were not material, individually or in the aggregate, to our consolidated financial statements. Those other misstatements were primarily related to a historical restructuring liability and amounts related to our separation of Baxalta in 2015. The impacts of the other miscellaneous adjustments on each period are discussed in restatement reference (g) throughout this note and in Note 19, Quarterly Financial Results (Unaudited) . Description of Restatement Tables The following tables present the impact of the adjustments described above to our previously reported consolidated balance sheet as of December 31, 2018 and the consolidated statements of income, comprehensive income, changes in equity, and cash flows for the years ended December 31, 2018 and 2017. Following the restated consolidated financial statement tables, we have presented reconciliations from our prior periods as previously reported to the restated amounts. The amounts as previously reported for the years ended December 31, 2018 and 2017 were derived from our Annual Report on Form 10-K for the year ended December 31, 2018 filed on February 21, 2019. Baxter International Inc. Consolidated Balance Sheet (in millions, except per share) December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 1,832 $ 6 (e) $ 1,838 Accounts receivable, net 1,812 28 (e)(g) 1,840 Inventories 1,653 14 (e)(g) 1,667 Prepaid expenses and other current assets 622 (8) (b)(e)(g) 614 Total current assets 5,919 40 5,959 Property, plant and equipment, net 4,542 (12) (c)(e) 4,530 Goodwill 2,958 44 (e) 3,002 Other intangible assets, net 1,398 12 (e)(g) 1,410 Other non-current assets 824 (5) (a)(c)(e)(g) 819 Total assets $ 15,641 $ 79 $ 15,720 Current liabilities: Short-term debt $ 2 $ — $ 2 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,832 (22) (b)(e)(g) 2,810 Total current liabilities 2,836 (22) 2,814 Long-term debt and finance lease obligations 3,473 8 (e) 3,481 Other non-current liabilities 1,516 43 (a)(c)(e)(g) 1,559 Total liabilities 7,825 29 7,854 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 170,495,859 shares (9,989) — (9,989) Additional contributed capital 5,898 — 5,898 Retained earnings 15,626 (551) (a)(b)(c)(e)(g) 15,075 Accumulated other comprehensive (loss) income (4,424) 601 (a)(e) (3,823) Total Baxter stockholders’ equity 7,794 50 7,844 Noncontrolling interests 22 — 22 Total equity 7,816 50 7,866 Total liabilities and equity $ 15,641 $ 79 $ 15,720 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $487 million and accumulated other comprehensive loss of $482 million and increases to other non-current assets of $8 million and other non-current liabilities of $13 million as of December 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $2 million, accounts payable and accrued liabilities of $1 million, and retained earnings of $1 million as of December 31, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $53 million, other non-current liabilities of $5 million, and retained earnings of $38 million and an increase to other non-current assets of $10 million as of December 31, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $6 million, accounts receivable, net of $22 million, inventories of $19 million, prepaid expenses and other current assets of $2 million, property, plant and equipment of $41 million, goodwill of $44 million, other intangible assets, net of $13 million, other non-current assets of $6 million, accounts payable and accrued liabilities of $24 million, long-term debt and finance lease obligations of $8 million and other non-current liabilities of $19 million as of December 31, 2018. The correction of these misstatements also resulted in decreases to retained earnings of $17 million and accumulated other comprehensive loss of $119 million as of December 31, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million, and increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million as of December 31, 2018. Baxter International Inc. Consolidated Statement of Income (in millions, except per share) Year ended December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Net sales $ 11,127 $ (28) (e) $ 11,099 Cost of sales 6,346 (6) (c)(e) 6,340 Gross margin 4,781 (22) 4,759 Selling, general and administrative expenses 2,617 3 (e)(f) 2,620 Research and development expenses 655 (1) (e) 654 Other operating income, net (90) (9) (f) (99) Operating income 1,599 (15) 1,584 Interest expense, net 45 — 45 Other (income) expense, net (139) 61 (a)(b)(e) (78) Income from continuing operations before income taxes 1,693 (76) 1,617 Income tax expense (benefit) 63 2 (c)(e)(g) 65 Income from continuing operations 1,630 (78) 1,552 Loss from discontinued operations, net of tax (6) — (6) Net income $ 1,624 $ (78) $ 1,546 Earnings per share from continuing operations Basic $ 3.05 $ (0.14) $ 2.91 Diluted $ 2.99 $ (0.15) $ 2.84 Loss per share from discontinued operations Basic $ (0.01) $ — $ (0.01) Diluted $ (0.02) $ 0.01 $ (0.01) Earnings per share Basic $ 3.04 $ (0.14) $ 2.90 Diluted $ 2.97 $ (0.14) $ 2.83 Weighted-average number of shares outstanding Basic 534 — 534 Diluted 546 — 546 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in a decrease to other (income) expense, net of $64 million for the year ended December 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $5 million for the year ended December 31, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $11 million and a decrease to income tax expense of $3 million for the year ended December 31, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in decreases to net sales of $28 million, cost of sales of $17 million, SG&A expense of $6 million, R&D expense of $1 million, other (income) expense, net of $2 million, and income tax expense of $2 million for the year ended December 31, 2018. (f) Income Statement Classification of Transition Services Income—The correction of these misstatements resulted in increases to SG&A expense and other operating income, net of $9 million for the year ended December 31, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in an increase to income tax expense of $7 million for the year ended December 31, 2018. Baxter International Inc. Consolidated Statement of Income (in millions, except per share) Year ended December 31, 2017 As previously reported Restatement impacts Restatement reference As restated Net sales $ 10,561 $ 23 (e) $ 10,584 Cost of sales 6,091 19 (c)(e) 6,110 Gross margin 4,470 4 4,474 Selling, general and administrative expenses 2,566 61 (e)(f) 2,627 Research and development expenses 613 2 (e) 615 Other operating income, net — (56) (f) (56) Operating income 1,291 (3) 1,288 Interest expense, net 55 — 55 Other (income) expense, net 19 114 (a)(b)(e) 133 Income from continuing operations before income taxes 1,217 (117) 1,100 Income tax expense (benefit) 493 (2) (c)(e) 491 Income from continuing operations 724 (115) 609 Loss from discontinued operations, net of tax (7) $ — (7) Net income $ 717 $ (115) $ 602 Earnings per share from continuing operations Basic $ 1.33 $ (0.21) $ 1.12 Diluted $ 1.30 $ (0.20) $ 1.10 Loss per share from discontinued operations Basic $ (0.01) $ — $ (0.01) Diluted $ (0.01) $ (0.01) $ (0.02) Earnings per share Basic $ 1.32 $ (0.21) $ 1.11 Diluted $ 1.29 $ (0.21) $ 1.08 Weighted-average number of shares outstanding Basic 543 — 543 Diluted 555 — 555 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to other (income) expense, net of $96 million. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $17 million. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $8 million and a decrease to income tax expense of $3 million for the year ended December 31, 2017. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to net sales of $23 million, cost of sales of $11 million, SG&A expense of $5 million, R&D expense of $2 million, other (income) expense, net of $1 million and income tax expense of $1 million for the year ended December 31, 2017. Baxter International Inc. Consolidated Statement of Comprehensive Income (in millions) Year ended December 31, 2018 As previously reported Restatement impacts As restated Net income $ 1,624 $ (78) $ 1,546 Other comprehensive (loss) income, net of tax: Currency translation adjustments (461) 138 (323) Pension and other postretirement benefit plans 32 1 33 Hedging activities 9 — 9 Total other comprehensive (loss) income, net of tax (420) 139 (281) Comprehensive income $ 1,204 $ 61 $ 1,265 The $78 million decrease to net income was driven by the items described above in the consolidated statement of income for the year ended December 31, 2018 section. The $138 million decrease to currency translation adjustments for the year ended December 31, 2018 is comprised of a $74 million decrease to correct the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars and a $64 million decrease from the offsetting balance sheet impact of the adjustments to foreign exchange gains and losses. The $1 million increase to pension and other postretirement benefit plans for the year ended December 31, 2018 is a result of the correction of the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars. Baxter International Inc. Consolidated Statement of Comprehensive Income (in millions) Year ended December 31, 2017 As previously reported Restatement impacts As restated Net income $ 717 $ (115) $ 602 Other comprehensive (loss) income, net of tax: Currency translation adjustments 425 174 599 Pension and other postretirement benefit plans 141 (7) 134 Hedging activities (13) — (13) Available-for-sale securities 2 — 2 Total other comprehensive (loss) income, net of tax 555 167 722 Comprehensive income $ 1,272 $ 52 $ 1,324 The $115 million decrease to net income was driven by the items described above in the consolidated statement of income for the year ended December 31, 2017 section. The $174 million increase to currency translation adjustments for the year ended December 31, 2017 is comprised of a $78 million increase to correct the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars and a $96 million increase from the offsetting balance sheet impact of the adjustments to foreign exchange gains and losses. The $7 million decrease to pension and other postretirement benefit plans for the year ended December 31, 2017 is a result of the correction of the foreign exchange rates used to translate the financial position and results of operations of our foreign operations into U.S. dollars. Baxter International Inc. Consolidated Statement of Changes in Equity (in millions) Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity As previously reported Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,483 $ (4,001) $ 9,124 $ (8) $ 9,116 Adoption of new accounting standards — — — — — (18) (3) (21) — (21) Net income — — — — — 1,624 — 1,624 — 1,624 Other comprehensive income (loss) — — — — — — (420) (420) — (420) Purchases of treasury stock — — 36 (2,415) (60) — — (2,475) — (2,475) Stock issued under employee benefit plans and other — — (8) 407 18 (71) — 354 — 354 Dividends declared on common stock — — — — — (392) — (392) — (392) Changes in noncontrolling interests — — — — — — — — 30 30 Balance as of December 31, 2018 683 $ 683 170 $ (9,989) $ 5,898 $ 15,626 $ (4,424) $ 7,794 $ 22 $ 7,816 Restatement impacts Balance as of January 1, 2018 — $ — — $ — $ — $ (469) $ 462 $ (7) $ — $ (7) Adoption of new accounting standards — — — — — (4) — (4) — (4) Net income — — — — — (78) — (78) — (78) Other comprehensive income (loss) — — — — — — 139 139 — 139 Balance as of December 31, 2018 — $ — — $ — $ — $ (551) $ 601 $ 50 $ — $ 50 As restated Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (22) (3) (25) — (25) Net income — — — — — 1,546 — 1,546 — 1,546 Other comprehensive income (loss) — — — — — — (281) (281) — (281) Purchases of treasury stock — — 36 (2,415) (60) — — (2,475) — (2,475) Stock issued under employee benefit plans and other — — (8) 407 18 (71) — 354 — 354 Dividends declared on common stock — — — — — (392) — (392) — (392) Changes in noncontrolling interests — — — — — — — — 30 30 Balance as of December 31, 2018 683 683 170 (9,989) 5,898 15,075 (3,823) 7,844 22 7,866 See descriptions of the net income and other comprehensive income impacts in the consolidated statement of income and consolidated statement of comprehensive income for the year ended December 31, 2018 sections above. Additionally, we recorded an adjustment to the opening balance of retained earnings on January 1, 2018 for the adoption of ASU No. 2016-16, which was impacted by our adjustments to equipment leased to customers under operating leases. Baxter International Inc. Consolidated Statement of Changes in Equity (in millions) Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity As previously reported Balance as of January 1, 2017 683 $ 683 144 $ (7,995) $ 5,958 $ 14,200 $ (4,556) $ 8,290 $ (10) $ 8,280 Net income — — — — — 717 — $ 717 — $ 717 Other comprehensive income (loss) — — — — — — 555 555 — 555 Purchases of treasury stock — — 9 (564) — — — (564) — (564) Stock issued under employee benefit plans and other — — (11) 578 (18) (134) — 426 — 426 Dividends declared on common stock — — — — — (334) — (334) — (334) Distribution of Baxalta — — — — — 34 — 34 — 34 Changes in noncontrolling interests — — — — — — — — 2 2 Balance as of December 31, 2017 683 $ 683 142 $ (7,981) $ 5,940 $ 14,483 $ (4,001) $ 9,124 $ (8) $ 9,116 Restatement impacts Balance as of January 1, 2017 — $ — — $ — $ — $ (354) $ 295 $ (59) $ — $ (59) Net income — — — — — (115) — (115) — (115) Other comprehensive income (loss) — — — — — — 167 167 — 167 Balance as of December 31, 2017 — $ — — $ — $ — $ (469) $ 462 $ (7) $ — $ (7) As restated Balance as of January 1, 2017 683 $ 683 144 $ (7,995) $ 5,958 $ 13,846 $ (4,261) $ 8,231 $ (10) $ 8,221 Net income — — — — — 602 — 602 — 602 Other comprehensive income (loss) — — — — — — 722 722 — 722 Purchases of treasury stock — — 9 (564) — — — (564) — (564) Stock issued under employee benefit plans and other — — (11) 578 (18) (134) — 426 — 426 Dividends declared on common stock — — — — — (334) — (334) — (334) Distribution of Baxalta — — — — — 34 — 34 — 34 Changes in noncontrolling interests — — — — — — — — 2 2 Balance as of December 31, 2017 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 The adjustment to the January 1, 2017 retained earnings and accumulated other comprehensive loss represent the cumulative impacts of foreign exchange gains and losses and the translation of our financial position and results of operations for our foreign operations into U.S. dollars for the periods prior to January 1, 2017. Retained earnings also includes the cumulative impacts of equipment leased to customers under operating leases and other miscellaneous adjustments for the periods prior to January 1, 2017. See descriptions of the net income and other comprehensive income impacts in the consolidated statement of income and consolidated statement of comprehensive income for the year ended December 31, 2017 sections above. Baxter International Inc. Consolidated Statement of Cash Flows (in millions) Year ended December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Cash flows from operations Net income $ 1,624 $ (78) $ 1,546 Adjustments to reconcile income from continuing operations to net cash from operating activities: Loss from discontinued operations, net of tax 6 — 6 Depreciation and amortization 785 (14) (c)(g) 771 Pension settlement charges 1 — 1 Net periodic pension benefit and other postretirement costs 39 — 39 Deferred income taxes (267) 4 (c)(g) (263) Stock compensation 115 — 115 Other 43 7 (d) 50 Changes in balance sheet items: Accounts receivable, net (12) — (12) Inventories (197) — (197) Accounts payable and accrued liabilities 64 (4) (b) 60 Other (105) 6 (b)(e)(g) (99) Cash flows from operations 2,096 (79) 2,017 Cash flows from investing activities Capital expenditures (681) 22 (c) (659) Acquisitions and investments, net of cash acquired (268) — (268) Other investing activities, net 11 — 11 Cash flows from investing activities (938) 22 (916) Cash flows from financing activities Cash dividends on common stock (376) — (376) Proceeds from stock issued under employee benefit plans 258 — 258 Purchases of treasury stock (2,452) — (2,452) Other financing activities, net (33) — (33) Cash flows from financing activities (2,603) — (2,603) Effect of foreign exchange rate changes on cash and cash equivalents (117) 54 (a)(d)(e) (63) Increase (decrease) in cash and cash equivalents (1,562) (3) (1,565) Cash and cash equivalents at beginning of year 3,394 9 (e) 3,403 Cash and cash equivalents at end of year $ 1,832 $ 6 (e) $ 1,838 Other supplemental information Interest paid, net of portion capitalized $ 94 — $ 94 Income taxes paid $ 302 (1) (e) $ 301 The $78 million decrease to net income was driven by the items described above in the consolidated statement of income for the year ended December 31, 2018 sect

SEPARATION OF BAXALTA INCORPORA

SEPARATION OF BAXALTA INCORPORATED	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
SEPARATION OF BAXALTA INCORPORATED	SEPARATION OF BAXALTA On July 1, 2015, we completed the distribution of approximately 80.5% of the outstanding common stock of Baxalta to our stockholders (the Distribution). After giving effect to the Distribution, we retained 19.5% of the outstanding common stock, or 131,902,719 shares of Baxalta (Retained Shares). The Distribution was made to our stockholders of record as of the close of business on June 17, 2015 (Record Date), who received one share of Baxalta common stock for each of our shares held as of the Record Date. As a result of the Distribution, Baxalta became an independent public company. In 2016, we disposed of our remaining 19.5% interest in Baxalta through a series of transactions including debt-for-equity exchanges, an equity-for-equity exchange and a contribution to our U.S. pension plan. We entered into several additional agreements with Baxalta as a result of the July 1, 2015 separation, including a transition services agreement (TSA), separation and distribution agreement, manufacturing and supply agreements (MSA), tax matters agreement and a long-term services agreement. Pursuant to the TSA, we and our subsidiaries, along with Baxalta and their respective subsidiaries, provided to each other, on an interim, transitional basis, various services. Services provided by us included, among others, finance, information technology, human resources, quality, supply chain and certain other administrative services. The services generally commenced on the Distribution date and terminated as of July 1, 2018. Billings by us under the TSA are presented within other operating income, net in the consolidated statements of income. In 2018 and 2017, we recognized approximately $9 million and $56 million, respectively, related to the TSA. Cash outflows of $6 million, zero and $16 million in 2019, 2018 and 2017, respectively, were reported in cash flows from operations – discontinued operations. These cash flows relate to payments under the tax matters agreement, non-assignable tenders whereby we remained the seller of Baxalta products, transactions related to importation services we provided in certain countries and trade payables settled following local separation on Baxalta’s behalf.

ACQUISITIONS AND OTHER ARRANGEM

ACQUISITIONS AND OTHER ARRANGEMENTS	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
ACQUISITIONS AND OTHER ARRANGEMENTS	ACQUISITIONS AND OTHER ARRANGEMENTS Results of operations of acquired companies are included in our results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent consideration related to business combinations is recognized at its estimated fair value on the acquisition date. Subsequent changes to the fair value of those contingent consideration arrangements are recognized in earnings. Contingent consideration related to acquisitions may consist of development, regulatory and commercial milestone payments, and sales or earnings-based payments, and are valued using discounted cash flow techniques. The fair value of development, regulatory and commercial milestone payments reflects management’s expectations of the probability of payment, and increases or decreases as the probability of payment or expectation of timing or amount of payments changes. The fair value of sales-based payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing or amount of payments changes. Cheetah Medical, Inc. On October 25, 2019, we acquired 100 percent of Cheetah Medical, Inc. (Cheetah) for total upfront cash consideration of $195 million, net of cash acquired, with the potential for additional cash consideration, up to $40 million, based on clinical and commercial milestones for which the acquisition date fair value was $18 million. Cheetah is a leading provider of hemodynamic monitoring technologies. The fair value of the potential contingent consideration payments was estimated by applying a probability-weighted expected payment model for the clinical milestone and a Monte Carlo simulation model for the commercial milestone, which were then discounted to present value. The fair value measurements were based on Level 3 inputs. Refer to Note 17 for additional information regarding fair value measurements. The following table summarizes the fair value of consideration transferred: (in millions) Cash consideration transferred $ 197 Contingent consideration 18 Total consideration $ 215 The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash $ 2 Accounts receivable, net 3 Inventories 1 Prepaid expenses and other current assets 1 Property, plant and equipment 1 Goodwill 111 Other intangible assets 131 Operating lease right-of-use assets 1 Accounts payable and other accrued liabilities (4) Other non-current liabilities (32) Total assets acquired and liabilities assumed $ 215 The results of operations of the acquired business have been included in our consolidated statement of income since the date the business was acquired and were not significant. Acquisition and integration costs associated with the acquisition were $3 million in 2019. We allocated $123 million of the total consideration to the developed product rights with a weighted-average useful life of 15 years and $8 million to customer relationships with a useful life of 13 years. The fair values of the intangible assets were determined using the income approach. The discount rates used to measure the intangible assets were 11.0% for developed product rights and 10.0% for customer relationships. We consider the fair value of the intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values. The goodwill, which is not deductible for tax purposes, includes the value of potential future technologies as well as the overall strategic benefits provided to our product portfolio and is included primarily in the Americas segment. RECOTHROM and PREVELEAK On March 16, 2018, we acquired two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction. We concluded that the acquired assets met the definition of a business and accounted for the transaction as a business combination using the acquisition method of accounting. The purchase price included an upfront payment of approximately $163 million in 2018. In addition, the purchase price included new and assumed contingent payments in the future related to inventory and technology transfer milestones and net revenue royalty payments with an estimated fair value of $21 million as of the acquisition date. The maximum aggregate amounts payable for the inventory and technology transfer and net revenue royalties were $7 million, $15 million and $143 million, respectively. The fair value of the potential contingent consideration payments was estimated by applying a probability-weighted expected payment model for the inventory and technology transfer payments and a Monte Carlo simulation model for contingent royalty payments, which were then discounted to present value. The following table summarizes the fair value of consideration transferred: (in millions) Cash consideration transferred $ 163 Contingent consideration 21 Total consideration $ 184 The following table summarizes the fair value of the assets acquired as of the acquisition date: (in millions) Assets acquired Accounts receivable, net $ 2 Inventory 80 Goodwill 2 Other intangible assets 100 Total assets acquired $ 184 The results of operations of the acquired business have been included in our consolidated statement of income since the date the business was acquired. The RECOTHROM and PREVELEAK acquisitions contributed $80 million and $52 million of net sales for the years ended December 31, 2019 and 2018, respectively. Acquisition and integration costs, including incremental cost of sales relating to inventory fair value step-ups, associated with the acquisition were $20 million and $17 million, respectively, in 2019 and 2018. We allocated $100 million of the total consideration to the RECOTHROM and PREVELEAK developed product rights with a weighted-average useful life of 10 years. The fair value of the intangible assets was determined using the income approach. The discount rates used to measure the RECOTHROM and PREVELEAK intangible assets were 12.5% and 13.0%, respectively. We consider the fair value of the intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values. The goodwill, which is deductible for tax purposes, includes the value of potential future technologies as well as the overall strategic benefits provided to our surgical portfolio of hemostats and sealants, and is included in the Americas segment. Saudi Arabia Joint Venture In November 2018, we acquired additional equity to obtain a 51% controlling financial interest of our joint venture in Saudi Arabia that was previously accounted for under the equity method of accounting. The acquisition allows us to increase manufacturing output and utilize the facilities for additional capacity for certain products in the region. Beginning in the fourth quarter of 2018, we consolidated the financial statements of the joint venture with our consolidated financial statements. The results of operations of the joint venture have been included in our consolidated statement of income since the date the business was acquired and were not significant. The guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity interest in an acquiree at its acquisition date fair value and recognize the resulting gain or loss in earnings. Thus, in connection with the acquisition, the carrying amount of our previously held equity interest in the joint venture was remeasured to fair value at the acquisition date, resulting in a gain in the fourth quarter of 2018 of $24 million, which was included in other (income) expense, net in the consolidated statement of income. The fair value of the equity interest on the acquisition date was $39 million and we consider the fair value to be a Level 3 measurement due to the significant estimates and assumptions used by management in establishing the estimated fair value. The following table summarizes the fair value of consideration transferred: (in millions) Consideration transferred Cash $ 2 Fair value of equity investment 39 Noncontrolling interest 39 Total consideration transferred $ 80 The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash $ 4 Accounts receivable, net 25 Inventories 8 Property, plant and equipment 12 Goodwill 17 Other intangible assets 40 Other non-current assets 2 Short-term debt (4) Accounts payable and accrued liabilities (16) Other non-current liabilities (8) Total assets acquired and liabilities assumed $ 80 The goodwill, which is not deductible for tax purposes, includes the value to create a more fully integrated supply chain and go-to-market business model and is included in the EMEA segment. In connection with the acquisition, we reacquired certain license rights which had provided the joint venture with the exclusive and perpetual rights to manufacture and distribute our products for sale in specified territories. Reacquired license rights with fair values totaling $10 million were assigned a useful life of 12 years. Other amortizable intangible assets consist of customer relationships and have a weighted-average estimated useful life of 10 years. The intangible assets were valued using the income approach. The discount rates used to measure the reacquired rights and customer relationship intangible assets were 13.0% and 14.0%, respectively. We consider the fair value of each of the acquired intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values. The fair value of the 49% noncontrolling interest in the joint venture is estimated to be $39 million. The fair value of the noncontrolling interest was estimated using the income approach applied to the projected cash flows of the joint venture. As the joint venture is a private company, the fair value measurement is based on significant inputs that are not observable in the market and thus represents a Level 3 measurement. Claris Injectables Limited On July 27, 2017, we acquired 100 percent of Claris, a wholly owned subsidiary of Claris Lifesciences Limited, for total cash consideration of approximately $629 million, net of cash acquired. Through the acquisition, we added capabilities in production of essential generic injectable medicines, such as anesthesia and analgesics, renal, anti-infectives and critical care in a variety of presentations including bags, vials and ampoules. In the third quarter of 2018, we finalized our valuation of the acquisition date assets acquired and liabilities assumed. The measurement period adjustments in 2018 included a $2 million reduction in property, plant and equipment, a $1 million increase in accounts payable and accrued liabilities and a $2 million increase in other non-current liabilities. These adjustments resulted in a corresponding increase to goodwill of $5 million. The measurement period adjustments did not have a material impact on our results of operations in 2018. The following table summarizes the fair value of the assets acquired and liabilities assumed as of the acquisition date for our acquisition of Claris: (in millions) Assets acquired and liabilities assumed Cash $ 11 Accounts receivable, net 16 Inventories 30 Prepaid expenses and other current assets 16 Property, plant and equipment 130 Goodwill 296 Other intangible assets 280 Other non-current assets 20 Accounts payable and accrued liabilities (23) Other non-current liabilities (136) Total assets acquired and liabilities assumed $ 640 The results of operations of Claris have been included in our consolidated statement of income since the date the business was acquired. The Claris acquisition contributed $140 million and $57 million, respectively, of net sales for the years ended December 31, 2018 and 2017. Acquisition and integration costs associated with the Claris acquisition were $27 million in 2019, $33 million in 2018 and $28 million in 2017, and were primarily included within SG&A in the consolidated statements of income. We allocated $280 million of the total consideration to acquired intangible assets. The acquired intangible assets include $140 million of developed technology with a weighted-average useful life of 8 years and $140 million of IPR&D with an indefinite useful life. For the IPR&D, additional R&D will be required prior to technological feasibility. The fair value of intangible assets was determined using the income approach. The income approach is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset will generate over its remaining useful life, discounted to present value. The discount rates used to measure the developed technology and IPR&D intangible assets were 12.0% and 13.0%, respectively. We consider the fair value of each of the acquired intangible assets to be Level 3 measurements due to the significant estimates and assumptions used by management in establishing the estimated fair values. The goodwill, which is not deductible for tax purposes, includes the value of potential future technologies as well as the overall strategic benefits to us in the injectables market, and is included in the Americas segment. In the first quarter of 2018, we settled certain claims with Claris Lifesciences Limited related to the acquired operations and terminated a development agreement with Dorizoe Lifesciences Limited. As a result, we received cash of $73 million in February 2018 and were released from an accrued liability to Claris Lifesciences Limited of $7 million. The total of $80 million is reflected as a benefit within other operating income, net in the 2018 consolidated statement of income. Other Business Combinations Total consideration transferred for other acquisitions totaled $10 million, $36 million and $16 million in 2019, 2018 and 2017, respectively, and primarily resulted in the recognition of intangible assets. These acquisitions did not materially affect our results of operations. We have not presented pro forma financial information for any of the 2019, 2018 or 2017 acquisitions because their results are not material to our consolidated financial statements. Other Business Development Activities Celerity Pharmaceuticals, LLC In September 2013, we entered into an agreement with Celerity Pharmaceutical, LLC (Celerity) to develop certain acute care generic injectable premix and oncolytic molecules through regulatory approval. We transferred our rights in these molecules to Celerity and Celerity assumed ownership and responsibility for development of the molecules. We are obligated to purchase the individual product rights from Celerity if the products obtain regulatory approval. In 2019, 2018 and 2017, we paid $86 million, $72 million and $20 million, respectively, to acquire the rights to various molecules that have received regulatory approval. The payment in 2018 for one of the molecules was based on tentative approval from the U.S. Food and Drug Administration (FDA). Full approval from FDA was received in the third quarter of 2018. We capitalized the purchase prices of products that were purchased upon regulatory approval as intangible assets and are amortizing the assets over their estimated useful lives of 12 years. As of December 31, 2019, our contingent future payments total up to $79 million upon Celerity’s achievement of specified regulatory approvals. Seprafilm Adhesion Barrier In December 2019, we entered into a definitive agreement to acquire Seprafilm Adhesion Barrier (Seprafilm) from Sanofi. The transaction closed in February 2020 and we paid approximately $345 million for the acquired assets, subject to a post-close adjustment. Seprafilm is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder. As the acquisition was completed after December 31, 2019, our consolidated financial statements do not include the financial condition or results of operations of Seprafilm in any of the periods presented herein. We expect that most of the purchase price will be allocated to intangible assets and we are evaluating whether this transaction will be accounted for as an asset acquisition or a business combination. Other Intangible Acquisitions During the year ended December 31, 2019, we acquired the rights to multiple products for an aggregate purchase price of $80 million. The purchase prices were capitalized primarily as developed-technology intangible assets and are being amortized over a weighted-average useful of 10 years. Net sales related to these products for the year ended December 31, 2019 were not material. In January 2020, we acquired the U.S. rights to an additional product for $60 million. The purchase price will be capitalized as a developed-technology intangible asset in the quarter ending March 31, 2020 and will be amortized over its estimated useful life of 11 years. Other In addition to the significant arrangements described above, we have entered into several other collaborative arrangements. We could make additional payments of up to $26 million upon the achievement of certain development and regulatory milestones, in addition to future payments related to contingent commercialization milestones, profit-sharing and royalties.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	SUPPLEMENTAL FINANCIAL INFORMATION Inventories As Restated as of December 31 (in millions) 2019 2018 Raw materials $ 377 $ 367 Work in process 185 207 Finished goods 1,091 1,093 Inventories $ 1,653 $ 1,667 Prepaid Expenses and Other Current Assets As Restated as of December 31 (in millions) 2019 2018 Prepaid value added taxes $ 140 $ 131 Prepaid income taxes 90 79 Other 389 404 Prepaid expenses and other current assets $ 619 $ 614 Property, Plant and Equipment, Net As Restated as of December 31 (in millions) 2019 2018 Land $ 148 $ 142 Buildings and leasehold improvements 1,761 1,703 Machinery and equipment 6,671 6,423 Equipment with customers 1,489 1,364 Construction in progress 591 701 Total property, plant and equipment, at cost 10,660 10,333 Accumulated depreciation (6,148) (5,803) Property, plant and equipment (PP&E), net $ 4,512 $ 4,530 Purchases of property, plant and equipment included in accounts payable and accrued liabilities as of December 31, 2019 and 2018 was $87 million and $97 million, respectively. Depreciation expense was $606 million in 2019, $602 million in 2018 and $596 million in 2017. Other Non-Current Assets As Restated as of December 31 (in millions) 2019 2018 Deferred tax assets $ 621 $ 483 Non-current receivables, net 163 146 Contract assets 68 30 Investments 76 44 Other 141 116 Other non-current assets $ 1,069 $ 819 Accounts Payable and Accrued Liabilities As Restated as of December 31 (in millions) 2019 2018 Accounts payable $ 892 $ 998 Common stock dividends payable 111 101 Employee compensation and withholdings 456 486 Property, payroll and certain other taxes 113 131 Restructuring reserves 83 90 Accrued rebates 208 193 Operating lease liabilities 101 — Income taxes payable 85 104 Other 640 707 Accounts payable and accrued liabilities $ 2,689 $ 2,810 Other Non-Current Liabilities As Restated as of December 31 (in millions) 2019 2018 Pension and other postretirement benefits $ 1,260 $ 1,087 Deferred tax liabilities 192 215 Long-term tax liabilities 81 77 Interest rate contracts 52 3 Litigation and environmental reserves 30 31 Restructuring reserves 9 11 Other 108 135 Other non-current liabilities $ 1,732 $ 1,559 Interest Expense, net years ended December 31 (in millions) 2019 2018 2017 Interest costs $ 120 $ 105 $ 98 Interest costs capitalized (9) (12) (13) Interest expense 111 93 85 Interest income (40) (48) (30) Interest expense, net $ 71 $ 45 $ 55 Other (Income) Expense, net As Restated years ended December 31 (in millions) 2019 2018 2017 Foreign exchange losses (gains), net $ 37 $ (14) $ 63 Gain on sale of investments (1) (3) (3) Saudi Arabia joint venture gain — (24) — Venezuela deconsolidation — — 33 Pension settlement 755 1 2 Pension and other postretirement benefit plans (53) (49) 31 Other, net (7) 11 7 Other (income) expense, net $ 731 $ (78) $ 133

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS, NET	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The following table is a summary of the activity in goodwill by segment. (in millions) Americas EMEA APAC Total December 31, 2017 (As Restated) $ 2,476 $ 393 $ 233 $ 3,102 Additions 15 17 — $ 32 Currency translation and other adjustments (105) (17) (10) $ (132) December 31, 2018 (As Restated) $ 2,386 $ 393 $ 223 $ 3,002 Additions 101 10 — 111 Currency translation and other adjustments (59) (18) (6) (83) December 31, 2019 $ 2,428 $ 385 $ 217 $ 3,030 As of December 31, 2019, there were no reductions in goodwill relating to impairment losses. Other Intangible Assets, Net The following table is a summary of our other intangible assets. (in millions) Developed technology, Other amortized Indefinite-lived Total December 31, 2019 Gross other intangible assets $ 2,309 $ 464 $ 173 $ 2,946 Accumulated amortization (1,190) (285) — $ (1,475) Other intangible assets, net $ 1,119 $ 179 $ 173 $ 1,471 December 31, 2018 (As Restated) Gross other intangible assets $ 2,135 $ 457 $ 188 $ 2,780 Accumulated amortization (1,117) (253) — $ (1,370) Other intangible assets, net $ 1,018 $ 204 $ 188 $ 1,410 Intangible asset amortization expense was $183 million in 2019, $169 million in 2018, and $154 million in 2017. The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2019 is $188 million in 2020, $184 million in 2021, $179 million in 2022, $167 million in 2023 and $145 million in 2024. In the second quarter of 2019, we recognized a $31 million impairment charge related to a developed-technology intangible asset due to a decline in market expectations for the related product. The fair value of the intangible asset was measured using a discounted cash flow approach and the charge is classified within cost of sales in the accompanying consolidated statement of income for the year ended December 31, 2019. We consider the fair

DEBT, CREDIT FACILITIES AND LEA

DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Debt and Credit Facilities	DEBT AND CREDIT FACILITIES Debt Outstanding At December 31, 2019 and 2018, we had the following debt outstanding: As Restated as of December 31 (in millions) Effective interest rate in 2019 2019 1 2018 1 Variable-rate loan due 2020 1.0 % $ 313 $ 310 1.7% notes due 2021 1.9 % 398 398 2.4% notes due 2022 2.5 % 203 202 0.40% notes due 2024 0.6 % 834 — 1.3% notes due in 2025 1.4 % 669 684 2.6% notes due 2026 2.7 % 746 745 7.65% debentures due 2027 7.7 % 5 5 6.625% debentures due 2028 6.7 % 98 98 1.3% notes due 2029 1.3 % 830 — 6.25% notes due 2037 6.3 % 265 265 3.65% notes due 2042 3.7 % 6 6 4.5% notes due 2043 4.5 % 255 255 3.5% notes due 2046 3.6 % 440 439 Finance leases and other 10.0 % 62 76 Total debt 5,124 3,483 Current portion (315) (2) Long-term portion $ 4,809 $ 3,481 1 Book values include any discounts, premiums and adjustments related to hedging instruments. Significant Debt Issuances In May 2017, we issued €600 million of 1.3% senior notes due May 2025. In May 2019, we issued €750 million of 0.40% senior notes due May 2024 and €750 million of 1.3% senior notes due May 2029. We have designated these debt instruments as net investment hedges of our European operations. Refer to Note 16 for additional information. Credit Facilities In December 2019, we entered into new U.S. and Euro-denominated credit facilities. Our U.S. dollar-denominated revolving credit facility has a capacity of $2.0 billion and our Euro-denominated senior revolving credit facility has a capacity of approximately €200 million. Each of the facilities matures in 2024. As of December 31, 2019, we had €200 million ($224 million) outstanding under our Euro-denominated facility at a 0.91% interest rate and no borrowings outstanding under our U.S. dollar-denominated credit facility. The facilities enable us to borrow funds on an unsecured basis at variable interest rates, and contain various covenants, including a maximum net leverage ratio. Fees under the credit facilities are 0.09% annually as of December 31, 2019 and are based on our credit ratings and the total capacity of the facility. Prior to entering into these new credit facilities, our previous U.S. dollar-denominated revolving credit facility and Euro-denominated senior revolving credit facility had a maximum capacity of $1.5 billion and €200 million, respectively. Fees under these credit facilities were 0.10% annually as of December 31, 2018 and were based on our credit ratings and the total capacity of the facility. There were no borrowings outstanding under these credit facilities as of December 31, 2018. We also maintain other credit arrangements, which totaled approximately $200 million as of December 31, 2019 and 2018, respectively. We had $2 million outstanding under these arrangements as of December 31, 2019 and 2018, respectively. As of December 31, 2019, we were in compliance with the financial covenants in these agreements. The non-performance of any financial institution supporting any of the credit facilities would reduce the maximum capacity of these facilities by each institution’s respective commitment. Future Debt Maturities as of and for the years ended December 31 (in millions) Debt maturities 2020 $ 315 2021 402 2022 207 2023 1 2024 842 Thereafter 3,393 Total obligations and commitments 5,160 Discounts, premiums, and adjustments relating to hedging instruments (36) Total debt $ 5,124

LEASES

LEASES	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	NOTE 8 LEASES Lessee Activity We have entered into operating and finance leases primarily for office, manufacturing and R&D facilities, vehicles and equipment. Our leases have remaining terms from one one Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations and usage-based amounts. For all asset classes, we have elected to apply a practical expedient to account for other services within lease contracts as components of the lease. We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. We classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are operating leases. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. We determine the present value of payments under a lease based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to our adoption of Topic 842, we measured the lease liabilities and right-of-use assets using our incremental borrowing rate as of January 1, 2019. The components of lease cost for the year ended December 31, 2019 were: (in millions) 2019 Operating lease cost $ 121 Finance lease cost Amortization of right-of-use assets 5 Interest on lease liabilities 5 Variable lease cost 89 Lease cost $ 220 The following table contains supplemental cash flow information related to leases for the year ended December 31, 2019: (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 119 Operating cash flows from finance leases 4 Financing cash flows from finance leases 4 Right-of-use operating lease assets obtained in exchange for lease obligations 207 There were no material lease transactions that we entered into but have not yet commenced as of December 31, 2019. Supplemental balance sheet information related to leases as of December 31, 2019 includes: (in millions) December 31, 2019 Operating leases Operating lease right-of-use assets $ 608 Accounts payable and accrued liabilities $ 101 Operating lease liabilities 510 Total operating lease liabilities $ 611 Finance leases Property, plant and equipment, at cost $ 63 Accumulated depreciation (19) Property, plant and equipment, net $ 44 Current maturities of long-term debt and finance lease obligations $ — Long-term debt and finance lease obligations 54 Total finance lease liabilities $ 54 Lease term and discount rates as of December 31, 2019 were: December 31, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.6 % Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611 Maturities of operating and finance lease liabilities as of December 31, 2018 were: As Restated (in millions) Capital Leases Operating Leases 2019 $ 7 $ 123 2020 7 94 2021 8 86 2022 8 72 2023 6 64 Thereafter 88 212 Total minimum lease payments 124 $ 651 Less: imputed interest (62) Present value of lease liabilities $ 62 For the years ended December 31, 2018 and 2017, rent expense was $152 million and $155 million, respectively. Lessor Activity We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, intravenous (IV) fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the year ended December 31, 2019 were: (in millions) 2019 Sales-type lease revenue $ 35 Operating lease revenue 61 Variable lease revenue 85 Total lease revenue $ 181 The components of our net investment in sales-type leases as of December 31, 2019 were: (in millions) 2019 Minimum lease payments $ 110 Unguaranteed residual values 11 Net investment in leases $ 121 Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets: (in millions) December 31, 2019 Accounts receivable, net $ 45 Other non-current assets 76 Total $ 121 Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110
LEASES	NOTE 8 LEASES Lessee Activity We have entered into operating and finance leases primarily for office, manufacturing and R&D facilities, vehicles and equipment. Our leases have remaining terms from one one Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations and usage-based amounts. For all asset classes, we have elected to apply a practical expedient to account for other services within lease contracts as components of the lease. We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. We classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are operating leases. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. We determine the present value of payments under a lease based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to our adoption of Topic 842, we measured the lease liabilities and right-of-use assets using our incremental borrowing rate as of January 1, 2019. The components of lease cost for the year ended December 31, 2019 were: (in millions) 2019 Operating lease cost $ 121 Finance lease cost Amortization of right-of-use assets 5 Interest on lease liabilities 5 Variable lease cost 89 Lease cost $ 220 The following table contains supplemental cash flow information related to leases for the year ended December 31, 2019: (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 119 Operating cash flows from finance leases 4 Financing cash flows from finance leases 4 Right-of-use operating lease assets obtained in exchange for lease obligations 207 There were no material lease transactions that we entered into but have not yet commenced as of December 31, 2019. Supplemental balance sheet information related to leases as of December 31, 2019 includes: (in millions) December 31, 2019 Operating leases Operating lease right-of-use assets $ 608 Accounts payable and accrued liabilities $ 101 Operating lease liabilities 510 Total operating lease liabilities $ 611 Finance leases Property, plant and equipment, at cost $ 63 Accumulated depreciation (19) Property, plant and equipment, net $ 44 Current maturities of long-term debt and finance lease obligations $ — Long-term debt and finance lease obligations 54 Total finance lease liabilities $ 54 Lease term and discount rates as of December 31, 2019 were: December 31, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.6 % Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611 Maturities of operating and finance lease liabilities as of December 31, 2018 were: As Restated (in millions) Capital Leases Operating Leases 2019 $ 7 $ 123 2020 7 94 2021 8 86 2022 8 72 2023 6 64 Thereafter 88 212 Total minimum lease payments 124 $ 651 Less: imputed interest (62) Present value of lease liabilities $ 62 For the years ended December 31, 2018 and 2017, rent expense was $152 million and $155 million, respectively. Lessor Activity We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, intravenous (IV) fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the year ended December 31, 2019 were: (in millions) 2019 Sales-type lease revenue $ 35 Operating lease revenue 61 Variable lease revenue 85 Total lease revenue $ 181 The components of our net investment in sales-type leases as of December 31, 2019 were: (in millions) 2019 Minimum lease payments $ 110 Unguaranteed residual values 11 Net investment in leases $ 121 Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets: (in millions) December 31, 2019 Accounts receivable, net $ 45 Other non-current assets 76 Total $ 121 Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110
LEASES	NOTE 8 LEASES Lessee Activity We have entered into operating and finance leases primarily for office, manufacturing and R&D facilities, vehicles and equipment. Our leases have remaining terms from one one Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations and usage-based amounts. For all asset classes, we have elected to apply a practical expedient to account for other services within lease contracts as components of the lease. We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. We classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are operating leases. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. We determine the present value of payments under a lease based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to our adoption of Topic 842, we measured the lease liabilities and right-of-use assets using our incremental borrowing rate as of January 1, 2019. The components of lease cost for the year ended December 31, 2019 were: (in millions) 2019 Operating lease cost $ 121 Finance lease cost Amortization of right-of-use assets 5 Interest on lease liabilities 5 Variable lease cost 89 Lease cost $ 220 The following table contains supplemental cash flow information related to leases for the year ended December 31, 2019: (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 119 Operating cash flows from finance leases 4 Financing cash flows from finance leases 4 Right-of-use operating lease assets obtained in exchange for lease obligations 207 There were no material lease transactions that we entered into but have not yet commenced as of December 31, 2019. Supplemental balance sheet information related to leases as of December 31, 2019 includes: (in millions) December 31, 2019 Operating leases Operating lease right-of-use assets $ 608 Accounts payable and accrued liabilities $ 101 Operating lease liabilities 510 Total operating lease liabilities $ 611 Finance leases Property, plant and equipment, at cost $ 63 Accumulated depreciation (19) Property, plant and equipment, net $ 44 Current maturities of long-term debt and finance lease obligations $ — Long-term debt and finance lease obligations 54 Total finance lease liabilities $ 54 Lease term and discount rates as of December 31, 2019 were: December 31, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.6 % Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611 Maturities of operating and finance lease liabilities as of December 31, 2018 were: As Restated (in millions) Capital Leases Operating Leases 2019 $ 7 $ 123 2020 7 94 2021 8 86 2022 8 72 2023 6 64 Thereafter 88 212 Total minimum lease payments 124 $ 651 Less: imputed interest (62) Present value of lease liabilities $ 62 For the years ended December 31, 2018 and 2017, rent expense was $152 million and $155 million, respectively. Lessor Activity We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, intravenous (IV) fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the year ended December 31, 2019 were: (in millions) 2019 Sales-type lease revenue $ 35 Operating lease revenue 61 Variable lease revenue 85 Total lease revenue $ 181 The components of our net investment in sales-type leases as of December 31, 2019 were: (in millions) 2019 Minimum lease payments $ 110 Unguaranteed residual values 11 Net investment in leases $ 121 Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets: (in millions) December 31, 2019 Accounts receivable, net $ 45 Other non-current assets 76 Total $ 121 Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110
LEASES	NOTE 8 LEASES Lessee Activity We have entered into operating and finance leases primarily for office, manufacturing and R&D facilities, vehicles and equipment. Our leases have remaining terms from one one Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations and usage-based amounts. For all asset classes, we have elected to apply a practical expedient to account for other services within lease contracts as components of the lease. We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. We classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are operating leases. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. We determine the present value of payments under a lease based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. For operating leases that commenced prior to our adoption of Topic 842, we measured the lease liabilities and right-of-use assets using our incremental borrowing rate as of January 1, 2019. The components of lease cost for the year ended December 31, 2019 were: (in millions) 2019 Operating lease cost $ 121 Finance lease cost Amortization of right-of-use assets 5 Interest on lease liabilities 5 Variable lease cost 89 Lease cost $ 220 The following table contains supplemental cash flow information related to leases for the year ended December 31, 2019: (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 119 Operating cash flows from finance leases 4 Financing cash flows from finance leases 4 Right-of-use operating lease assets obtained in exchange for lease obligations 207 There were no material lease transactions that we entered into but have not yet commenced as of December 31, 2019. Supplemental balance sheet information related to leases as of December 31, 2019 includes: (in millions) December 31, 2019 Operating leases Operating lease right-of-use assets $ 608 Accounts payable and accrued liabilities $ 101 Operating lease liabilities 510 Total operating lease liabilities $ 611 Finance leases Property, plant and equipment, at cost $ 63 Accumulated depreciation (19) Property, plant and equipment, net $ 44 Current maturities of long-term debt and finance lease obligations $ — Long-term debt and finance lease obligations 54 Total finance lease liabilities $ 54 Lease term and discount rates as of December 31, 2019 were: December 31, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.6 % Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611 Maturities of operating and finance lease liabilities as of December 31, 2018 were: As Restated (in millions) Capital Leases Operating Leases 2019 $ 7 $ 123 2020 7 94 2021 8 86 2022 8 72 2023 6 64 Thereafter 88 212 Total minimum lease payments 124 $ 651 Less: imputed interest (62) Present value of lease liabilities $ 62 For the years ended December 31, 2018 and 2017, rent expense was $152 million and $155 million, respectively. Lessor Activity We lease medical equipment, such as renal dialysis equipment and infusion pumps, to customers, primarily in conjunction with arrangements to provide consumable medical products such as dialysis therapies, intravenous (IV) fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices. The components of lease revenue for the year ended December 31, 2019 were: (in millions) 2019 Sales-type lease revenue $ 35 Operating lease revenue 61 Variable lease revenue 85 Total lease revenue $ 181 The components of our net investment in sales-type leases as of December 31, 2019 were: (in millions) 2019 Minimum lease payments $ 110 Unguaranteed residual values 11 Net investment in leases $ 121 Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets: (in millions) December 31, 2019 Accounts receivable, net $ 45 Other non-current assets 76 Total $ 121 Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Refer to Note 4 for information regarding our unfunded contingent payments associated with collaborative and other arrangements. Indemnifications During the normal course of business, we make indemnities, commitments and guarantees pursuant to which we may be required to make payments related to specific transactions. Indemnifications include: (i) intellectual property indemnities to customers in connection with the use, sales or license of products and services; (ii) indemnities to customers in connection with losses incurred while performing services on their premises; (iii) indemnities to vendors and service providers pertaining to claims based on negligence or willful misconduct; (iv) indemnities involving the representations and warranties in certain contracts; (v) contractual indemnities related to the separation and distribution as set forth in certain of the agreements entered into in connection with such transactions (including the separation and distribution agreement and the tax matters agreement with Baxalta); and (vi) contractual indemnities for our directors and certain of our executive officers for services provided to or at the request of us. In addition, under our Amended and Restated Certificate of Incorporation, and consistent with Delaware General Corporation Law, we have agreed to indemnify our directors and officers for certain losses and expenses upon the occurrence of certain prescribed events. The majority of these indemnities, commitments and guarantees do not provide for any limitation on the maximum potential for future payments that we could be obligated to make. To help address some of these risks, we maintain various insurance coverages. Based on historical experience and evaluation of the agreements, we do not believe that any payments related to our indemnities will have a material impact on our financial condition or results of operations. Legal Contingencies We are involved in product liability, patent, commercial, and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of December 31, 2019 and 2018, our total recorded reserves with respect to legal and environmental matters were $56 million and $46 million, respectively, and there were no related receivables. We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any reporting period could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims. In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on our operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. Environmental We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from the Superfund cases noted above, we are involved in an ongoing voluntary environmental remediation associated with historic operations at our Irvine, California, United States, facility. In 2017, we recorded a pre-tax charge of $15 million related to a former location and included that charge within loss from discontinued operations, net of tax, on the consolidated statement of income. As of December 31, 2019 and 2018, our environmental reserves, which are measured on an undiscounted basis, were $18 million and $19 million, respectively. After considering these reserves, management is of the opinion that the outcome of these matters will not have a material adverse effect on our financial position or results of operations. General litigation In November 2016, a purported antitrust class action complaint seeking monetary and injunctive relief was filed in the United States District Court for the Northern District of Illinois. The complaint alleges a conspiracy among manufacturers of IV solutions to restrict output and affect pricing in connection with a shortage of such solutions. Similar parallel actions subsequently were filed. In January 2017, a single consolidated complaint covering these matters was filed in the Northern District of Illinois. We filed a motion to dismiss the consolidated complaint in February 2017. The court granted our motion to dismiss the consolidated complaint without prejudice in July 2018. The plaintiffs filed an amended complaint on September 6, 2018. We filed a motion to dismiss the amended complaint on November 9, 2018. In April 2017, we became aware of a criminal investigation by the U.S. Department of Justice (DOJ), Antitrust Division and a federal grand jury in the United States District Court for the Eastern District of Pennsylvania. We and an employee received subpoenas seeking production of documents and testimony regarding the manufacturing, selling, pricing and shortages of IV solutions and containers (including saline solutions and certain other injectable medicines sold by us) and communications with competitors regarding the same. On November 30, 2018, the DOJ notified us that it had closed the investigation. The New York Attorney General has also requested that we provide information regarding business practices in the IV saline industry. We are cooperating with the New York Attorney General. In August 2019, we were named in an amended complaint filed by Fayette County, Georgia in the MDL In re: National Prescription Opiate Litigation pending in the U.S. District Court, Northern District of Ohio. The complaint alleges that multiple manufacturers and distributors of opiate products improperly marketed and diverted these products, which caused harm to Fayette County. The complaint is limited in its allegations as to Baxter and does not distinguish between injectable opiate products and orally administered opiates. We manufactured generic injectable opiate products in our facility in Cherry Hill, NJ, which we divested in 2011. In November 2019, we and certain of our officers were named in a class action complaint captioned Ethan E. Silverman et al. v. Baxter International Inc. et al. that was filed in the United States District Court for the Northern District of Illinois. The plaintiff, who allegedly purchased shares of our common stock during the specified class period, filed this putative class action on behalf of himself and shareholders who acquired Baxter common stock between February 21, 2019 and October 23, 2019. The plaintiff alleges that we and certain officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder by making allegedly false and misleading statements and failing to disclose material facts relating to certain intra-company transactions undertaken for the purpose of generating foreign exchange gains or avoiding foreign exchange losses, as well as our internal controls over financial reporting. On January 29, 2020, the Court appointed Varma Mutual Pension Insurance Company and Louisiana Municipal Police Employees Retirement System as lead plaintiffs in the case. In addition, we have received a stockholder request for inspection of our books and records in connection with the announcement made in our Form 8-K on October 24, 2019 that we had commenced an internal investigation into certain intra-company transactions that impacted our previously reported non-operating foreign exchange gains and losses. As initially disclosed on October 24, 2019, we also voluntarily advised the staff of the SEC of our previously disclosed internal investigation and we are continuing to cooperate with the staff of the SEC. In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize certain of our products. The plaintiffs seek damages, including compensatory and punitive damages in an unspecified amount, and unspecified injunctive and declaratory relief. Other As previously disclosed, in 2008 we recalled our heparin sodium injection products in the United States. Following the recall, more than 1,000 lawsuits alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities, were filed. In January 2019, the last of these cases was settled. In 2019, following the resolution of an insurance dispute, we received cash proceeds of $39 million for our allocation of the insurance proceeds under a settlement and cost-sharing agreement related to the defense of the heparin product liability cases. We recognized a $37 million gain in connection with the resolution of the dispute with the insurer that is classified within other operating income, net on the consolidated statement of income for the year ended December 31, 2019. In September 2017, Hurricane Maria caused damage to certain of our assets in Puerto Rico and disrupted operations. Insurance, less applicable deductibles and subject to any coverage exclusions, covered the repair or replacement of our assets that suffered loss or damage, and also provided coverage for interruption to our business, including lost profits, and reimbursement for other expenses and costs that have been incurred relating to the damages and losses suffered. In 2017, we recorded $32 million of pre-tax charges related to damages caused by the hurricane, including $11 million related to the impairment of damaged inventory and fixed assets as well as $21 million of idle facility and other costs. These amounts were recorded as a component of cost of sales in the consolidated statement of income for year ended December 31, 2017. In 2019 and 2018, we recognized $100 million and $42 million, respectively, of insurance recoveries related to the previously mentioned asset impairments and idle facility and other costs suffered as a result of the hurricane. These benefits were recorded as a reduction of cost of sales and within other operating income, net on the consolidated statements of income for the years ended December 31, 2019 and 2018. No further insurance recoveries are expected.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock-Based Compensation Our stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share units (PSUs) and purchases under our employee stock purchase plan. Shares issued relating to our stock-based plans are generally issued out of treasury stock. As of December 31, 2019, approximately 24 million authorized shares are available for future awards under our stock-based compensation plans. Stock Compensation Expense Stock compensation expense was $122 million, $115 million and $107 million in 2019, 2018 and 2017, respectively. The related tax benefit recognized was $70 million in 2019, $61 million in 2018 and $87 million in 2017. Included in the benefit in 2019, 2018 and 2017 were realized excess tax benefits for stock-based compensation of $54 million, $40 million and $56 million, respectively. Stock compensation expense is recorded at the corporate level and is not allocated to the segments. Approximately 80% of stock compensation expense is classified in SG&A expenses, with the remainder classified in cost of sales and R&D expenses. Costs capitalized in the consolidated balance sheets at December 31, 2019 and 2018 were not material. Stock compensation expense is based on awards expected to vest, and therefore has been reduced by estimated forfeitures. Stock Options Stock options are granted to employees and non-employee directors with exercise prices equal to 100% of the market value on the date of grant. Stock options granted to employees generally vest in one-third increments over a three six The fair value of stock options is determined using the Black-Scholes model. The weighted-average assumptions used in estimating the fair value of stock options granted during each year, along with the weighted-average grant-date fair values, were as follows: years ended December 31 2019 2018 2017 Expected volatility 19 % 18 % 19 % Expected life (in years) 5.5 5.5 5.5 Risk-free interest rate 2.5 % 2.6 % 2.1 % Dividend yield 1.0 % 1.0 % 1.0 % Fair value per stock option $ 15 $ 13 $ 10 The following table summarizes stock option activity for the year ended December 31, 2019 and the outstanding stock options as of December 31, 2019. (options and aggregate intrinsic values in thousands) Options Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 25,314 $ 43.76 Granted 3,801 $ 75.03 Exercised (8,043) $ 38.52 Forfeited (596) $ 66.91 Expired (132) $ 46.44 Outstanding as of December 31, 2019 20,344 $ 50.99 6.1 $ 663,620 Vested or expected to vest as of December 31, 2019 20,029 $ 50.66 6.0 $ 660,342 Exercisable as of December 31, 2019 12,945 $ 41.74 4.9 $ 542,128 The aggregate intrinsic value in the table above represents the difference between the exercise price and our closing stock price on the last trading day of the year. The total intrinsic value of options exercised in 2019, 2018 and 2017 was $272 million, $222 million and $203 million, respectively. As of December 31, 2019, $55 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. RSUs RSUs are granted to employees and non-employee directors. RSUs granted to employees generally vest in one-third increments over a three six value of RSUs is determined based on the number of shares granted and the closing price of our common stock on the date of grant. The following table summarizes nonvested RSU activity for the year ended December 31, 2019. (share units in thousands) Share units Weighted- Nonvested RSUs as of January 1, 2019 1,611 $ 56.45 Granted 537 $ 75.60 Vested (740) $ 51.82 Forfeited (134) $ 63.90 Nonvested RSUs as of December 31, 2019 1,274 $ 66.46 As of December 31, 2019, $46 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. The weighted-average grant-date fair value of RSUs granted in 2019, 2018 and 2017 was $75.60, $67.11 and $55.11, respectively. The fair value of RSUs vested in 2019, 2018 and 2017 was $57 million, $69 million and $88 million, respectively. PSUs Our annual equity awards stock compensation program for senior management includes the issuance of PSUs based on adjusted operating margin as well as stock performance relative to our peer group. Fifty percent of the PSUs granted in 2015 were based on return on invested capital (ROIC) instead of adjusted operating margin. The vesting condition for adjusted operating margin or ROIC PSUs is set at the beginning of the year for each tranche of the award during the 3-year service period. Compensation cost for the adjusted operating margin or ROIC PSUs is measured based on the fair value of the awards on the date that the specific vesting terms for each tranche of the award are established. The fair value of the awards is determined based on the quoted price of our stock on the grant date for each tranche of the award. The compensation cost for adjusted operating margin or ROIC PSUs is adjusted at each reporting date to reflect the estimated vesting outcome. The fair value for PSUs based on stock performance relative to our peer group is determined using a Monte Carlo model. The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows: years ended December 31 2019 2018 2017 Baxter volatility 19 % 19 % 19 % Peer group volatility 18%-113% 16%-53% 16%-54% Correlation of returns 0.13-0.63 0.16-0.61 0.19-0.58 Risk-free interest rate 2.5 % 2.3 % 1.6 % Fair value per PSU $ 106 $ 90 $ 69 Unrecognized compensation cost related to all unvested PSUs of $18 million at December 31, 2019 is expected to be recognized as expense over a weighted-average period of 1.6 years. The following table summarizes nonvested PSU activity for the year ended December 31, 2019. (share units in thousands) Share units Weighted- Nonvested PSUs as of January 1, 2019 913 $ 63.88 Granted 626 $ 69.36 Vested (559) $ 46.47 Forfeited (50) $ 77.70 Nonvested PSUs as of December 31, 2019 930 $ 75.50 Employee Stock Purchase Plan Nearly all employees are eligible to participate in our employee stock purchase plan. The employee purchase price is 85% of the closing market price on the purchase date. The Baxter International Inc. Employee Stock Purchase Plan provides for 10 million shares of common stock available for issuance to eligible participants, of which approximately three million shares were available for future purchases as of December 31, 2019. During 2019, 2018, and 2017, we issued approximately 0.7 million, 0.8 million and 0.8 million shares, respectively, under the employee stock purchase plan. Cash Dividends Total cash dividends declared per share for 2019, 2018, and 2017 were $0.85, $0.73 and $0.61, respectively. A quarterly dividend of $0.19 per share ($0.76 on an annualized basis) was declared in February 2019 and was paid in April 2019. Quarterly dividends of $0.22 per share ($0.88 on an annualized basis) were declared in May and July of 2019 and were paid in July and October of 2019, respectively. Our Board of Directors declared a quarterly dividend of $0.22 per share in November of 2019, which was paid in January of 2020. Stock Repurchase Programs As authorized by the Board of Directors, we repurchase our stock depending on our cash flows, net debt level and market conditions. In July 2012, the Board of Directors authorized the repurchase of up to $2.0 billion of our common stock. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018 and by an additional $2.0 billion in November 2018. We repurchased 16.5 million shares under this authority pursuant to Rule 10b5-1 plans and otherwise for $1.3 billion in cash in 2019, 35.8 million shares under this authority pursuant to Rule 10b5-1 plans and otherwise for $2.5 billion in cash in 2018 and 9.2 million shares under this authority pursuant to Rule 10b5-1 plans for $564 million in cash in 2017. As of December 31, 2018, we recognized a liability within accounts payable and accrued liabilities of $23 million for share repurchases that settled in early January 2019. We had $897 million of purchase authority available as of December 31, 2019. Accelerated Share Repurchase Agreement In December 2018, we entered into a $300 million accelerated share repurchase agreement (ASR Agreement) with an investment bank. We funded the ASR Agreement with available cash. The ASR Agreement was executed pursuant to the 2012 Repurchase Authorization described above. Under the ASR Agreement, we received 3.6 million shares upon execution. Based on the volume-weighted average price of our common stock during the term of the ASR Agreement, we received an additional 0.6 million shares from the investment bank at settlement on May 7, 2019.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive income includes all changes in stockholders’ equity that do not arise from transactions with stockholders, and consists of net income, CTA, certain gains and losses from other postretirement benefit (OPEB) plans, gains and losses on cash flow hedges and, prior to 2018, unrealized gains and losses on available-for-sale equity securities. As a result of changes in accounting guidance related to available-for-sale equity securities, the unrealized gains and losses associated with these assets are no longer recognized in AOCI beginning January 1, 2018. The following table is a net-of-tax summary of the changes in AOCI by component for the years ended December 31, 2019 and 2018. (in millions) CTA Pension and OPEB plans Hedging Total Gains (losses) Balance as of December 31, 2018 (as restated) $ (2,868) $ (954) $ (1) $ (3,823) Adoption of new accounting standard 9 (169) (1) (161) Other comprehensive (loss) income before reclassifications (95) (184) (36) (315) Amounts reclassified from AOCI (a) — 592 (3) 589 Net other comprehensive (loss) income (95) 408 (39) 274 Balance as of December 31, 2019 $ (2,954) $ (715) $ (41) $ (3,710) As Restated (in millions) CTA Pension and OPEB plans Hedging Available-for- Total Gains (losses) Balance as of December 31, 2017 $ (2,545) $ (987) $ (10) $ 3 $ (3,539) Adoption of new accounting standard — — — (3) (3) Other comprehensive income (loss) before reclassifications (323) (23) (1) — (347) Amounts reclassified from AOCI (a) — 56 10 — 66 Net other comprehensive (loss) income (323) 33 9 — (281) Balance as of December 31, 2018 $ (2,868) $ (954) $ (1) $ — $ (3,823) (a) See table below for details about these reclassifications. The following table is a summary of the amounts reclassified from AOCI to net income during the years ended December 31, 2019 and 2018. Amounts reclassified from AOCI (a) As Restated (in millions) 2019 2018 Location of impact Pension and OPEB items Amortization of net losses and prior service costs or credits $ (31) $ (69) Other (income) expense, net Settlement charge (755) (1) Other (income) expense, net (786) (70) Total before tax Less: Tax effect 194 14 Income tax expense $ (592) $ (56) Net of tax Gains (losses) on hedging activities Foreign exchange contracts $ 4 $ (12) Cost of sales Less: Tax effect (1) 2 Income tax expense $ 3 $ (10) Net of tax Total reclassification for the period $ (589) $ (66) Total net of tax (a) Amounts in parentheses indicate reductions to net income. Refer to Note 13 for additional information regarding the amortization of pension and OPEB items and Note 16 for additional information regarding hedging activity.

BUSINESS OPTIMIZATION CHARGES

BUSINESS OPTIMIZATION CHARGES	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
BUSINESS OPTIMIZATION CHARGES	BUSINESS OPTIMIZATION CHARGES In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. From the commencement of our business optimization activities through December 31, 2019, we have incurred cumulative pre-tax costs of approximately $980 million related to these actions. The costs consisted primarily of employee termination, implementation costs, asset impairments and accelerated depreciation. We currently expect to incur additional pre-tax cash costs of approximately $50 million through the completion of these initiatives under our current program. These costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. To the extent further cost savings opportunities are identified, we may incur additional business optimization expenses. We recorded the following charges related to business optimization programs in 2019, 2018, and 2017: years ended December 31 (in millions) 2019 2018 2017 Restructuring charges $ 134 $ 117 $ 70 Costs to implement business optimization programs 45 94 89 Accelerated depreciation 5 9 10 Total business optimization charges $ 184 $ 220 $ 169 For segment reporting, business optimization charges are unallocated expenses. Costs to implement business optimization programs for the years ended December 31, 2019, 2018 and 2017, consisted primarily of external consulting and transition costs, including employee compensation and related costs. The costs were generally included within cost of sales, SG&A expense and R&D expense. For the years ended December 31, 2019, 2018 and 2017, we recognized accelerated depreciation, primarily associated with facilities to be closed. The costs were recorded within cost of sales and SG&A expense. During the years ended December 31, 2019, 2018 and 2017, we recorded the following restructuring charges: 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 13 $ 37 $ 25 $ 75 Contract termination and other costs 10 1 — 11 Asset impairments 37 2 9 48 Total restructuring charges $ 60 $ 40 $ 34 $ 134 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 30 $ 51 $ 19 $ 100 Contract termination and other costs 4 6 — 10 Asset impairments 1 6 — 7 Total restructuring charges $ 35 $ 63 $ 19 $ 117 2017 (in millions) COGS SG&A R&D Total Employee termination costs $ 22 $ 39 $ (2) $ 59 Contract termination and other costs — 5 — 5 Asset impairments 5 1 — 6 Total restructuring charges $ 27 $ 45 $ (2) $ 70 The following table summarizes activity in the liability related to our restructuring initiatives. (in millions) Liability balance as of December 31, 2016 (As Restated) $ 164 Charges 83 Payments (140) Reserve adjustments (19) Currency translation 24 Liability balance as of December 31, 2017 (As Restated) 112 Charges 126 Payments (96) Reserve adjustments (16) Currency translation (25) Liability balance as of December 31, 2018 (As Restated) 101 Charges 113 Payments (93) Reserve adjustments (27) Currency translation (2) Liability balance as of December 31, 2019 $ 92 Reserve adjustments primarily relate to employee termination cost reserves established in prior periods. Substantially all of our restructuring liabilities as of December 31, 2019 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2020.

RETIREMENT AND OTHER BENEFIT PR

RETIREMENT AND OTHER BENEFIT PROGRAMS	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
RETIREMENT AND OTHER BENEFIT PROGRAMS	PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS We sponsor a number of qualified and nonqualified pension plans for eligible employees. We also sponsor certain unfunded contributory healthcare and life insurance benefits for substantially all domestic retired employees. Newly hired employees in the United States and Puerto Rico are not eligible to participate in the pension plans but receive a higher level of company contributions in the defined contribution plans. Reconciliation of Pension and Other Postretirement Benefit Plan Obligations, Assets and Funded Status The benefit plan information in the table below pertains to all of our pension and OPEB plans, both in the United States and in other countries. Pension benefits OPEB As Restated as of and for the years ended December 31 (in millions) 2019 2018 2019 2018 Benefit obligations Beginning of period $ 5,635 $ 6,182 $ 211 $ 235 Service cost 74 87 1 1 Interest cost 172 178 8 7 Participant contributions 4 5 — — Actuarial (gain) loss 924 (431) 26 (14) Benefit payments (267) (259) (18) (18) Settlements (2,550) (6) — — Curtailment (13) (56) — — Foreign exchange and other (6) (65) — — End of period 3,973 5,635 228 211 Fair value of plan assets Beginning of period 4,774 5,261 — — Actual return on plan assets 939 (237) — — Employer contributions 69 51 18 18 Participant contributions 4 5 — — Benefit payments (267) (259) (18) (18) Settlements (2,550) (6) — — Foreign exchange and other 4 (41) — — End of period 2,973 4,774 — — Funded status at December 31 $ (1,000) $ (861) $ (228) $ (211) Amounts recognized in the consolidated balance sheets Noncurrent asset $ 77 $ 60 $ — $ — Current liability (25) (25) (20) (20) Noncurrent liability (1,052) (896) (208) (191) Net liability recognized at December 31 $ (1,000) $ (861) $ (228) $ (211) The pension obligation information in the table above represents the projected benefit obligation (PBO). The PBO incorporates assumptions relating to future compensation levels. The accumulated benefit obligation (ABO) is the same as the PBO except that it includes no assumptions relating to future compensation levels. The ABO for all of our pension plans was $3.7 billion and $5.4 billion at the 2019 and 2018 measurement dates, respectively. The information in the funded status table above represents the totals for all of our pension plans. The following table is information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets. As Restated as of December 31 (in millions) 2019 2018 ABO $ 3,240 $ 4,981 Fair value of plan assets $ 2,339 $ 4,246 The following table presents information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets (many of which also have an ABO in excess of assets and are therefore also included in the table directly above). As Restated as of December 31 (in millions) 2019 2018 PBO $ 3,688 $ 5,386 Fair value of plan assets $ 2,611 $ 4,465 Expected Net Pension and OPEB Plan Payments for the Next 10 Years (in millions) Pension benefits OPEB 2020 $ 86 $ 20 2021 104 18 2022 118 17 2023 132 17 2024 149 16 2024 through 2028 917 71 Total expected net benefit payments for next 10 years $ 1,506 $ 159 The expected net benefit payments above reflect the total net benefits expected to be paid from the plans’ assets (for funded plans) or from our assets (for unfunded plans). The federal subsidies relating to the Medicare Prescription Drug, Improvement and Modernization Act are not expected to be significant. Amounts Recognized in AOCI The pension and OPEB plans’ gains or losses, prior service costs or credits, and transition assets or obligations not yet recognized in net periodic benefit cost are recognized on a net-of-tax basis in AOCI and will be amortized from AOCI to net periodic benefit cost in the future. For active employees, we utilize the average future working lifetime as the amortization period for prior service. For inactive employees, we utilize the average remaining life expectancy as the amortization period for prior service. The following table is a summary of the pre-tax losses included in AOCI at December 31, 2019 and December 31, 2018. (in millions) Pension benefits OPEB Actuarial loss (gain) $ 1,025 $ (41) Prior service credit and transition obligation (9) (59) Total pre-tax loss recognized in AOCI at December 31, 2019 $ 1,016 $ (100) Actuarial loss (gain) $ 1,607 $ (79) Prior service credit and transition obligation (10) (74) Total pre-tax loss (gain) recognized in AOCI at December 31, 2018 (As Restated) $ 1,597 $ (153) Refer to Note 11 for the net-of-tax balances included in AOCI as of each of the year-end dates. The following table is a summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans. As Restated Year ended December 31 (in millions) 2019 2018 2017 Gain (loss) arising during the year, net of tax expense (benefit) of $(64) in 2019, $(4) in 2018 and $25 in 2017 $ (184) $ (22) $ 32 Amortization of loss to earnings, net of tax benefit of $6 in 2019, $14 in 2018 and $35 in 2017 25 55 102 Settlement charge, net of tax benefit of $188 in 2019 $ 567 $ — $ — Pension and other employee benefits gain $ 408 $ 33 $ 134 In 2019, OCI activity for pension and OPEB plans was primarily related to the U.S. pension settlement charge, further discussed below, and actuarial gains and losses. In 2018 and 2017, OCI activity for pension and OPEB plans was primarily related to actuarial gains and losses. Amounts Expected to be Amortized from AOCI to Net Periodic Benefit Cost in 2020 With respect to the AOCI balance at December 31, 2019, the following table is a summary of the pre-tax amounts expected to be amortized to net periodic benefit cost in 2020. (in millions) Pension benefits OPEB Actuarial loss/(gain) $ 78 $ (4) Prior service credit and transition obligation (1) (14) Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2020 $ 77 $ (18) Net Periodic Benefit Cost – Continuing Operations As Restated Year ended December 31 (in millions) 2019 2018 2017 Pension benefits Service cost $ 74 $ 87 $ 91 Interest cost 172 178 180 Expected return on plan assets (264) (303) (291) Amortization of net losses and other deferred amounts 58 94 163 Settlement charges 755 1 2 Other — — (2) Net periodic pension benefit cost $ 795 $ 57 $ 143 OPEB Service cost $ 1 $ 1 $ 1 Interest cost 8 7 7 Amortization of net losses and prior service credit (27) (25) (26) Net periodic OPEB cost $ (18) $ (17) $ (18) Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date Pension benefits OPEB 2019 2018 2019 2018 Discount rate U.S. and Puerto Rico plans 3.44 % 4.31 % 3.16 % 4.20 % International plans 1.34 % 2.02 % n/a n/a Rate of compensation increase U.S. and Puerto Rico plans 3.68 % 3.66 % n/a n/a International plans 3.03 % 3.08 % n/a n/a Annual rate of increase in the per-capita cost n/a n/a 6.75 % 7.00 % Rate decreased to n/a n/a 5.00 % 5.00 % by the year ended n/a n/a 2027 2027 The assumptions above, which were used in calculating the December 31, 2019 measurement date benefit obligations, will be used in the calculation of net periodic benefit cost in 2020. Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost Pension benefits OPEB 2019 2018 2017 2019 2018 2017 Discount rate U.S. and Puerto Rico plans 4.18 % 3.60 % 4.09 % 4.20 % 3.51 % 3.89 % International plans 2.02 % 2.02 % 2.03 % n/a n/a n/a Expected return on plan assets U.S. and Puerto Rico plans 6.29 % 6.25 % 6.50 % n/a n/a n/a International plans 5.45 % 5.58 % 5.77 % n/a n/a n/a Rate of compensation increase U.S. and Puerto Rico plans 3.66 % 3.42 % 3.75 % n/a n/a n/a International plans 3.08 % 3.05 % 3.11 % n/a n/a n/a Annual rate of increase in the per-capita cost n/a n/a n/a 6.75 % 7.00 % 6.25 % Rate decreased to n/a n/a n/a 5.00 % 5.00 % 5.00 % by the year ended n/a n/a n/a 2027 2027 2023 We established the expected return on plan assets assumption primarily based on a review of historical compound average asset returns, both company-specific and relating to the broad market (based on our asset allocation), as well as an analysis of current market and economic information and future expectations. We plan to use a 6.50% assumption for our U.S. and Puerto Rico plans for 2020. Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and revised mortality rates). Actuarial losses in 2019 and gains in 2018 related to plan benefit obligations were primarily the result of changes in discount rates. Effect of a One-Percent Change in Assumed Healthcare Cost Trend Rate on the OPEB Plan The effect of a one-percent change in the assumed healthcare cost trend rate on the service and interest cost components of OPEB cost as well as the OPEB obligation were not significant for 2019 or 2018, respectively. Pension Plan Assets An investment committee of members of senior management is responsible for supervising, monitoring and evaluating the invested assets of our funded pension plans. The investment committee, which meets at least quarterly, abides by documented policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, and other relevant factors and considerations. The investment committee’s policies and procedures include the following: • Ability to pay all benefits when due; • Targeted long-term performance expectations relative to applicable market indices, such as Russell, MSCI EAFE, and other indices; • Targeted asset allocation percentage ranges (summarized below), and periodic reviews of these allocations; • Diversification of assets among third-party investment managers, and by geography, industry, stage of business cycle and other measures; • Specified investment holding and transaction prohibitions (for example, private placements or other restricted securities, securities that are not traded in a sufficiently active market, short sales, certain derivatives, commodities and margin transactions); • Specified portfolio percentage limits on holdings in a single corporate or other entity (generally 5% at time of purchase, except for holdings in U.S. government or agency securities); • Specified average credit quality for the fixed-income securities portfolio (at least A- by Standard & Poor’s or A3 by Moody’s); • Specified portfolio percentage limits on foreign holdings; and • Periodic monitoring of investment manager performance and adherence to the investment committee’s policies. Plan assets are invested using a total return investment approach whereby a mix of equity securities, debt securities and other investments are used to preserve asset values, diversify risk and exceed the planned benchmark investment return. Investment strategies and asset allocations are based on consideration of plan liabilities, the plans’ funded status and other factors, such as the plans’ demographics and liability durations. Investment performance is reviewed by the investment committee on a quarterly basis and asset allocations are reviewed at least annually. Plan assets are managed in a balanced portfolio comprised of two major components: return-seeking investments and liability hedging investments. The target allocations for plan assets are 53% in return-seeking investments and 47% in liability hedging investments and other holdings. The documented policy includes an allocation range based on each individual investment type within the major components that allows for a variance from the target allocations depending on the investment type. Return-seeking investments primarily include common stock of U.S. and international companies, common/collective trust funds, mutual funds, hedge funds, and partnership investments. Liability hedging investments and other holdings primarily include cash, money market funds with an original maturity of three months or less, U.S. and foreign government and governmental agency issues, corporate bonds, municipal securities, derivative contracts and asset-backed securities. While the investment committee provides oversight over plan assets for U.S. and international plans, the summary above is specific to the plans in the United States. The plan assets for international plans are managed and allocated by the entities in each country, with input and oversight provided by the investment committee. The plan assets for the U.S. and international plans are included in the table below. The following tables summarize our pension plan financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance at December 31, 2019 Quoted prices Significant Significant Measured at NAV Assets Fixed income securities Cash and cash equivalents $ 224 $ 72 $ 152 $ — $ — U.S. government and government agency issues 452 — 452 — — Corporate bonds 352 — 352 — — Equity securities Common stock: Large cap 231 231 — — — Mid cap 158 158 — — — Small cap 37 37 — — — Total common stock 426 426 — — — Mutual funds 442 189 253 — — Common/collective trust funds 668 19 272 — 377 Partnership investments 333 — — — 333 Other holdings 76 8 58 10 — Collateral held on loaned securities 9 — 9 — — Liabilities Collateral to be paid on loaned securities (9) (9) — — — Fair value of pension plan assets $ 2,973 $ 705 $ 1,548 $ 10 $ 710 As Restated Basis of fair value measurement (in millions) Balance at December 31, 2018 Quoted prices Significant Significant Measured at NAV Assets Fixed income securities Cash and cash equivalents $ 145 $ 21 $ 124 $ — $ — U.S. government and government agency issues 735 — 735 — — Corporate bonds 1,127 — 1,127 — — Equity securities Common stock: Large cap 541 541 — — — Mid cap 298 298 — — — Small cap 91 91 — — — Total common stock 930 930 — — — Mutual funds 356 135 221 — — Common/collective trust funds 919 — 210 — 709 Partnership investments 390 — — — 390 Other holdings 172 11 151 10 — Collateral held on loaned securities 196 — 196 — — Liabilities Collateral to be paid on loaned securities (196) (34) (162) — — Fair value of pension plan assets $ 4,774 $ 1,063 $ 2,602 $ 10 $ 1,099 The following table is a reconciliation of changes in fair value measurements that used significant unobservable inputs (Level 3). (in millions) Total Common/collective Other Balance at December 31, 2017 $ 18 $ 8 $ 10 Transfers out (8) (8) — Balance at December 31, 2018 10 — 10 Purchases — — — Balance at December 31, 2019 $ 10 $ — $ 10 The assets and liabilities of our pension plans are valued using the following valuation methods: Investment category Valuation methodology Cash and cash equivalents These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value U.S. government and government agency issues Values are based on reputable pricing vendors, who typically use pricing matrices or models that use observable inputs Corporate bonds Values are based on reputable pricing vendors, who typically use pricing matrices or models that use observable inputs Common stock Values are based on the closing prices on the valuation date in an active market on national and international stock exchanges Mutual funds Values are based on the net asset value of the units held in the respective fund which are obtained from national and international exchanges or based on the net asset value of the underlying assets of the fund provided by the fund manager Common/collective trust funds Values are based on the net asset value of the units held at year end Partnership investments Values are based on the net asset value of the participation by us in the investment as determined by the general partner or investment manager of the respective partnership Other holdings The value of these assets vary by investment type, but primarily are determined by reputable pricing vendors, who use pricing matrices or models that use observable inputs Collateral held on loaned securities Values are based on the net asset value per unit of the fund in which the collateral is invested Collateral to be paid on loaned securities Values are based on the fair value of the underlying securities loaned on the valuation date Expected Pension and OPEB Plan Funding Our funding policy for our pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that we may determine to be appropriate considering the funded status of the plans, tax deductibility, the cash flows generated by us, and other factors. Volatility in the global financial markets could have an unfavorable impact on future funding requirements. We have no obligation to fund our principal plans in the United States in 2020. We continually reassess the amount and timing of any discretionary contributions. In 2020, we expect to make contributions of at least $5 million to our Puerto Rico pension plan and $41 million to our foreign pension plans. We expect to have net cash outflows relating to our OPEB plan of approximately $20 million in 2020. The following table details the funded status percentage of our pension plans as of December 31, 2019, including certain plans that are unfunded in accordance with the guidelines of our funding policy outlined above. United States and Puerto Rico International as of December 31, 2019 (in millions) Qualified Nonqualified Funded Unfunded Total Fair value of plan assets $ 2,060 n/a $ 913 n/a $ 2,973 PBO 2,278 $ 243 1,001 $ 451 3,973 Funded status percentage 90 % n/a 91 % n/a 75 % Pension Annuitization As part of our continued effort to reduce pension plan obligations, we transferred approximately $2.4 billion of U.S. qualified pension plan liabilities to an insurance company through the purchase of a group annuity contract in October 2019. As a result of this transaction, we recognized a non-cash pretax pension settlement charge of $755 million in the fourth quarter of 2019. Pension Plan Amendments and Other Events In January 2018, we announced changes to our U.S. pension plans. We spun off the assets and liabilities of the qualified plan attributable to current employees into a new plan and will freeze the pay and service amounts used to calculate pension benefits for active participants in the U.S. pension plans as of December 31, 2022. The assets and liabilities attributable to retired and former company employees remained with the original qualified plan. Years of additional service earned and eligible compensation received after December 31, 2022 will not be included in the determination of the benefits payable to participants. These changes resulted in a $57 million decline in the PBO upon the effective date of the changes. As a result of these changes, net periodic pension and OPEB expense decreased in 2019 and 2018. U.S. Defined Contribution Plan Most U.S. employees are eligible to participate in a qualified defined contribution plan. We recognized expense of $53 million in 2019, $50 million in 2018 and $45 million in 2017 related to contributions to this plan.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income from Continuing Operations Before Income Tax Expense by Category As Restated years ended December 31 (in millions) 2019 2018 2017 United States $ (586) $ 7 $ (320) International 1,556 1,610 1,420 Income from continuing operations before income taxes $ 970 $ 1,617 $ 1,100 Income Tax Expense Related to Continuing Operations As Restated years ended December 31 (in millions) 2019 2018 2017 Current United States Federal $ 8 $ 21 $ 8 State and local 3 (1) 11 International 258 308 261 Current income tax expense 269 328 280 Deferred United States Federal (140) (228) 230 State and local (29) — 1 International (141) (35) (20) Deferred income tax expense (benefit) (310) (263) 211 Income tax expense (benefit) $ (41) $ 65 $ 491 Deferred Tax Assets and Liabilities As Restated as of December 31 (in millions) 2019 2018 Deferred tax assets Accrued liabilities and other $ 209 $ 227 Pension and other postretirement benefits 258 222 Tax credit and net operating loss carryforwards 928 862 Swiss tax reform net asset basis step-up 159 — Operating lease liabilities 153 — Valuation allowances (420) (310) Total deferred tax assets 1,287 1,001 Deferred tax liabilities Subsidiaries’ unremitted earnings 57 43 Long-lived assets and other 649 690 Operating lease right-of-use assets 152 — Total deferred tax liabilities 858 733 Net deferred tax asset $ 429 $ 268 At December 31, 2019, we had U.S. state operating loss carryforwards totaling $1.1 billion, U.S. federal operating loss carryforwards totaling $58 million and tax credit carryforwards totaling $410 million, which includes a U.S. foreign tax credit carryforward of $395 million. The U.S. federal and state operating loss carryforwards expire between 2020 and 2038 and the tax credits expire between 2020 and 2038. At December 31, 2019, with respect to our operations outside the U.S., we had foreign operating loss carryforwards totaling $1.3 billion and foreign tax credit carryforwards totaling $49 million. The foreign operating loss carryforwards expire between 2020 and 2031 with $814 million having no expiration date. The foreign tax credits expire between 2021 and 2027 with $48 million having no expiration date. Realization of these operating loss and tax credit carryforwards depends on generating sufficient future earnings. A valuation allowance of $420 million and $310 million was recognized as of December 31, 2019 and 2018, respectively, to reduce the deferred tax assets associated with net operating loss and tax credit carryforwards because we do not believe it is more likely than not that these assets will be fully realized prior to expiration. After evaluating the 2017 Tax Act and related U.S. Treasury Regulations, any elections or other opportunities that may be available, and the future expiration of certain U.S. tax provisions that will impact the utilization of our U.S. foreign tax credit carryforwards, management expects to be able to realize some, but not all, of the U.S. foreign tax credit deferred tax assets up to its overall domestic loss balance plus other recurring and non-recurring foreign inclusions. Therefore, a valuation allowance of $180 million and $175 million was recognized with respect to the foreign tax credit carryforwards as of December 31, 2019 and 2018, respectively. We will continue to evaluate the need for additional valuation allowances and, as circumstances change, the valuation allowance may change. As a result of Swiss tax reform legislation enacted during 2019, we recognized an $863 million net asset basis step-up that is amortizable as a tax deduction ratably over tax years 2025 through 2029. The net asset basis step-up resulted in a $159 million deferred tax asset. We expect to realize some, but not all, of the Swiss deferred tax assets based principally on expected future earnings generated by the Swiss subsidiary during the period in which the tax basis will be amortized. Therefore, a valuation allowance of $69 million was recognized on the Swiss deferred tax assets as of December 31, 2019, resulting in a net deferred tax benefit of $90 million for the year ended December 31, 2019. Income Tax Expense (Benefit) Reconciliation As Restated years ended December 31 (in millions) 2019 2018 2017 Income tax expense at U.S. statutory rate $ 204 $ 340 $ 383 Tax incentives (140) (161) (139) State and local taxes, net of federal benefit (17) 5 (6) Impact of foreign taxes 65 122 (41) Swiss tax reform net asset basis step-up (159) — — Deferred tax revaluation due to 2017 Tax Act and foreign tax reform (19) (8) (283) Transition tax due to 2017 Tax Act (16) (5) 529 U.S. valuation allowance due to 2017 Tax Act — (194) 339 Other valuation allowances 110 21 (6) Stock compensation windfall tax benefits (54) (40) (56) Foreign tax credits — — (246) Research and development tax credits (13) (17) (5) Other, net (2) 2 22 Income tax expense (benefit) $ (41) $ 65 $ 491 In the above reconciliation, the 2017 income tax expense associated with deferred tax revaluation, the transition tax and the U.S. valuation allowance, all of which result directly or indirectly from the enactment of the 2017 Tax Act, included, or were, provisional amounts. In 2018, we completed our one-year measurement period adjustments to the 2017 Tax Act provisional amounts in accordance with SAB 118. In addition, the tax impact of non-deductible corrections of misstatements related to foreign exchange gains and losses for the years ended December 31, 2018 and 2017 is included above within the impact of foreign taxes. The 2017 Tax Act reduced the U.S. statutory tax rate from 35% to 21% for years after 2017. Accordingly, upon its enactment in 2017, we remeasured our deferred tax assets and liabilities as of December 31, 2017 to reflect the reduced rate that will apply in future periods when these deferred taxes are settled or realized. We recognized a SAB 118 provisional deferred tax benefit of $283 million to reflect the reduced U.S. tax rate and other effects of the 2017 Tax Act. In 2018, we collected all of the necessary data to complete our analysis of the effect of the 2017 Tax Act on the remeasurement of the underlying deferred taxes and recognized an additional deferred tax benefit of $8 million. The 2017 Tax Act requires us to pay U.S. income taxes on accumulated foreign subsidiary earnings not previously subject to U.S. income tax at a rate of 15.5% to the extent of foreign cash and certain other net current assets and 8% on the remaining earnings. We recognized a $529 million provisional charge in 2017 for that one-time transitional tax, the majority of which was non-cash. This charge was inclusive of relevant non-U.S. withholding taxes and U.S. state income taxes on the portion of the earnings expected to be repatriated. In 2018, after further study of the 2017 Tax Act and related U.S. Treasury Regulations, and further analysis of historical earnings and profits and tax pools, as well as refinements of the cash portion of the charge, which was provisional due to certain foreign subsidiaries with non-calendar tax year-ends, we reduced our one-time transitional tax expense by $5 million. Additionally, the 2017 Tax Act changed the rules that enabled taxpayers to generate foreign source income related to export sales that were eligible to utilize foreign tax credits. Consequently, we did not believe in 2017 that it would be more likely than not that we would be able to utilize our existing foreign tax credit deferred tax assets within the applicable carryforward periods. As such, a provisional $339 million U.S. valuation allowance was recognized in respect of our foreign tax credit deferred tax assets in accordance with SAB118. After studying the 2017 Tax Act and related U.S. Treasury Regulations and evaluating any elections or other opportunities that may be available, we currently expect to be able to realize some, but not all, of the foreign tax credit deferred tax assets up to our overall domestic loss (ODL) balance plus recurring and non-recurring foreign inclusions. Accordingly, we reduced our provisional foreign tax credit deferred tax asset valuation allowance and recognized a 2018 benefit of $194 million. Our tax provisions for 2019 and 2018 do not include any tax charges related to either the Base Erosion and Anti-Abuse Tax (BEAT) or Global Intangible Low Taxed Income (GILTI) provisions, except for the inability to fully utilize foreign tax credits against such GILTI. While we are not expecting to be subject to a tax charge under the 2017 Tax Act GILTI provisions in the near term, our accounting policy is to recognize this charge as a period cost. The enactment of the 2017 Tax Act created a territorial tax system that allows companies to repatriate certain foreign earnings without incurring additional U.S. federal tax by providing for a 100% dividend exemption. Under the dividend-exemption provision, 100% of the foreign-source portion of dividends paid by certain foreign corporations to a U.S. corporate stockholder are exempt from U.S. federal taxation. As a result of the U.S. change to a territorial tax system and the incurrence of the one-time transition tax charge, we plan to repatriate our foreign earnings that were previously considered indefinitely reinvested with the exception of approximately $192 million of accumulated earnings as of December 31, 2019 related to one of our foreign operations. Additional withholding taxes of $19 million would be incurred if such earnings were remitted currently. In 2019, Switzerland and India enacted tax reform legislation that had a material impact on our effective tax rate. We recognized a deferred tax benefit of $90 million to reflect a tax basis step-up, net of a valuation allowance, partially offset by a $5 million deferred tax revaluation to reflect an increase in the statutory tax rate, under the newly enacted Swiss tax laws. We also recognized a net deferred tax benefit of $24 million associated with deferred tax revaluation in India to reflect a decrease in the statutory tax rate. Our effective tax rate was also favorably impacted by $57 million in 2019 related to a notional interest deduction on the share capital of a foreign subsidiary. The gross tax benefit of the deduction is included in the table above within impact of foreign taxes and the portion not expected to be realized is included within other valuation allowances. Unrecognized Tax Benefits We classify interest and penalties associated with income taxes in income tax expense (benefit) within the consolidated statements of income. Net interest and penalties recognized were not significant during 2019, 2018 and 2017. The liability recognized related to interest and penalties was $21 million and $22 million as of December 31, 2019 and 2018, respectively. The total amount of gross unrecognized tax benefits that, if recognized, would impact the effective tax rate are $70 million, $84 million and $88 million as of December 31, 2019, 2018 and 2017, respectively. The following table is a reconciliation of our unrecognized tax benefits, including those related to discontinued operations, for the years ended December 31, 2019, 2018 and 2017. as of and for the years ended (in millions) 2019 2018 2017 Balance at beginning of the year $ 127 $ 108 $ 82 Increase associated with tax positions taken during the current year 8 33 33 Increase (decrease) associated with tax positions taken during a prior year (3) 13 2 Settlements (20) (5) (6) Decrease associated with lapses in statutes of limitations (1) (22) (3) Balance at end of the year $ 111 $ 127 $ 108 Of the gross unrecognized tax benefits, $62 million and $68 million were recognized as liabilities in the consolidated balance sheets as of December 31, 2019 and 2018, respectively. We have recognized net indemnification receivables from Baxalta in the amount of $6 million, $6 million and $13 million as of December 31, 2019, 2018 and 2017, respectively, related to the unrecognized tax benefits for which we are the primary obligor but economically relate to Baxalta operations. Tax Incentives We have received tax incentives in Puerto Rico, Switzerland, Dominican Republic, Costa Rica and certain other tax jurisdictions outside the United States. The financial impact of the reductions as compared to the statutory tax rates is indicated in the income tax expense reconciliation table above. The tax reductions as compared to the local statutory rate favorably impacted earnings per diluted share from continuing operations by $0.27 in 2019, $0.29 in 2018, and $0.25 in 2017. The above grants provide that our manufacturing operations are and will be partially exempt from local taxes with varying expirations from 2025 to 2027. Examinations of Tax Returns As of December 31, 2019, we had ongoing audits in the United States, Germany, Sweden, Belgium and other jurisdictions. During 2019, Baxter obtained a settlement in a transfer pricing Competent Authority proceeding, covering the period from 2009 through 2013, between the U.S. and Switzerland. Tax years 2009 and forward remain under examination by the IRS while additional Competent Authority proceedings take place. We believe that it is reasonably possible that our gross unrecognized tax benefits will be reduced within the next 12 months by $27 million. While the final outcome of these matters is inherently uncertain, we believe we have made adequate tax provisions for all years subject to examination.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The numerator for both basic and diluted earnings per share (EPS) is either net income, income from continuing operations, or loss from discontinued operations. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted EPS using the treasury stock method. The following table is a reconciliation of income from continuing operations to net income attributable to Baxter stockholders. years ended December 31(in millions) 2019 2018 2017 Income from continuing operations $ 1,011 $ 1,552 $ 609 Less: Income from continuing operations attributable to noncontrolling interests $ 10 $ — $ — Income from continuing operations attributable to Baxter stockholders $ 1,001 $ 1,552 $ 609 Loss from discontinued operations attributable to Baxter stockholders $ — $ (6) $ (7) Net income attributable to Baxter stockholders $ 1,001 $ 1,546 $ 602 The following table is a reconciliation of basic shares to diluted shares. years ended December 31(in millions) 2019 2018 2017 Basic shares 509 534 543 Effect of dilutive securities 10 12 12 Diluted shares 519 546 555 The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 4 million, 3 million, and 2 million equity awards in 2019, 2018, and 2017, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 10 for additional information regarding items impacting basic shares.

FINANCIAL INSTRUMENTS, DERIVATI

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	FINANCIAL INSTRUMENTS, DERIVATIVES AND HEDGING ACTIVITIES Accounts Receivable Sales For accounts receivable originated in Japan, we have entered into agreements with financial institutions in which the entire interest in and ownership of the receivable is sold. We continue to service the receivables in this arrangement. Servicing assets or liabilities are not recognized because we receive adequate compensation to service the sold receivables. The Japanese arrangement includes limited recourse provisions, which are not material. The following is a summary of the activity relating to the arrangement. As Restated as of and for the years ended December 31 (in millions) 2019 2018 2017 Sold receivables at beginning of year $ 69 $ 70 $ 67 Proceeds from sales of receivables $ 292 $ 267 $ 270 Cash collections (remitted to the owners of the receivables) $ (282) $ (270) $ (270) Effect of foreign exchange rate changes $ — $ 2 $ 3 Sold receivables at end of year $ 79 $ 69 $ 70 The net losses relating to the sales of accounts receivable were immaterial for each year. Concentrations of Credit Risk We invest excess cash in certificates of deposit or money market funds and diversify the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, we have diversified our selection of counterparties, and have arranged collateralization and master-netting agreements to minimize the risk of loss. Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Global economic conditions, governmental actions and customer-specific factors may require us to re-evaluate the collectability of our receivables and we could potentially incur additional credit losses. These conditions may also impact the stability of the Euro. Foreign Currency and Interest Rate Risk Management We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs. We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, British Pound, Chinese Yuan, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures. We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using a mix of fixed- and floating-rate debt that we believe is appropriate. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features. Cash Flow Hedges We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. The notional amounts of foreign exchange contracts designated as cash flow hedges were $617 million and $706 million as of December 31, 2019 and 2018, respectively. The maximum term over which we have cash flow hedge contracts in place related to forecasted transactions at December 31, 2019 is 12 months for foreign exchange contracts. The total notional amounts of interest rate contracts designated as cash flow hedges were $550 million and $150 million as of December 31, 2019 and 2018, respectively. The interest rate contracts have maturity dates in 2022 and hedge the variability in future benchmark interest payments attributable to changes in interest rates on the forecasted issuance of fixed-rate debt. Fair Value Hedges We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. There were no outstanding interest rate contracts designated as fair value hedges as of December 31, 2019 and 2018. Net Investment Hedges In May 2017, we issued €600 million of senior notes due May 2025. In May 2019, we issued €750 million of senior notes due May 2024 and €750 million of senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances are recorded as a component of AOCI. As of December 31, 2019, we had an accumulated pre-tax unrealized translation loss in AOCI of $21 million related to the Euro-denominated senior notes. In May 2019, we entered into forward contracts designated as net investment hedges to reduce exposure to changes in currency rates on €1.2 billion of our net investment in our European operations. Those hedges were entered into in advance of the issuance of our senior notes mentioned above, were settled in the second quarter of 2019 and resulted in an insignificant loss. Dedesignations If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. There were no cash flow hedge dedesignations in 2019, 2018 or 2017 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated in 2019 or 2017. In 2018, we terminated our interest rate fair value hedges and the cumulative fair value adjustment to the hedged item was insignificant. If we terminate a net investment hedge, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In 2019, we dedesignated €1.2 billion of forward contracts designated as a net investment hedge of our European operations. There were no net investment hedge dedesignations in 2018 or 2017. Undesignated Derivative Instruments We use forward contracts to hedge foreign exchange gains and losses relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month. The total notional amount of undesignated derivative instruments was $619 million and $487 million as of December 31, 2019 and 2018, respectively. Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments The following table summarizes the income statement locations and gains and losses on our hedging instruments for the years ended December 31, 2019, 2018, and 2017. (in millions) Gain (loss) Location of gain Gain (loss) reclassified from As Restated 2019 2018 2017 2019 2018 2017 Cash flow hedges Interest rate contracts $ (37) $ (3) $ (3) Interest expense, net $ — $ — $ — Foreign exchange contracts (9) 3 (24) Cost of sales 4 (12) (8) Net investment hedges 12 32 (65) Other (income) expense, net — — — Total $ (34) $ 32 $ (92) $ 4 $ (12) $ (8) Location of gain (loss) in Gain (loss) recognized As Restated (in millions) 2019 2018 2017 Fair value hedges Interest rate contracts Interest expense, net $ — $ (4) $ (3) Undesignated derivative instruments Foreign exchange contracts Other (income) expense, net $ (17) $ — $ (37) For our fair value hedges, equal and offsetting gains of $4 million and $3 million were recognized in interest expense, net as an adjustment to the underlying hedged items, fixed-rate debt, in 2018 and 2017, respectively. The following table summarizes net-of-tax activity in AOCI, a component of stockholders’ equity, related to our cash flow hedges. as of and for the year ended December 31 (in millions) 2019 2018 2017 Accumulated other comprehensive income (loss) balance at beginning of year $ (1) $ (10) $ 3 Adoption of new accounting standard (1) — — (Loss) gain in fair value of derivatives during the year (36) (1) (18) Amount reclassified to earnings during the year (3) 10 5 Accumulated other comprehensive income (loss) balance at end of year $ (41) $ (1) $ (10) As of December 31, 2019, $6 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. Derivative Assets and Liabilities The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2019. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ 10 Other non-current liabilities $ 52 Foreign exchange contracts Prepaid expenses and other current assets 10 Accounts payable and — Foreign exchange contracts Other non-current assets — Other non-current liabilities — Total derivative instruments designated as hedges 20 52 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other current assets 1 Accounts payable and 2 Total derivative instruments $ 21 $ 54 The following table summarizes the classification and fair values of derivative instruments reported in the consolidated balance sheet as of December 31, 2018. Derivatives in asset positions Derivatives in liability positions As Restated As Restated (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current $ 3 Foreign exchange contracts Prepaid expenses and other current assets 22 Accounts payable and 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 23 4 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other current assets 2 Accounts payable and 2 Total derivative instruments $ 25 $ 6 While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives. The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. December 31, 2019 December 31, 2018 As Restated (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheets $ 21 $ 54 $ 25 $ 6 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheets (11) (11) (3) (3) Total $ 10 $ 43 $ 22 $ 3 The following table presents the amounts recorded on the consolidated balance sheets related to fair value hedges: Carrying amount of hedged item Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a) (in millions) Balance as of December 31, 2019 Balance as of December 31, 2018 Balance as of December 31, 2019 Balance as of December 31, 2018 Long-term debt $ 103 $ 103 $ 6 $ 7 (a) These fair value hedges were terminated prior to December 31, 2018.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The fair value hierarchy under the accounting standard for fair value measurements consists of the following three levels: • Level 1 — Quoted prices in active markets that we have the ability to access for identical assets or liabilities; • Level 2 — Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuations in which all significant inputs are observable in the market; and • Level 3 — Valuations using significant inputs that are unobservable in the market and include the use of judgment by management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance as of December 31, Quoted prices Significant Significant Assets Foreign exchange contracts $ 11 $ — $ 11 $ — Interest rate contracts 10 — 10 — Marketable equity securities 3 3 — — Total $ 24 $ 3 $ 21 $ — Liabilities Foreign exchange contracts $ 2 $ — $ 2 $ — Interest rate contracts 52 — 52 — Contingent payments related to acquisitions 39 — — 39 Total $ 93 $ — $ 54 $ 39 As Restated Basis of fair value measurement (in millions) Balance as of December 31, Quoted prices Significant Significant Assets Foreign exchange contracts $ 25 $ — $ 25 $ — Marketable equity securities 3 3 — — Total $ 28 $ 3 $ 25 $ — Liabilities Foreign exchange contracts $ 3 $ — $ 3 $ — Interest rate contracts 3 — 3 — Contingent payments related to acquisitions 32 — — 32 Total $ 38 $ — $ 6 $ 32 As of December 31, 2019 and 2018, cash and cash equivalents of $3.3 billion and $1.8 billion, respectively, included money market and other short-term funds of approximately $1.7 billion and $169 million, respectively, which are considered Level 2 in the fair value hierarchy. For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility. Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques. The fair value of milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated. The following table is a reconciliation of our recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions. as of and for the years ended December 31 (in millions) 2019 2018 Fair value at beginning of period $ 32 $ 9 Additions 18 24 Change in fair value recognized in earnings (4) — Payments (7) (1) Fair value at end of period $ 39 $ 32 Equity investments not measured at fair value are comprised of other equity investments without readily determinable fair values and were $73 million and $41 million at December 31, 2019 and 2018, respectively. These amounts are included in Other non-current assets. Fair Values of Financial Instruments Not Measured at Fair Value In addition to the financial instruments that we are required to recognize at fair value in the consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the consolidated balance sheets and the estimated fair values. Book values Fair values(a) As Restated As Restated as of December 31 (in millions) 2019 2018 2019 2018 Liabilities Short-term debt $ 226 $ 2 $ 226 $ 2 Current maturities of long-term debt and finance lease obligations 315 2 315 2 Long-term debt and finance lease obligations 4,809 3,481 5,156 3,469 (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs. The carrying value of short-term debt approximates its fair value due to the short-term maturities of the obligations. The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments approximate their fair values due to the short-term maturities of most of those assets and liabilities.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We manage our business based on three geographical segments: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia Pacific). Our segments provide a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. We use operating income on a segment basis to make resource allocation decisions and assess the ongoing performance of our business segments. Intersegment sales are eliminated in consolidation. Certain items are maintained at Corporate and are not allocated to a segment. They primarily include the majority of foreign currency hedging activities, corporate headquarters costs, certain R&D costs, certain GBU support costs, stock compensation expense, certain employee benefit plan costs, and certain gains, losses, and other charges (such as business optimization, acquisition and integration costs, intangible asset amortization and asset impairments). Our chief operating decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Financial information for our segments is as follows: As Restated for the years ended December 31 (in millions) 2019 2018 2017 Net sales: Americas $ 6,094 $ 5,951 $ 5,718 EMEA 2,968 2,946 2,752 APAC 2,300 2,202 2,114 Total net sales $ 11,362 $ 11,099 $ 10,584 Operating income: Americas $ 2,374 $ 2,411 $ 2,238 EMEA 652 666 562 APAC 549 532 510 Total segment operating income $ 3,575 $ 3,609 $ 3,310 Depreciation Expense: Americas $ 255 $ 229 $ 231 EMEA 149 158 149 APAC 85 95 84 Corporate and other 117 120 132 Total depreciation expense $ 606 $ 602 $ 596 Capital expenditures: Americas $ 325 $ 296 $ 269 EMEA 143 140 141 APAC 98 122 95 Corporate and other 120 134 101 Total capital expenditures $ 686 $ 692 $ 606 The following table is a reconciliation of segment operating income to income from continuing operations before income taxes per the consolidated statements of income. As Restated for the years ended December 31 (in millions) 2019 2018 2017 Total segment operating income $ 3,575 $ 3,609 $ 3,310 Corporate and other (1,803) (2,025) (2,022) Total operating income 1,772 1,584 1,288 Net interest expense 71 45 55 Other (income) expense, net 731 (78) 133 Income from continuing operations before income taxes $ 970 $ 1,617 $ 1,100 Geographic information As Restated for the years ended December 31 (in millions) 2019 2018 2017 Net sales: United States $ 4,826 $ 4,723 $ 4,510 Latin America and Canada 1,268 1,228 1,208 Total Americas $ 6,094 $ 5,951 $ 5,718 EMEA 2,968 2,946 2,752 APAC 2,300 2,202 2,114 Total net sales $ 11,362 $ 11,099 $ 10,584 As Restated as of December 31 (in millions) 2019 2018 PP&E and operating lease right-of-use assets, net: United States $ 1,889 $ 1,786 EMEA 1,447 1,204 APAC 959 892 Latin America and Canada 825 648 Consolidated PP&E and operating lease right-of-use assets, net $ 5,120 $ 4,530

QUARTERLY FINANCIAL DATA (UNAUD

QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY FINANCIAL DATA (UNAUDITED)	QUARTERLY FINANCIAL DATA (UNAUDITED) As Restated years ended December 31 (in millions, except per share data) First quarter Second quarter Third quarter Fourth quarter¹ Full year 2019 Net sales $ 2,638 $ 2,834 $ 2,851 $ 3,039 $ 11,362 Gross margin 1,080 1,153 1,230 1,298 4,761 Net income (loss) attributable to Baxter stockholders 342 313 369 (23) 1,001 Earnings (loss) per share Basic 0.67 0.61 0.72 (0.05) 1.97 Diluted 0.66 0.60 0.71 (0.05) 1.93 Cash dividends declared per share 0.190 0.220 0.220 0.220 0.850 Market price per share High 81.31 82.41 89.78 88.45 89.78 Low 64.48 73.44 81.40 76.70 64.48 As Restated As Restated First quarter Second quarter Third quarter Fourth quarter Full year 2018 Net sales $ 2,692 $ 2,813 $ 2,761 $ 2,833 $ 11,099 Gross margin 1,121 1,223 1,232 1,183 4,759 Income from continuing operations 382 341 518 311 1,552 Earnings per share from continuing operations Basic 0.71 0.64 0.97 0.59 2.91 Diluted 0.69 0.62 0.95 0.58 2.84 Loss from discontinued operations, net of tax — — — (6) (6) Loss per share from discontinued operations Basic — — — (0.01) (0.01) Diluted — — — (0.01) (0.01) Net income 382 341 518 305 1,546 Earnings per share Basic 0.71 0.64 0.97 0.58 2.90 Diluted 0.69 0.62 0.95 0.57 2.83 Cash dividends declared per share 0.160 0.190 0.190 0.190 0.730 Market price per share High 72.26 75.41 77.75 77.80 77.80 Low 62.56 63.43 70.71 61.45 61.45 ¹Results for the fourth quarter and full year of 2019 include a $755 million pre-tax charge related to the annuitization of a portion of our U.S. pension plan. We are presenting herein restated unaudited condensed consolidated financial information for each quarterly and year-to-date interim period within the six months ended June 30, 2019 and the year ended December 31, 2018, except for the three and nine months ended September 30, 2018. See Note 2, Restatement of Previously Issued Consolidated Financial Statements , for additional information and refer to our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, filed on March 17, 2020, for information about the restatement of our unaudited interim financial statements for the three and nine months ended September 30, 2018. The amounts as previously reported for the quarters ended June 30, 2019 and March 31, 2019 were derived from our Quarterly Reports on Form 10-Q filed on July 30, 2019 and May 8, 2019, respectively. The amounts as previously reported for the quarter ended December 31, 2018 were derived from our Annual Report on Form 10-K for the year ended December 31, 2018 filed on February 21, 2019. The amounts as previously reported as of September 30, 2018 and for the quarters and year-to-date interim periods ended June 30, 2018 and March 31, 2018 were derived from our Quarterly Reports on Form 10-Q filed on November 5, 2018, August 6, 2018 and May 9, 2018, respectively. See Note 2, Restatement of Previously Issued Consolidated Financial Statements , for a description of the misstatements in each category of restatements referenced by (a) through (g). Baxter International Inc. Condensed Consolidated Balance Sheets (in millions, except per share) As Restated June 30, March 31, Current assets: Cash and cash equivalents $ 2,934 $ 1,902 Accounts receivable, net 1,897 1,801 Inventories 1,756 1,743 Prepaid expenses and other current assets 642 614 Total current assets 7,229 6,060 Property, plant and equipment, net 4,485 4,476 Goodwill 2,937 2,929 Other intangible assets, net 1,363 1,440 Operating lease right-of-use assets 595 513 Other non-current assets 894 823 Total assets $ 17,503 $ 16,241 Current liabilities: Short-term debt $ 2 $ 796 Current maturities of long-term debt and finance lease obligations 2 2 Accounts payable and accrued liabilities 2,553 2,478 Total current liabilities 2,557 3,276 Long-term debt and finance lease obligations 5,157 3,451 Operating lease liabilities 496 417 Other non-current liabilities 1,490 1,504 Total liabilities 9,700 8,648 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares at June 30, 2019 and March 31, 2019 683 683 Common stock in treasury, at cost, 173,275,586 shares at June 30, 2019 and 173,447,198 shares at March 31, 2019 (10,322) (10,284) Additional contributed capital 5,906 5,839 Retained earnings 15,598 15,414 Accumulated other comprehensive (loss) income (4,086) (4,082) Total Baxter stockholders’ equity 7,779 7,570 Noncontrolling interests 24 23 Total equity 7,803 7,593 Total liabilities and equity $ 17,503 $ 16,241 Baxter International Inc. Condensed Consolidated Balance Sheets (in millions, except per share) As Restated September 30, June 30, March 31, Current assets: Cash and cash equivalents $ 2,863 $ 2,858 $ 2,949 Accounts receivable, net 1,837 1,789 1,818 Inventories 1,716 1,616 1,578 Prepaid expenses and other current assets 615 621 610 Total current assets 7,031 6,884 6,955 Property, plant and equipment, net 4,476 4,486 4,576 Goodwill 2,978 2,981 3,103 Other intangible assets, net 1,400 1,424 1,505 Other non-current assets 918 744 704 Total assets $ 16,803 $ 16,519 $ 16,843 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ 3 $ 3 Accounts payable and accrued liabilities 2,660 2,583 2,598 Total current liabilities 2,663 2,586 2,601 Long-term debt and finance lease obligations 3,480 3,491 3,550 Other non-current liabilities 1,570 1,612 1,630 Total liabilities 7,713 7,689 7,781 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares at September 30, 2018, June 30, 2018 and March 31, 2018 683 683 683 Common stock in treasury, at cost, 150,213,621 shares at September 30, 2018, 148,485,202 shares at June 30, 2018 and 146,993,164 shares at March 31, 2018 (8,639) (8,485) (8,354) Additional contributed capital 5,931 5,916 5,912 Retained earnings 14,886 14,484 14,254 Accumulated other comprehensive (loss) income (3,754) (3,756) (3,427) Total Baxter stockholders’ equity 9,107 8,842 9,068 Noncontrolling interests (17) (12) (6) Total equity 9,090 8,830 9,062 Total liabilities and equity $ 16,803 $ 16,519 $ 16,843 Baxter International Inc. Condensed Consolidated Statements of Income (in millions, except per share) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net sales $ 5,472 $ 2,834 $ 2,638 Cost of sales 3,239 1,681 1,558 Gross margin 2,233 1,153 1,080 Selling, general and administrative expenses 1,242 641 601 Research and development expenses 295 166 129 Other operating income, net (37) (4) (33) Operating income 733 350 383 Interest expense, net 38 20 18 Other (income) expense, net (17) 4 (21) Income before income taxes 712 326 386 Income tax expense 57 13 44 Net income $ 655 $ 313 $ 342 Earnings per share Basic $ 1.28 $ 0.61 $ 0.67 Diluted $ 1.26 $ 0.60 $ 0.66 Weighted-average number of shares outstanding Basic 511 510 512 Diluted 520 519 522 Baxter International Inc. Condensed Consolidated Statements of Income (in millions, except per share) As Restated December 31, June 30, March 31, Three months ended Six months ended Three months ended Three months ended Net sales $ 2,833 $ 5,505 $ 2,813 $ 2,692 Cost of sales 1,650 3,161 1,590 1,571 Gross margin 1,183 2,344 1,223 1,121 Selling, general and administrative expenses 627 1,309 676 633 Research and development expenses 175 313 172 141 Other operating income, net (10) (89) (2) (87) Operating income 391 811 377 434 Interest expense, net 11 23 11 12 Other (income) expense, net (33) (44) (38) (6) Income from continuing operations before income taxes 413 832 404 428 Income tax expense 102 109 63 46 Income from continuing operations 311 723 341 382 Loss from discontinued operations, net of tax (6) — — — Net income $ 305 $ 723 $ 341 $ 382 Earnings per share from continuing operations Basic $ 0.59 $ 1.35 $ 0.64 $ 0.71 Diluted $ 0.58 $ 1.32 $ 0.62 $ 0.69 Loss per share from discontinued operations Basic $ (0.01) $ — $ — $ — Diluted $ (0.01) $ — $ — $ — Earnings per share Basic $ 0.58 $ 1.35 $ 0.64 $ 0.71 Diluted $ 0.57 $ 1.32 $ 0.62 $ 0.69 Weighted-average number of shares outstanding Basic 528 537 535 539 Diluted 538 549 547 551 Baxter International Inc. Condensed Consolidated Statements of Comprehensive Income (in millions) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net income $ 655 $ 313 $ 342 Other comprehensive (loss) income, net of tax: Currency translation adjustments (95) 2 (97) Pension and other postretirement benefit plans 20 6 14 Hedging activities (27) (12) (15) Total other comprehensive (loss) income, net of tax (102) (4) (98) Comprehensive income $ 553 $ 309 $ 244 Baxter International Inc. Condensed Consolidated Statements of Comprehensive Income (in millions) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net income $ 723 $ 341 $ 382 Other comprehensive (loss) income, net of tax: Currency translation adjustments (305) (368) 63 Pension and other postretirement benefit plans 85 28 57 Hedging activities 6 11 (5) Total other comprehensive (loss) income, net of tax (214) (329) 115 Comprehensive income $ 509 $ 12 $ 497 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended June 30, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of April 1, 2019 683 $ 683 173 $ (10,284) $ 5,839 $ 15,414 $ (4,082) $ 7,570 $ 23 $ 7,593 Net income — — — — — 313 — 313 — 313 Other comprehensive income (loss) — — — — — — (4) (4) — (4) Purchases of treasury stock — — 2 (157) 46 — — (111) — (111) Stock issued under employee benefit plans and other — — (2) 119 21 (17) — 123 — 123 Dividends declared on common stock — — — — — (112) — (112) — (112) Change in noncontrolling interests — — — — — — — — 1 1 Balance as of June 30, 2019 683 $ 683 173 $ (10,322) $ 5,906 $ 15,598 $ (4,086) $ 7,779 $ 24 $ 7,803 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Six Months Ended June 30, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2019 683 $ 683 170 $ (9,989) $ 5,898 $ 15,075 $ (3,823) $ 7,844 $ 22 $ 7,866 Adoption of new accounting standards — — — — — 161 (161) — — — Net income — — — — — 655 — 655 — 655 Other comprehensive income (loss) — — — — — — (102) (102) — (102) Purchases of treasury stock — — 10 (743) 46 — — (697) — (697) Stock issued under employee benefit plans and other — — (7) 410 (38) (83) — 289 — 289 Dividends declared on common stock — — — — — (210) — (210) — (210) Change in noncontrolling interests — — — — — — — — 2 2 Balance as of June 30, 2019 683 $ 683 173 $ (10,322) $ 5,906 $ 15,598 $ (4,086) $ 7,779 $ 24 $ 7,803 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended March 31, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2019 683 $ 683 170 $ (9,989) $ 5,898 $ 15,075 $ (3,823) $ 7,844 $ 22 $ 7,866 Adoption of new accounting standards — — — — — 161 (161) — — — Net income — — — — — 342 — 342 — 342 Other comprehensive income (loss) — — — — — — (98) (98) — (98) Purchases of treasury stock — — 8 (586) — — — (586) — (586) Stock issued under employee benefit plans and other — — (5) 291 (59) (66) — 166 — 166 Dividends declared on common stock — — — — — (98) — (98) — (98) Change in noncontrolling interests — — — — — — — — 1 1 Balance as of March 31, 2019 683 $ 683 173 $ (10,284) $ 5,839 $ 15,414 $ (4,082) $ 7,570 $ 23 $ 7,593 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended June 30, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of April 1, 2018 683 $ 683 147 $ (8,354) $ 5,912 $ 14,254 $ (3,427) $ 9,068 $ (6) $ 9,062 Net income — — — — — 341 — 341 — 341 Other comprehensive income (loss) — — — — — — (329) (329) — (329) Purchases of treasury stock — — 3 (259) — — — (259) — (259) Stock issued under employee benefit plans and other — — (2) 128 4 (9) — 123 — 123 Dividends declared on common stock — — — — — (102) — (102) — (102) Change in noncontrolling interests — — — — — — — — (6) (6) Balance as of June 30, 2018 683 683 148 (8,485) 5,916 14,484 (3,756) 8,842 (12) 8,830 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Six Months Ended June 30, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (20) (3) (23) — (23) Net income — — — — — 723 — 723 — 723 Other comprehensive income (loss) — — — — — — (214) (214) — (214) Purchases of treasury stock — — 11 (781) — — — (781) — (781) Stock issued under employee benefit plans and other — — (5) 277 (24) (45) — 208 — 208 Dividends declared on common stock — — — — — (188) — (188) — (188) Change in noncontrolling interests — — — — — — — — (4) (4) Balance as of June 30, 2018 683 $ 683 148 $ (8,485) $ 5,916 $ 14,484 $ (3,756) $ 8,842 $ (12) $ 8,830 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended March 31, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (20) (3) (23) — (23) Net income — — — — — 382 — 382 — 382 Other comprehensive income (loss) — — — — — — 115 115 — 115 Purchases of treasury stock — — 8 (522) — — — (522) — (522) Stock issued under employee benefit plans and other — — (3) 149 (28) (36) — 85 — 85 Dividends declared on common stock — — — — — (86) — (86) — (86) Change in noncontrolling interests — — — — — — — — 2 2 Balance as of March 31, 2018 683 $ 683 147 $ (8,354) $ 5,912 $ 14,254 $ (3,427) $ 9,068 $ (6) $ 9,062 Baxter International Inc. Condensed Consolidated Statements of Cash Flows (in millions) As Restated Six months ended June 30, 2019 Three months ended March 31, 2019 Cash flows from operations Net income $ 655 $ 342 Adjustments to reconcile net income to net cash from operating activities: Depreciation and amortization 385 192 Deferred income taxes (63) (6) Stock compensation 57 22 Net periodic pension benefit and other postretirement costs 7 3 Intangible asset impairment 31 — Other 44 14 Changes in balance sheet items: Accounts receivable, net (60) 32 Inventories (91) (82) Accounts payable and accrued liabilities (299) (335) Other (86) (48) Cash flows from operations – continuing operations 580 134 Cash flows from operations – discontinued operations (6) (6) Cash flows from operations 574 128 Cash flows from investing activities Capital expenditures (338) (193) Acquisitions and investments, net of cash acquired (111) (109) Other investing activities, net 1 1 Cash flows from investing activities (448) (301) Cash flows from financing activities Issuances of debt 1,661 — Net increases in debt obligations with original maturities of three months or less — 795 Cash dividends on common stock (198) (101) Proceeds from stock issued under employee benefit plans 262 173 Purchases of treasury stock (720) (597) Other financing activities, net (37) (32) Cash flows from financing activities 968 238 Effect of foreign exchange rate changes on cash and cash equivalents 2 (1) Increase in cash and cash equivalents 1,096 64 Cash and cash equivalents at beginning of period 1,838 1,838 Cash and cash equivalents at end of period $ 2,934 $ 1,902 Baxter International Inc. Condensed Consolidated Statements of Cash Flows (in millions) As Restated Six months ended June 30, 2018 Three months ended March 31, 2018 Cash flows from operations Net income $ 723 $ 382 Adjustments to reconcile income from continuing operations to net cash from operating activities: Depreciation and amortization 382 190 Deferred income taxes (51) (38) Stock compensation 54 20 Net periodic pension benefit and other postretirement costs 21 10 Other — (1) Changes in balance sheet items: Accounts receivable, net 43 76 Inventories (134) (56) Accounts payable and accrued liabilities (124) (119) Other (82) (34) Cash flows from operations 832 430 Cash flows from investing activities Capital expenditures (303) (152) Acquisitions and investments, net of cash acquired (228) (219) Cash flows from investing activities (531) (371) Cash flows from financing activities Cash dividends on common stock (173) (87) Proceeds from stock issued under employee benefit plans 170 82 Purchases of treasury stock (781) (522) Other financing activities, net (24) (18) Cash flows from financing activities (808) (545) Effect of foreign exchange rate changes on cash and cash equivalents (38) 32 Decrease in cash and cash equivalents (545) (454) Cash and cash equivalents at beginning of period 3,403 3,403 Cash and cash equivalents at end of period $ 2,858 $ 2,949 Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) June 30, 2019 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,925 $ 9 (e) $ 2,934 Accounts receivable, net 1,885 12 (e)(g) 1,897 Inventories 1,757 (1) (e)(g) 1,756 Prepaid expenses and other current assets 651 (9) (b)(e)(g) 642 Total current assets 7,218 11 7,229 Property, plant and equipment, net 4,541 (56) (c)(e) 4,485 Goodwill 2,938 (1) (e) 2,937 Other intangible assets, net 1,364 (1) (g) 1,363 Operating lease right-of-use assets 588 7 (e) 595 Other non-current assets 895 (1) (a)(c)(e)(g) 894 Total assets $ 17,544 $ (41) $ 17,503 Current liabilities: Short-term debt $ 2 $ — $ 2 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,593 (40) (b)(e)(g) 2,553 Total current liabilities 2,597 (40) 2,557 Long-term debt and finance lease obligations 5,157 — 5,157 Operating lease liabilities 490 6 (e) 496 Other non-current liabilities 1,464 26 (a)(c)(e)(g) 1,490 Total liabilities 9,708 (8) 9,700 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 173,275,586 shares (10,322) — (10,322) Additional contributed capital 5,906 — 5,906 Retained earnings 16,184 (586) (a)(b)(c)(e)(g) 15,598 Accumulated other comprehensive (loss) income (4,639) 553 (a)(e) (4,086) Total Baxter stockholders’ equity 7,812 (33) 7,779 Noncontrolling interests 24 — 24 Total equity 7,836 (33) 7,803 Total liabilities and equity $ 17,544 $ (41) $ 17,503 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $514 million and accumulated other comprehensive loss of $514 million and increases to other non-current assets of $12 million and other non-current liabilities of $12 million as of June 30, 2019. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $2 million and accounts payable and other accrued liabilities of $4 million and a decrease to retained earnings of $2 million as of June 30, 2019. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $61 million, other non-current liabilities of $6 million, and retained earnings of $44 million and an increase to other non-current assets of $11 million as of June 30, 2019. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $9 million, accounts receivable, net of $6 million, inventories of $4 million, prepaid expenses and other current assets of $1 million, property, plant and equipment, net of $5 million, operating lease right-of-use assets of $7 million, other non-current assets of $5 million, accounts payable and accrued liabilities of $3 million, operating lease liabilities of $6 million, and other non-current liabilities of $4 million and decreases to goodwill of $1 million, retained earnings of $16 million, and accumulated other comprehensive loss of $39 million as of June 30, 2019. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million and retained earnings of $10 million as of June 30, 2019. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) March 31, 2019 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 1,908 $ (6) (e) $ 1,902 Accounts receivable, net 1,802 (1) (e)(g) 1,801 Inventories 1,751 (8) (e)(g) 1,743 Prepaid expenses and other current assets 626 (12) (b)(e)(g) 614 Total current assets 6,087 (27) 6,060 Property, plant and equipment, net 4,539 (63) (c)(e) 4,476 Goodwill 2,930 (1) (e) 2,929 Other intangible assets, net 1,441 (1) (g) 1,440 Operating lease right-of-use assets 517 (4) (e) 513 Other non-current assets 836 (13) (a)(c)(e)(g) 823 Total assets $ 16,350 $ (109) $ 16,241 Current liabilities: Short-term debt $ 796 $ — $ 796 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,529 (51) (e)(g) 2,478 Total current liabilities 3,327 (51) 3,276 Long-term debt and finance lease obligations 3,451 — 3,451 Operating lease liabilities 420 (3) (e) 417 Other non-current liabilities 1,483 21 (a)(c)(e)(g) 1,504 Total liabilities 8,681 (33) 8,648 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 173,447,198 shares (10,284) — (10,284) Additional contributed capital 5,839 — 5,839 Retained earnings 15,970 (556) (a)(b)(c)(e)(g) 15,414 Accumulated other comprehensive (loss) income (4,562) 480 (a)(e) (4,082) Total Baxter stockholders’ equity 7,646 (76) 7,570 Noncontrolling interests 23 — 23 Total equity 7,669 (76) 7,593 Total liabilities and equity $ 16,350 $ (109) $ 16,241 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $491 million and accumulated other comprehensive loss of $487 million and increases to other non-current assets of $9 million and other non-current liabilities of $13 million as of March 31, 2019. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $1 million and retained earnings of $1 million as of March 31, 2019. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $55 million, other non-current liabilities of $5 million, and retained earnings of $40 million and an increase to other non-current assets of $10 million as of March 31, 2019. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in decreases to cash and cash equivalents of $6 million, accounts receivable, net of $7 million, inventories of $3 million, prepaid expenses and other current assets of $1 million, property, plant and equipment, net of $8 million, goodwill of $1 million, operating lease right-of-use assets of $4 million, other non-current assets of $3 million, accounts payable and accrued liabilities of $4 million, operating lease liabilities of $3 million, other non-current liabilities of $3 million, retained earnings of $16 million and an increase to accumulated other comprehensive loss of $7 million as of March 31, 2019. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million as of March 31, 2019. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) September 30, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,860 $ 3 (e) $ 2,863 Accounts receivable, net 1,826 11 (e)(g) 1,837 Inventories 1,718 (2) (e)(g) 1,716 Prepaid expenses and other current assets 624 (9) (b)(g) 615 Total current assets 7,028 3 7,031 Property, plant and equipment, net 4,520 (44) (c)(e) 4,476 Goodwill 2,980 (2) (e) 2,978 Other intangible assets, net 1,402 (2) (e)(g) 1,400 Other non-current assets 917 1 (a)(c)(e)(g) 918 Total assets $ 16,847 $ (44) $ 16,803 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ — $ 3 Accounts payable and accrued liabilities 2,701 (41) (b)(e)(g) 2,660 Total current liabilities 2,704 (41) 2,663 Long-term debt and finance lease obligations 3,485 (5) (e) 3,480 Other non-current liabilities 1,545 25 (a)(c)(e)(g) 1,570 Total liabilities 7,734 (21) 7,713 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 150,213,621 shares (8,639) — (8,639) Additional contributed capital 5,931 — 5,931 Retained earnings 15,394 (508) (a)(b)(c)(e)(g) 14,886 Accumulated other comprehensive (loss) income (4,239) 485 (a)(e) (3,754) Total Baxter stockholders’ equity 9,130 (23) 9,107 Noncontrolling interests (17) — (17) Total equity 9,113 (23) 9,090 Total liabilities and equity $ 16,847 $ (44) $ 16,803 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $448 million and accumulated other comprehensive loss of $456 million and increases to other non-current assets of $20 million and other non-current liabilities of $12 million as of September 30, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $3 million and accounts payable and accrued liabilities of $4 million and a decrease to retained earnings of $1 million as of September 30, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $49 million, other non-current liabilities of $2 million, and retained earnings of $35 million and an increase to other non-current assets of $12 million as of September 30, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $3 million, accounts receivable, net of $5 million, inventories of $3 million, property, plant and equipment, net of $5 million and accounts payable and accrued liabilities of $2 million and decreases to goodwill of $2 million, other intangible assets, net of $1 million, other non-current assets of $2 million, long-term debt and finance lease obligations of $5 million, other non-current liabilities of $1 million, retained earnings of $14 million, and accumulated other comprehensive loss of $29 million as of September 30, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million as of September 30, 2018. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) June 30, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,857 $ 1 (e) $ 2,858 Accounts receivable, net 1,783 6 (g) 1,789 Inventories 1,622 (6) (e)(g) 1,616 Prepaid expenses and other current assets 628 (7) (b)(e)(g) 621 Total current assets 6,890 (6) 6,884 Property, plant and equipment, net 4,531 (45) (c) 4,486 Goodwill 2,984 (3) (e) 2,981 Other intangible assets, net 1,427 (3) (e)(g) 1,424 Other non-current assets 746 (2) (a)(c)(g) 744 Total assets $ 16,578 $ (59) $ 16,519 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ — $ 3 Accounts payable and accrued liabilities 2,626 (43) (b)(g) 2,583 Total current liabilities 2,629 (43) 2,586 Long-term debt and finance lease obligations 3,495 (4) (e) 3,491 Other non-current liabilities 1,585 27 (a)(c)(g) 1,612 Total liabilities 7,709 (20) 7,689 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 148,485,202 shares (8,485) — (8,485) Additional contributed capital 5,916 — 5,916 Retained earnings 14,966 (482) (a)(c)(e)(g) 14,484 Accumulated other comprehensive (loss) income (4,199) 443 (a)(e) (3,756) Total Baxter stockholders’ equity 8,881 (39) 8,842 Noncontrolling interests (12) — (12) Total equity 8,869 (39) 8,830 Total liabilities and equity $ 16,578 $ (59) $ 16,519 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $425 million and accumulated other comprehensive loss of $428 million and increases to other non-current assets of $16 million and other non-current liabilities of $13 million as of June 30, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $4 million and accounts payable and accrued liabilities of $4 million as of June 30, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $45 million, other non-current liabilities of $2 million, and retained earnings of $32 million and an increase to other non-current assets of $11 million as of June 30, 2018. (e) Translation of the Financial Position

Schedule II - Qualifying And Va

Schedule II - Qualifying And Valuation Accounts	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Qualifying And Valuation Accounts	SCHEDULE II – Qualifying and Valuation accounts for each of the three years in the period ended December 31, 2019 Additions Valuation and Qualifying Accounts (in millions) Balance at Charged to (Credited) Deductions Balance at Year ended December 31, 2019: Allowance for doubtful accounts $ 110 18 (8) (8) $ 112 Deferred tax asset valuation allowance $ 310 117 — (7) $ 420 Year ended December 31, 2018: Allowance for doubtful accounts $ 120 4 (7) (7) $ 110 Deferred tax asset valuation allowance (as restated) $ 483 20 (4) (189) $ 310 Year ended December 31, 2017: Allowance for doubtful accounts $ 127 4 8 (19) $ 120 Deferred tax asset valuation allowance $ 150 350 — (17) $ 483 ______________________________________ (1) Valuation accounts of acquired or divested companies and foreign currency translation adjustments. Reserves are deducted from assets to which they apply.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Baxter International Inc., through our subsidiaries (collectively, Baxter, we, our or us), provides a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and patients at home under physician supervision. We operate in three segments: Americas, EMEA and APAC, which are described in Note 18.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with U.S. Generally Accepted Accounting Principles (U.S. GAAP) requires us to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those estimates.
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of Baxter and our majority-owned subsidiaries that we control, after elimination of intra-company transactions. Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.
Revenue Recognition	Revenue Recognition We adopted Accounting Standards Update (ASU) No. 2014-9, Revenue from Contracts with Customers (Topic 606) as of January 1, 2018. Results for the years ended December 31, 2019 and 2018 are presented under Topic 606, while the 2017 period is presented under previous guidance. See further discussion of the impact of Topic 606 below under the header “New Accounting Standards.” Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days. The majority of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our geographic segments, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. For a majority of these sales, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. To a lesser extent, in all of our segments, we enter into other types of contracts, including contract manufacturing arrangements, equipment leases, and certain subscription software and licensing arrangements. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or when our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed. As of December 31, 2019, we had $8.6 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more, which are primarily included in the Americas segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue in each of 2020 and 2021, 20% in each of 2022 and 2023, 5% in 2024, and the remaining balance thereafter. Significant Judgments Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration related to rebates, product returns, sales discounts and wholesaler chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accounts receivable, net and accounts payable and accrued liabilities on the consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized in years ended December 31, 2019 and 2018 related to performance obligations satisfied in prior periods was not material. Contract Balances The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets, and customer advances and deposits (contract liabilities) on our consolidated balance sheets. Net trade accounts receivable was $1.8 billion as of December 31, 2019 and 2018.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful AccountsIn the normal course of business, we provide credit to our customers, perform credit evaluations of these customers and maintain reserves for potential credit losses. In determining the amount of the allowance for doubtful accounts, we consider, among other items, historical credit losses, the past-due status of receivables, payment histories and other customer-specific information.
Product Warranties	Shipping and Handling CostsShipping costs, which are costs incurred to physically move product from our premises to the customer’s premises, are classified as selling, general and administrative (SG&A) expenses. Handling costs, which are costs incurred to store, move and prepare products for shipment, are classified as cost of sales.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash, certificates of deposit and money market and other short-term funds with original maturities of three months or less.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. We review inventories on hand at least quarterly and record provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value.
Property, Plant and Equipment, Net	Property, Plant and Equipment, NetProperty, plant and equipment are stated at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the related assets, which range from 20 to 50 years for buildings and improvements and from three three
Research and Development	Research and Development Research and development (R&D) costs, including R&D acquired in transactions that are not business combinations, are expensed as incurred. Pre-regulatory approval contingent milestone obligations to counterparties in collaborative arrangements, which include acquired R&D, are expensed when the milestone is achieved. Contingent milestone payments made to such counterparties on or after regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangible assets, net. Acquired in-process R&D (IPR&D) is the value assigned to technology or products under development acquired in a business combination which have not received regulatory approval and have no alternative future use. Acquired IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and amortized on a straight-line basis over the
Collaborative Arrangements	Collaborative Arrangements We enter into collaborative arrangements in the normal course of business. These collaborative arrangements take a number of forms and structures and are designed to enhance and expedite long-term sales and profitability growth. These arrangements may provide for us to obtain commercialization rights to a product under development, and require us to make upfront payments, contingent milestone payments, profit-sharing, and/or royalty payments. We may be responsible for ongoing costs associated with the arrangements, including R&D cost reimbursements to the counterparty. See the R&D section of this note regarding the accounting treatment of upfront and contingent milestone payments. Any royalty and profit-sharing payments during the commercialization phase are expensed as cost of sales when they become due and payable.
Restructuring Charges	Restructuring Charges We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are primarily recorded when actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Refer to the discussion below regarding the accounting for asset impairment charges.
Goodwill, Intangible Assets, and Other Long-Lived Assets	Goodwill, Intangible Assets, and Other Long-Lived Assets Goodwill is the excess of the purchase price over the fair value of acquired assets and liabilities in a business combination. Goodwill is not amortized but is subject to an impairment review annually and whenever indicators of impairment exist. We have the option to assess goodwill for impairment by initially performing a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then the two-step goodwill impairment test is not required to be performed. If we determine that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, or if we do not elect the option to perform an initial qualitative assessment, we perform the two-step goodwill impairment test. In the first step, the fair value of the reporting unit is compared with its book value including goodwill. If the fair value of the reporting unit is in excess of its book value, the related goodwill is not impaired and no further analysis is necessary. If the fair value of the reporting unit is less than its book value, there is an indication of potential impairment and a second step is performed. When required, the second step of testing involves calculating the implied fair value of goodwill for the reporting unit. The implied fair value of goodwill is determined in the same manner as goodwill recognized in a business combination, which is the excess of the fair value of the reporting unit determined in step one over the fair value of its net assets, including identifiable intangible assets, as if the reporting unit had been acquired. If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. Indefinite-lived intangible assets, such as IPR&D acquired in business combinations and certain trademarks with indefinite lives, are subject to an impairment review annually and whenever indicators of impairment exist. We have the option to assess indefinite-lived intangible assets for impairment by first performing qualitative assessments to determine whether it is more-likely-than-not that the fair values of its indefinite-lived intangible assets are less than the carrying amounts. If we determine that it is more-likely-than-not that an indefinite-lived intangible asset is impaired, or if we elect not to perform an initial qualitative assessment, we then perform the quantitative impairment test by comparing the fair value of the indefinite-lived intangible asset with its carrying amount. If the carrying amount exceeds the fair value of the indefinite-lived intangible asset, we write the carrying amount down to the fair value. We review the carrying amounts of long-lived assets, other than goodwill and intangible assets not subject to amortization, for potential impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In evaluating recoverability, we group assets and liabilities at the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows of other assets and liabilities. We then compare the carrying amounts of the assets or asset groups with the related estimated undiscounted future cash flows. In the event impairment exists, an impairment charge is recorded as the amount by which the carrying amount of the asset or asset group exceeds the fair value.
Income Taxes	Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We maintain valuation allowances unless it is more-likely-than-not that the deferred tax asset will be realized. With respect to uncertain tax positions, we determine whether the position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. Any tax position that meets the more-likely-than-not recognition threshold is measured and recognized in the consolidated financial statements at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The liability relating to uncertain tax positions is classified as current in the consolidated balance sheets to the extent that we anticipate making a payment within one year. Interest and penalties associated with income taxes are classified in the income tax expense line in the consolidated statements of income. Refer to the Recently Adopted Accounting Pronouncements section of this note and Note 14 for additional information related to the Tax Cuts and Jobs Act of 2017 (2017 Tax Act).
Foreign Currency Translation	Foreign Currency TranslationCurrency translation adjustments (CTA) related to foreign operations are included in other comprehensive income (OCI).
Derivatives and Hedging Activities	Derivatives and Hedging Activities All derivative instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt instruments as hedging instruments in cash flow, fair value or net investment hedges. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to OCI over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted third-party sales denominated in foreign currencies, forecasted intra-company sales denominated in foreign currencies and anticipated issuances of debt, respectively. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk, such as changes in interest rates, of the hedged item, which are also recognized in earnings. Fair value hedges are classified in interest expense, net, as they hedge the interest rate risk associated with certain of our fixed-rate debt. We have designated our Euro-denominated senior notes as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI. For derivative instruments that are not designated as hedges, the change in fair value is recorded directly to other (income) expense, net. If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings. If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. If we remove a net investment hedge designation, any gains or losses recognized in AOCI are not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged.
New Accounting Standards	New Accounting Standards Recently adopted accounting pronouncements As of January 1, 2019, we adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under this guidance, lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all operating leases, other than those that meet the definition of a short-term lease. We adopted Topic 842 using the modified retrospective method. We elected the following practical expedients when assessing the transition impact: i) not to reassess whether any expired or existing contracts as of the adoption date are or contain leases; ii) not to reassess the lease classification for any expired or existing leases as of the adoption date; and iii) not to reassess initial direct costs for any existing leases as of the adoption date. The adjustment to record operating lease right-of-use assets and operating lease liabilities was $502 million as of January 1, 2019. The impact to the consolidated statements of income was not material and there was no net impact to the consolidated statements of cash flows. As of January 1, 2019, we adopted ASU No. 2017-12, Targeted Improvements to Accounting for Hedging Activities. The purpose of this ASU is to better align a company’s risk management activities and financial reporting for hedging relationships, simplify the hedge accounting requirements, and improve the disclosures of hedging arrangements. The adoption of this standard did not have a material impact on our consolidated financial statements. As of January 1, 2019, we adopted ASU No. 2018-02, Reclassification of Certain Tax Effects from AOCI. As a result of the enactment of the U.S. Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), this guidance provides for a reclassification of certain tax effects from AOCI to retained earnings. The impact of the adoption of this standard was a $161 million increase to retained earnings. As of January 1, 2018, we adopted ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory (ASU No. 2016-16) using the modified retrospective method. ASU No. 2016-16 generally accelerates the recognition of income tax consequences for intra-company asset transfers other than inventory. We recorded a $70 million reduction to retained earnings upon adoption of the standard on January 1, 2018 related to the unrecognized income tax effects of asset transfers that occurred prior to adoption. Net income increased $14 million for the year ended December 31, 2018 as a result of the adoption of the standard. As of January 1, 2018, we adopted ASU No. 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in earnings. For privately-held securities, we elected the measurement alternative approach for our investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of this standard did not have a material impact on our consolidated financial statements. As of January 1, 2018, we adopted Topic 606, which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. The primary impact of the new standard relates to our contract manufacturing operations and software arrangements. Certain contract manufacturing arrangements require revenue recognition over-time in situations in which we produce products that have no alternative use and we have an enforceable right to payment for performance completed to date, inclusive of a reasonable profit margin. This results in an acceleration of revenue recognition for certain contractual arrangements as compared to recognition under prior accounting literature. The new guidance also impacts our arrangements subject to previous software revenue recognition guidance, as we are required to recognize as revenue a significant portion of the contract consideration upon delivery of the software compared to the previous practice of recognizing the contract consideration ratably over time for certain arrangements. We adopted Topic 606 using the modified retrospective method. The adjustment upon adoption increased our opening balance of retained earnings by approximately $45 million, net of tax, on January 1, 2018. The impact to net sales as a result of the adoption was an increase of $7 million for the year ended December 31, 2018. The impact to cost of sales was not material for the year ended December 31, 2018. In December 2017, the SEC issued guidance for situations where the accounting for certain elements of the 2017 Tax Act could not be completed prior to the release of a company's financial statements. For specific elements of the 2017 Tax Act, we determined a reasonable estimate for certain effects and recorded that estimate as a provisional amount in 2017. The guidance provided a measurement period to allow a company to account for these specific elements, which began in the reporting period that included the enactment of the 2017 Tax Act and ended when we obtained, prepared and analyzed the information needed in order to complete its accounting assessments or one year, whichever occurred sooner. The resulting tax effects were to be recognized in the period the assessment was complete, and included in income tax expense, accompanied by appropriate disclosures. The measurement period closed in 2018 and we recorded adjustments to reduce income tax expense by $207 million in 2018. Refer to Note 14 for additional information related to the 2017 Tax Act.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Disaggregation of Revenue	The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international: As Restated 2019 2018 2017 years ended December 31 (in millions) U.S. International Total U.S. International Total U.S. International Total Renal Care 1 $ 791 $ 2,848 $ 3,639 $ 816 $ 2,835 $ 3,651 $ 754 $ 2,737 $ 3,491 Medication Delivery 2 1,822 977 2,799 1,690 974 2,664 1,698 1,002 2,700 Pharmaceuticals 3 940 1,215 2,155 996 1,091 2,087 892 994 1,886 Clinical Nutrition 4 320 552 872 321 554 875 359 526 885 Advanced Surgery 5 535 342 877 466 332 798 403 305 708 Acute Therapies 6 184 351 535 174 341 515 147 310 457 Other 7 234 251 485 260 249 509 257 200 457 Total Baxter $ 4,826 $ 6,536 $ 11,362 $ 4,723 $ 6,376 $ 11,099 $ 4,510 $ 6,074 $ 10,584 1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements	Baxter International Inc. Consolidated Balance Sheet (in millions, except per share) December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 1,832 $ 6 (e) $ 1,838 Accounts receivable, net 1,812 28 (e)(g) 1,840 Inventories 1,653 14 (e)(g) 1,667 Prepaid expenses and other current assets 622 (8) (b)(e)(g) 614 Total current assets 5,919 40 5,959 Property, plant and equipment, net 4,542 (12) (c)(e) 4,530 Goodwill 2,958 44 (e) 3,002 Other intangible assets, net 1,398 12 (e)(g) 1,410 Other non-current assets 824 (5) (a)(c)(e)(g) 819 Total assets $ 15,641 $ 79 $ 15,720 Current liabilities: Short-term debt $ 2 $ — $ 2 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,832 (22) (b)(e)(g) 2,810 Total current liabilities 2,836 (22) 2,814 Long-term debt and finance lease obligations 3,473 8 (e) 3,481 Other non-current liabilities 1,516 43 (a)(c)(e)(g) 1,559 Total liabilities 7,825 29 7,854 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 170,495,859 shares (9,989) — (9,989) Additional contributed capital 5,898 — 5,898 Retained earnings 15,626 (551) (a)(b)(c)(e)(g) 15,075 Accumulated other comprehensive (loss) income (4,424) 601 (a)(e) (3,823) Total Baxter stockholders’ equity 7,794 50 7,844 Noncontrolling interests 22 — 22 Total equity 7,816 50 7,866 Total liabilities and equity $ 15,641 $ 79 $ 15,720 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $487 million and accumulated other comprehensive loss of $482 million and increases to other non-current assets of $8 million and other non-current liabilities of $13 million as of December 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $2 million, accounts payable and accrued liabilities of $1 million, and retained earnings of $1 million as of December 31, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $53 million, other non-current liabilities of $5 million, and retained earnings of $38 million and an increase to other non-current assets of $10 million as of December 31, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $6 million, accounts receivable, net of $22 million, inventories of $19 million, prepaid expenses and other current assets of $2 million, property, plant and equipment of $41 million, goodwill of $44 million, other intangible assets, net of $13 million, other non-current assets of $6 million, accounts payable and accrued liabilities of $24 million, long-term debt and finance lease obligations of $8 million and other non-current liabilities of $19 million as of December 31, 2018. The correction of these misstatements also resulted in decreases to retained earnings of $17 million and accumulated other comprehensive loss of $119 million as of December 31, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million, and increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million as of December 31, 2018. Baxter International Inc. Consolidated Statement of Income (in millions, except per share) Year ended December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Net sales $ 11,127 $ (28) (e) $ 11,099 Cost of sales 6,346 (6) (c)(e) 6,340 Gross margin 4,781 (22) 4,759 Selling, general and administrative expenses 2,617 3 (e)(f) 2,620 Research and development expenses 655 (1) (e) 654 Other operating income, net (90) (9) (f) (99) Operating income 1,599 (15) 1,584 Interest expense, net 45 — 45 Other (income) expense, net (139) 61 (a)(b)(e) (78) Income from continuing operations before income taxes 1,693 (76) 1,617 Income tax expense (benefit) 63 2 (c)(e)(g) 65 Income from continuing operations 1,630 (78) 1,552 Loss from discontinued operations, net of tax (6) — (6) Net income $ 1,624 $ (78) $ 1,546 Earnings per share from continuing operations Basic $ 3.05 $ (0.14) $ 2.91 Diluted $ 2.99 $ (0.15) $ 2.84 Loss per share from discontinued operations Basic $ (0.01) $ — $ (0.01) Diluted $ (0.02) $ 0.01 $ (0.01) Earnings per share Basic $ 3.04 $ (0.14) $ 2.90 Diluted $ 2.97 $ (0.14) $ 2.83 Weighted-average number of shares outstanding Basic 534 — 534 Diluted 546 — 546 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in a decrease to other (income) expense, net of $64 million for the year ended December 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $5 million for the year ended December 31, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $11 million and a decrease to income tax expense of $3 million for the year ended December 31, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in decreases to net sales of $28 million, cost of sales of $17 million, SG&A expense of $6 million, R&D expense of $1 million, other (income) expense, net of $2 million, and income tax expense of $2 million for the year ended December 31, 2018. (f) Income Statement Classification of Transition Services Income—The correction of these misstatements resulted in increases to SG&A expense and other operating income, net of $9 million for the year ended December 31, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in an increase to income tax expense of $7 million for the year ended December 31, 2018. Baxter International Inc. Consolidated Statement of Income (in millions, except per share) Year ended December 31, 2017 As previously reported Restatement impacts Restatement reference As restated Net sales $ 10,561 $ 23 (e) $ 10,584 Cost of sales 6,091 19 (c)(e) 6,110 Gross margin 4,470 4 4,474 Selling, general and administrative expenses 2,566 61 (e)(f) 2,627 Research and development expenses 613 2 (e) 615 Other operating income, net — (56) (f) (56) Operating income 1,291 (3) 1,288 Interest expense, net 55 — 55 Other (income) expense, net 19 114 (a)(b)(e) 133 Income from continuing operations before income taxes 1,217 (117) 1,100 Income tax expense (benefit) 493 (2) (c)(e) 491 Income from continuing operations 724 (115) 609 Loss from discontinued operations, net of tax (7) $ — (7) Net income $ 717 $ (115) $ 602 Earnings per share from continuing operations Basic $ 1.33 $ (0.21) $ 1.12 Diluted $ 1.30 $ (0.20) $ 1.10 Loss per share from discontinued operations Basic $ (0.01) $ — $ (0.01) Diluted $ (0.01) $ (0.01) $ (0.02) Earnings per share Basic $ 1.32 $ (0.21) $ 1.11 Diluted $ 1.29 $ (0.21) $ 1.08 Weighted-average number of shares outstanding Basic 543 — 543 Diluted 555 — 555 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to other (income) expense, net of $96 million. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in an increase to other (income) expense, net of $17 million. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in an increase to cost of sales of $8 million and a decrease to income tax expense of $3 million for the year ended December 31, 2017. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to net sales of $23 million, cost of sales of $11 million, SG&A expense of $5 million, R&D expense of $2 million, other (income) expense, net of $1 million and income tax expense of $1 million for the year ended December 31, 2017. Baxter International Inc. Consolidated Statement of Comprehensive Income (in millions) Year ended December 31, 2018 As previously reported Restatement impacts As restated Net income $ 1,624 $ (78) $ 1,546 Other comprehensive (loss) income, net of tax: Currency translation adjustments (461) 138 (323) Pension and other postretirement benefit plans 32 1 33 Hedging activities 9 — 9 Total other comprehensive (loss) income, net of tax (420) 139 (281) Comprehensive income $ 1,204 $ 61 $ 1,265 Baxter International Inc. Consolidated Statement of Comprehensive Income (in millions) Year ended December 31, 2017 As previously reported Restatement impacts As restated Net income $ 717 $ (115) $ 602 Other comprehensive (loss) income, net of tax: Currency translation adjustments 425 174 599 Pension and other postretirement benefit plans 141 (7) 134 Hedging activities (13) — (13) Available-for-sale securities 2 — 2 Total other comprehensive (loss) income, net of tax 555 167 722 Comprehensive income $ 1,272 $ 52 $ 1,324 Baxter International Inc. Consolidated Statement of Changes in Equity (in millions) Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity As previously reported Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,483 $ (4,001) $ 9,124 $ (8) $ 9,116 Adoption of new accounting standards — — — — — (18) (3) (21) — (21) Net income — — — — — 1,624 — 1,624 — 1,624 Other comprehensive income (loss) — — — — — — (420) (420) — (420) Purchases of treasury stock — — 36 (2,415) (60) — — (2,475) — (2,475) Stock issued under employee benefit plans and other — — (8) 407 18 (71) — 354 — 354 Dividends declared on common stock — — — — — (392) — (392) — (392) Changes in noncontrolling interests — — — — — — — — 30 30 Balance as of December 31, 2018 683 $ 683 170 $ (9,989) $ 5,898 $ 15,626 $ (4,424) $ 7,794 $ 22 $ 7,816 Restatement impacts Balance as of January 1, 2018 — $ — — $ — $ — $ (469) $ 462 $ (7) $ — $ (7) Adoption of new accounting standards — — — — — (4) — (4) — (4) Net income — — — — — (78) — (78) — (78) Other comprehensive income (loss) — — — — — — 139 139 — 139 Balance as of December 31, 2018 — $ — — $ — $ — $ (551) $ 601 $ 50 $ — $ 50 As restated Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (22) (3) (25) — (25) Net income — — — — — 1,546 — 1,546 — 1,546 Other comprehensive income (loss) — — — — — — (281) (281) — (281) Purchases of treasury stock — — 36 (2,415) (60) — — (2,475) — (2,475) Stock issued under employee benefit plans and other — — (8) 407 18 (71) — 354 — 354 Dividends declared on common stock — — — — — (392) — (392) — (392) Changes in noncontrolling interests — — — — — — — — 30 30 Balance as of December 31, 2018 683 683 170 (9,989) 5,898 15,075 (3,823) 7,844 22 7,866 See descriptions of the net income and other comprehensive income impacts in the consolidated statement of income and consolidated statement of comprehensive income for the year ended December 31, 2018 sections above. Additionally, we recorded an adjustment to the opening balance of retained earnings on January 1, 2018 for the adoption of ASU No. 2016-16, which was impacted by our adjustments to equipment leased to customers under operating leases. Baxter International Inc. Consolidated Statement of Changes in Equity (in millions) Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity As previously reported Balance as of January 1, 2017 683 $ 683 144 $ (7,995) $ 5,958 $ 14,200 $ (4,556) $ 8,290 $ (10) $ 8,280 Net income — — — — — 717 — $ 717 — $ 717 Other comprehensive income (loss) — — — — — — 555 555 — 555 Purchases of treasury stock — — 9 (564) — — — (564) — (564) Stock issued under employee benefit plans and other — — (11) 578 (18) (134) — 426 — 426 Dividends declared on common stock — — — — — (334) — (334) — (334) Distribution of Baxalta — — — — — 34 — 34 — 34 Changes in noncontrolling interests — — — — — — — — 2 2 Balance as of December 31, 2017 683 $ 683 142 $ (7,981) $ 5,940 $ 14,483 $ (4,001) $ 9,124 $ (8) $ 9,116 Restatement impacts Balance as of January 1, 2017 — $ — — $ — $ — $ (354) $ 295 $ (59) $ — $ (59) Net income — — — — — (115) — (115) — (115) Other comprehensive income (loss) — — — — — — 167 167 — 167 Balance as of December 31, 2017 — $ — — $ — $ — $ (469) $ 462 $ (7) $ — $ (7) As restated Balance as of January 1, 2017 683 $ 683 144 $ (7,995) $ 5,958 $ 13,846 $ (4,261) $ 8,231 $ (10) $ 8,221 Net income — — — — — 602 — 602 — 602 Other comprehensive income (loss) — — — — — — 722 722 — 722 Purchases of treasury stock — — 9 (564) — — — (564) — (564) Stock issued under employee benefit plans and other — — (11) 578 (18) (134) — 426 — 426 Dividends declared on common stock — — — — — (334) — (334) — (334) Distribution of Baxalta — — — — — 34 — 34 — 34 Changes in noncontrolling interests — — — — — — — — 2 2 Balance as of December 31, 2017 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 The adjustment to the January 1, 2017 retained earnings and accumulated other comprehensive loss represent the cumulative impacts of foreign exchange gains and losses and the translation of our financial position and results of operations for our foreign operations into U.S. dollars for the periods prior to January 1, 2017. Retained earnings also includes the cumulative impacts of equipment leased to customers under operating leases and other miscellaneous adjustments for the periods prior to January 1, 2017. See descriptions of the net income and other comprehensive income impacts in the consolidated statement of income and consolidated statement of comprehensive income for the year ended December 31, 2017 sections above. Baxter International Inc. Consolidated Statement of Cash Flows (in millions) Year ended December 31, 2018 As previously reported Restatement impacts Restatement reference As restated Cash flows from operations Net income $ 1,624 $ (78) $ 1,546 Adjustments to reconcile income from continuing operations to net cash from operating activities: Loss from discontinued operations, net of tax 6 — 6 Depreciation and amortization 785 (14) (c)(g) 771 Pension settlement charges 1 — 1 Net periodic pension benefit and other postretirement costs 39 — 39 Deferred income taxes (267) 4 (c)(g) (263) Stock compensation 115 — 115 Other 43 7 (d) 50 Changes in balance sheet items: Accounts receivable, net (12) — (12) Inventories (197) — (197) Accounts payable and accrued liabilities 64 (4) (b) 60 Other (105) 6 (b)(e)(g) (99) Cash flows from operations 2,096 (79) 2,017 Cash flows from investing activities Capital expenditures (681) 22 (c) (659) Acquisitions and investments, net of cash acquired (268) — (268) Other investing activities, net 11 — 11 Cash flows from investing activities (938) 22 (916) Cash flows from financing activities Cash dividends on common stock (376) — (376) Proceeds from stock issued under employee benefit plans 258 — 258 Purchases of treasury stock (2,452) — (2,452) Other financing activities, net (33) — (33) Cash flows from financing activities (2,603) — (2,603) Effect of foreign exchange rate changes on cash and cash equivalents (117) 54 (a)(d)(e) (63) Increase (decrease) in cash and cash equivalents (1,562) (3) (1,565) Cash and cash equivalents at beginning of year 3,394 9 (e) 3,403 Cash and cash equivalents at end of year $ 1,832 $ 6 (e) $ 1,838 Other supplemental information Interest paid, net of portion capitalized $ 94 — $ 94 Income taxes paid $ 302 (1) (e) $ 301 The $78 million decrease to net income was driven by the items described above in the consolidated statement of income for the year ended December 31, 2018 section. (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents of $64 million for the year ended December 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in decreases to changes in accounts payable and accrued liabilities of $4 million and other changes in balance sheet items of $1 million for the year ended December 31, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to depreciation and amortization of $11 million, deferred income taxes of $3 million and capital expenditures of $22 million for the year ended December 31, 2018. (d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows - The corrections of these misstatements resulted in a decrease to the effect of foreign exchange rate changes on cash and cash equivalents and an increase to other adjustments to reconcile net income to net cash from operating activities of $7 million for the year ended December 31, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars - The corrections of these misstatements resulted in increases to cash and cash equivalents at the beginning of the period of $9 million, at the end of the period of $6 million, and to other changes in balance sheet items of $4 million and decreases in the effect of foreign exchange rate changes on cash and cash equivalents of $3 million and income taxes paid of $1 million for the year ended December 31, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in a decrease to depreciation and amortization of $3 million and increases to deferred income taxes of $7 million and other changes in balance sheet items of $3 million for the year ended December 31, 2018. Baxter International Inc. Consolidated Statement of Cash Flows (in millions) Year ended December 31, 2017 As previously reported Restatement impacts Restatement reference As restated Cash flows from operations Net income $ 717 $ (115) $ 602 Adjustments to reconcile income from continuing operations to net cash from operating activities: Loss from discontinued operations, net of tax 7 — 7 Depreciation and amortization 761 (11) (c)(g) 750 Pension settlement charges 2 — 2 Net periodic pension benefit and other postretirement costs 123 — 123 Deferred income taxes 211 — 211 Stock compensation 107 — 107 Other 43 (5) (d)(g) 38 Changes in balance sheet items: Accounts receivable, net 30 — 30 Inventories 76 — 76 Accounts payable and accrued liabilities 5 6 (b) 11 Other (229) 2 (b)(c)(e) (227) Cash flows from operations - continuing operations 1,853 (123) 1,730 Cash flows from operations - discontinued operations (16) — (16) Cash flows from operations 1,837 (123) 1,714 Cash flows from investing activities Capital expenditures (634) 18 (c) (616) Acquisitions and investments, net of cash acquired (686) — (686) Other investing activities, net 10 — 10 Cash flows from investing activities (1,310) 18 (1,292) Cash flows from financing activities Issuances of debt 633 32 (a) 665 Cash dividends on common stock (315) — (315) Proceeds from stock issued under employee benefit plans 347 — 347 Purchases of treasury stock (564) — (564) Other financing activities, net (40) — (40) Cash flows from financing activities 61 32 93 Effect of foreign exchange rate changes on cash and cash equivalents 5 97 (a)(d)(e) 102 Increase (decrease) in cash and cash equivalents 593 24 617 Cash and cash equivalents at beginning of year 2,801 (15) (e) 2,786 Cash and cash equivalents at end of year $ 3,394 $ 9 (e) $ 3,403 Other supplemental information Interest paid, net of portion capitalized $ 80 — $ 80 Income taxes paid $ 255 (2) (e) $ 253 The $115 million decrease to net income was driven by the items described above in the consolidated statement of income for the year ended December 31, 2017 section. (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents of $99 million for the year ended December 31, 2017. Additionally, issuances of debt increased $32 million with an offsetting decrease to the effect of foreign exchange rate changes on cash and cash equivalents to remeasure the proceeds received from the issuance of our Euro-denominated senior notes in May 2017. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to changes in accounts payable and accrued liabilities of $6 million and other changes in balance sheet items of $8 million for the year ended December 31, 2017. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to depreciation and amortization of $10 million, other changes in balance sheet items of $3 million and capital expenditures of $18 million for the year ended December 31, 2017. (d) Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows - The corrections of these misstatements resulted in an increase to the effect of foreign exchange rate changes on cash and cash equivalents and a decrease to other adjustments to reconcile net income to net cash from operating activities of $6 million for the year ended December 31, 2017. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars - The corrections of these misstatements resulted in increases in cash and cash equivalents at the end of the period of $9 million and the effect of foreign exchange rate changes on cash and cash equivalents of $24 million and decreases to cash and cash equivalents at the beginning of the period of $15 million, other changes in balance sheet items of $3 million and income taxes paid of $2 million for the year ended December 31, 2017. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in a decrease to depreciation and amortization and an increase to other adjustments to reconcile net income to net changes from operating activities of $1 million for the year ended December 31, 2017.

ACQUISITIONS AND OTHER ARRANG_2

ACQUISITIONS AND OTHER ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Total Consideration	The following table summarizes the fair value of consideration transferred: (in millions) Cash consideration transferred $ 197 Contingent consideration 18 Total consideration $ 215 The following table summarizes the fair value of consideration transferred: (in millions) Cash consideration transferred $ 163 Contingent consideration 21 Total consideration $ 184 The following table summarizes the fair value of consideration transferred: (in millions) Consideration transferred Cash $ 2 Fair value of equity investment 39 Noncontrolling interest 39 Total consideration transferred $ 80
Summary of Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash $ 2 Accounts receivable, net 3 Inventories 1 Prepaid expenses and other current assets 1 Property, plant and equipment 1 Goodwill 111 Other intangible assets 131 Operating lease right-of-use assets 1 Accounts payable and other accrued liabilities (4) Other non-current liabilities (32) Total assets acquired and liabilities assumed $ 215 The following table summarizes the fair value of the assets acquired as of the acquisition date: (in millions) Assets acquired Accounts receivable, net $ 2 Inventory 80 Goodwill 2 Other intangible assets 100 Total assets acquired $ 184 The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash $ 4 Accounts receivable, net 25 Inventories 8 Property, plant and equipment 12 Goodwill 17 Other intangible assets 40 Other non-current assets 2 Short-term debt (4) Accounts payable and accrued liabilities (16) Other non-current liabilities (8) Total assets acquired and liabilities assumed $ 80 The following table summarizes the fair value of the assets acquired and liabilities assumed as of the acquisition date for our acquisition of Claris: (in millions) Assets acquired and liabilities assumed Cash $ 11 Accounts receivable, net 16 Inventories 30 Prepaid expenses and other current assets 16 Property, plant and equipment 130 Goodwill 296 Other intangible assets 280 Other non-current assets 20 Accounts payable and accrued liabilities (23) Other non-current liabilities (136) Total assets acquired and liabilities assumed $ 640

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories	Inventories As Restated as of December 31 (in millions) 2019 2018 Raw materials $ 377 $ 367 Work in process 185 207 Finished goods 1,091 1,093 Inventories $ 1,653 $ 1,667
Prepaid Expenses and Other	Prepaid Expenses and Other Current Assets As Restated as of December 31 (in millions) 2019 2018 Prepaid value added taxes $ 140 $ 131 Prepaid income taxes 90 79 Other 389 404 Prepaid expenses and other current assets $ 619 $ 614
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net As Restated as of December 31 (in millions) 2019 2018 Land $ 148 $ 142 Buildings and leasehold improvements 1,761 1,703 Machinery and equipment 6,671 6,423 Equipment with customers 1,489 1,364 Construction in progress 591 701 Total property, plant and equipment, at cost 10,660 10,333 Accumulated depreciation (6,148) (5,803) Property, plant and equipment (PP&E), net $ 4,512 $ 4,530
Other Long-Term Assets	As Restated as of December 31 (in millions) 2019 2018 Deferred tax assets $ 621 $ 483 Non-current receivables, net 163 146 Contract assets 68 30 Investments 76 44 Other 141 116 Other non-current assets $ 1,069 $ 819
Accounts Payable and Accrued Liabilities	As Restated as of December 31 (in millions) 2019 2018 Accounts payable $ 892 $ 998 Common stock dividends payable 111 101 Employee compensation and withholdings 456 486 Property, payroll and certain other taxes 113 131 Restructuring reserves 83 90 Accrued rebates 208 193 Operating lease liabilities 101 — Income taxes payable 85 104 Other 640 707 Accounts payable and accrued liabilities $ 2,689 $ 2,810
Other Long-Term Liabilities	As Restated as of December 31 (in millions) 2019 2018 Pension and other postretirement benefits $ 1,260 $ 1,087 Deferred tax liabilities 192 215 Long-term tax liabilities 81 77 Interest rate contracts 52 3 Litigation and environmental reserves 30 31 Restructuring reserves 9 11 Other 108 135 Other non-current liabilities $ 1,732 $ 1,559
Net Interest Expense	years ended December 31 (in millions) 2019 2018 2017 Interest costs $ 120 $ 105 $ 98 Interest costs capitalized (9) (12) (13) Interest expense 111 93 85 Interest income (40) (48) (30) Interest expense, net $ 71 $ 45 $ 55
Other (Income) Expense, Net	As Restated years ended December 31 (in millions) 2019 2018 2017 Foreign exchange losses (gains), net $ 37 $ (14) $ 63 Gain on sale of investments (1) (3) (3) Saudi Arabia joint venture gain — (24) — Venezuela deconsolidation — — 33 Pension settlement 755 1 2 Pension and other postretirement benefit plans (53) (49) 31 Other, net (7) 11 7 Other (income) expense, net $ 731 $ (78) $ 133

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	The following table is a summary of the activity in goodwill by segment. (in millions) Americas EMEA APAC Total December 31, 2017 (As Restated) $ 2,476 $ 393 $ 233 $ 3,102 Additions 15 17 — $ 32 Currency translation and other adjustments (105) (17) (10) $ (132) December 31, 2018 (As Restated) $ 2,386 $ 393 $ 223 $ 3,002 Additions 101 10 — 111 Currency translation and other adjustments (59) (18) (6) (83) December 31, 2019 $ 2,428 $ 385 $ 217 $ 3,030
Other Intangible Assets, Net	The following table is a summary of our other intangible assets. (in millions) Developed technology, Other amortized Indefinite-lived Total December 31, 2019 Gross other intangible assets $ 2,309 $ 464 $ 173 $ 2,946 Accumulated amortization (1,190) (285) — $ (1,475) Other intangible assets, net $ 1,119 $ 179 $ 173 $ 1,471 December 31, 2018 (As Restated) Gross other intangible assets $ 2,135 $ 457 $ 188 $ 2,780 Accumulated amortization (1,117) (253) — $ (1,370) Other intangible assets, net $ 1,018 $ 204 $ 188 $ 1,410

DEBT, CREDIT FACILITIES AND L_2

DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Debt Outstanding	At December 31, 2019 and 2018, we had the following debt outstanding: As Restated as of December 31 (in millions) Effective interest rate in 2019 2019 1 2018 1 Variable-rate loan due 2020 1.0 % $ 313 $ 310 1.7% notes due 2021 1.9 % 398 398 2.4% notes due 2022 2.5 % 203 202 0.40% notes due 2024 0.6 % 834 — 1.3% notes due in 2025 1.4 % 669 684 2.6% notes due 2026 2.7 % 746 745 7.65% debentures due 2027 7.7 % 5 5 6.625% debentures due 2028 6.7 % 98 98 1.3% notes due 2029 1.3 % 830 — 6.25% notes due 2037 6.3 % 265 265 3.65% notes due 2042 3.7 % 6 6 4.5% notes due 2043 4.5 % 255 255 3.5% notes due 2046 3.6 % 440 439 Finance leases and other 10.0 % 62 76 Total debt 5,124 3,483 Current portion (315) (2) Long-term portion $ 4,809 $ 3,481 1 Book values include any discounts, premiums and adjustments related to hedging instruments.
Schedule of Maturities of Long-term Debt	Future Debt Maturities as of and for the years ended December 31 (in millions) Debt maturities 2020 $ 315 2021 402 2022 207 2023 1 2024 842 Thereafter 3,393 Total obligations and commitments 5,160 Discounts, premiums, and adjustments relating to hedging instruments (36) Total debt $ 5,124

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Lease, Cost	The components of lease cost for the year ended December 31, 2019 were: (in millions) 2019 Operating lease cost $ 121 Finance lease cost Amortization of right-of-use assets 5 Interest on lease liabilities 5 Variable lease cost 89 Lease cost $ 220 The following table contains supplemental cash flow information related to leases for the year ended December 31, 2019: (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 119 Operating cash flows from finance leases 4 Financing cash flows from finance leases 4 Right-of-use operating lease assets obtained in exchange for lease obligations 207 Lease term and discount rates as of December 31, 2019 were: December 31, 2019 Weighted-average remaining lease term (years) Operating leases 10 Finance leases 15 Weighted-average discount rate Operating leases 2.8 % Finance leases 10.6 %
Assets And Liabilities, Lessee	Supplemental balance sheet information related to leases as of December 31, 2019 includes: (in millions) December 31, 2019 Operating leases Operating lease right-of-use assets $ 608 Accounts payable and accrued liabilities $ 101 Operating lease liabilities 510 Total operating lease liabilities $ 611 Finance leases Property, plant and equipment, at cost $ 63 Accumulated depreciation (19) Property, plant and equipment, net $ 44 Current maturities of long-term debt and finance lease obligations $ — Long-term debt and finance lease obligations 54 Total finance lease liabilities $ 54
Lessee, Operating Lease, Liability, Maturity	Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611
Finance Lease, Liability, Maturity	Maturities of operating and finance lease liabilities as of December 31, 2019 were: (in millions) Finance Leases Operating Leases 2020 $ 7 $ 112 2021 7 96 2022 7 80 2023 6 67 2024 6 54 Thereafter 78 267 Total minimum lease payments 111 676 Less: imputed interest (57) (65) Present value of lease liabilities $ 54 $ 611
Contractual Obligation, Fiscal Year Maturity Schedule	Maturities of operating and finance lease liabilities as of December 31, 2018 were: As Restated (in millions) Capital Leases Operating Leases 2019 $ 7 $ 123 2020 7 94 2021 8 86 2022 8 72 2023 6 64 Thereafter 88 212 Total minimum lease payments 124 $ 651 Less: imputed interest (62) Present value of lease liabilities $ 62
Operating Lease, Lease Income	The components of lease revenue for the year ended December 31, 2019 were: (in millions) 2019 Sales-type lease revenue $ 35 Operating lease revenue 61 Variable lease revenue 85 Total lease revenue $ 181
Sales-type Lease, Lease Income	The components of our net investment in sales-type leases as of December 31, 2019 were: (in millions) 2019 Minimum lease payments $ 110 Unguaranteed residual values 11 Net investment in leases $ 121 Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets: (in millions) December 31, 2019 Accounts receivable, net $ 45 Other non-current assets 76 Total $ 121
Sales-type and Direct Financing Leases, Lease Receivable, Maturity	Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110
Lessor, Operating Lease, Payments to be Received, Maturity	Maturities of sales-type and operating leases as of December 31, 2019 were: (in millions) Sales-type Leases Operating Leases 2020 $ 45 $ 61 2021 32 60 2022 22 60 2023 14 33 2024 7 15 Thereafter 1 4 Total minimum lease payments 121 $ 233 Less: imputed interest (11) Present value of minimum lease payments $ 110

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stock Options Fair Value Assumptions	The weighted-average assumptions used in estimating the fair value of stock options granted during each year, along with the weighted-average grant-date fair values, were as follows: years ended December 31 2019 2018 2017 Expected volatility 19 % 18 % 19 % Expected life (in years) 5.5 5.5 5.5 Risk-free interest rate 2.5 % 2.6 % 2.1 % Dividend yield 1.0 % 1.0 % 1.0 % Fair value per stock option $ 15 $ 13 $ 10
Summary of Stock Option Activity	The following table summarizes stock option activity for the year ended December 31, 2019 and the outstanding stock options as of December 31, 2019. (options and aggregate intrinsic values in thousands) Options Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 25,314 $ 43.76 Granted 3,801 $ 75.03 Exercised (8,043) $ 38.52 Forfeited (596) $ 66.91 Expired (132) $ 46.44 Outstanding as of December 31, 2019 20,344 $ 50.99 6.1 $ 663,620 Vested or expected to vest as of December 31, 2019 20,029 $ 50.66 6.0 $ 660,342 Exercisable as of December 31, 2019 12,945 $ 41.74 4.9 $ 542,128
Summary of Nonvested RSU Activity	The following table summarizes nonvested RSU activity for the year ended December 31, 2019. (share units in thousands) Share units Weighted- Nonvested RSUs as of January 1, 2019 1,611 $ 56.45 Granted 537 $ 75.60 Vested (740) $ 51.82 Forfeited (134) $ 63.90 Nonvested RSUs as of December 31, 2019 1,274 $ 66.46
Performance Stock Units Fair Value	The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows: years ended December 31 2019 2018 2017 Baxter volatility 19 % 19 % 19 % Peer group volatility 18%-113% 16%-53% 16%-54% Correlation of returns 0.13-0.63 0.16-0.61 0.19-0.58 Risk-free interest rate 2.5 % 2.3 % 1.6 % Fair value per PSU $ 106 $ 90 $ 69
Summary of Nonvested Performance Stock Unit Activity	The following table summarizes nonvested PSU activity for the year ended December 31, 2019. (share units in thousands) Share units Weighted- Nonvested PSUs as of January 1, 2019 913 $ 63.88 Granted 626 $ 69.36 Vested (559) $ 46.47 Forfeited (50) $ 77.70 Nonvested PSUs as of December 31, 2019 930 $ 75.50

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Summary of Changes in AOCI by Component	The following table is a net-of-tax summary of the changes in AOCI by component for the years ended December 31, 2019 and 2018. (in millions) CTA Pension and OPEB plans Hedging Total Gains (losses) Balance as of December 31, 2018 (as restated) $ (2,868) $ (954) $ (1) $ (3,823) Adoption of new accounting standard 9 (169) (1) (161) Other comprehensive (loss) income before reclassifications (95) (184) (36) (315) Amounts reclassified from AOCI (a) — 592 (3) 589 Net other comprehensive (loss) income (95) 408 (39) 274 Balance as of December 31, 2019 $ (2,954) $ (715) $ (41) $ (3,710) As Restated (in millions) CTA Pension and OPEB plans Hedging Available-for- Total Gains (losses) Balance as of December 31, 2017 $ (2,545) $ (987) $ (10) $ 3 $ (3,539) Adoption of new accounting standard — — — (3) (3) Other comprehensive income (loss) before reclassifications (323) (23) (1) — (347) Amounts reclassified from AOCI (a) — 56 10 — 66 Net other comprehensive (loss) income (323) 33 9 — (281) Balance as of December 31, 2018 $ (2,868) $ (954) $ (1) $ — $ (3,823) (a) See table below for details about these reclassifications.
Summary of Reclassification from AOCI to Net Income	The following table is a summary of the amounts reclassified from AOCI to net income during the years ended December 31, 2019 and 2018. Amounts reclassified from AOCI (a) As Restated (in millions) 2019 2018 Location of impact Pension and OPEB items Amortization of net losses and prior service costs or credits $ (31) $ (69) Other (income) expense, net Settlement charge (755) (1) Other (income) expense, net (786) (70) Total before tax Less: Tax effect 194 14 Income tax expense $ (592) $ (56) Net of tax Gains (losses) on hedging activities Foreign exchange contracts $ 4 $ (12) Cost of sales Less: Tax effect (1) 2 Income tax expense $ 3 $ (10) Net of tax Total reclassification for the period $ (589) $ (66) Total net of tax (a) Amounts in parentheses indicate reductions to net income.

BUSINESS OPTIMIZATION CHARGES (

BUSINESS OPTIMIZATION CHARGES (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring and Related Activities [Abstract]
Business Optimization Charges	We recorded the following charges related to business optimization programs in 2019, 2018, and 2017: years ended December 31 (in millions) 2019 2018 2017 Restructuring charges $ 134 $ 117 $ 70 Costs to implement business optimization programs 45 94 89 Accelerated depreciation 5 9 10 Total business optimization charges $ 184 $ 220 $ 169
Components of Restructuring Costs	During the years ended December 31, 2019, 2018 and 2017, we recorded the following restructuring charges: 2019 (in millions) COGS SG&A R&D Total Employee termination costs $ 13 $ 37 $ 25 $ 75 Contract termination and other costs 10 1 — 11 Asset impairments 37 2 9 48 Total restructuring charges $ 60 $ 40 $ 34 $ 134 2018 (in millions) COGS SG&A R&D Total Employee termination costs $ 30 $ 51 $ 19 $ 100 Contract termination and other costs 4 6 — 10 Asset impairments 1 6 — 7 Total restructuring charges $ 35 $ 63 $ 19 $ 117 2017 (in millions) COGS SG&A R&D Total Employee termination costs $ 22 $ 39 $ (2) $ 59 Contract termination and other costs — 5 — 5 Asset impairments 5 1 — 6 Total restructuring charges $ 27 $ 45 $ (2) $ 70
Summary of Activity in Reserves related to Business Optimization Initiatives	The following table summarizes activity in the liability related to our restructuring initiatives. (in millions) Liability balance as of December 31, 2016 (As Restated) $ 164 Charges 83 Payments (140) Reserve adjustments (19) Currency translation 24 Liability balance as of December 31, 2017 (As Restated) 112 Charges 126 Payments (96) Reserve adjustments (16) Currency translation (25) Liability balance as of December 31, 2018 (As Restated) 101 Charges 113 Payments (93) Reserve adjustments (27) Currency translation (2) Liability balance as of December 31, 2019 $ 92

RETIREMENT AND OTHER BENEFIT _2

RETIREMENT AND OTHER BENEFIT PROGRAMS (Tables)	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Reconciliation of Pension and OPEB Plan Obligations, Assets and Funded Status	The benefit plan information in the table below pertains to all of our pension and OPEB plans, both in the United States and in other countries. Pension benefits OPEB As Restated as of and for the years ended December 31 (in millions) 2019 2018 2019 2018 Benefit obligations Beginning of period $ 5,635 $ 6,182 $ 211 $ 235 Service cost 74 87 1 1 Interest cost 172 178 8 7 Participant contributions 4 5 — — Actuarial (gain) loss 924 (431) 26 (14) Benefit payments (267) (259) (18) (18) Settlements (2,550) (6) — — Curtailment (13) (56) — — Foreign exchange and other (6) (65) — — End of period 3,973 5,635 228 211 Fair value of plan assets Beginning of period 4,774 5,261 — — Actual return on plan assets 939 (237) — — Employer contributions 69 51 18 18 Participant contributions 4 5 — — Benefit payments (267) (259) (18) (18) Settlements (2,550) (6) — — Foreign exchange and other 4 (41) — — End of period 2,973 4,774 — — Funded status at December 31 $ (1,000) $ (861) $ (228) $ (211) Amounts recognized in the consolidated balance sheets Noncurrent asset $ 77 $ 60 $ — $ — Current liability (25) (25) (20) (20) Noncurrent liability (1,052) (896) (208) (191) Net liability recognized at December 31 $ (1,000) $ (861) $ (228) $ (211)
Information Relating to Individual Plans in Funded Status that have ABO in Excess of Plan Assets	The following table is information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets. As Restated as of December 31 (in millions) 2019 2018 ABO $ 3,240 $ 4,981 Fair value of plan assets $ 2,339 $ 4,246
Information Relating to Individual Plans in Funded Status that have PBO in Excess of Plan Assets	The following table presents information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets (many of which also have an ABO in excess of assets and are therefore also included in the table directly above). As Restated as of December 31 (in millions) 2019 2018 PBO $ 3,688 $ 5,386 Fair value of plan assets $ 2,611 $ 4,465
Expected Net Pension and OPEB Plan Payments for Next 10 Years	(in millions) Pension benefits OPEB 2020 $ 86 $ 20 2021 104 18 2022 118 17 2023 132 17 2024 149 16 2024 through 2028 917 71 Total expected net benefit payments for next 10 years $ 1,506 $ 159
Summary of Pre-Tax losses Included in AOCI	The following table is a summary of the pre-tax losses included in AOCI at December 31, 2019 and December 31, 2018. (in millions) Pension benefits OPEB Actuarial loss (gain) $ 1,025 $ (41) Prior service credit and transition obligation (9) (59) Total pre-tax loss recognized in AOCI at December 31, 2019 $ 1,016 $ (100) Actuarial loss (gain) $ 1,607 $ (79) Prior service credit and transition obligation (10) (74) Total pre-tax loss (gain) recognized in AOCI at December 31, 2018 (As Restated) $ 1,597 $ (153)
Summary of Net-of-Tax Amounts Recorded in OCI Relating to Pension and OPEB Plans	The following table is a summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans. As Restated Year ended December 31 (in millions) 2019 2018 2017 Gain (loss) arising during the year, net of tax expense (benefit) of $(64) in 2019, $(4) in 2018 and $25 in 2017 $ (184) $ (22) $ 32 Amortization of loss to earnings, net of tax benefit of $6 in 2019, $14 in 2018 and $35 in 2017 25 55 102 Settlement charge, net of tax benefit of $188 in 2019 $ 567 $ — $ — Pension and other employee benefits gain $ 408 $ 33 $ 134
Summary of Pre-tax Amounts Expected to be Amortized to Net Periodic Benefit Cost in 2019	With respect to the AOCI balance at December 31, 2019, the following table is a summary of the pre-tax amounts expected to be amortized to net periodic benefit cost in 2020. (in millions) Pension benefits OPEB Actuarial loss/(gain) $ 78 $ (4) Prior service credit and transition obligation (1) (14) Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2020 $ 77 $ (18)
Net Periodic Benefit Cost - Continuing Operations	As Restated Year ended December 31 (in millions) 2019 2018 2017 Pension benefits Service cost $ 74 $ 87 $ 91 Interest cost 172 178 180 Expected return on plan assets (264) (303) (291) Amortization of net losses and other deferred amounts 58 94 163 Settlement charges 755 1 2 Other — — (2) Net periodic pension benefit cost $ 795 $ 57 $ 143 OPEB Service cost $ 1 $ 1 $ 1 Interest cost 8 7 7 Amortization of net losses and prior service credit (27) (25) (26) Net periodic OPEB cost $ (18) $ (17) $ (18)
Weighted-Average Assumptions Used in Determining Benefit Obligations at Measurement Date	Pension benefits OPEB 2019 2018 2019 2018 Discount rate U.S. and Puerto Rico plans 3.44 % 4.31 % 3.16 % 4.20 % International plans 1.34 % 2.02 % n/a n/a Rate of compensation increase U.S. and Puerto Rico plans 3.68 % 3.66 % n/a n/a International plans 3.03 % 3.08 % n/a n/a Annual rate of increase in the per-capita cost n/a n/a 6.75 % 7.00 % Rate decreased to n/a n/a 5.00 % 5.00 % by the year ended n/a n/a 2027 2027 Pension benefits OPEB 2019 2018 2017 2019 2018 2017 Discount rate U.S. and Puerto Rico plans 4.18 % 3.60 % 4.09 % 4.20 % 3.51 % 3.89 % International plans 2.02 % 2.02 % 2.03 % n/a n/a n/a Expected return on plan assets U.S. and Puerto Rico plans 6.29 % 6.25 % 6.50 % n/a n/a n/a International plans 5.45 % 5.58 % 5.77 % n/a n/a n/a Rate of compensation increase U.S. and Puerto Rico plans 3.66 % 3.42 % 3.75 % n/a n/a n/a International plans 3.08 % 3.05 % 3.11 % n/a n/a n/a Annual rate of increase in the per-capita cost n/a n/a n/a 6.75 % 7.00 % 6.25 % Rate decreased to n/a n/a n/a 5.00 % 5.00 % 5.00 % by the year ended n/a n/a n/a 2027 2027 2023
Fair Value of Pension Plan Assets and Liabilities	The following tables summarize our pension plan financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance at December 31, 2019 Quoted prices Significant Significant Measured at NAV Assets Fixed income securities Cash and cash equivalents $ 224 $ 72 $ 152 $ — $ — U.S. government and government agency issues 452 — 452 — — Corporate bonds 352 — 352 — — Equity securities Common stock: Large cap 231 231 — — — Mid cap 158 158 — — — Small cap 37 37 — — — Total common stock 426 426 — — — Mutual funds 442 189 253 — — Common/collective trust funds 668 19 272 — 377 Partnership investments 333 — — — 333 Other holdings 76 8 58 10 — Collateral held on loaned securities 9 — 9 — — Liabilities Collateral to be paid on loaned securities (9) (9) — — — Fair value of pension plan assets $ 2,973 $ 705 $ 1,548 $ 10 $ 710 As Restated Basis of fair value measurement (in millions) Balance at December 31, 2018 Quoted prices Significant Significant Measured at NAV Assets Fixed income securities Cash and cash equivalents $ 145 $ 21 $ 124 $ — $ — U.S. government and government agency issues 735 — 735 — — Corporate bonds 1,127 — 1,127 — — Equity securities Common stock: Large cap 541 541 — — — Mid cap 298 298 — — — Small cap 91 91 — — — Total common stock 930 930 — — — Mutual funds 356 135 221 — — Common/collective trust funds 919 — 210 — 709 Partnership investments 390 — — — 390 Other holdings 172 11 151 10 — Collateral held on loaned securities 196 — 196 — — Liabilities Collateral to be paid on loaned securities (196) (34) (162) — — Fair value of pension plan assets $ 4,774 $ 1,063 $ 2,602 $ 10 $ 1,099
Changes in Fair Value Measurements that Used Significant Unobservable Inputs	The following table is a reconciliation of changes in fair value measurements that used significant unobservable inputs (Level 3). (in millions) Total Common/collective Other Balance at December 31, 2017 $ 18 $ 8 $ 10 Transfers out (8) (8) — Balance at December 31, 2018 10 — 10 Purchases — — — Balance at December 31, 2019 $ 10 $ — $ 10
Funded Status Percentage of Pension Plans	The following table details the funded status percentage of our pension plans as of December 31, 2019, including certain plans that are unfunded in accordance with the guidelines of our funding policy outlined above. United States and Puerto Rico International as of December 31, 2019 (in millions) Qualified Nonqualified Funded Unfunded Total Fair value of plan assets $ 2,060 n/a $ 913 n/a $ 2,973 PBO 2,278 $ 243 1,001 $ 451 3,973 Funded status percentage 90 % n/a 91 % n/a 75 %

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Before Income Tax Expense by Category	As Restated years ended December 31 (in millions) 2019 2018 2017 United States $ (586) $ 7 $ (320) International 1,556 1,610 1,420 Income from continuing operations before income taxes $ 970 $ 1,617 $ 1,100
Income Tax Expense	As Restated years ended December 31 (in millions) 2019 2018 2017 Current United States Federal $ 8 $ 21 $ 8 State and local 3 (1) 11 International 258 308 261 Current income tax expense 269 328 280 Deferred United States Federal (140) (228) 230 State and local (29) — 1 International (141) (35) (20) Deferred income tax expense (benefit) (310) (263) 211 Income tax expense (benefit) $ (41) $ 65 $ 491
Deferred Tax Assets and Liabilities	As Restated as of December 31 (in millions) 2019 2018 Deferred tax assets Accrued liabilities and other $ 209 $ 227 Pension and other postretirement benefits 258 222 Tax credit and net operating loss carryforwards 928 862 Swiss tax reform net asset basis step-up 159 — Operating lease liabilities 153 — Valuation allowances (420) (310) Total deferred tax assets 1,287 1,001 Deferred tax liabilities Subsidiaries’ unremitted earnings 57 43 Long-lived assets and other 649 690 Operating lease right-of-use assets 152 — Total deferred tax liabilities 858 733 Net deferred tax asset $ 429 $ 268
Income Tax Expense (Benefit) Reconciliation	Income Tax Expense (Benefit) Reconciliation As Restated years ended December 31 (in millions) 2019 2018 2017 Income tax expense at U.S. statutory rate $ 204 $ 340 $ 383 Tax incentives (140) (161) (139) State and local taxes, net of federal benefit (17) 5 (6) Impact of foreign taxes 65 122 (41) Swiss tax reform net asset basis step-up (159) — — Deferred tax revaluation due to 2017 Tax Act and foreign tax reform (19) (8) (283) Transition tax due to 2017 Tax Act (16) (5) 529 U.S. valuation allowance due to 2017 Tax Act — (194) 339 Other valuation allowances 110 21 (6) Stock compensation windfall tax benefits (54) (40) (56) Foreign tax credits — — (246) Research and development tax credits (13) (17) (5) Other, net (2) 2 22 Income tax expense (benefit) $ (41) $ 65 $ 491
Reconciliation of Unrecognized Tax Benefits	The following table is a reconciliation of our unrecognized tax benefits, including those related to discontinued operations, for the years ended December 31, 2019, 2018 and 2017. as of and for the years ended (in millions) 2019 2018 2017 Balance at beginning of the year $ 127 $ 108 $ 82 Increase associated with tax positions taken during the current year 8 33 33 Increase (decrease) associated with tax positions taken during a prior year (3) 13 2 Settlements (20) (5) (6) Decrease associated with lapses in statutes of limitations (1) (22) (3) Balance at end of the year $ 111 $ 127 $ 108

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table is a reconciliation of income from continuing operations to net income attributable to Baxter stockholders. years ended December 31(in millions) 2019 2018 2017 Income from continuing operations $ 1,011 $ 1,552 $ 609 Less: Income from continuing operations attributable to noncontrolling interests $ 10 $ — $ — Income from continuing operations attributable to Baxter stockholders $ 1,001 $ 1,552 $ 609 Loss from discontinued operations attributable to Baxter stockholders $ — $ (6) $ (7) Net income attributable to Baxter stockholders $ 1,001 $ 1,546 $ 602
Reconciliation of Basic Shares to Diluted Shares	The following table is a reconciliation of basic shares to diluted shares. years ended December 31(in millions) 2019 2018 2017 Basic shares 509 534 543 Effect of dilutive securities 10 12 12 Diluted shares 519 546 555

FINANCIAL INSTRUMENTS, DERIVA_2

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Activity Relating to Securitization Arrangement	The following is a summary of the activity relating to the arrangement. As Restated as of and for the years ended December 31 (in millions) 2019 2018 2017 Sold receivables at beginning of year $ 69 $ 70 $ 67 Proceeds from sales of receivables $ 292 $ 267 $ 270 Cash collections (remitted to the owners of the receivables) $ (282) $ (270) $ (270) Effect of foreign exchange rate changes $ — $ 2 $ 3 Sold receivables at end of year $ 79 $ 69 $ 70
Summary of Gains and Losses on Derivative Instruments	The following table summarizes the income statement locations and gains and losses on our hedging instruments for the years ended December 31, 2019, 2018, and 2017. (in millions) Gain (loss) Location of gain Gain (loss) reclassified from As Restated 2019 2018 2017 2019 2018 2017 Cash flow hedges Interest rate contracts $ (37) $ (3) $ (3) Interest expense, net $ — $ — $ — Foreign exchange contracts (9) 3 (24) Cost of sales 4 (12) (8) Net investment hedges 12 32 (65) Other (income) expense, net — — — Total $ (34) $ 32 $ (92) $ 4 $ (12) $ (8) Location of gain (loss) in Gain (loss) recognized As Restated (in millions) 2019 2018 2017 Fair value hedges Interest rate contracts Interest expense, net $ — $ (4) $ (3) Undesignated derivative instruments Foreign exchange contracts Other (income) expense, net $ (17) $ — $ (37)
Net of Tax Activity in Accumulated Other Comprehensive Income Related to Cash Flow Hedges	The following table summarizes net-of-tax activity in AOCI, a component of stockholders’ equity, related to our cash flow hedges. as of and for the year ended December 31 (in millions) 2019 2018 2017 Accumulated other comprehensive income (loss) balance at beginning of year $ (1) $ (10) $ 3 Adoption of new accounting standard (1) — — (Loss) gain in fair value of derivatives during the year (36) (1) (18) Amount reclassified to earnings during the year (3) 10 5 Accumulated other comprehensive income (loss) balance at end of year $ (41) $ (1) $ (10)
Classification and Fair Value Amounts of Derivative Instruments	The following table summarizes the classification and fair value amounts of derivative instruments reported in the consolidated balance sheet as of December 31, 2019. Derivatives in asset positions Derivatives in liability positions (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ 10 Other non-current liabilities $ 52 Foreign exchange contracts Prepaid expenses and other current assets 10 Accounts payable and — Foreign exchange contracts Other non-current assets — Other non-current liabilities — Total derivative instruments designated as hedges 20 52 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other current assets 1 Accounts payable and 2 Total derivative instruments $ 21 $ 54 The following table summarizes the classification and fair values of derivative instruments reported in the consolidated balance sheet as of December 31, 2018. Derivatives in asset positions Derivatives in liability positions As Restated As Restated (in millions) Balance sheet location Fair value Balance sheet location Fair value Derivative instruments designated as hedges Interest rate contracts Other non-current assets $ — Other non-current $ 3 Foreign exchange contracts Prepaid expenses and other current assets 22 Accounts payable and 1 Foreign exchange contracts Other non-current assets 1 Other non-current liabilities — Total derivative instruments designated as hedges 23 4 Undesignated derivative instruments Foreign exchange contracts Prepaid expenses and other current assets 2 Accounts payable and 2 Total derivative instruments $ 25 $ 6
Derivative Positions Presented on Net Basis	The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty. December 31, 2019 December 31, 2018 As Restated (in millions) Asset Liability Asset Liability Gross amounts recognized in the consolidated balance sheets $ 21 $ 54 $ 25 $ 6 Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheets (11) (11) (3) (3) Total $ 10 $ 43 $ 22 $ 3
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location	The following table presents the amounts recorded on the consolidated balance sheets related to fair value hedges: Carrying amount of hedged item Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item (a) (in millions) Balance as of December 31, 2019 Balance as of December 31, 2018 Balance as of December 31, 2019 Balance as of December 31, 2018 Long-term debt $ 103 $ 103 $ 6 $ 7 (a) These fair value hedges were terminated prior to December 31, 2018.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes financial instruments that are measured at fair value on a recurring basis. Basis of fair value measurement (in millions) Balance as of December 31, Quoted prices Significant Significant Assets Foreign exchange contracts $ 11 $ — $ 11 $ — Interest rate contracts 10 — 10 — Marketable equity securities 3 3 — — Total $ 24 $ 3 $ 21 $ — Liabilities Foreign exchange contracts $ 2 $ — $ 2 $ — Interest rate contracts 52 — 52 — Contingent payments related to acquisitions 39 — — 39 Total $ 93 $ — $ 54 $ 39 As Restated Basis of fair value measurement (in millions) Balance as of December 31, Quoted prices Significant Significant Assets Foreign exchange contracts $ 25 $ — $ 25 $ — Marketable equity securities 3 3 — — Total $ 28 $ 3 $ 25 $ — Liabilities Foreign exchange contracts $ 3 $ — $ 3 $ — Interest rate contracts 3 — 3 — Contingent payments related to acquisitions 32 — — 32 Total $ 38 $ — $ 6 $ 32
Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs	The following table is a reconciliation of our recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions. as of and for the years ended December 31 (in millions) 2019 2018 Fair value at beginning of period $ 32 $ 9 Additions 18 24 Change in fair value recognized in earnings (4) — Payments (7) (1) Fair value at end of period $ 39 $ 32
Book Values and Fair Values of Financial Instruments	For these financial instruments, the following table provides the values recognized in the consolidated balance sheets and the estimated fair values. Book values Fair values(a) As Restated As Restated as of December 31 (in millions) 2019 2018 2019 2018 Liabilities Short-term debt $ 226 $ 2 $ 226 $ 2 Current maturities of long-term debt and finance lease obligations 315 2 315 2 Long-term debt and finance lease obligations 4,809 3,481 5,156 3,469 (a) These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	Financial information for our segments is as follows: As Restated for the years ended December 31 (in millions) 2019 2018 2017 Net sales: Americas $ 6,094 $ 5,951 $ 5,718 EMEA 2,968 2,946 2,752 APAC 2,300 2,202 2,114 Total net sales $ 11,362 $ 11,099 $ 10,584 Operating income: Americas $ 2,374 $ 2,411 $ 2,238 EMEA 652 666 562 APAC 549 532 510 Total segment operating income $ 3,575 $ 3,609 $ 3,310 Depreciation Expense: Americas $ 255 $ 229 $ 231 EMEA 149 158 149 APAC 85 95 84 Corporate and other 117 120 132 Total depreciation expense $ 606 $ 602 $ 596 Capital expenditures: Americas $ 325 $ 296 $ 269 EMEA 143 140 141 APAC 98 122 95 Corporate and other 120 134 101 Total capital expenditures $ 686 $ 692 $ 606
Operating Income to Income from Continuing Operations Reconciliation	The following table is a reconciliation of segment operating income to income from continuing operations before income taxes per the consolidated statements of income. As Restated for the years ended December 31 (in millions) 2019 2018 2017 Total segment operating income $ 3,575 $ 3,609 $ 3,310 Corporate and other (1,803) (2,025) (2,022) Total operating income 1,772 1,584 1,288 Net interest expense 71 45 55 Other (income) expense, net 731 (78) 133 Income from continuing operations before income taxes $ 970 $ 1,617 $ 1,100
Geographic Information	As Restated for the years ended December 31 (in millions) 2019 2018 2017 Net sales: United States $ 4,826 $ 4,723 $ 4,510 Latin America and Canada 1,268 1,228 1,208 Total Americas $ 6,094 $ 5,951 $ 5,718 EMEA 2,968 2,946 2,752 APAC 2,300 2,202 2,114 Total net sales $ 11,362 $ 11,099 $ 10,584 As Restated as of December 31 (in millions) 2019 2018 PP&E and operating lease right-of-use assets, net: United States $ 1,889 $ 1,786 EMEA 1,447 1,204 APAC 959 892 Latin America and Canada 825 648 Consolidated PP&E and operating lease right-of-use assets, net $ 5,120 $ 4,530

QUARTERLY FINANCIAL DATA (UNA_2

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Results and Market for Company's Stock	As Restated years ended December 31 (in millions, except per share data) First quarter Second quarter Third quarter Fourth quarter¹ Full year 2019 Net sales $ 2,638 $ 2,834 $ 2,851 $ 3,039 $ 11,362 Gross margin 1,080 1,153 1,230 1,298 4,761 Net income (loss) attributable to Baxter stockholders 342 313 369 (23) 1,001 Earnings (loss) per share Basic 0.67 0.61 0.72 (0.05) 1.97 Diluted 0.66 0.60 0.71 (0.05) 1.93 Cash dividends declared per share 0.190 0.220 0.220 0.220 0.850 Market price per share High 81.31 82.41 89.78 88.45 89.78 Low 64.48 73.44 81.40 76.70 64.48 As Restated As Restated First quarter Second quarter Third quarter Fourth quarter Full year 2018 Net sales $ 2,692 $ 2,813 $ 2,761 $ 2,833 $ 11,099 Gross margin 1,121 1,223 1,232 1,183 4,759 Income from continuing operations 382 341 518 311 1,552 Earnings per share from continuing operations Basic 0.71 0.64 0.97 0.59 2.91 Diluted 0.69 0.62 0.95 0.58 2.84 Loss from discontinued operations, net of tax — — — (6) (6) Loss per share from discontinued operations Basic — — — (0.01) (0.01) Diluted — — — (0.01) (0.01) Net income 382 341 518 305 1,546 Earnings per share Basic 0.71 0.64 0.97 0.58 2.90 Diluted 0.69 0.62 0.95 0.57 2.83 Cash dividends declared per share 0.160 0.190 0.190 0.190 0.730 Market price per share High 72.26 75.41 77.75 77.80 77.80 Low 62.56 63.43 70.71 61.45 61.45
Schedule of Error Corrections and Prior Period Adjustments	Baxter International Inc. Condensed Consolidated Balance Sheets (in millions, except per share) As Restated June 30, March 31, Current assets: Cash and cash equivalents $ 2,934 $ 1,902 Accounts receivable, net 1,897 1,801 Inventories 1,756 1,743 Prepaid expenses and other current assets 642 614 Total current assets 7,229 6,060 Property, plant and equipment, net 4,485 4,476 Goodwill 2,937 2,929 Other intangible assets, net 1,363 1,440 Operating lease right-of-use assets 595 513 Other non-current assets 894 823 Total assets $ 17,503 $ 16,241 Current liabilities: Short-term debt $ 2 $ 796 Current maturities of long-term debt and finance lease obligations 2 2 Accounts payable and accrued liabilities 2,553 2,478 Total current liabilities 2,557 3,276 Long-term debt and finance lease obligations 5,157 3,451 Operating lease liabilities 496 417 Other non-current liabilities 1,490 1,504 Total liabilities 9,700 8,648 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares at June 30, 2019 and March 31, 2019 683 683 Common stock in treasury, at cost, 173,275,586 shares at June 30, 2019 and 173,447,198 shares at March 31, 2019 (10,322) (10,284) Additional contributed capital 5,906 5,839 Retained earnings 15,598 15,414 Accumulated other comprehensive (loss) income (4,086) (4,082) Total Baxter stockholders’ equity 7,779 7,570 Noncontrolling interests 24 23 Total equity 7,803 7,593 Total liabilities and equity $ 17,503 $ 16,241 Baxter International Inc. Condensed Consolidated Balance Sheets (in millions, except per share) As Restated September 30, June 30, March 31, Current assets: Cash and cash equivalents $ 2,863 $ 2,858 $ 2,949 Accounts receivable, net 1,837 1,789 1,818 Inventories 1,716 1,616 1,578 Prepaid expenses and other current assets 615 621 610 Total current assets 7,031 6,884 6,955 Property, plant and equipment, net 4,476 4,486 4,576 Goodwill 2,978 2,981 3,103 Other intangible assets, net 1,400 1,424 1,505 Other non-current assets 918 744 704 Total assets $ 16,803 $ 16,519 $ 16,843 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ 3 $ 3 Accounts payable and accrued liabilities 2,660 2,583 2,598 Total current liabilities 2,663 2,586 2,601 Long-term debt and finance lease obligations 3,480 3,491 3,550 Other non-current liabilities 1,570 1,612 1,630 Total liabilities 7,713 7,689 7,781 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares at September 30, 2018, June 30, 2018 and March 31, 2018 683 683 683 Common stock in treasury, at cost, 150,213,621 shares at September 30, 2018, 148,485,202 shares at June 30, 2018 and 146,993,164 shares at March 31, 2018 (8,639) (8,485) (8,354) Additional contributed capital 5,931 5,916 5,912 Retained earnings 14,886 14,484 14,254 Accumulated other comprehensive (loss) income (3,754) (3,756) (3,427) Total Baxter stockholders’ equity 9,107 8,842 9,068 Noncontrolling interests (17) (12) (6) Total equity 9,090 8,830 9,062 Total liabilities and equity $ 16,803 $ 16,519 $ 16,843 Baxter International Inc. Condensed Consolidated Statements of Income (in millions, except per share) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net sales $ 5,472 $ 2,834 $ 2,638 Cost of sales 3,239 1,681 1,558 Gross margin 2,233 1,153 1,080 Selling, general and administrative expenses 1,242 641 601 Research and development expenses 295 166 129 Other operating income, net (37) (4) (33) Operating income 733 350 383 Interest expense, net 38 20 18 Other (income) expense, net (17) 4 (21) Income before income taxes 712 326 386 Income tax expense 57 13 44 Net income $ 655 $ 313 $ 342 Earnings per share Basic $ 1.28 $ 0.61 $ 0.67 Diluted $ 1.26 $ 0.60 $ 0.66 Weighted-average number of shares outstanding Basic 511 510 512 Diluted 520 519 522 Baxter International Inc. Condensed Consolidated Statements of Income (in millions, except per share) As Restated December 31, June 30, March 31, Three months ended Six months ended Three months ended Three months ended Net sales $ 2,833 $ 5,505 $ 2,813 $ 2,692 Cost of sales 1,650 3,161 1,590 1,571 Gross margin 1,183 2,344 1,223 1,121 Selling, general and administrative expenses 627 1,309 676 633 Research and development expenses 175 313 172 141 Other operating income, net (10) (89) (2) (87) Operating income 391 811 377 434 Interest expense, net 11 23 11 12 Other (income) expense, net (33) (44) (38) (6) Income from continuing operations before income taxes 413 832 404 428 Income tax expense 102 109 63 46 Income from continuing operations 311 723 341 382 Loss from discontinued operations, net of tax (6) — — — Net income $ 305 $ 723 $ 341 $ 382 Earnings per share from continuing operations Basic $ 0.59 $ 1.35 $ 0.64 $ 0.71 Diluted $ 0.58 $ 1.32 $ 0.62 $ 0.69 Loss per share from discontinued operations Basic $ (0.01) $ — $ — $ — Diluted $ (0.01) $ — $ — $ — Earnings per share Basic $ 0.58 $ 1.35 $ 0.64 $ 0.71 Diluted $ 0.57 $ 1.32 $ 0.62 $ 0.69 Weighted-average number of shares outstanding Basic 528 537 535 539 Diluted 538 549 547 551 Baxter International Inc. Condensed Consolidated Statements of Comprehensive Income (in millions) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net income $ 655 $ 313 $ 342 Other comprehensive (loss) income, net of tax: Currency translation adjustments (95) 2 (97) Pension and other postretirement benefit plans 20 6 14 Hedging activities (27) (12) (15) Total other comprehensive (loss) income, net of tax (102) (4) (98) Comprehensive income $ 553 $ 309 $ 244 Baxter International Inc. Condensed Consolidated Statements of Comprehensive Income (in millions) As Restated June 30, March 31, Six months ended Three months ended Three months ended Net income $ 723 $ 341 $ 382 Other comprehensive (loss) income, net of tax: Currency translation adjustments (305) (368) 63 Pension and other postretirement benefit plans 85 28 57 Hedging activities 6 11 (5) Total other comprehensive (loss) income, net of tax (214) (329) 115 Comprehensive income $ 509 $ 12 $ 497 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended June 30, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of April 1, 2019 683 $ 683 173 $ (10,284) $ 5,839 $ 15,414 $ (4,082) $ 7,570 $ 23 $ 7,593 Net income — — — — — 313 — 313 — 313 Other comprehensive income (loss) — — — — — — (4) (4) — (4) Purchases of treasury stock — — 2 (157) 46 — — (111) — (111) Stock issued under employee benefit plans and other — — (2) 119 21 (17) — 123 — 123 Dividends declared on common stock — — — — — (112) — (112) — (112) Change in noncontrolling interests — — — — — — — — 1 1 Balance as of June 30, 2019 683 $ 683 173 $ (10,322) $ 5,906 $ 15,598 $ (4,086) $ 7,779 $ 24 $ 7,803 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Six Months Ended June 30, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2019 683 $ 683 170 $ (9,989) $ 5,898 $ 15,075 $ (3,823) $ 7,844 $ 22 $ 7,866 Adoption of new accounting standards — — — — — 161 (161) — — — Net income — — — — — 655 — 655 — 655 Other comprehensive income (loss) — — — — — — (102) (102) — (102) Purchases of treasury stock — — 10 (743) 46 — — (697) — (697) Stock issued under employee benefit plans and other — — (7) 410 (38) (83) — 289 — 289 Dividends declared on common stock — — — — — (210) — (210) — (210) Change in noncontrolling interests — — — — — — — — 2 2 Balance as of June 30, 2019 683 $ 683 173 $ (10,322) $ 5,906 $ 15,598 $ (4,086) $ 7,779 $ 24 $ 7,803 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended March 31, 2019 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2019 683 $ 683 170 $ (9,989) $ 5,898 $ 15,075 $ (3,823) $ 7,844 $ 22 $ 7,866 Adoption of new accounting standards — — — — — 161 (161) — — — Net income — — — — — 342 — 342 — 342 Other comprehensive income (loss) — — — — — — (98) (98) — (98) Purchases of treasury stock — — 8 (586) — — — (586) — (586) Stock issued under employee benefit plans and other — — (5) 291 (59) (66) — 166 — 166 Dividends declared on common stock — — — — — (98) — (98) — (98) Change in noncontrolling interests — — — — — — — — 1 1 Balance as of March 31, 2019 683 $ 683 173 $ (10,284) $ 5,839 $ 15,414 $ (4,082) $ 7,570 $ 23 $ 7,593 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended June 30, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of April 1, 2018 683 $ 683 147 $ (8,354) $ 5,912 $ 14,254 $ (3,427) $ 9,068 $ (6) $ 9,062 Net income — — — — — 341 — 341 — 341 Other comprehensive income (loss) — — — — — — (329) (329) — (329) Purchases of treasury stock — — 3 (259) — — — (259) — (259) Stock issued under employee benefit plans and other — — (2) 128 4 (9) — 123 — 123 Dividends declared on common stock — — — — — (102) — (102) — (102) Change in noncontrolling interests — — — — — — — — (6) (6) Balance as of June 30, 2018 683 683 148 (8,485) 5,916 14,484 (3,756) 8,842 (12) 8,830 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Six Months Ended June 30, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (20) (3) (23) — (23) Net income — — — — — 723 — 723 — 723 Other comprehensive income (loss) — — — — — — (214) (214) — (214) Purchases of treasury stock — — 11 (781) — — — (781) — (781) Stock issued under employee benefit plans and other — — (5) 277 (24) (45) — 208 — 208 Dividends declared on common stock — — — — — (188) — (188) — (188) Change in noncontrolling interests — — — — — — — — (4) (4) Balance as of June 30, 2018 683 $ 683 148 $ (8,485) $ 5,916 $ 14,484 $ (3,756) $ 8,842 $ (12) $ 8,830 Baxter International Inc. Condensed Consolidated Statements of Changes in Equity (in millions) As Restated For the Three Months Ended March 31, 2018 Baxter International Inc. stockholders' equity Common stock shares Common stock Common stock shares in treasury Common stock in treasury Additional contributed capital Retained earnings Accumulated other comprehensive income (loss) Total Baxter stockholders' equity Noncontrolling interests Total equity Balance as of January 1, 2018 683 $ 683 142 $ (7,981) $ 5,940 $ 14,014 $ (3,539) $ 9,117 $ (8) $ 9,109 Adoption of new accounting standards — — — — — (20) (3) (23) — (23) Net income — — — — — 382 — 382 — 382 Other comprehensive income (loss) — — — — — — 115 115 — 115 Purchases of treasury stock — — 8 (522) — — — (522) — (522) Stock issued under employee benefit plans and other — — (3) 149 (28) (36) — 85 — 85 Dividends declared on common stock — — — — — (86) — (86) — (86) Change in noncontrolling interests — — — — — — — — 2 2 Balance as of March 31, 2018 683 $ 683 147 $ (8,354) $ 5,912 $ 14,254 $ (3,427) $ 9,068 $ (6) $ 9,062 Baxter International Inc. Condensed Consolidated Statements of Cash Flows (in millions) As Restated Six months ended June 30, 2019 Three months ended March 31, 2019 Cash flows from operations Net income $ 655 $ 342 Adjustments to reconcile net income to net cash from operating activities: Depreciation and amortization 385 192 Deferred income taxes (63) (6) Stock compensation 57 22 Net periodic pension benefit and other postretirement costs 7 3 Intangible asset impairment 31 — Other 44 14 Changes in balance sheet items: Accounts receivable, net (60) 32 Inventories (91) (82) Accounts payable and accrued liabilities (299) (335) Other (86) (48) Cash flows from operations – continuing operations 580 134 Cash flows from operations – discontinued operations (6) (6) Cash flows from operations 574 128 Cash flows from investing activities Capital expenditures (338) (193) Acquisitions and investments, net of cash acquired (111) (109) Other investing activities, net 1 1 Cash flows from investing activities (448) (301) Cash flows from financing activities Issuances of debt 1,661 — Net increases in debt obligations with original maturities of three months or less — 795 Cash dividends on common stock (198) (101) Proceeds from stock issued under employee benefit plans 262 173 Purchases of treasury stock (720) (597) Other financing activities, net (37) (32) Cash flows from financing activities 968 238 Effect of foreign exchange rate changes on cash and cash equivalents 2 (1) Increase in cash and cash equivalents 1,096 64 Cash and cash equivalents at beginning of period 1,838 1,838 Cash and cash equivalents at end of period $ 2,934 $ 1,902 Baxter International Inc. Condensed Consolidated Statements of Cash Flows (in millions) As Restated Six months ended June 30, 2018 Three months ended March 31, 2018 Cash flows from operations Net income $ 723 $ 382 Adjustments to reconcile income from continuing operations to net cash from operating activities: Depreciation and amortization 382 190 Deferred income taxes (51) (38) Stock compensation 54 20 Net periodic pension benefit and other postretirement costs 21 10 Other — (1) Changes in balance sheet items: Accounts receivable, net 43 76 Inventories (134) (56) Accounts payable and accrued liabilities (124) (119) Other (82) (34) Cash flows from operations 832 430 Cash flows from investing activities Capital expenditures (303) (152) Acquisitions and investments, net of cash acquired (228) (219) Cash flows from investing activities (531) (371) Cash flows from financing activities Cash dividends on common stock (173) (87) Proceeds from stock issued under employee benefit plans 170 82 Purchases of treasury stock (781) (522) Other financing activities, net (24) (18) Cash flows from financing activities (808) (545) Effect of foreign exchange rate changes on cash and cash equivalents (38) 32 Decrease in cash and cash equivalents (545) (454) Cash and cash equivalents at beginning of period 3,403 3,403 Cash and cash equivalents at end of period $ 2,858 $ 2,949 Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) June 30, 2019 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,925 $ 9 (e) $ 2,934 Accounts receivable, net 1,885 12 (e)(g) 1,897 Inventories 1,757 (1) (e)(g) 1,756 Prepaid expenses and other current assets 651 (9) (b)(e)(g) 642 Total current assets 7,218 11 7,229 Property, plant and equipment, net 4,541 (56) (c)(e) 4,485 Goodwill 2,938 (1) (e) 2,937 Other intangible assets, net 1,364 (1) (g) 1,363 Operating lease right-of-use assets 588 7 (e) 595 Other non-current assets 895 (1) (a)(c)(e)(g) 894 Total assets $ 17,544 $ (41) $ 17,503 Current liabilities: Short-term debt $ 2 $ — $ 2 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,593 (40) (b)(e)(g) 2,553 Total current liabilities 2,597 (40) 2,557 Long-term debt and finance lease obligations 5,157 — 5,157 Operating lease liabilities 490 6 (e) 496 Other non-current liabilities 1,464 26 (a)(c)(e)(g) 1,490 Total liabilities 9,708 (8) 9,700 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 173,275,586 shares (10,322) — (10,322) Additional contributed capital 5,906 — 5,906 Retained earnings 16,184 (586) (a)(b)(c)(e)(g) 15,598 Accumulated other comprehensive (loss) income (4,639) 553 (a)(e) (4,086) Total Baxter stockholders’ equity 7,812 (33) 7,779 Noncontrolling interests 24 — 24 Total equity 7,836 (33) 7,803 Total liabilities and equity $ 17,544 $ (41) $ 17,503 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $514 million and accumulated other comprehensive loss of $514 million and increases to other non-current assets of $12 million and other non-current liabilities of $12 million as of June 30, 2019. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $2 million and accounts payable and other accrued liabilities of $4 million and a decrease to retained earnings of $2 million as of June 30, 2019. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $61 million, other non-current liabilities of $6 million, and retained earnings of $44 million and an increase to other non-current assets of $11 million as of June 30, 2019. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $9 million, accounts receivable, net of $6 million, inventories of $4 million, prepaid expenses and other current assets of $1 million, property, plant and equipment, net of $5 million, operating lease right-of-use assets of $7 million, other non-current assets of $5 million, accounts payable and accrued liabilities of $3 million, operating lease liabilities of $6 million, and other non-current liabilities of $4 million and decreases to goodwill of $1 million, retained earnings of $16 million, and accumulated other comprehensive loss of $39 million as of June 30, 2019. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million and retained earnings of $10 million as of June 30, 2019. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) March 31, 2019 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 1,908 $ (6) (e) $ 1,902 Accounts receivable, net 1,802 (1) (e)(g) 1,801 Inventories 1,751 (8) (e)(g) 1,743 Prepaid expenses and other current assets 626 (12) (b)(e)(g) 614 Total current assets 6,087 (27) 6,060 Property, plant and equipment, net 4,539 (63) (c)(e) 4,476 Goodwill 2,930 (1) (e) 2,929 Other intangible assets, net 1,441 (1) (g) 1,440 Operating lease right-of-use assets 517 (4) (e) 513 Other non-current assets 836 (13) (a)(c)(e)(g) 823 Total assets $ 16,350 $ (109) $ 16,241 Current liabilities: Short-term debt $ 796 $ — $ 796 Current maturities of long-term debt and finance lease obligations 2 — 2 Accounts payable and accrued liabilities 2,529 (51) (e)(g) 2,478 Total current liabilities 3,327 (51) 3,276 Long-term debt and finance lease obligations 3,451 — 3,451 Operating lease liabilities 420 (3) (e) 417 Other non-current liabilities 1,483 21 (a)(c)(e)(g) 1,504 Total liabilities 8,681 (33) 8,648 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 173,447,198 shares (10,284) — (10,284) Additional contributed capital 5,839 — 5,839 Retained earnings 15,970 (556) (a)(b)(c)(e)(g) 15,414 Accumulated other comprehensive (loss) income (4,562) 480 (a)(e) (4,082) Total Baxter stockholders’ equity 7,646 (76) 7,570 Noncontrolling interests 23 — 23 Total equity 7,669 (76) 7,593 Total liabilities and equity $ 16,350 $ (109) $ 16,241 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $491 million and accumulated other comprehensive loss of $487 million and increases to other non-current assets of $9 million and other non-current liabilities of $13 million as of March 31, 2019. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $1 million and retained earnings of $1 million as of March 31, 2019. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $55 million, other non-current liabilities of $5 million, and retained earnings of $40 million and an increase to other non-current assets of $10 million as of March 31, 2019. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in decreases to cash and cash equivalents of $6 million, accounts receivable, net of $7 million, inventories of $3 million, prepaid expenses and other current assets of $1 million, property, plant and equipment, net of $8 million, goodwill of $1 million, operating lease right-of-use assets of $4 million, other non-current assets of $3 million, accounts payable and accrued liabilities of $4 million, operating lease liabilities of $3 million, other non-current liabilities of $3 million, retained earnings of $16 million and an increase to accumulated other comprehensive loss of $7 million as of March 31, 2019. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million as of March 31, 2019. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) September 30, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,860 $ 3 (e) $ 2,863 Accounts receivable, net 1,826 11 (e)(g) 1,837 Inventories 1,718 (2) (e)(g) 1,716 Prepaid expenses and other current assets 624 (9) (b)(g) 615 Total current assets 7,028 3 7,031 Property, plant and equipment, net 4,520 (44) (c)(e) 4,476 Goodwill 2,980 (2) (e) 2,978 Other intangible assets, net 1,402 (2) (e)(g) 1,400 Other non-current assets 917 1 (a)(c)(e)(g) 918 Total assets $ 16,847 $ (44) $ 16,803 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ — $ 3 Accounts payable and accrued liabilities 2,701 (41) (b)(e)(g) 2,660 Total current liabilities 2,704 (41) 2,663 Long-term debt and finance lease obligations 3,485 (5) (e) 3,480 Other non-current liabilities 1,545 25 (a)(c)(e)(g) 1,570 Total liabilities 7,734 (21) 7,713 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 150,213,621 shares (8,639) — (8,639) Additional contributed capital 5,931 — 5,931 Retained earnings 15,394 (508) (a)(b)(c)(e)(g) 14,886 Accumulated other comprehensive (loss) income (4,239) 485 (a)(e) (3,754) Total Baxter stockholders’ equity 9,130 (23) 9,107 Noncontrolling interests (17) — (17) Total equity 9,113 (23) 9,090 Total liabilities and equity $ 16,847 $ (44) $ 16,803 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $448 million and accumulated other comprehensive loss of $456 million and increases to other non-current assets of $20 million and other non-current liabilities of $12 million as of September 30, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $3 million and accounts payable and accrued liabilities of $4 million and a decrease to retained earnings of $1 million as of September 30, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $49 million, other non-current liabilities of $2 million, and retained earnings of $35 million and an increase to other non-current assets of $12 million as of September 30, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $3 million, accounts receivable, net of $5 million, inventories of $3 million, property, plant and equipment, net of $5 million and accounts payable and accrued liabilities of $2 million and decreases to goodwill of $2 million, other intangible assets, net of $1 million, other non-current assets of $2 million, long-term debt and finance lease obligations of $5 million, other non-current liabilities of $1 million, retained earnings of $14 million, and accumulated other comprehensive loss of $29 million as of September 30, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million as of September 30, 2018. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) June 30, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,857 $ 1 (e) $ 2,858 Accounts receivable, net 1,783 6 (g) 1,789 Inventories 1,622 (6) (e)(g) 1,616 Prepaid expenses and other current assets 628 (7) (b)(e)(g) 621 Total current assets 6,890 (6) 6,884 Property, plant and equipment, net 4,531 (45) (c) 4,486 Goodwill 2,984 (3) (e) 2,981 Other intangible assets, net 1,427 (3) (e)(g) 1,424 Other non-current assets 746 (2) (a)(c)(g) 744 Total assets $ 16,578 $ (59) $ 16,519 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ — $ 3 Accounts payable and accrued liabilities 2,626 (43) (b)(g) 2,583 Total current liabilities 2,629 (43) 2,586 Long-term debt and finance lease obligations 3,495 (4) (e) 3,491 Other non-current liabilities 1,585 27 (a)(c)(g) 1,612 Total liabilities 7,709 (20) 7,689 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 148,485,202 shares (8,485) — (8,485) Additional contributed capital 5,916 — 5,916 Retained earnings 14,966 (482) (a)(c)(e)(g) 14,484 Accumulated other comprehensive (loss) income (4,199) 443 (a)(e) (3,756) Total Baxter stockholders’ equity 8,881 (39) 8,842 Noncontrolling interests (12) — (12) Total equity 8,869 (39) 8,830 Total liabilities and equity $ 16,578 $ (59) $ 16,519 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $425 million and accumulated other comprehensive loss of $428 million and increases to other non-current assets of $16 million and other non-current liabilities of $13 million as of June 30, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and other current assets of $4 million and accounts payable and accrued liabilities of $4 million as of June 30, 2018. (c) Equipment Leased to Customers under Operating Leases—The correction of these misstatements resulted in decreases to property, plant and equipment, net of $45 million, other non-current liabilities of $2 million, and retained earnings of $32 million and an increase to other non-current assets of $11 million as of June 30, 2018. (e) Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars—The correction of these misstatements resulted in increases to cash and cash equivalents of $1 million and prepaid expenses and other current assets of $1 million and decreases to inventories of $1 million, goodwill of $3 million, other intangible assets, net of $2 million, long-term debt and finance lease obligations of $4 million, retained earnings of $15 million, and accumulated other comprehensive loss of $15 million as of June 30, 2018. (g) Other miscellaneous adjustments - The correction of these misstatements resulted in increases to accounts receivable, net of $6 million and other non-current liabilities of $16 million and decreases to inventories of $5 million, prepaid expenses and other current assets of $12 million, other intangible assets, net of $1 million, other non-current assets of $29 million, accounts payable and accrued liabilities of $47 million, and retained earnings of $10 million as of June 30, 2018. Baxter International Inc. Condensed Consolidated Balance Sheet (in millions, except per share) March 31, 2018 As previously reported Restatement impacts Restatement reference As restated Current assets: Cash and cash equivalents $ 2,947 $ 2 (e) $ 2,949 Accounts receivable, net 1,807 11 (e)(g) 1,818 Inventories 1,581 (3) (e)(g) 1,578 Prepaid expenses and other current assets 621 (11) (b)(g) 610 Total current assets 6,956 (1) 6,955 Property, plant and equipment, net 4,614 (38) (c)(e) 4,576 Goodwill 3,107 (4) (e) 3,103 Other intangible assets, net 1,507 (2) (e)(g) 1,505 Other non-current assets 706 (2) (a)(c)(e)(g) 704 Total assets $ 16,890 $ (47) $ 16,843 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 3 $ — $ 3 Accounts payable and accrued liabilities 2,639 (41) (b)(e)(g) 2,598 Total current liabilities 2,642 (41) 2,601 Long-term debt and finance lease obligations 3,550 — 3,550 Other non-current liabilities 1,605 25 (a)(c)(e)(g) 1,630 Total liabilities 7,797 (16) 7,781 Commitments and contingencies Equity: Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares 683 — 683 Common stock in treasury, at cost, 146,993,164 shares (8,354) — (8,354) Additional contributed capital 5,912 — 5,912 Retained earnings 14,734 (480) (a)(b)(c)(e)(g) 14,254 Accumulated other comprehensive (loss) income (3,876) 449 (a)(e) (3,427) Total Baxter stockholders’ equity 9,099 (31) 9,068 Noncontrolling interests (6) — (6) Total equity 9,093 (31) 9,062 Total liabilities and equity $ 16,890 $ (47) $ 16,843 (a) Foreign Currency Denominated Monetary Assets and Liabilities—The correction of these misstatements resulted in decreases to retained earnings of $426 million and accumulated other comprehensive loss of $432 million and increases to other non-current assets of $20 million and other non-current liabilities of $14 million as of March 31, 2018. (b) Foreign Currency Derivative Contracts—The correction of these misstatements resulted in increases to prepaid expenses and ot

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nature of Operations - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019Segment
Accounting Policies [Abstract]
Number of segments	3

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation - Additional Information (Details) $ in Millions	Oct. 25, 2019USD ($)	Mar. 16, 2018USD ($)Product	Jul. 27, 2017USD ($)	Mar. 16, 2016USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of segments | Segment									3
Total cash consideration, net of cash acquired					$ 109	$ 219	$ 111	$ 228	$ 418	$ 268	$ 686
Pre-tax charge recorded due to deconsolidation									$ 0	$ 0	33
Devaluation of Venezuelan Bolivar | Other (Income) Expense
Summary Of Significant Accounting Policies [Line Items]
Pre-tax charge recorded due to deconsolidation											$ (33)
Cheetah Medical, Inc.
Summary Of Significant Accounting Policies [Line Items]
Percentage of ownership acquired	100.00%
Total cash consideration, net of cash acquired	$ 195
Consideration transferred, additional potential amounts	40
Contingent consideration	18
Consideration transferred	$ 215
Mallinckrodt plc | RECOTHROM and PREVELEAK
Summary Of Significant Accounting Policies [Line Items]
Contingent consideration				$ 21
Number of products acquired | Product		2
Consideration transferred		$ 184		$ 184
Claris Injectables Limited
Summary Of Significant Accounting Policies [Line Items]
Percentage of ownership acquired			100.00%
Total cash consideration, net of cash acquired			$ 629

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary Of Significant Accounting Policies [Line Items]
Transaction price allocated to remaining performance obligations	$ 8,600,000,000
Net trade accounts receivable	$ 1,800,000,000	$ 1,800,000,000
Revenue, description of timing	For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are provided and billed, generally over one to seven years.
Contract assets	$ 131,000,000	80,000,000
Contract assets	68,000,000	30,000,000
Other Long-Term Assets
Summary Of Significant Accounting Policies [Line Items]
Contract assets	68,000,000	30,000,000
Trade Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Contract assets	63,000,000	50,000,000
Long-term Contract with Customer
Summary Of Significant Accounting Policies [Line Items]
Contract liabilities	12,000,000	0
Manufacturing Arrangements
Summary Of Significant Accounting Policies [Line Items]
Contract assets	36,000,000	33,000,000
Software Arrangements
Summary Of Significant Accounting Policies [Line Items]
Contract assets	43,000,000	$ 47,000,000
Accounts and Other Current Receivables, Net
Summary Of Significant Accounting Policies [Line Items]
Contract assets	$ 52,000,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Global payment terms	30
Maximum
Summary Of Significant Accounting Policies [Line Items]
Global payment terms	90 days
Amortization period for cost incurred to obtain contract	1 year
Contract with customer period for goods or service transfers and customer pays for goods or service	1 year

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Summary Of Significant Accounting Policies [Line Items]
Remaining performance obligations period	2 years
Remaining revenue performance obligation, percentage of revenue expected to be recognized	25.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Summary Of Significant Accounting Policies [Line Items]
Remaining performance obligations period	2 years
Remaining revenue performance obligation, percentage of revenue expected to be recognized	20.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Summary Of Significant Accounting Policies [Line Items]
Remaining performance obligations period
Remaining revenue performance obligation, percentage of revenue expected to be recognized	5.00%

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Disaggregation of Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 11,362	$ 11,099	$ 10,584
Renal Care
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	3,639	3,651	3,491
Medication Delivery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	2,799	2,664	2,700
Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	2,155	2,087	1,886
Clinical Nutrition
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	872	875	885
Advanced Surgery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	877	798	708
Acute Therapies
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	535	515	457
Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	485	509	457
U.S. and Puerto Rico plans
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	4,826	4,723	4,510
U.S. and Puerto Rico plans | Renal Care
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	791	816	754
U.S. and Puerto Rico plans | Medication Delivery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	1,822	1,690	1,698
U.S. and Puerto Rico plans | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	940	996	892
U.S. and Puerto Rico plans | Clinical Nutrition
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	320	321	359
U.S. and Puerto Rico plans | Advanced Surgery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	535	466	403
U.S. and Puerto Rico plans | Acute Therapies
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	184	174	147
U.S. and Puerto Rico plans | Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	234	260	257
International
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	6,536	6,376	6,074
International | Renal Care
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	2,848	2,835	2,737
International | Medication Delivery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	977	974	1,002
International | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	1,215	1,091	994
International | Clinical Nutrition
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	552	554	526
International | Advanced Surgery
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	342	332	305
International | Acute Therapies
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	351	341	310
International | Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 251	$ 249	$ 200

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable and Allowance for Doubtful Accounts - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 112	$ 110

SUMMARY OF SIGNIFICANT ACCOU_10

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Shipping and Handling Costs - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Shipping costs included in marketing and administrative expenses	$ 324	$ 329	$ 292

SUMMARY OF SIGNIFICANT ACCOU_11

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment, Net - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019
Minimum | Building and Building Improvements
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	20 years
Minimum | Machinery and equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Minimum | Software and Software Development Costs
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Maximum | Building and Building Improvements
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	50 years
Maximum | Machinery and equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	15 years
Maximum | Software and Software Development Costs
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years

SUMMARY OF SIGNIFICANT ACCOU_12

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - New Accounting Standards - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019	Jan. 01, 2018
Summary Of Significant Accounting Policies [Line Items]
Retained earnings, adjustment	$ 15,718		$ 15,598	$ 15,414	$ 15,075	$ 14,886	$ 14,484	$ 14,254	$ 15,598	$ 14,484	$ 15,718	$ 15,075
Net sales	3,039	$ 2,851	2,834	2,638	2,833	2,761	2,813	2,692	5,472	5,505	11,362	11,099	$ 10,584
Operating lease right-of-use assets	608		595	513					595		608
Retained earnings	$ 15,718		$ 15,598	$ 15,414	$ 15,075	$ 14,886	$ 14,484	$ 14,254	$ 15,598	$ 14,484	$ 15,718	15,075
Measurement period adjustments												(207)
ASU 2016-02, Leases
Summary Of Significant Accounting Policies [Line Items]
Operating lease right-of-use assets														$ 502
Accounting Standards Update 2018-02
Summary Of Significant Accounting Policies [Line Items]
Tax Cuts And Jobs Act Of2017 Reclassification From Aoci To Retained Earnings Tax Effect														$ 161
ASU 2016-16, Income Taxes
Summary Of Significant Accounting Policies [Line Items]
Retained earnings, adjustment															$ 70
Increase in net income												14
Retained earnings															70
ASU No. 2014-09, Revenue from Contracts with Customers | Adjustments
Summary Of Significant Accounting Policies [Line Items]
Retained earnings, adjustment															45
Net sales												$ 7
Retained earnings															$ 45

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Narratives (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Other operating income (expense), net								$ 141	$ 99	$ 56
Selling, general and administrative expenses	$ 641	$ 601	$ 627	$ 676	$ 633	$ 1,242	$ 1,309	2,535	2,620	2,627
Income from continuing operations	313	342	311	341	382	655	723	$ 1,011	1,552	609
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Other operating income (expense), net									9	56
Selling, general and administrative expenses	(1)	1	(2)	(5)	11	0	6		3	61
Income from continuing operations	(30)	(5)	(43)	(2)	(7)	$ (35)	(9)		(78)	(115)
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses									9	56
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses	$ (1)	$ 1	$ (2)	$ (7)	$ 4		$ (3)		(6)	5
Foreign Currency Denominated Monetary Assets And Liabilities And Foreign Currency Derivative Contracts | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Other operating income (expense), net									$ 59
Income from continuing operations										$ 113

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Balance Sheet (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,335	$ 2,934	$ 1,902	$ 1,838	$ 2,863	$ 2,858	$ 2,949
Accounts receivable, net		1,897	1,801		1,837	1,789	1,818
Accounts receivable, net	1,896			1,840
Inventory, Net	1,653	1,756	1,743	1,667	1,716	1,616	1,578
Prepaid expenses and other current assets	619	642	614	614	615	621	610
Total current assets	7,503	7,229	6,060	5,959	7,031	6,884	6,955
Property, Plant and Equipment, Net	4,512	4,485	4,476	4,530	4,476	4,486	4,576
Goodwill	3,030	2,937	2,929	3,002	2,978	2,981	3,103	$ 3,102
Intangible Assets, Net (Excluding Goodwill)	1,471	1,363	1,440	1,410	1,400	1,424	1,505
Other non-current assets	1,069	894	823	819	918	744	704
Total assets	18,193	17,503	16,241	15,720	16,803	16,519	16,843
Current liabilities:
Short-term debt	226	2	796	2
Current maturities of long-term debt and finance lease obligations	315	2	2	2	3	3	3
Accounts payable and accrued liabilities	2,689	2,553	2,478	2,810	2,660	2,583	2,598
Total current liabilities	3,230	2,557	3,276	2,814	2,663	2,586	2,601
Long-term debt and finance lease obligations	4,809	5,157	3,451	3,481	3,480	3,491	3,550
Other non-current liabilities	1,732	1,490	1,504	1,559	1,570	1,612	1,630
Total liabilities	10,281	9,700	8,648	7,854	7,713	7,689	7,781
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2019 and 2018	683	683	683	683	683	683	683
Common stock in treasury, at cost, 170,495,859 shares	(10,764)	(10,322)	(10,284)	(9,989)	(8,639)	(8,485)	(8,354)
Additional contributed capital	5,955	5,906	5,839	5,898	5,931	5,916	5,912
Retained earnings	15,718	15,598	15,414	15,075	14,886	14,484	14,254
Accumulated other comprehensive (loss) income	(3,710)	(4,086)	(4,082)	(3,823)	(3,754)	(3,756)	(3,427)
Total Baxter stockholders’ equity	7,882	7,779	7,570	7,844	9,107	8,842	9,068
Noncontrolling interests	30	24	23	22	(17)	(12)	(6)
Total equity	7,912	7,803	7,593	7,866	9,090	8,830	9,062	9,109	$ 8,221
Total liabilities and equity	18,193	$ 17,503	$ 16,241	15,720	$ 16,803	$ 16,519	$ 16,843
Other	$ 389			$ 404
Common stock, par value (in dollars per share)	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Common stock, authorized (in shares)	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000
Common stock, issued (in shares)	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944
Treasury stock, shares (in shares)	177,340,358	173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164
Equipment Leased to Customers under Operating Leases
Current assets:
Other non-current assets		$ 11	$ 10	$ 10
Current liabilities:
Other non-current liabilities				5
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Current assets:
Property, Plant and Equipment, Net		5
Equity:
Other				2
As previously reported
Current assets:
Cash and cash equivalents		2,925	1,908	1,832	$ 2,860	$ 2,857	$ 2,947
Accounts receivable, net		1,885	1,802	1,812	1,826	1,783	1,807
Inventory, Net		1,757	1,751	1,653	1,718	1,622	1,581
Prepaid expenses and other current assets		651	626	622	624	628	621
Total current assets		7,218	6,087	5,919	7,028	6,890	6,956
Property, Plant and Equipment, Net		4,541	4,539	4,542	4,520	4,531	4,614
Goodwill		2,938	2,930	2,958	2,980	2,984	3,107
Intangible Assets, Net (Excluding Goodwill)		1,364	1,441	1,398	1,402	1,427	1,507
Other non-current assets		895	836	824	917	746	706
Total assets		17,544	16,350	15,641	16,847	16,578	16,890
Current liabilities:
Short-term debt		2	796	2
Current maturities of long-term debt and finance lease obligations		2	2	2	3	3	3
Accounts payable and accrued liabilities		2,593	2,529	2,832	2,701	2,626	2,639
Total current liabilities		2,597	3,327	2,836	2,704	2,629	2,642
Long-term debt and finance lease obligations		5,157	3,451	3,473	3,485	3,495	3,550
Other non-current liabilities		1,464	1,483	1,516	1,545	1,585	1,605
Total liabilities		9,708	8,681	7,825	7,734	7,709	7,797
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2019 and 2018		683	683	683	683	683	683
Common stock in treasury, at cost, 170,495,859 shares		(10,322)	(10,284)	(9,989)	(8,639)	(8,485)	(8,354)
Additional contributed capital		5,906	5,839	5,898	5,931	5,916	5,912
Retained earnings		16,184	15,970	15,626	15,394	14,966	14,734
Accumulated other comprehensive (loss) income		(4,639)	(4,562)	(4,424)	(4,239)	(4,199)	(3,876)
Total Baxter stockholders’ equity		7,812	7,646	7,794	9,130	8,881	9,099
Noncontrolling interests		24	23	22	(17)	(12)	(6)
Total equity		7,836	7,669	7,816	9,113	8,869	9,093	9,116	8,280
Total liabilities and equity		17,544	16,350	15,641	16,847	16,578	16,890
Restatement impacts
Current assets:
Cash and cash equivalents		9	(6)	6	3	1	2
Accounts receivable, net		12	(1)	28	11	6	11
Inventory, Net		(1)	(8)	14	(2)	(6)	(3)
Prepaid expenses and other current assets		(9)	(12)	(8)	(9)	(7)	(11)
Total current assets		11	(27)	40	3	(6)	(1)
Property, Plant and Equipment, Net		(56)	(63)	(12)	(44)	(45)	(38)
Goodwill		(1)	(1)	44	(2)	(3)	(4)
Intangible Assets, Net (Excluding Goodwill)		(1)	(1)	12	(2)	(3)	(2)
Other non-current assets		(1)	(13)	(5)	1	(2)	(2)
Total assets		(41)	(109)	79	(44)	(59)	(47)
Current liabilities:
Short-term debt		0	0	0
Current maturities of long-term debt and finance lease obligations		0	0	0	0	0	0
Accounts payable and accrued liabilities		(40)	(51)	(22)	(41)	(43)	(41)
Total current liabilities		(40)	(51)	(22)	(41)	(43)	(41)
Long-term debt and finance lease obligations		0	0	8	(5)	(4)	0
Other non-current liabilities		26	21	43	25	27	25
Total liabilities		(8)	(33)	29	(21)	(20)	(16)
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2019 and 2018		0	0	0	0	0	0
Common stock in treasury, at cost, 170,495,859 shares		0	0	0	0	0	0
Additional contributed capital		0	0	0	0	0	0
Retained earnings		(586)	(556)	(551)	(508)	(482)	(480)
Accumulated other comprehensive (loss) income		553	480	601	485	443	449
Total Baxter stockholders’ equity		(33)	(76)	50	(23)	(39)	(31)
Noncontrolling interests		0	0	0	0	0	0
Total equity		(33)	(76)	50	(23)	(39)	(31)	$ (7)	$ (59)
Total liabilities and equity		(41)	(109)	79	(44)	(59)	(47)
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Current assets:
Prepaid expenses and other current assets					448
Other non-current assets		12	(9)	8	20	16	(20)
Current liabilities:
Other non-current liabilities		12	(13)	13	12	13	(14)
Equity:
Retained earnings		(514)	(491)	487		(425)	(426)
Accumulated other comprehensive (loss) income		514	487	482	456	428	432
Restatement impacts | Foreign Currency Derivative Contracts
Current assets:
Prepaid expenses and other current assets		2
Current liabilities:
Accounts payable and accrued liabilities		4
Equity:
Retained earnings		2
Restatement impacts | Equipment Leased to Customers under Operating Leases
Current assets:
Property, Plant and Equipment, Net		(61)	(55)	53	(49)	(45)	(44)
Other non-current assets					(12)	11	11
Current liabilities:
Other non-current liabilities		6	5		(2)	(2)	(2)
Equity:
Retained earnings		(44)	(40)	38	(35)	(32)	(31)
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Current assets:
Cash and cash equivalents		9	(6)	6	3	1	2
Accounts receivable, net		6	(7)	22	5		5
Inventory, Net		4	(3)	19	3	(1)	2
Prepaid expenses and other current assets		1	(1)			1
Property, Plant and Equipment, Net			(8)	41	5		6
Goodwill		(1)	(1)	44	(2)	(3)	(4)
Intangible Assets, Net (Excluding Goodwill)				13	(1)	(2)	(1)
Other non-current assets		5	(3)	6	(2)		(4)
Current liabilities:
Accounts payable and accrued liabilities		3	(4)	24	2		2
Long-term debt and finance lease obligations				8	(5)	(4)
Other non-current liabilities		4	(3)	19	(1)		(3)
Equity:
Retained earnings		(16)	(16)	17	(14)	(15)	(10)
Accumulated other comprehensive (loss) income		39	(7)	119	(29)	(15)	(17)
Restatement impacts | Other miscellaneous adjustments
Current assets:
Accounts receivable, net		6	6	6	6	6	6
Inventory, Net		(5)	(5)	5	(5)	(5)	(5)
Prepaid expenses and other current assets		(12)	(12)	12	(12)	(12)	(12)
Intangible Assets, Net (Excluding Goodwill)		(1)	(1)	1	(1)	(1)	(1)
Other non-current assets		(29)	(29)	29	(29)	(29)	(29)
Current liabilities:
Accounts payable and accrued liabilities		(47)	(47)	47	(47)	(47)	(47)
Other non-current liabilities		16	16	16	16	16	16
Equity:
Retained earnings		$ (10)	(10)	10	(10)	(10)	(10)
Restatement impacts | Foreign exchange contract | Foreign Currency Derivative Contracts
Current assets:
Prepaid expenses and other current assets			1	2	(3)	4	(1)
Current liabilities:
Accounts payable and accrued liabilities				1	(4)	$ (4)	(4)
Equity:
Retained earnings			$ 1	$ 1	$ (1)		$ 3

RESTATEMENT OF PREVIOUSLY ISS_5

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Income (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Net sales	$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Cost of sales			1,681	1,558	1,650		1,590	1,571	3,239	3,161	6,601	6,340	6,110
Gross margin	$ 1,298	$ 1,230	1,153	1,080	1,183	1,232	1,223	1,121	2,233	2,344	4,761	4,759	4,474
Selling, general and administrative expenses			641	601	627		676	633	1,242	1,309	2,535	2,620	2,627
Research and development expenses			166	129	175		172	141	295	313	595	654	615
Other operating income (expense), net											141	99	56
Operating income			350	383	391		377	434	733	811	1,772	1,584	1,288
Interest expense, net			20	18	11		11	12	38	23	71	45	55
Other (income) expense, net			4	(21)	(33)		(38)	(6)	(17)	(44)	731	(78)	133
Income from continuing operations before income taxes			326	386	413		404	428	712	832	970	1,617	1,100
Income tax expense (benefit)			13	44	102		63	46	57	109	(41)	65	491
Income from continuing operations			313	342	311		341	382	655	723	1,011	1,552	609
Loss from discontinued operations, net of tax					(6)	$ 0	0	0		0	0	(6)	(7)
Net income			$ 313	$ 342	$ 305		$ 341	$ 382	$ 655	$ 723	$ 1,011	$ 1,546	$ 602
Earnings per share from continuing operations
Basic (in dollars per share)					$ 0.59	$ 0.97	$ 0.64	$ 0.71		$ 1.35	$ 1.97	$ 2.91	$ 1.12
Diluted (in dollars per share)					0.58	0.95	0.62	0.69		1.32	1.93	2.84	1.10
Loss per share from discontinued operations
Basic (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.01)
Diluted (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.02)
Earnings per share
Basic (in dollars per share)	$ (0.05)	$ 0.72	$ 0.61	$ 0.67	0.58	0.97	0.64	0.71	$ 1.28	1.35	1.97	2.90	1.11
Diluted (in dollars per share)	$ (0.05)	$ 0.71	$ 0.60	$ 0.66	$ 0.57	$ 0.95	$ 0.62	$ 0.69	$ 1.26	$ 1.32	$ 1.93	$ 2.83	$ 1.08
Weighted-average number of shares outstanding
Basic (in shares)			510	512	528		535	539	511	537	509	534	543
Diluted (in shares)			519	522	538		547	551	520	549	519	546	555
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses												$ 9	$ 56
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Net sales			$ 2,840	$ 2,632	$ 2,841		$ 2,842	$ 2,677	$ 5,472	$ 5,519		11,127	10,561
Cost of sales			1,681	1,552	1,649		1,603	1,563	3,233	3,166		6,346	6,091
Gross margin			1,159	1,080	1,192		1,239	1,114	2,239	2,353		4,781	4,470
Selling, general and administrative expenses			642	600	629		681	622	1,242	1,303		2,617	2,566
Research and development expenses			166	129	175		174	140	295	314		655	613
Other operating income (expense), net												90	0
Operating income			355	384	398		384	432	739	816		1,599	1,291
Interest expense, net			20	18	11		11	12	38	23		45	55
Other (income) expense, net			(28)	(25)	(58)		(31)	(18)	(53)	(49)		(139)	19
Income from continuing operations before income taxes			363	391	445		404	438	754	842		1,693	1,217
Income tax expense (benefit)			20	44	91		61	49	64	110		63	493
Income from continuing operations			$ 343	$ 347	354		$ 343	$ 389	$ 690	$ 732		1,630	724
Loss from discontinued operations, net of tax					(6)							(6)	(7)
Net income					$ 348							$ 1,624	$ 717
Earnings per share from continuing operations
Basic (in dollars per share)					$ 0.67							$ 3.05	$ 1.33
Diluted (in dollars per share)					0.66							2.99	1.30
Loss per share from discontinued operations
Basic (in dollars per share)					(0.01)							(0.01)	(0.01)
Diluted (in dollars per share)					(0.01)							(0.02)	(0.01)
Earnings per share
Basic (in dollars per share)			$ 0.67	$ 0.68	0.66		$ 0.64	$ 0.72	$ 1.35	$ 1.36		3.04	1.32
Diluted (in dollars per share)			$ 0.66	$ 0.66	$ 0.65		$ 0.63	$ 0.71	$ 1.33	$ 1.33		$ 2.97	$ 1.29
Weighted-average number of shares outstanding
Basic (in shares)			510	512	528		535	539	511	537		534	543
Diluted (in shares)			519	522	538		547	551	520	549		546	555
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Net sales			$ (6)	$ 6	$ (8)		$ (29)	$ 15	$ 0	$ (14)		$ (28)	$ 23
Cost of sales			0	6	1		(13)	8	6	(5)		(6)	19
Gross margin			(6)	0	(9)		(16)	7	(6)	(9)		(22)	4
Selling, general and administrative expenses			(1)	1	(2)		(5)	11	0	6		3	61
Research and development expenses			0	0	0		(2)	1	0	(1)		(1)	2
Other operating income (expense), net												9	56
Operating income			(5)	(1)	(7)		(7)	2	(6)	(5)		(15)	(3)
Interest expense, net			0	0	0		0	0	0	0		0	0
Other (income) expense, net			32	4	25		(7)	12	36	5		61	114
Income from continuing operations before income taxes			(37)	(5)	(32)		0	(10)	(42)	(10)		(76)	(117)
Income tax expense (benefit)			(7)	0	11		2	(3)	(7)	(1)		2	(2)
Income from continuing operations			$ (30)	$ (5)	(43)		$ (2)	$ (7)	$ (35)	$ (9)		(78)	(115)
Loss from discontinued operations, net of tax					0							0	0
Net income					$ (43)							$ (78)	$ (115)
Earnings per share from continuing operations
Basic (in dollars per share)					$ (0.08)							$ (0.14)	$ (0.21)
Diluted (in dollars per share)					(0.08)							(0.15)	(0.20)
Loss per share from discontinued operations
Basic (in dollars per share)					0							0	0
Diluted (in dollars per share)					0							0.01	(0.01)
Earnings per share
Basic (in dollars per share)			$ (0.06)	$ (0.01)	(0.08)		$ 0	$ (0.01)	$ (0.07)	$ (0.01)		(0.14)	(0.21)
Diluted (in dollars per share)			$ (0.06)	$ 0	$ (0.08)		$ (0.01)	$ (0.02)	$ (0.07)	$ (0.01)		$ (0.14)	$ (0.21)
Weighted-average number of shares outstanding
Basic (in shares)			0	0	0		0	0	0	0		0	0
Diluted (in shares)			0	0	0		0	0	0	0		0	0
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Error Corrections and Prior Period Adjustments Restatement
Other (income) expense, net			$ (26)	$ (5)	$ (26)			$ (9)	$ (31)	$ (9)		$ 64	$ 96
Income tax expense (benefit)			(5)		(5)			(3)	(4)	(3)
Restatement impacts | Equipment Leased to Customers under Operating Leases
Error Corrections and Prior Period Adjustments Restatement
Cost of sales			5	2	4		$ 2	1	7	3		11	8
Income tax expense (benefit)			(2)		(1)		(1)		(2)	(1)		(3)	3
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement
Net sales			(6)	6	(8)		(29)	15		(14)		(28)	23
Cost of sales			(5)	4	(3)		(15)	7	(1)	(8)		(17)	11
Selling, general and administrative expenses			(1)	1	(2)		(7)	4		(3)		(6)	5
Research and development expenses							(2)	1		(1)		(1)	2
Other (income) expense, net							(1)			(1)		(2)	(1)
Income tax expense (benefit)							(1)			(1)		(2)	1
Restatement impacts | Income Statement Classification Of Transition Services Income
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses							2	7		9		9	56
Restatement impacts | Other Miscellaneous Adjustments to Income Statement
Error Corrections and Prior Period Adjustments Restatement
Income tax expense (benefit)												7
Restatement impacts | Foreign exchange contract | Foreign Currency Derivative Contracts
Error Corrections and Prior Period Adjustments Restatement
Other (income) expense, net			$ (6)	$ (1)	$ (1)		(8)	$ (3)	(5)	(5)		$ 5	$ 17
Income tax expense (benefit)							$ (4)		$ (1)	$ 4

RESTATEMENT OF PREVIOUSLY ISS_6

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Other comprehensive income (loss), net of tax:
Currency translation adjustments			2	(97)			(368)	63	(95)	(305)	(95)	(323)	599
Pension and other postretirement benefit plans			6	14			28	57	20	85	408	33	134
Hedging activities											(11)
Hedging activities			(12)	(15)			11	(5)	(27)	6		9	(13)
Available-for-sale securities											0	0	2
Total other comprehensive (loss) income, net of tax			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Comprehensive income			309	244			12	497	553	509	$ 1,285	1,265	1,324
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss), net of tax:
Currency translation adjustments			(78)	30			(363)	81	(48)	(282)		(461)	425
Pension and other postretirement benefit plans			13	8			29	52	21	81		32	141
Hedging activities			(12)	(15)			11	(5)	(27)	6		9	(13)
Available-for-sale securities													2
Total other comprehensive (loss) income, net of tax			(77)	23			(323)	128	(54)	(195)		(420)	555
Comprehensive income			266	370			20	517	636	537		1,204	1,272
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss), net of tax:
Currency translation adjustments			80	(127)			(5)	(18)	(47)	(23)		138	174
Pension and other postretirement benefit plans			(7)	6			(1)	5	(1)	4		1	7
Hedging activities			0	0			0	0	0	0		0	0
Available-for-sale securities													0
Total other comprehensive (loss) income, net of tax			73	(121)			(6)	(13)	(48)	(19)		139	167
Comprehensive income			43	(126)			(8)	(20)	(83)	(28)		61	52
Restatement impacts | Foreign Exchange Rate Used To Translate
Other comprehensive income (loss), net of tax:
Currency translation adjustments			(54)	132			$ 5	27	78	32		74	78
Restatement impacts | Offsetting Balance Sheet Impact Adjustments
Other comprehensive income (loss), net of tax:
Currency translation adjustments			$ (26)	$ 5				$ 9	$ (31)	$ 9		$ 64	$ 96

RESTATEMENT OF PREVIOUSLY ISS_7

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Changes in Equity (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 7,803	$ 7,593	$ 7,866	$ 9,090	$ 8,830	$ 9,062	$ 9,109	$ 7,866	$ 9,109	$ 7,866	$ 9,109	$ 8,221
Beginning of year (in shares)		683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944		683,494,944		683,494,944
Beginning of year (in shares)		173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164		170,495,859		170,495,859
Adoption of new accounting standards				$ 0				(23)	$ 0	(23)	$ 0	(25)
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	342	$ 305	$ 518	$ 341	382	655	723	1,001	1,546	602
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Purchases of treasury stock			(111)	(586)			(259)	(522)	(697)	(781)	$ (1,247)	$ (2,475)	$ (564)
Purchases of treasury stock (in shares)											16,500,000	35,800,000	9,200,000
Stock issued under employee benefit plans and other			123	166			123	85	289	208	$ 445	$ 354	$ 426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
Distribution													34
Changes in noncontrolling interests			1	1			(6)	2	2	(4)	(2)	30	2
End of year	$ 7,912		$ 7,803	$ 7,593	$ 7,866	$ 9,090	$ 8,830	$ 9,062	$ 7,803	$ 8,830	$ 7,912	$ 7,866	9,109
End of year (in shares)	683,494,944		683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944
End of year (in shares)	177,340,358		173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164	173,275,586	148,485,202	177,340,358	170,495,859
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,836	$ 7,669	$ 7,816	$ 9,113	$ 8,869	$ 9,093	$ 9,116	$ 7,816	$ 9,116	$ 7,816	$ 9,116	8,280
Adoption of new accounting standards				0				(19)	0	(19)		(21)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
Purchases of treasury stock			(111)	(586)			(259)	(522)	(697)	(781)		(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208		354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
Distribution													34
Changes in noncontrolling interests			1	1			(6)	2	2	(4)		30	2
End of year			7,836	7,669	7,816	9,113	8,869	9,093	7,836	8,869		7,816	9,116
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(33)	(76)	50	(23)	(39)	(31)	(7)	50	(7)	50	(7)	(59)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			(33)	(76)	50	(23)	(39)	(31)	(33)	(39)		50	(7)
Common stock
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683
Beginning of year (in shares)		683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000
End of year	$ 683		$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683
End of year (in shares)	683,000,000		683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000
Common stock | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683
Beginning of year (in shares)		683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000
End of year			$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683		$ 683	$ 683
End of year (in shares)			683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000		683,000,000	683,000,000
Common stock | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Beginning of year (in shares)		0	0	0		0	0	0	0	0	0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0
End of year (in shares)			0	0	0		0	0	0	0		0	0
Common stock in treasury
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (7,981)	$ (9,989)	$ (7,981)	$ (9,989)	$ (7,981)	$ (7,995)
Beginning of year (in shares)		173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	142,000,000	170,000,000	142,000,000	170,000,000	142,000,000	144,000,000
Purchases of treasury stock			$ (157)	$ (586)			$ (259)	$ (522)	$ (743)	$ (781)	$ (1,293)	$ (2,415)	$ (564)
Purchases of treasury stock (in shares)			2,000,000	8,000,000			3,000,000	8,000,000	10,000,000	11,000,000	16,000,000	36,000,000	9,000,000
Stock issued under employee benefit plans and other			$ 119	$ 291			$ 128	$ 149	$ 410	$ 277	$ 518	$ 407	$ 578
Stock issued under employee benefit plans and other (in shares)			(2,000,000)	(5,000,000)			(2,000,000)	(3,000,000)	(7,000,000)	(5,000,000)	9,000,000	8,000,000	11,000,000
End of year	$ (10,764)		$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (10,322)	$ (8,485)	$ (10,764)	$ (9,989)	$ (7,981)
End of year (in shares)	177,000,000		173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	173,000,000	148,000,000	177,000,000	170,000,000	142,000,000
Common stock in treasury | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (7,981)	$ (9,989)	$ (7,981)	$ (9,989)	$ (7,981)	$ (7,995)
Beginning of year (in shares)		173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	142,000,000	170,000,000	142,000,000	170,000,000	142,000,000	144,000,000
Purchases of treasury stock			$ (157)	$ (586)			$ (259)	$ (522)	$ (743)	$ (781)		$ (2,415)	$ (564)
Purchases of treasury stock (in shares)			2,000,000	8,000,000			3,000,000	8,000,000	10,000,000	11,000,000		36,000,000	9,000,000
Stock issued under employee benefit plans and other			$ 119	$ 291			$ 128	$ 149	$ 410	$ 277		$ 407	$ 578
Stock issued under employee benefit plans and other (in shares)			(2,000,000)	(5,000,000)			(2,000,000)	(3,000,000)	(7,000,000)	(5,000,000)		(8,000,000)	(11,000,000)
End of year			$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (10,322)	$ (8,485)		$ (9,989)	$ (7,981)
End of year (in shares)			173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	173,000,000	148,000,000		170,000,000	142,000,000
Common stock in treasury | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Beginning of year (in shares)		0	0	0		0	0	0	0	0	0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0
End of year (in shares)			0	0	0		0	0	0	0		0	0
Additional contributed capital
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 5,906	$ 5,839	$ 5,898		$ 5,916	$ 5,912	$ 5,940	$ 5,898	$ 5,940	$ 5,898	$ 5,940	$ 5,958
Purchases of treasury stock			46						46		46	(60)
Stock issued under employee benefit plans and other			21	(59)			4	(28)	(38)	(24)	11	18	(18)
End of year	$ 5,955		5,906	5,839	$ 5,898		5,916	5,912	5,906	5,916	5,955	5,898	5,940
Additional contributed capital | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		5,906	5,839	5,898		5,916	5,912	5,940	5,898	5,940	5,898	5,940	5,958
Purchases of treasury stock			46						46			(60)	0
Stock issued under employee benefit plans and other			21	(59)			4	(28)	(38)	(24)		18	(18)
End of year			5,906	5,839	5,898		5,916	5,912	5,906	5,916		5,898	5,940
Additional contributed capital | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		0	0	0		0	0	0	0	0	0	0	0
End of year			0	0	0		0	0	0	0		0	0
Retained earnings
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		15,598	15,414	15,075		14,484	14,254	14,014	15,075	14,014	15,075	14,014	13,846
Adoption of new accounting standards				161				(20)	161	(20)	161	(22)
Net income attributable to Baxter stockholders			313	342			341	382	655	723	1,001	1,546	602
Stock issued under employee benefit plans and other			(17)	(66)			(9)	(36)	(83)	(45)	(84)	(71)	(134)
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
Distribution													34
End of year	15,718		15,598	15,414	15,075		14,484	14,254	15,598	14,484	15,718	15,075	14,014
Retained earnings | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		16,184	15,970	15,626		14,966	14,734	14,483	15,626	14,483	15,626	14,483	14,200
Adoption of new accounting standards				161				(16)	161	(16)		(18)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Stock issued under employee benefit plans and other			(17)	(66)			(9)	(36)	(83)	(45)		(71)	(134)
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
Distribution													34
End of year			16,184	15,970	15,626		14,966	14,734	16,184	14,966		15,626	14,483
Retained earnings | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(586)	(556)	(551)		(482)	(480)	(469)	(551)	(469)	(551)	(469)	(354)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
End of year			(586)	(556)	(551)		(482)	(480)	(586)	(482)		(551)	(469)
Accumulated other comprehensive income (loss)
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(4,086)	(4,082)	(3,823)		(3,756)	(3,427)	(3,539)	(3,823)	(3,539)	(3,823)	(3,539)	(4,261)
Adoption of new accounting standards				(161)				(3)	(161)	(3)	(161)	(3)
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
End of year	(3,710)		(4,086)	(4,082)	(3,823)		(3,756)	(3,427)	(4,086)	(3,756)	(3,710)	(3,823)	(3,539)
Accumulated other comprehensive income (loss) | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(4,639)	(4,562)	(4,424)		(4,199)	(3,876)	(4,001)	(4,424)	(4,001)	(4,424)	(4,001)	(4,556)
Adoption of new accounting standards				(161)				(3)	(161)	(3)		(3)
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
End of year			(4,639)	(4,562)	(4,424)		(4,199)	(3,876)	(4,639)	(4,199)		(4,424)	(4,001)
Accumulated other comprehensive income (loss) | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		553	480	601		443	449	462	601	462	601	462	295
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			553	480	601		443	449	553	443		601	462
Total Baxter stockholders' equity
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,779	7,570	7,844		8,842	9,068	9,117	7,844	9,117	7,844	9,117	8,231
Adoption of new accounting standards								(23)		(23)		(25)
Net income attributable to Baxter stockholders			313	342			341	382	655	723	1,001	1,546	602
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Purchases of treasury stock			(111)	(586)			(259)	(522)	(697)	(781)	(1,247)	(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208	445	354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
Distribution													34
End of year	7,882		7,779	7,570	7,844		8,842	9,068	7,779	8,842	7,882	7,844	9,117
Total Baxter stockholders' equity | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,812	7,646	7,794		8,881	9,099	9,124	7,794	9,124	7,794	9,124	8,290
Adoption of new accounting standards								(19)		(19)		(21)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
Purchases of treasury stock			(111)	(586)			(259)	(522)	(697)	(781)		(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208		354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
End of year			7,812	7,646	7,794		8,881	9,099	7,812	8,881		7,794	9,124
Total Baxter stockholders' equity | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(33)	(76)	50		(39)	(31)	(7)	50	(7)	50	(7)	(59)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			(33)	(76)	50		(39)	(31)	(33)	(39)		50	(7)
Noncontrolling interests
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		24	23	22		(12)	(6)	(8)	22	(8)	22	(8)	(10)
Net income attributable to Baxter stockholders											10
Changes in noncontrolling interests			1	1			(6)	2	2	(4)	(2)	30	2
End of year	$ 30		24	23	22		(12)	(6)	24	(12)	30	22	(8)
Noncontrolling interests | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		24	23	22		(12)	(6)	(8)	22	(8)	22	(8)	(10)
Changes in noncontrolling interests			1	1			(6)	2	2	(4)		30	2
End of year			24	23	22		(12)	(6)	24	(12)		22	(8)
Noncontrolling interests | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 0	0	0		$ 0	0	0	0	0	$ 0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0

RESTATEMENT OF PREVIOUSLY ISS_8

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS - Consolidated Statement of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operations
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Loss from discontinued operations, net of tax					6	0	0	0		0	0	6	7
Depreciation and amortization				192				190	385	382	789	771	750
Settlement charge	755										(755)	(1)	(2)
Net periodic pension benefit and other postretirement costs				3				10	7	21	22	39	123
Deferred income taxes				(6)				(38)	(63)	(51)	(310)	(263)	211
Stock compensation				22				20	57	54	122	115	107
Other				14				(1)	44	0	115	50	38
Changes in balance sheet items:
Accounts receivable, net				32				76	(60)	43	(65)	(12)	30
Inventories				(82)				(56)	(91)	(134)	4	(197)	76
Accounts payable and accrued liabilities				(335)				(119)	(299)	(124)	(212)	60	11
Other				(48)				(34)	(86)	(82)	(152)	(99)	(227)
Cash flows from operations – continuing operations				134					580		2,110	2,017	1,730
Cash flows from operations - discontinued operations				(6)					(6)		(6)	0	(16)
Cash flows from operations				128				430	574	832	2,104	2,017	1,714
Cash flows from investing activities
Capital expenditures				(193)				(152)	(338)	(303)	(696)	(659)	(616)
Acquisitions and investments, net of cash acquired				(109)				(219)	(111)	(228)	(418)	(268)	(686)
Other investing activities, net				1					1		14	11	10
Cash flows from investing activities				(301)				(371)	(448)	(531)	(1,100)	(916)	(1,292)
Cash flows from financing activities
Payments of Ordinary Dividends, Common Stock				101				87	198	173	423	376	315
Proceeds from stock issued under employee benefit plans											356	258	347
Payments for Repurchase of Common Stock				597				522	720	781	1,270	2,452	564
Other financing activities, net				(32)				(18)	(37)	(24)	(48)	(33)	(40)
Cash flows from financing activities				238				(545)	968	(808)	498	(2,603)	93
Effect of foreign exchange rate changes on cash and cash equivalents				(1)				32	2	(38)	(5)	(63)	102
Increase (decrease) in cash and cash equivalents				64				(454)	1,096	(545)	1,497	(1,565)	617
Cash and cash equivalents at beginning of year		2,934	1,902	1,838		2,858	2,949	3,403	1,838	3,403	1,838	3,403	2,786
Cash and cash equivalents at end of year	3,335		2,934	1,902	1,838		2,858	2,949	2,934	2,858	3,335	1,838	3,403
Other supplemental information
Interest paid, net of portion capitalized											103	94	80
Income taxes paid											294	301	253
Payments of Ordinary Dividends, Common Stock				101				87	198	173	423	376	315
As previously reported
Cash flows from operations
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Loss from discontinued operations, net of tax					6							6	7
Depreciation and amortization				195				192	393	387		785	761
Settlement charge												(1)	2
Net periodic pension benefit and other postretirement costs				3				10	7	21		39	123
Deferred income taxes				(6)				(33)	(55)	(51)		(267)	211
Stock compensation				22				20	57	54		115	107
Other				19				2	34	10		43	43
Changes in balance sheet items:
Accounts receivable, net				32				76	(60)	43		(12)	30
Inventories				(82)				(56)	(91)	(134)		(197)	76
Accounts payable and accrued liabilities				(333)				(120)	(303)	(126)		64	5
Other				(49)				(33)	(86)	(84)		(105)	(229)
Cash flows from operations – continuing operations				148					617				1,853
Cash flows from operations - discontinued operations				(6)					(6)				(16)
Cash flows from operations				142				447	611	852		2,096	1,837
Cash flows from investing activities
Capital expenditures				(198)				(155)	(352)	(311)		(681)	(634)
Acquisitions and investments, net of cash acquired				(109)				(219)	(111)	(228)		(268)	(686)
Other investing activities, net				1					1			11	10
Cash flows from investing activities				(306)				(374)	(462)	(539)		(938)	(1,310)
Cash flows from financing activities
Payments of Ordinary Dividends, Common Stock				101				87	198	173		376	315
Proceeds from stock issued under employee benefit plans												258
Payments for Repurchase of Common Stock				597				522	720	781		2,452	564
Other financing activities, net				(32)				(18)	(37)	(24)		(33)	(40)
Cash flows from financing activities				238				(545)	968	(808)		(2,603)	61
Effect of foreign exchange rate changes on cash and cash equivalents				2				25	(24)	(42)		(117)	5
Increase (decrease) in cash and cash equivalents				76				(447)	1,093	(537)		(1,562)	593
Cash and cash equivalents at beginning of year		2,925	1,908	1,832		2,857	2,947	3,394	1,832	3,394	1,832	3,394	2,801
Cash and cash equivalents at end of year			2,925	1,908	1,832		2,857	2,947	2,925	2,857		1,832	3,394
Other supplemental information
Interest paid, net of portion capitalized												94	80
Income taxes paid												302	255
Payments of Ordinary Dividends, Common Stock				101				87	198	173		376	315
As previously reported | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Cash flows from financing activities
Cash and cash equivalents at beginning of year								15		15		15
Cash and cash equivalents at end of year													15
Restatement impacts
Cash flows from operations
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Loss from discontinued operations, net of tax					0							0	0
Depreciation and amortization				(3)				(2)	(8)	(5)		(14)	(11)
Settlement charge												0	0
Net periodic pension benefit and other postretirement costs				0				0	0	0		0	0
Deferred income taxes				0				(5)	(8)	0		4	0
Stock compensation				0				0	0	0		0	0
Other				(5)				(3)	10	(10)		7	(5)
Changes in balance sheet items:
Accounts receivable, net				0				0	0	0		0	0
Inventories				0				0	0	0		0	0
Accounts payable and accrued liabilities				(2)				1	4	2		(4)	6
Other				1				(1)	0	2		6	2
Cash flows from operations – continuing operations				(14)					(37)				(123)
Cash flows from operations - discontinued operations				0					0				0
Cash flows from operations				(14)				(17)	(37)	(20)		(79)	(123)
Cash flows from investing activities
Capital expenditures				5				3	14	8		22	18
Acquisitions and investments, net of cash acquired				0				0	0	0		0	0
Other investing activities, net				0					0			0	0
Cash flows from investing activities				5				3	14	8		22	18
Cash flows from financing activities
Payments of Ordinary Dividends, Common Stock				0				0	0	0		0	0
Proceeds from stock issued under employee benefit plans												0
Payments for Repurchase of Common Stock				0				0	0	0		0	0
Other financing activities, net				0				0	0	0		0	0
Cash flows from financing activities				0				0	0	0		0	32
Effect of foreign exchange rate changes on cash and cash equivalents				(3)				7	26	4		54	97
Increase (decrease) in cash and cash equivalents				(12)				(7)	3	(8)		(3)	24
Cash and cash equivalents at beginning of year		9	(6)	6		1	2	9	6	9	6	9	(15)
Cash and cash equivalents at end of year			9	(6)	6		1	2	9	1		6	9
Other supplemental information
Interest paid, net of portion capitalized												0	0
Income taxes paid												(1)	(2)
Payments of Ordinary Dividends, Common Stock				0				0	0	0		0	0
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Cash flows from financing activities
Effect of foreign exchange rate changes on cash and cash equivalents				4				11	33	2		64	99
Restatement impacts | Foreign Currency Derivative Contracts
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Other								(2)
Changes in balance sheet items:
Accounts payable and accrued liabilities				1				1	4	2
Other				1
Restatement impacts | Foreign Currency Derivative Contracts | Foreign exchange contract
Changes in balance sheet items:
Accounts payable and accrued liabilities												4	6
Other												1	8
Restatement impacts | Equipment Leased to Customers under Operating Leases
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Depreciation and amortization				3				2	7	5		11	10
Deferred income taxes									2	1		3	3
Cash flows from investing activities
Capital expenditures				(5)				(3)	(14)	(8)		(22)	(18)
Restatement impacts | Correction of Classification of Foreign Currency Gains and Losses in our Consolidated Statements of Cash Flows [Member]
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Other				(5)				(3)	(10)	(10)
Cash flows from financing activities
Effect of foreign exchange rate changes on cash and cash equivalents												7	6
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Changes in balance sheet items:
Other				(1)				3	1	2		4	3
Cash flows from financing activities
Effect of foreign exchange rate changes on cash and cash equivalents				12				7	3	8		3	24
Cash and cash equivalents at beginning of year		$ 9	6	6		$ 1	2	9	6	9	6	9
Cash and cash equivalents at end of year	$ 6		$ 9	6	$ 6		$ 1	2	9	1	$ 6	6	9
Other supplemental information
Income taxes paid												1	2
Restatement impacts | Other Miscellaneous Adjustments to Cash Flows [Member]
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Depreciation and amortization									1			3	1
Deferred income taxes								5	6	$ 1		7
Other													$ (1)
Changes in balance sheet items:
Accounts payable and accrued liabilities				1				$ 2
Other				$ 1					$ 1			$ 3

SEPARATION OF BAXALTA INCORPO_2

SEPARATION OF BAXALTA INCORPORATED - Additional Information (Detail) - USD ($) $ in Millions	Jul. 01, 2015	Mar. 31, 2019	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of common stock retained				100.00%
Cash flows from operations - discontinued operations		$ (6)	$ (6)	$ (6)	$ 0	$ (16)
Transition Services Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reduction in marketing and administrative expense					9	56
Baxalta Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash flows from operations - discontinued operations				$ (6)	$ 0	$ (16)
Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of outstanding common stock distributed	80.50%
Percentage of common stock retained	19.50%
Common stock, outstanding (in shares)	131,902,719
Number Of Shares Issued In Spin Off For Each Share Owned In Former Parent	1
Percentage of ownership for equity method investment	19.50%

ACQUISITIONS AND OTHER ARRANG_3

ACQUISITIONS AND OTHER ARRANGEMENTS - Cheetah Medical, Inc. Narrative (Details) - USD ($) $ in Millions	Oct. 25, 2019	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2019
Acquisitions And Collaborations [Line Items]
Total cash consideration, net of cash acquired		$ 109	$ 219	$ 111	$ 228	$ 418	$ 268	$ 686
Cheetah Medical, Inc.
Acquisitions And Collaborations [Line Items]
Percentage of ownership acquired	100.00%
Total cash consideration, net of cash acquired	$ 195
Maximum contingent future payments	40
Contingent consideration	18
Integration costs						$ 3
Other intangible assets	$ 131
Cheetah Medical, Inc. | Developed Product Rights
Acquisitions And Collaborations [Line Items]
Other intangible assets									$ 123
Acquired intangible assets, weighted-average useful life	15 years
Cheetah Medical, Inc. | Customer Relationship
Acquisitions And Collaborations [Line Items]
Other intangible assets	$ 8
Acquired intangible assets, weighted-average useful life	13 years
Cheetah Medical, Inc. | Measurement Input Discount Rate | Developed Product Rights
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.110
Cheetah Medical, Inc. | Measurement Input Discount Rate | Customer Relationship
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.100

ACQUISITIONS AND OTHER ARRANG_4

ACQUISITIONS AND OTHER ARRANGEMENTS - Schedule of Total Consideration for Cheetah Medical, Inc. (Details) - Cheetah Medical, Inc. $ in Millions	Oct. 25, 2019USD ($)
Acquisitions And Collaborations [Line Items]
Cash consideration transferred	$ 197
Contingent consideration	18
Total consideration transferred	$ 215

ACQUISITIONS AND OTHER ARRANG_5

ACQUISITIONS AND OTHER ARRANGEMENTS - Summary of Fair Value of Assets Acquired and Liabilities Assumed for Cheetah Medical, Inc. (Details) - USD ($) $ in Millions	Dec. 31, 2019	Oct. 25, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Acquisitions And Collaborations [Line Items]
Goodwill	$ 3,030		$ 2,937	$ 2,929	$ 3,002	$ 2,978	$ 2,981	$ 3,103	$ 3,102
Cheetah Medical, Inc.
Acquisitions And Collaborations [Line Items]
Cash		$ 2
Accounts receivable, net		3
Inventories		1
Prepaid expenses and other current assets		1
Property, plant and equipment		1
Goodwill		111
Other intangible assets		131
Operating lease right-of-use assets		1
Accounts payable and other accrued liabilities		(4)
Other non-current liabilities		(32)
Total assets acquired and liabilities assumed		$ 215

Acquisitions and Other Arrang_6

Acquisitions and Other Arrangements - Recothrom and Preveleak Narrative (Details) $ in Millions

Mar. 16, 2018USD ($)Product

Mar. 16, 2016USD ($)

Dec. 31, 2019USD ($)

Sep. 30, 2019USD ($)

Jun. 30, 2019USD ($)

Mar. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Jun. 30, 2018USD ($)

Mar. 31, 2018USD ($)

Jun. 30, 2019USD ($)

Jun. 30, 2018USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Acquisitions And Collaborations [Line Items]

Net sales

$ 3,039

$ 2,851

$ 2,834

$ 2,638

$ 2,833

$ 2,761

$ 2,813

$ 2,692

$ 5,472

$ 5,505

$ 11,362

$ 11,099

$ 10,584

Mallinckrodt plc

Acquisitions And Collaborations [Line Items]

Net sales

80

52

RECOTHROM and PREVELEAK | Mallinckrodt plc

Acquisitions And Collaborations [Line Items]

Number of products acquired | Product

2

Cash consideration transferred

$ 163

Consideration transferred

$ 184

$ 184

Contingent payments related to acquisitions

21

Maximum contingent future payments

7

Integration costs

$ 20

$ 17

Other intangible assets

$ 100

Acquired intangible assets, weighted-average useful life

10 years

RECOTHROM and PREVELEAK | Mallinckrodt plc | Minimum | Measurement Input Discount Rate

Acquisitions And Collaborations [Line Items]

Discount rate used to measure intangible assets

0.125

RECOTHROM and PREVELEAK | Mallinckrodt plc | Maximum | Measurement Input Discount Rate

Acquisitions And Collaborations [Line Items]

Discount rate used to measure intangible assets

0.130

Technology Transfer | Mallinckrodt plc

Acquisitions And Collaborations [Line Items]

Maximum contingent future payments

$ 15

Net Revenue Royalties | Mallinckrodt plc

Acquisitions And Collaborations [Line Items]

Maximum contingent future payments

$ 143

ACQUISITIONS AND OTHER ARRANG_7

ACQUISITIONS AND OTHER ARRANGEMENTS - Schedule of Total Consideration for Mallinckrodt Plc (Details) - RECOTHROM and PREVELEAK - Mallinckrodt plc - USD ($) $ in Millions	Mar. 16, 2018	Mar. 16, 2016
Acquisitions And Collaborations [Line Items]
Cash consideration transferred		$ 163
Contingent consideration		21
Total consideration transferred	$ 184	$ 184

ACQUISITIONS AND OTHER ARRANG_8

ACQUISITIONS AND OTHER ARRANGEMENTS - Summary of Fair Value of Assets Acquired and Liabilities Assumed for Mallinckrodt Plc (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 16, 2018	Dec. 31, 2017
Acquisitions And Collaborations [Line Items]
Goodwill	$ 3,030	$ 2,937	$ 2,929	$ 3,002	$ 2,978	$ 2,981	$ 3,103		$ 3,102
RECOTHROM and PREVELEAK | Mallinckrodt plc
Acquisitions And Collaborations [Line Items]
Accounts receivable, net								$ 2
Inventories								80
Goodwill								2
Other intangible assets								100
Total assets acquired								$ 184

ACQUISITIONS AND OTHER ARRANG_9

ACQUISITIONS AND OTHER ARRANGEMENTS - Saudia Arabia Joint Venture Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 30, 2018	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Nov. 30, 2019
Acquisitions And Collaborations [Line Items]
Cash			$ 0	$ 24	$ 0
Estimated useful lives			10 years
Percentage of common stock retained			100.00%
Saudi Arabia Joint Venture
Acquisitions And Collaborations [Line Items]
Percentage of ownership acquired	51.00%
Cash		$ 24
Fair value of equity investment	$ 39
Percentage of common stock retained	49.00%
Estimated noncontrolling interest in joint venture	$ 39
Saudi Arabia Joint Venture | Customer Relationship
Acquisitions And Collaborations [Line Items]
Acquired intangible assets, weighted-average useful life	10 years
Saudi Arabia Joint Venture | Customer Relationship | Measurement Input Discount Rate
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.140
Saudi Arabia Joint Venture | Reacquired License Rights
Acquisitions And Collaborations [Line Items]
Reacquired license rights fair value total	$ 10
Estimated useful lives	12 years
Saudi Arabia Joint Venture | Reacquired License Rights | Measurement Input Discount Rate
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.130
Saudi Arabia Joint Venture | Significant unobservable inputs (Level 3)
Acquisitions And Collaborations [Line Items]
Equity Method Investment, Underlying Equity in Net Assets						$ 39

ACQUISITIONS AND OTHER ARRAN_10

ACQUISITIONS AND OTHER ARRANGEMENTS - Schedule of Total Consideration for Saudia Arabia Joint Venture (Details) - Saudi Arabia Joint Venture $ in Millions	1 Months Ended
	Nov. 30, 2018USD ($)
Acquisitions And Collaborations [Line Items]
Cash consideration transferred	$ 2
Fair value of equity investment	39
Noncontrolling interest	39
Total consideration transferred	$ 80

ACQUISITIONS AND OTHER ARRAN_11

ACQUISITIONS AND OTHER ARRANGEMENTS - Summary of Fair Value of Assets Acquired and Liabilities Assumed for Saudia Arabia Joint Venture (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Acquisitions And Collaborations [Line Items]
Goodwill	$ 3,030	$ 2,937	$ 2,929	$ 3,002		$ 2,978	$ 2,981	$ 3,103	$ 3,102
Saudi Arabia Joint Venture
Acquisitions And Collaborations [Line Items]
Cash					$ 4
Accounts receivable, net					25
Inventories					8
Property, plant and equipment					12
Goodwill					17
Other intangible assets					40
Other non-current assets					2
Short-term debt					(4)
Accounts payable and other accrued liabilities					(16)
Other non-current liabilities					(8)
Total assets acquired and liabilities assumed					$ 80

ACQUISITIONS AND OTHER ARRAN_12

ACQUISITIONS AND OTHER ARRANGEMENTS - Claris Injectables Limited Narrative (Details) - USD ($) $ in Millions	Jul. 27, 2017	Feb. 22, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Acquisitions And Collaborations [Line Items]
Total cash consideration, net of cash acquired						$ 109				$ 219	$ 111	$ 228	$ 418	$ 268	$ 686
Net sales			$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	11,362	11,099	10,584
Claris Injectables Limited [Member]
Acquisitions And Collaborations [Line Items]
Percentage of ownership acquired	100.00%
Total cash consideration, net of cash acquired	$ 629
Measurement period adjustments, reduction in property, plant and equipment								2
Measurement period adjustments, increase in accounts payable and accrued liabilities								1
Measurement period adjustments, increase in other long-term liabilities								2
Measurement period adjustments, increase (decrease) in goodwill								$ 5
Net sales														140	57
Other intangible assets	280
Business acquisition settlement claims received		$ 73
Accrued liabilities released		$ 7
Business acquisition benefit of settlement claims and accrued liabilities released													(80)
Claris Injectables Limited [Member] | IPR&D
Acquisitions And Collaborations [Line Items]
Amount allocated from total consideration to acquire in-process research and development with indefinite useful life	$ 140
Claris Injectables Limited [Member] | IPR&D | Measurement Input Discount Rate
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.130
Claris Injectables Limited [Member] | Developed Technology Rights
Acquisitions And Collaborations [Line Items]
Other intangible assets	$ 140
Acquired intangible assets, weighted-average useful life	8 years
Claris Injectables Limited [Member] | Developed Technology Rights | Measurement Input Discount Rate
Acquisitions And Collaborations [Line Items]
Discount rate used to measure intangible assets	0.120
Claris Injectables Limited [Member] | Marketing and Administrative Expenses
Acquisitions And Collaborations [Line Items]
Integration costs													$ 27	$ 33	$ 28

ACQUISITIONS AND OTHER ARRAN_13

ACQUISITIONS AND OTHER ARRANGEMENTS - Summary of Fair Value of Assets Acquired and Liabilities Assumed for Claris Injectables Limited (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Jul. 27, 2017
Acquisitions And Collaborations [Line Items]
Goodwill	$ 3,030	$ 2,937	$ 2,929	$ 3,002	$ 2,978	$ 2,981	$ 3,103	$ 3,102
Claris Injectables Limited [Member]
Acquisitions And Collaborations [Line Items]
Cash									$ 11
Accounts receivable, net									16
Inventories									30
Prepaid expenses and other current assets									16
Property, plant and equipment									130
Goodwill									296
Other intangible assets									280
Other non-current assets									20
Accounts payable and accrued liabilities									23
Other non-current liabilities									136
Total assets acquired and liabilities assumed									$ 640

ACQUISITIONS AND OTHER ARRAN_14

ACQUISITIONS AND OTHER ARRANGEMENTS - Other Business Acquisitions (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Acquisitions And Collaborations [Line Items]
Estimated useful lives			10 years
Developed Technology Rights Acquisition
Acquisitions And Collaborations [Line Items]
Reacquired license rights fair value total			$ 80
Developed Technology Rights Acquisition | Subsequent Event
Acquisitions And Collaborations [Line Items]
Reacquired license rights fair value total	$ 60
Developed Technology Rights | Developed Technology Rights Acquisition | Subsequent Event
Acquisitions And Collaborations [Line Items]
Estimated useful lives	11 years
Celerity Pharmaceutical LLC
Acquisitions And Collaborations [Line Items]
Payment to acquire the rights			86	$ 72	$ 20
Maximum contingent future payments		$ 79	$ 79
Celerity Pharmaceutical LLC | Developed Technology Rights
Acquisitions And Collaborations [Line Items]
Estimated useful lives			12 years
Seprafilm Adhesion Barrier
Acquisitions And Collaborations [Line Items]
Cash consideration transferred		345
Other Acquisitions
Acquisitions And Collaborations [Line Items]
Consideration transferred			$ 10	$ 36	$ 16
Development and regulatory milestone payments, maximum		$ 26	$ 26

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 377			$ 367
Work in process	185			207
Finished goods	1,091			1,093
Inventories	$ 1,653	$ 1,756	$ 1,743	$ 1,667	$ 1,716	$ 1,616	$ 1,578

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Prepaid Expenses and Other (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Prepaid expenses and other
Prepaid value added taxes	$ 140			$ 131
Prepaid income taxes	90			79
Other	389			404
Prepaid expenses and other current assets	$ 619	$ 642	$ 614	$ 614	$ 615	$ 621	$ 610

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 10,660	$ 10,333
Accumulated depreciation	(6,148)	(5,803)
Property, plant and equipment (PP&E), net	4,512	4,530		$ 4,485	$ 4,476	$ 4,476	$ 4,486	$ 4,576
Property, plant and equipment, purchases	87	97
Depreciation expense	606	602	$ 596
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	148	142
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	1,761	1,703
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	6,671	6,423
Equipment with customers
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	1,489	1,364
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 591	$ 701

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Other Long-Term Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Other Assets, Noncurrent
Deferred tax assets	$ 621			$ 483
Non-current receivables, net	163			146
Contract assets	68			30
Investments	76			44
Other	141			116
Other non-current assets	$ 1,069	$ 894	$ 823	$ 819	$ 918	$ 744	$ 704

SUPPLEMENTAL FINANCIAL INFORM_7

SUPPLEMENTAL FINANCIAL INFORMATION - Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Accounts Payable and Accrued Liabilities, Current
Accounts payable	$ 892			$ 998
Common stock dividends payable	111			101
Employee compensation and withholdings	456			486
Property, payroll and certain other taxes	113			131
Restructuring reserves	83			90
Accrued rebates	208			193
Operating lease liabilities	101
Income taxes payable	85			104
Other	640			707
Accounts payable and accrued liabilities	$ 2,689	$ 2,553	$ 2,478	$ 2,810	$ 2,660	$ 2,583	$ 2,598

SUPPLEMENTAL FINANCIAL INFORM_8

SUPPLEMENTAL FINANCIAL INFORMATION - Other Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Other Liabilities Noncurrent
Pension and other postretirement benefits	$ 1,260			$ 1,087
Deferred tax liabilities	192			215
Long-term tax liabilities	81			77
Interest rate contracts	52			3
Litigation and environmental reserves	30			31
Restructuring reserves	9			11
Other	108			135
Other non-current liabilities	$ 1,732	$ 1,490	$ 1,504	$ 1,559	$ 1,570	$ 1,612	$ 1,630

SUPPLEMENTAL FINANCIAL INFORM_9

SUPPLEMENTAL FINANCIAL INFORMATION - Net Interest Expense (Detail) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Interest Income Expense Net
Interest costs								$ 120	$ 105	$ 98
Interest costs capitalized								(9)	(12)	(13)
Interest expense								111	93	85
Interest income								(40)	(48)	(30)
Interest expense, net	$ 20	$ 18	$ 11	$ 11	$ 12	$ 38	$ 23	$ 71	$ 45	$ 55

SUPPLEMENTAL FINANCIAL INFOR_10

SUPPLEMENTAL FINANCIAL INFORMATION - Other (Income) Expense, net (Detail) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Income, net
Foreign exchange losses (gains), net								$ 37	$ (14)	$ 63
Gain on sale of investments								(1)	(3)	(3)
Saudi Arabia joint venture gain								0	(24)	0
Venezuela deconsolidation								0	0	33
Pension settlement charges								755	1	2
Pension and other postretirement benefit plans								(53)	(49)	31
Other, net								(7)	11	7
Other (income) expense, net	$ 4	$ (21)	$ (33)	$ (38)	$ (6)	$ (17)	$ (44)	$ 731	$ (78)	$ 133

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 3,002	$ 3,102
Additions	111	32
Currency translation and other adjustments	(83)	(132)
Goodwill, ending balance	3,030	3,002
U.S. and Puerto Rico plans
Goodwill [Roll Forward]
Goodwill, beginning balance	2,386	2,476
Additions	101	15
Currency translation and other adjustments	(59)	(105)
Goodwill, ending balance	2,428	2,386
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	393	393
Additions	10	17
Currency translation and other adjustments	(18)	(17)
Goodwill, ending balance	385	393
APAC
Goodwill [Roll Forward]
Goodwill, beginning balance	223	233
Additions	0	0
Currency translation and other adjustments	(6)	(10)
Goodwill, ending balance	$ 217	$ 223

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Other Intangible Assets, Net (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Intangible Asset Excluding Goodwill [Line Items]
Accumulated amortization	$ (1,475)			$ (1,370)
Gross other intangible assets	2,946			2,780
Other intangible assets, net	1,471	$ 1,363	$ 1,440	1,410	$ 1,400	$ 1,424	$ 1,505
Indefinite-lived intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets, indefinite-lived intangible assets	173			188
Developed technology, including patents
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets, developed technology including patents	2,309			2,135
Accumulated amortization	(1,190)			(1,117)
Other intangible assets, net	1,119			1,018
Other amortized intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets, developed technology including patents	464			457
Accumulated amortization	(285)			(253)
Other intangible assets, net	$ 179			$ 204

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Intangible Asset Excluding Goodwill [Line Items]
Goodwill, impairment loss		$ 0
Intangible asset amortization expense		183,000,000	$ 169,000,000	$ 154,000,000
Anticipated annual amortization expense of other intangible assets for 2020		188,000,000
Anticipated annual amortization expense of other intangible assets for 2021		184,000,000
Anticipated annual amortization expense of other intangible assets for 2022		179,000,000
Anticipated annual amortization expense of other intangible assets for 2023		167,000,000
Anticipated annual amortization expense of other intangible assets for 2024		145,000,000
Impairment of intangible assets		$ 31,000,000	$ 0	$ 0
Developed Technology Rights
Intangible Asset Excluding Goodwill [Line Items]
Impairment of intangible assets	$ 31,000,000

DEBT, CREDIT FACILITIES AND L_3

DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS - Schedule of Debt (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	May 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	May 31, 2017
Debt Instrument [Line Items]
Debt and capital lease obligations	$ 5,124				$ 3,483
Current portion	(315)	$ (2)		$ (2)	(2)	$ (3)	$ (3)	$ (3)
Long-term debt and finance lease obligations	$ 4,809	$ 5,157		$ 3,451	3,481	$ 3,480	$ 3,491	$ 3,550
Variable-rate loan due 2020
Debt Instrument [Line Items]
Effective Interest Rate	1.00%
Debt and capital lease obligations	$ 313				310
1.7% notes due 2021
Debt Instrument [Line Items]
Senior notes, coupon rates	1.70%
Effective Interest Rate	1.90%
Debt and capital lease obligations	$ 398				398
2.4% notes due 2022
Debt Instrument [Line Items]
Senior notes, coupon rates	2.40%
Effective Interest Rate	2.50%
Debt and capital lease obligations	$ 203				202
0.40% notes due 2024
Debt Instrument [Line Items]
Senior notes, coupon rates	0.40%								0.40%
Effective Interest Rate	0.60%
Debt and capital lease obligations	$ 834				0
1.3% notes due 2025
Debt Instrument [Line Items]
Senior notes, coupon rates	1.30%
Effective Interest Rate	1.40%
Debt and capital lease obligations	$ 669				684
2.6% notes due 2026
Debt Instrument [Line Items]
Senior notes, coupon rates	2.60%
Effective Interest Rate	2.70%
Debt and capital lease obligations	$ 746				745
7.65% Debentures due 2027
Debt Instrument [Line Items]
Senior notes, coupon rates	7.65%
Effective Interest Rate	7.70%
Debt and capital lease obligations	$ 5				5
6.625% Debentures due 2028
Debt Instrument [Line Items]
Senior notes, coupon rates	6.625%
Effective Interest Rate	6.70%
Debt and capital lease obligations	$ 98				98
1.3% notes due 2029
Debt Instrument [Line Items]
Senior notes, coupon rates	1.30%		1.30%
Effective Interest Rate	1.30%
Debt and capital lease obligations	$ 830				0
6.25% notes due 2037
Debt Instrument [Line Items]
Senior notes, coupon rates	6.25%
Effective Interest Rate	6.30%
Debt and capital lease obligations	$ 265				265
3.65% Notes due 2042
Debt Instrument [Line Items]
Senior notes, coupon rates	3.65%
Effective Interest Rate	3.70%
Debt and capital lease obligations	$ 6				6
4.5% notes due 2043
Debt Instrument [Line Items]
Senior notes, coupon rates	4.50%
Effective Interest Rate	4.50%
Debt and capital lease obligations	$ 255				255
3.5% notes due 2046
Debt Instrument [Line Items]
Senior notes, coupon rates	3.50%
Effective Interest Rate	3.60%
Debt and capital lease obligations	$ 440				439
Finance leases and other
Debt Instrument [Line Items]
Effective Interest Rate	10.00%
Debt and capital lease obligations	$ 62				$ 76

DEBT, CREDIT FACILITIES AND L_4

DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019EUR (€)	Nov. 30, 2019USD ($)	Nov. 30, 2019EUR (€)	May 31, 2019EUR (€)	May 31, 2017EUR (€)
Debt Instrument [Line Items]
Fees under the credit facilities	0.09%	0.10%
Line of Credit Facility, Remaining Borrowing Capacity	$ 0
Domestic Line of Credit
Debt Instrument [Line Items]
Credit facility, maximum capacity				$ 1,500,000,000
Foreign Line of Credit
Debt Instrument [Line Items]
Credit facility, current capacity | €					€ 200,000,000
Line of credit, borrowings outstanding	$ 224,000,000
Line of Credit Facility, Interest Rate at Period End	0.91%		0.91%
Other Line Of Credit
Debt Instrument [Line Items]
Credit facility, maximum capacity	$ 200,000,000
Line of credit, borrowings outstanding	$ 2,000,000	$ 2,000,000
1.30% Senior Notes due May 2025
Debt Instrument [Line Items]
Senior notes | €							€ 600,000,000
Senior notes, coupon rates							1.30%
0.40% Senior Notes due May 2024
Debt Instrument [Line Items]
Senior notes | €						€ 750,000,000
Senior notes, coupon rates	0.40%		0.40%				0.40%
0.40% Senior Notes due May 2024 | Domestic Line of Credit
Debt Instrument [Line Items]
Credit facility, current capacity	$ 2,000,000,000
0.40% Senior Notes due May 2024 | Foreign Line of Credit
Debt Instrument [Line Items]
Credit facility, current capacity | €			€ 200,000,000
1.3% Senior Notes due May 2029
Debt Instrument [Line Items]
Senior notes | €						€ 750,000,000
Senior notes, coupon rates	1.30%		1.30%			1.30%

DEBT, CREDIT FACILITIES AND L_5

DEBT, CREDIT FACILITIES AND LEASE COMMITMENTS - Schedule of Maturities of Long-term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2020	$ 315
2021	402
2022	207
2023	1
2024	842
Thereafter	3,393
Total obligations and commitments	5,160
Discounts, premiums, and adjustments relating to hedging instruments	(36)
Total debt	$ 5,124	$ 3,483

LEASES - Additional Information

LEASES - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019
Maximum
Leases [Line Items]
Lessee operating and finance lease remaining term of contract	25 years
Lessee, renewal term	16 years
Minimum
Leases [Line Items]
Lessee operating and finance lease remaining term of contract	1 year
Lessee, renewal term	1 year

LEASES - Components of Lease Co

LEASES - Components of Lease Cost (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 121
Finance leases
Amortization of right-of-use assets	5
Interest on lease liabilities	5
Variable lease cost	89
Lease cost	$ 220

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information Related to Leases (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 119
Operating cash flows from finance leases	4
Financing cash flows from finance leases	4
Right-of-use operating lease assets obtained in exchange for lease obligations	$ 207

LEASES - Assets and Liabilities

LEASES - Assets and Liabilities of Lessee (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019
Operating leases
Operating lease right-of-use assets	$ 608	$ 595	$ 513
Accounts payable and accrued liabilities	101
Operating lease liabilities	510	$ 496	$ 417
Total operating lease liabilities	611
Finance leases
Property, plant and equipment, at cost	63
Accumulated depreciation	(19)
Property, plant and equipment, net	44
Current maturities of long-term debt and finance lease obligations	0
Long-term debt and finance lease obligations	54
Total finance lease liabilities	$ 54

LEASES - Schedule of Lease Term

LEASES - Schedule of Lease Term and Discount Rates (Details)	Dec. 31, 2019
Leases [Abstract]
Operating lease, weighted average remaining lease term	10 years
Finance lease, weighted average remaining lease term	15 years
Operating lease, weighted average discount rate	2.80%
Finance lease, weighted average discount rate	10.60%

LEASES - Maturities of Operatin

LEASES - Maturities of Operating and Finance Lease Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Finance Leases
2020			$ 7
2021			7
2022			7
2023			6
2024			6
Thereafter			78
Total minimum lease payments			111
Less: imputed interest			(57)
Total finance lease liabilities			54
Operating Leases
2020			112
Operating lease rent expense	$ 152	$ 155
2021			96
2022			80
2023			67
2024			54
Thereafter			267
Total minimum lease payments			676
Less: imputed interest			(65)
Total operating lease liabilities			$ 611

LEASES - Schedule of Future Min

LEASES - Schedule of Future Minimum Lease Payments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Capital Leases
2019	$ 7
2020	7
2021	8
2022	8
2023	6
Thereafter	88
Total minimum lease payments	124
Less: imputed interest	(62)
Present value of lease liabilities	62
Operating Leases
2019	123
2020	94
2021	86
2022	72
2023	64
Thereafter	212
Total minimum lease payments	651
Operating lease rent expense	$ 152	$ 155

LEASES - Components of Operatin

LEASES - Components of Operating Lease Income (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Sales-type lease revenue	$ 35
Operating lease revenue	61
Variable lease revenue	85
Total lease revenue	$ 181

LEASES - Components of Net Inve

LEASES - Components of Net Investment in Sales-type Lease (Details) $ in Millions	Dec. 31, 2019USD ($)
Leases [Abstract]
Minimum lease payments	$ 110
Unguaranteed residual values	11
Net investment in leases	$ 121

LEASES - Components of Sales Ty

LEASES - Components of Sales Type Lease Income (Details) $ in Millions	Dec. 31, 2019USD ($)
Leases [Abstract]
Accounts receivable, net	$ 45
Other non-current assets	76
Total	$ 121

LEASES - Maturities of Sales-ty

LEASES - Maturities of Sales-type and Operating Leases (Details) $ in Millions	Dec. 31, 2019USD ($)
Sales-type and Direct Financing Leases, Lease Receivable, Fiscal Year Maturity [Abstract]
2019	$ 45
2021	32
2022	22
2023	14
2024	7
Thereafter	1
Total minimum lease payments	121
Less: imputed interest	(11)
Total minimum lease payments	110
Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]
2019	61
2021	60
2022	60
2023	33
2024	15
Thereafter	4
Present value of minimum lease payments	$ 233

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019USD ($)Site	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2008Lawsuit
Loss Contingencies [Line Items]
Litigation reserve	$ 56,000,000	$ 46,000,000
Insurance settlements receivable	0	0
Proceeds from legal settlements	39,000,000
Gain related litigation settlement	37,000,000
Hurricane Maria
Loss Contingencies [Line Items]
Pre-tax charges related to damages caused by hurricane			$ 32,000,000
Impairment of Damaged Inventory and Fixed Assets | Hurricane Maria
Loss Contingencies [Line Items]
Pre-tax charges related to damages caused by hurricane			11,000,000
Idle Facility and Other Costs | Hurricane Maria
Loss Contingencies [Line Items]
Pre-tax charges related to damages caused by hurricane			21,000,000
Asset Impairments and Idle Facility and Other Costs | Hurricane Maria
Loss Contingencies [Line Items]
Insurance recoveries	$ 100,000,000	42,000,000
Minimum
Loss Contingencies [Line Items]
Number of law suits filed | Lawsuit				1,000
Environmental Clean-up | Superfund Sites
Loss Contingencies [Line Items]
Number of sites | Site	6
Pretax charge from discontinued operations			$ 15,000,000
Environmental reserves	$ 18,000,000	$ 19,000,000

STOCKHOLDERS_ EQUITY - Stock-ba

STOCKHOLDERS’ EQUITY - Stock-based Compensation Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity Note [Line Items]
Shares available for future awards under the stock-based compensation plans (in shares)					24
Stock compensation	$ 22	$ 20	$ 57	$ 54	$ 122	$ 115	$ 107
Tax benefit related to stock based compensation					70	61	87
Excess tax benefit for stock based compensation					$ 54	$ 40	$ 56
Marketing and Administrative Expenses
Stockholders Equity Note [Line Items]
Stock compensation expense allocation percentage					80.00%	80.00%

STOCKHOLDERS_ EQUITY - Stock Op

STOCKHOLDERS’ EQUITY - Stock Options Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity Note [Line Items]
Percentage of common stock retained	100.00%
Employee stock option
Stockholders Equity Note [Line Items]
Target service period	3 years
Stock options granted contractual term	10 years
Total intrinsic value of stock options exercised	$ 272	$ 222	$ 203
Unrecognized compensation cost related to all unvested	$ 55
Weighted-average period for all unvested	1 year 8 months 12 days
Stock repurchase program, period in force	6 months

STOCKHOLDERS_ EQUITY - Stock _2

STOCKHOLDERS’ EQUITY - Stock Options Fair Value Assumptions (Details) - Employee stock option - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	19.00%	18.00%	19.00%
Expected life (in years)	5 years 6 months	5 years 6 months	5 years 6 months
Risk-free interest rate	2.50%	2.60%	2.10%
Dividend yield	1.00%	1.00%	1.00%
Fair value per stock option	$ 15	$ 13	$ 10

STOCKHOLDERS_ EQUITY - Summary

STOCKHOLDERS’ EQUITY - Summary of Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Number of options
Number of options, Outstanding at beginning of year (in shares) | shares	25,314
Number of options, Granted (in shares) | shares	3,801
Number of options, Exercised (in shares) | shares	(8,043)
Number of options, Forfeited (in shares) | shares	(596)
Number of options, Expired (in shares) | shares	(132)
Number of options, Outstanding at end of year (in shares) | shares	20,344
Number of options, Vested or expected to vest at end of year (in shares) | shares	20,029
Number of options , Exercisable at end of year (in shares) | shares	12,945
Stock options grant weighted-average exercise price
Weighted-average exercise price, Outstanding at beginning of year (in dollars per share) | $ / shares	$ 43.76
Weighted-average exercise price, Granted (in dollars per share) | $ / shares	75.03
Weighted-average exercise price, Exercised (in dollars per share) | $ / shares	38.52
Weighted-average exercise price, Forfeited (in dollars per share) | $ / shares	66.91
Weighted-average exercise price, Expired (in dollars per share) | $ / shares	46.44
Weighted Average Exercise Price Outstanding at end of year (in dollars per share) | $ / shares	50.99
Weighted Average Exercise Price Vested or expected to vest at end of year (in dollars per share) | $ / shares	50.66
Weighted Average Exercise Price Exercisable at end of year (in dollars per share) | $ / shares	$ 41.74
Stock options grant Weighted-average remaining contractual life
Weighted average remaining contractual life, Outstanding at end of year	6 years 1 month 6 days
Weighted average remaining contractual life, Vested or expected to vest at end of year	6 years
Weighted average remaining contractual life, Exercisable at end of year	4 years 10 months 24 days
Stock options grant aggregate intrinsic value
Aggregate intrinsic value, outstanding, ending balance | $	$ 663,620
Aggregate intrinsic value,Vested or expected to vest at end of year | $	660,342
Aggregate intrinsic value, Exercisable at end of year | $	$ 542,128

STOCKHOLDERS_ EQUITY - Summar_2

STOCKHOLDERS’ EQUITY - Summary of Nonvested Restricted Stock Units Activity (Detail) - Restricted Stock Units - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
RSUs shares
Nonvested Units at beginning of year (in shares)	1,611
Granted (in shares)	537
Vested (in shares)	(740)
Forfeited (in shares)	(134)
Nonvested Units at end of year (in shares)	1,274	1,611
RSUs weighted-average grant date fair value
Weighted-average grant date fair value Nonvested Units at beginning of year (in dollars per share)	$ 56.45
Weighted-average grant date fair value Granted (in dollars per share)	75.60	$ 67.11	$ 55.11
Weighted-average grant date fair value Vested (in dollars per share)	51.82
Weighted-average grant date fair value Forfeited (in dollars per share)	63.90
Weighted-average grant date fair value Nonvested Units at end of year (in dollars per share)	$ 66.46	$ 56.45

STOCKHOLDERS_ EQUITY - RSUs Nar

STOCKHOLDERS’ EQUITY - RSUs Narrative (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity Note [Line Items]
Target service period	3 years
Stock repurchase program, period in force	6 months
Unrecognized compensation cost related to all unvested	$ 46
Weighted-average period for all unvested	1 year 8 months 12 days
Weighted average fair value (in dollars per share)	$ 75.60	$ 67.11	$ 55.11
Fair value of RSUs and restricted stock vested	$ 57	$ 69	$ 88

STOCKHOLDERS' EQUITY - Performa

STOCKHOLDERS' EQUITY - Performance Stock Units Fair Value Assumptions (Detail) - Performance Shares - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Baxter volatility	19.00%	19.00%	19.00%
Peer group volatility
Peer group volatility minimum	18.00%	16.00%	16.00%
Peer group volatility maximum	113.00%	53.00%	54.00%
Correlation of returns
Correlation of returns minimum	0.13	0.16	0.19
Correlation of returns maximum	0.63	0.61	0.58
Risk-free interest rate	2.50%	2.30%	1.60%
Fair value per PSU (in dollars per share)	$ 106	$ 90	$ 69

STOCKHOLDERS_ EQUITY - PSUs Nar

STOCKHOLDERS’ EQUITY - PSUs Narrative (Details) - Performance Shares $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Stockholders Equity Note [Line Items]
Unrecognized compensation cost related to all unvested	$ 18
Weighted-average period for all unvested	1 year 7 months 6 days

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Nonvested Performance Stock Unit Activity (Detail) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2019$ / sharesshares
PSUs shares
Nonvested Units at beginning of year (in shares) | shares	913
Granted (in shares) | shares	626
Vested (in shares) | shares	(559)
Forfeited (in shares) | shares	(50)
Nonvested Units at end of year (in shares) | shares	930
PSUs weighted-average grant date fair value
Weighted-average grant date fair value Nonvested Units at beginning of year (in dollars per share) | $ / shares	$ 63.88
Weighted-average grant date fair value Granted (in dollars per share) | $ / shares	69.36
Weighted-average grant date fair value Vested (in dollars per share) | $ / shares	46.47
Weighted-average grant date fair value Forfeited (in dollars per share) | $ / shares	77.70
Weighted-average grant date fair value Nonvested Units at end of year (in dollars per share) | $ / shares	$ 75.50

STOCKHOLDERS_ EQUITY - Employee

STOCKHOLDERS’ EQUITY - Employee Purchase Plan Narrative (Details) - USD ($)	May 07, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Nov. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2018	Nov. 30, 2016	Jul. 31, 2012
Stockholders Equity Note [Line Items]
Shares available for future awards under the stock-based compensation plans (in shares)							24,000,000										24,000,000
Cash dividends declared per common share (in dollars per share)		$ 0.22	$ 0.22	$ 0.19	$ 0.19	$ 0.22	$ 0.220	$ 0.220	$ 0.220	$ 0.190	$ 0.190	$ 0.190	$ 0.190	$ 0.160			$ 0.85	$ 0.73	$ 0.61
Cash dividends declared per common share annualized basis (in dollars per share)		$ 0.88	$ 0.88	$ 0.76	$ 0.76
Stock repurchase program, authorized amount																						$ 2,000,000,000
Stock repurchase program, additional authorized amount						$ 2,000,000,000														$ 1,500,000,000	$ 1,500,000,000
Purchases of common stock (in shares)																	16,500,000	35,800,000	9,200,000
Purchases of common stock									$ (111,000,000)	$ (586,000,000)			$ (259,000,000)	$ (522,000,000)	$ (697,000,000)	$ (781,000,000)	$ (1,247,000,000)	$ (2,475,000,000)	$ (564,000,000)
Stock repurchase program, liability							$ 23,000,000										23,000,000
Remaining value available under stock repurchase programs							$ 897,000,000										$ 897,000,000
ASR Agreement
Stockholders Equity Note [Line Items]
Stock repurchase program, authorized amount											$ 300,000,000							$ 300,000,000
Purchases of common stock (in shares)	600,000																	3,600,000
Employee Stock Purchase Plan
Stockholders Equity Note [Line Items]
Employee purchase price, percent																	85.00%
Authorized shares available for future awards under the stock-based compensation plans (in shares)							10,000,000										10,000,000
Shares available for future awards under the stock-based compensation plans (in shares)							3,000,000										3,000,000
Share issued, ESPP (in shares)																	700,000	800,000	800,000

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME - Summary of Changes in AOCI by Component (Detail) - USD ($) $ in Millions	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019	Jan. 01, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year	$ 7,593	$ 7,866	$ 9,062	$ 9,109	$ 7,866	$ 9,109	$ 7,866	$ 9,109	$ 8,221
Adoption of new accounting standard										$ (161)	$ (3)
Other comprehensive (loss) income before reclassifications							(315)	(347)
Amounts reclassified from AOCI							589	66
Total other comprehensive income (loss), net of tax	4	98	329	(115)	102	214	(274)	281	(722)
End of year	$ 7,803	7,593	$ 8,830	9,062	7,803	8,830	7,912	7,866	9,109
CTA
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		(2,868)		(2,545)	(2,868)	(2,545)	(2,868)	(2,545)
Adoption of new accounting standard										9	0
Other comprehensive (loss) income before reclassifications							(95)	(323)
Amounts reclassified from AOCI							0	0
Total other comprehensive income (loss), net of tax							95	323
End of year							(2,954)	(2,868)	(2,545)
Pension and other employee benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		(954)		(987)	(954)	(987)	(954)	(987)
Adoption of new accounting standard										(169)	0
Other comprehensive (loss) income before reclassifications							(184)	(23)
Amounts reclassified from AOCI							592	56
Total other comprehensive income (loss), net of tax							(408)	(33)
End of year							(715)	(954)	(987)
Hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		(1)			(1)		(1)
Adoption of new accounting standard										$ (1)
Other comprehensive (loss) income before reclassifications							(36)
Amounts reclassified from AOCI							(3)
Total other comprehensive income (loss), net of tax							39
End of year							(41)	(1)
Hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		(1)		(10)	(1)	(10)	(1)	(10)
Adoption of new accounting standard											0
Other comprehensive (loss) income before reclassifications								(1)
Amounts reclassified from AOCI								10
Total other comprehensive income (loss), net of tax								(9)
End of year								(1)	(10)
Available-for-sale securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		0		3	0	3	0	3
Adoption of new accounting standard											$ (3)
Other comprehensive (loss) income before reclassifications								0
Amounts reclassified from AOCI								0
Total other comprehensive income (loss), net of tax								0
End of year								0	3
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning of year		$ (3,823)		$ (3,539)	$ (3,823)	$ (3,539)	(3,823)	(3,539)
End of year							$ (3,710)	$ (3,823)	$ (3,539)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME - Summary of Amounts Reclassification from AOCI to Net Income (Detail) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense, net			$ (4)	$ 21	$ 33		$ 38	$ 6	$ 17	$ 44	$ (731)	$ 78	$ (133)
Settlement charge	$ 755										(755)	(1)	(2)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest			326	386	413		404	428	712	832	970	1,617	1,100
Cost of sales			(1,681)	(1,558)	(1,650)		(1,590)	(1,571)	(3,239)	(3,161)	(6,601)	(6,340)	(6,110)
Reclassifications, Income tax expense (benefit)			(13)	(44)	(102)		(63)	(46)	(57)	(109)	41	(65)	(491)
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	1,001	1,546	$ 602
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income attributable to Baxter stockholders											(589)	(66)
Amortization of pension and other employee benefits items | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other (income) expense, net											(31)	(69)
Settlement charge											(755)	(1)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest											(786)	(70)
Reclassifications, Income tax expense (benefit)											194	14
Net income attributable to Baxter stockholders											(592)	(56)
Hedging activities | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales											(4)
Reclassifications, Income tax expense (benefit)											(1)
Net income attributable to Baxter stockholders											$ 3
Gains (losses) on hedging activities | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of sales												12
Reclassifications, Income tax expense (benefit)												2
Net income attributable to Baxter stockholders												$ (10)

BUSINESS OPTIMIZATION CHARGES -

BUSINESS OPTIMIZATION CHARGES - Additional Information (Details) $ in Millions	Dec. 31, 2019USD ($)
Restructuring and Related Activities [Abstract]
Cumulative pre-tax costs incurred	$ 980
Expected additional pre-tax cash costs	$ 50

BUSINESS OPTIMIZATION CHARGES_2

BUSINESS OPTIMIZATION CHARGES - Schedule of Business Optimization Charges (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 134	$ 117	$ 70
Costs to implement business optimization programs	45	94	89
Accelerated depreciation	5	9	10
Total business optimization charges	$ 184	$ 220	$ 169

BUSINESS OPTIMIZATION CHARGES_3

BUSINESS OPTIMIZATION CHARGES - Components of Restructuring Costs (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 134	$ 117	$ 70
Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	75	100	59
Contract Termination and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11	10	5
Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	48	7	6
Cost of Goods Sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	60	35	27
Cost of Goods Sold | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	13	30	22
Cost of Goods Sold | Contract Termination and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10	4	0
Cost of Goods Sold | Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	37	1	5
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	40	63	45
Selling, General and Administrative Expenses | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	37	51	39
Selling, General and Administrative Expenses | Contract Termination and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1	6	5
Selling, General and Administrative Expenses | Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	6	1
Research and Development Expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	34	19	(2)
Research and Development Expenses | Employee Termination Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	25	19	(2)
Research and Development Expenses | Contract Termination and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	0	0
Research and Development Expenses | Asset Impairments
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 9	$ 0	$ 0

BUSINESS OPTIMIZATION CHARGES_4

BUSINESS OPTIMIZATION CHARGES - Summary of Activity in Reserves related to Business Optimization Initiatives (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 134	$ 117	$ 70
Severance and Other Employee Related Costs
Restructuring Reserve [Roll Forward]
Reserve, beginning balance	101	112	164
Restructuring charges	113	126	83
Payments	(93)	(96)	(140)
Reserve adjustments	(27)	(16)	(19)
Currency translation	(2)	(25)	24
Reserve, ending balance	$ 92	$ 101	$ 112

RETIREMENT AND OTHER BENEFIT _3

RETIREMENT AND OTHER BENEFIT PROGRAMS - Additional Information (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation of company's pension plans	$ 3.7	$ 5.4
Allowed variance from target allocation of plan assets	6.50%
General investment portfolio limits on holdings, description	5.00%
Return-Seeking Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan assets	53.00%
Liability Hedging Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan assets	47.00%

RETIREMENT AND OTHER BENEFIT _4

RETIREMENT AND OTHER BENEFIT PROGRAMS - Reconciliation of Pension and OPEB Plan Obligations, Assets and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Benefit obligations
End of period	$ 3,973
Fair value of plan assets
Beginning of period	4,774
End of period	2,973	$ 4,774
Pension benefits
Benefit obligations
Beginning of period	5,635	6,182
Service cost	74	87	$ 91
Interest cost	172	178	180
Participant contributions	4	5
Actuarial (gain) loss	924	(431)
Benefit payments	(267)	(259)
Settlements	(2,550)	(6)
Curtailment	(13)	(56)
Foreign exchange and other	(6)	(65)
End of period	3,973	5,635	6,182
Fair value of plan assets
Beginning of period	4,774	5,261
Actual return on plan assets	939	(237)
Employer contributions	69	51
Participant contributions	4	5
Benefit payments	(267)	(259)
Settlements	(2,550)	(6)
Foreign exchange and other	4	(41)
End of period	2,973	4,774	5,261
43830	(1,000)	(861)
Amounts recognized in the consolidated balance sheets
Noncurrent asset	77	60
Current liability	(25)	(25)
Noncurrent liability	(1,052)	(896)
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position, Total	(1,000)	(861)
OPEB
Benefit obligations
Beginning of period	211	235
Service cost	1	1	1
Interest cost	8	7	7
Participant contributions	0	0
Actuarial (gain) loss	26	(14)
Benefit payments	(18)	(18)
Settlements	0	0
Curtailment	0	0
Foreign exchange and other	0	0
End of period	228	211	235
Fair value of plan assets
Beginning of period	0	0
Actual return on plan assets	0	0
Employer contributions	18	18
Participant contributions	0	0
Benefit payments	(18)	(18)
Settlements	0	0
Foreign exchange and other	0	0
End of period	0	0	$ 0
43830	(228)	(211)
Amounts recognized in the consolidated balance sheets
Noncurrent asset	0	0
Current liability	(20)	(20)
Noncurrent liability	(208)	(191)
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position, Total	$ (228)	$ (211)

RETIREMENT AND OTHER BENEFIT _5

RETIREMENT AND OTHER BENEFIT PROGRAMS - Information Relating to Individual Plans in Funded Status Table above that have ABO in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Information relating to the individual plans in the funded status table above that have an ABO in excess of plan assets
ABO	$ 3,240	$ 4,981
Fair value of plan assets	$ 2,339	$ 4,246

RETIREMENT AND OTHER BENEFIT _6

RETIREMENT AND OTHER BENEFIT PROGRAMS - Information Relating to Individual Plans in Funded Status Table that have PBO in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Information relating to the individual plans in the funded status table above that have a PBO in excess of plan assets
PBO	$ 3,688	$ 5,386
Fair value of plan assets	$ 2,611	$ 4,465

RETIREMENT AND OTHER BENEFIT _7

RETIREMENT AND OTHER BENEFIT PROGRAMS - Expected Net Pension and OPEB Plan Payments for Next 10 Years (Details) $ in Millions	Dec. 31, 2019USD ($)
Pension benefits
Expected Net Pension and OPEB Plan Payments for the Next 10 Years
2020	$ 86
2021	104
2022	118
2023	132
2024	149
2024 through 2028	917
Total expected net benefit payments for next 10 years	1,506
OPEB
Expected Net Pension and OPEB Plan Payments for the Next 10 Years
2020	20
2021	18
2022	17
2023	17
2024	16
2024 through 2028	71
Total expected net benefit payments for next 10 years	$ 159

RETIREMENT AND OTHER BENEFIT _8

RETIREMENT AND OTHER BENEFIT PROGRAMS - Summary of Pre-Tax losses Included in AOCI (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Pension benefits
Summary of the pre-tax losses included in AOCI
Actuarial loss (gain)	$ 1,025	$ 1,607
Prior service credit and transition obligation	(9)	(10)
Total pre-tax loss (gain) recognized in AOCI	1,016	1,597
OPEB
Summary of the pre-tax losses included in AOCI
Actuarial loss (gain)	(41)	(79)
Prior service credit and transition obligation	(59)	(74)
Total pre-tax loss (gain) recognized in AOCI	$ (100)	$ (153)

RETIREMENT AND OTHER BENEFIT _9

RETIREMENT AND OTHER BENEFIT PROGRAMS - Summary of Net-of-Tax Amounts Recorded in OCI Relating to Pension and OPEB Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans
Gain (loss) arising during the year, net of tax expense (benefit) of $(64) in 2019, $(4) in 2018 and $25 in 2017	$ (184)	$ (22)	$ 32
Amortization of loss to earnings, net of tax benefit of $6 in 2019, $14 in 2018 and $35 in 2017	25	55	102
Settlement charge, net of tax benefit of $188 in 2019	567	0	0
Pension and other employee benefits gain	408	33	134
Gain (loss) arising during the year, tax expense (benefit)	(64)	(4)	25
Amortization of loss to earnings, tax benefit	6	$ 14	$ 35
Settlement, tax benefit	$ (188)

RETIREMENT AND OTHER BENEFIT_10

RETIREMENT AND OTHER BENEFIT PROGRAMS - Amounts Expected to be Amortized from AOCI to Net Periodic Benefit Cost in 2019 (Details) $ in Millions	Dec. 31, 2019USD ($)
Pension benefits
Defined Benefit Plan Disclosure [Line Items]
Actuarial loss/(gain)	$ 78
Prior service credit and transition obligation	(1)
Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2019	77
OPEB
Defined Benefit Plan Disclosure [Line Items]
Actuarial loss/(gain)	(4)
Prior service credit and transition obligation	(14)
Total pre-tax amount expected to be amortized from AOCI to net pension and OPEB cost in 2019	$ (18)

RETIREMENT AND OTHER BENEFIT_11

RETIREMENT AND OTHER BENEFIT PROGRAMS - Net Periodic Benefit Cost - Continuing Operations (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net periodic benefit cost
Settlement charge	$ 755	$ (755)	$ (1)	$ (2)
Pension benefits
Net periodic benefit cost
Service cost		74	87	91
Interest cost		172	178	180
Expected return on plan assets		(264)	(303)	(291)
Amortization of net losses and other deferred amounts		58	94	163
Other		0	0	(2)
Net periodic benefit cost		795	57	143
OPEB
Net periodic benefit cost
Service cost		1	1	1
Interest cost		8	7	7
Amortization of net losses and prior service credit		(27)	(25)	(26)
Net periodic benefit cost		$ (18)	$ (17)	$ (18)

RETIREMENT AND OTHER BENEFIT_12

RETIREMENT AND OTHER BENEFIT PROGRAMS - Weighted-Average Assumptions Used in Determining (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Pension benefits | Unfunded Plan | International plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	1.34%	2.02%
Rate of compensation increase	3.03%	3.08%
Discount rate	2.02%	2.02%	2.03%
Expected return on plan assets	5.45%	5.58%	5.77%
Rate of compensation increase	3.08%	3.05%	3.11%
Pension benefits | Nonqualified Plan | U.S. and Puerto Rico plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.44%	4.31%
Rate of compensation increase	3.68%	3.66%
Discount rate	4.18%	3.60%	4.09%
Expected return on plan assets	6.29%	6.25%	6.50%
Rate of compensation increase	3.66%	3.42%	3.75%
OPEB
Defined Benefit Plan Disclosure [Line Items]
Annual rate of increase in the per-capita cost	6.75%	7.00%
Rate decreased to	5.00%	5.00%
Annual rate of increase in the per-capita cost	6.75%	7.00%	6.25%
Rate decreased to	5.00%	5.00%	5.00%
OPEB | Nonqualified Plan | U.S. and Puerto Rico plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.16%	4.20%
Discount rate	4.20%	3.51%	3.89%

RETIREMENT AND OTHER BENEFIT_13

RETIREMENT AND OTHER BENEFIT PROGRAMS - Fair Value of Pension Plan Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	$ 2,973	$ 4,774
Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	705	1,063
Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	1,548	2,602
Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	10	10	$ 18
Fair value of pension plan assets	10	10
Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	710	1,099
Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	224	145
Cash and Cash Equivalents | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	72	21
Cash and Cash Equivalents | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	152	124
Cash and Cash Equivalents | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0
Cash and Cash Equivalents | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0
U.S Government and Government Agency Issues
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	452	735
U.S Government and Government Agency Issues | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
U.S Government and Government Agency Issues | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	452	735
U.S Government and Government Agency Issues | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
U.S Government and Government Agency Issues | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Corporate Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	352	1,127
Corporate Debt Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Corporate Debt Securities | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	352	1,127
Corporate Debt Securities | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Corporate Debt Securities | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	231	541
Common Stock Large Cap | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	231	541
Common Stock Large Cap | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Large Cap | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Large Cap | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	158	298
Common Stock Mid Cap | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	158	298
Common Stock Mid Cap | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Mid Cap | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Mid Cap | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Small Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	37	91
Common Stock Small Cap | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	37	91
Common Stock Small Cap | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Small Cap | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock Small Cap | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	426	930
Common Stock | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	426	930
Common Stock | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common Stock | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Mutual Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	442	356
Mutual Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	189	135
Mutual Funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	253	221
Mutual Funds | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Mutual Funds | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Common/Collective Trust Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	668	919
Common/Collective Trust Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	19	0
Common/Collective Trust Funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	272	210
Common/Collective Trust Funds | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0	8
Common/Collective Trust Funds | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	377	709
Partnership Investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	333	390
Partnership Investments | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Partnership Investments | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Partnership Investments | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Partnership Investments | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	333	390
Other Holdings
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	76	172
Other Holdings | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	8	11
Other Holdings | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	58	151
Other Holdings | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	10	10	$ 10
Other Holdings | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Collateral Held on Loaned Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	9	196
Collateral Held on Loaned Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Collateral Held on Loaned Securities | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	9	196
Collateral Held on Loaned Securities | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Collateral Held on Loaned Securities | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets	0	0
Loaned Securities Pledged as Collateral
Defined Benefit Plan Disclosure [Line Items]
Collateral to be paid on loaned securities	(9)	(196)
Loaned Securities Pledged as Collateral | Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Collateral to be paid on loaned securities	(9)	(34)
Loaned Securities Pledged as Collateral | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Collateral to be paid on loaned securities	0	(162)
Loaned Securities Pledged as Collateral | Significant unobservable inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Collateral to be paid on loaned securities	0	0
Loaned Securities Pledged as Collateral | Fair Value, Measured at NAV
Defined Benefit Plan Disclosure [Line Items]
Collateral to be paid on loaned securities	$ 0	$ 0

RETIREMENT AND OTHER BENEFIT_14

RETIREMENT AND OTHER BENEFIT PROGRAMS - Changes in Fair Value Measurements that Used Significant Unobservable Inputs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Significant unobservable inputs (Level 3)
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning of period	$ 10	$ 18
Transfers out		(8)
Purchases	0
End of period	10	10
Common/Collective Trust Funds
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning of period	919
End of period	668	919
Common/Collective Trust Funds | Significant unobservable inputs (Level 3)
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning of period	0	8
Transfers out		(8)
Purchases	0
End of period	0	0
Other Holdings
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning of period	172
End of period	76	172
Other Holdings | Significant unobservable inputs (Level 3)
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]
Beginning of period	10	10
Transfers out		0
Purchases	0
End of period	$ 10	$ 10

RETIREMENT AND OTHER BENEFIT_15

RETIREMENT AND OTHER BENEFIT PROGRAMS - Funded Status Percentage of Company's Pension Plans (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Funded status percentage of the company's pension plans
Fair value of plan assets	$ 2,973	$ 4,774
PBO	$ 3,973
Funded status percentage	75.00%
OPEB
Funded status percentage of the company's pension plans
Defined benefit plan, expected future employer contributions, next fiscal year	$ 20
Fair value of plan assets	0	0	$ 0
PBO	228	$ 211	$ 235
International plans
Funded status percentage of the company's pension plans
Defined benefit plan, expected future employer contributions, next fiscal year	41
Qualified Pension Plan | U.S. and Puerto Rico plans
Funded status percentage of the company's pension plans
Fair value of plan assets	2,060
PBO	$ 2,278
Funded status percentage	90.00%
Qualified Pension Plan | International plans
Funded status percentage of the company's pension plans
Fair value of plan assets	$ 913
PBO	$ 1,001
Funded status percentage	91.00%
Non Qualified Pension Plan | U.S. and Puerto Rico plans
Funded status percentage of the company's pension plans
PBO	$ 243
Non Qualified Pension Plan | International plans
Funded status percentage of the company's pension plans
PBO	451
Puerto Rico Pension Plan | U.S. and Puerto Rico plans
Funded status percentage of the company's pension plans
Defined benefit plan, expected future employer contributions, next fiscal year	$ 5

RETIREMENT AND OTHER BENEFIT_16

RETIREMENT AND OTHER BENEFIT PROGRAMS - Pension Plan Amendments (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2018	Dec. 31, 2019	Oct. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Payment for pension benefits		$ 755
Defined benefit plan, decline in projected benefit obligation	$ (57)
Pension benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plan liabilities			$ 2,400

RETIREMENT AND OTHER BENEFIT_17

RETIREMENT AND OTHER BENEFIT PROGRAMS - U.S. Defined Contribution Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Defined contribution plan, contributions by employer	$ 53	$ 50	$ 45

INCOME TAXES - Income From Cont

INCOME TAXES - Income From Continuing Operations Before Income Tax Expense by Category (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
United States								$ (586)	$ 7	$ (320)
International								1,556	1,610	1,420
Income from continuing operations before income taxes	$ 326	$ 386	$ 413	$ 404	$ 428	$ 712	$ 832	$ 970	$ 1,617	$ 1,100

INCOME TAXES - Income Tax Expen

INCOME TAXES - Income Tax Expense Related To Continuing Operations (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current
Federal								$ 8	$ 21	$ 8
State and local								3	(1)	11
International								258	308	261
Current income tax expense								269	328	280
Deferred
Federal								(140)	(228)	230
State and local								(29)	0	1
International								141	35	20
Deferred income tax expense (benefit)								(310)	(263)	211
Income tax expense (benefit)	$ 13	$ 44	$ 102	$ 63	$ 46	$ 57	$ 109	$ (41)	$ 65	$ 491

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets
Accrued liabilities and other	$ 209	$ 227
Pension and other postretirement benefits	258	222
Tax credit and net operating loss carryforwards	928	862
Swiss tax reform net asset basis step-up	159	0
Operating lease liabilities	153	0
Valuation allowances	(420)	(310)
Total deferred tax assets	1,287	1,001
Deferred tax liabilities
Subsidiaries’ unremitted earnings	57	43
Long-lived assets and other	649	690
Operating lease right-of-use assets	152	0
Total deferred tax liabilities	858	733
Net deferred tax asset	$ 429	$ 268

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Valuation allowance			$ 310					$ 420	$ 310
Net asset basis step-up								863
Swiss tax reform net asset basis step-up			0					159	0
Deferred tax asset, swiss tax reform net asset basis step-up, valuation allowance								69
Deferred tax asset, swiss tax reform net asset basis step-up, net								90
Deferred tax benefit recognized due to reduced U.S tax rate and other effects of tax act								19	8	$ 283
Provisional charge recognized for one-time transitional tax expense								(16)	(5)	529
U.S. Valuation allowance recognized in respect of foreign tax credit DTA								0	194	(339)
Unrecognized interest and penalties expense								21	22
Unrecognized tax benefits that, if recognized, would impact effective tax rate			84					70	84	88
Gross unrecognized tax benefit liability			68					62	68
Net indemnification receivables			6					6	6	13
Expected reduction in gross unrecognized tax benefits								27
One Time transitional Tax Expense								192		5
Income tax expense (benefit)	$ 13	$ 44	102	$ 63	$ 46	$ 57	$ 109	(41)	65	491
Deferred Tax Assets, Net of Valuation Allowance			1,001					1,287	1,001
Deferred Tax Assets, Net			268					429	268
Transition tax due to 2017 Tax Act								(16)	(5)	529
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Would Be Incurred If Earnings Remitted								19
Increase (Decrease) Due To Notional Interest Deduction								$ 57
Maximum
Income Taxes [Line Items]
U.S statutory tax rate, percent								35.00%
Minimum
Income Taxes [Line Items]
U.S statutory tax rate, percent								21.00%
State and Local Jurisdiction
Income Taxes [Line Items]
Operating loss carryforwards								$ 1,100
Domestic Tax Authority
Income Taxes [Line Items]
Operating loss carryforwards								58
Tax credit carryforwards								410
Foreign Tax Credit Carryforward, Amount								395
Foreign Tax Authority
Income Taxes [Line Items]
Operating loss carryforwards								1,300
Tax credit carryforwards								49
Valuation allowance			$ 175					180	175	$ 339
Income tax expense (benefit)									$ (194)
Deferred Tax Assets, Net of Valuation Allowance								90
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount								5
Deferred Tax Assets, Net								$ 24
Impact on earnings from continuing operations per diluted shares								$ 0.27	$ 0.29	$ 0.25
Foreign Tax Authority | Tax Year No Expiration
Income Taxes [Line Items]
Operating loss carryforwards								$ 814
Tax credit carryforwards								$ 48

INCOME TAXES - Income Tax Exp_2

INCOME TAXES - Income Tax Expense Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Expense Reconciliation
Income tax expense at U.S. statutory rate								$ 204	$ 340	$ 383
Tax incentives								(140)	(161)	(139)
State and local taxes, net of federal benefit								(17)	5	(6)
Impact of foreign taxes								65	122	(41)
Swiss tax reform net asset basis step-up								(159)	0	0
Deferred tax revaluation due to 2017 Tax Act and foreign tax reform								(19)	(8)	(283)
Transition tax due to 2017 Tax Act								(16)	(5)	529
U.S. valuation allowance due to 2017 Tax Act								0	(194)	339
Other valuation allowances			$ 21					110	21	(6)
Stock compensation windfall tax benefits								(54)	(40)	(56)
Foreign tax credits								0	0	(246)
Research and development tax credits								(13)	(17)	(5)
Other, net								(2)	2	22
Income tax expense (benefit)	$ 13	$ 44	$ 102	$ 63	$ 46	$ 57	$ 109	$ (41)	$ 65	$ 491

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of Company's Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns
Balance at beginning of the year	$ 127	$ 108	$ 82
Increase associated with tax positions taken during the current year	8	33	33
Increase (decrease) associated with tax positions taken during a prior year	(3)	13	2
Settlements	(20)	(5)	(6)
Decrease associated with lapses in statutes of limitations	(1)	(22)	(3)
Balance at end of the year	$ 111	$ 127	$ 108

EARNINGS PER SHARE - Reconcilia

EARNINGS PER SHARE - Reconciliation of Basic Shares to Diluted Shares (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Income from continuing operations			$ 313	$ 342	$ 311		$ 341	$ 382	$ 655	$ 723	$ 1,011	$ 1,552	$ 609
Less: Income from continuing operations attributable to noncontrolling interests					311	$ 518	341	382			1,001	1,552	609
Loss from discontinued operations, net of tax					(6)	0	0	0		0	0	(6)	(7)
Less: Net income attributable to noncontrolling interests											10	0	0
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Basic (in shares)			510	512	528		535	539	511	537	509	534	543
Effect of dilutive securities											10	12	12
Diluted (in shares)			519	522	538		547	551	520	549	519	546	555

EARNINGS PER SHARE - Additional

EARNINGS PER SHARE - Additional Information (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from computation of EPS	4	3	2

FINANCIAL INSTRUMENTS, DERIVA_3

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Trade Receivables Held-for-sale, Net, Reconciliation to Cash Flow [Roll Forward]
Sold receivables at beginning of year	$ 69	$ 70	$ 67
Proceeds from sales of receivables	292	267	270
Cash collections (remitted to the owners of the receivables)	(282)	(270)	(270)
Effect of currency exchange rate changes	0	2	3
Sold receivables at end of year	$ 79	$ 69	$ 70

FINANCIAL INSTRUMENTS, DERIVA_4

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Additional Information (Details)	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	May 31, 2019EUR (€)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	May 31, 2017EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset								$ 21,000,000	$ 25,000,000
Derivative Liability, Fair Value, Gross Liability								54,000,000	6,000,000
Derivative, Notional Amount									0	$ 0
Terminated fair value hedges									150,000,000
Gain (loss) on hedged item in fair value hedge									4,000,000	3,000,000
Deferred, net after-tax gains on derivative instruments								6,000,000
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset								11,000,000	3,000,000
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability								11,000,000	3,000,000
Derivative assets								10,000,000	22,000,000
Derivative liabilities								43,000,000	3,000,000
Currency translation adjustments, net of tax expense (benefit) of ($5) in 2019, ($52) in 2018 and $89 in 2017		$ 2,000,000	$ (97,000,000)	$ (368,000,000)	$ 63,000,000	$ (95,000,000)	$ (305,000,000)	(95,000,000)	(323,000,000)	599,000,000
1.30% Senior Notes due May 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €											€ 600,000,000
0.40% Senior Notes due May 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €	€ 750,000,000
1.3% Senior Notes due May 2029
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Senior notes | €	750,000,000
Designated as Hedging Instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset								20,000,000	23,000,000
Derivative Liability, Fair Value, Gross Liability								52,000,000	4,000,000
Derivative, Notional Amount								0
Not Designated as Hedging Instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount								619,000,000	487,000,000
Net investment hedge
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Accumulated pre-tax unrealized translation losses in AOCI related to euro-denominated senior notes								21,000,000
Net investment hedge | Designated as Hedging Instrument | Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Currency translation adjustments, net of tax expense (benefit) of ($5) in 2019, ($52) in 2018 and $89 in 2017 | €	€ 1,200,000,000
Foreign exchange contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount								$ 617,000,000	706,000,000
Maximum length of time hedge in cash flow hedge								12 months
Interest rate contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount								$ 550,000,000
Gain (loss) on hedged item in fair value hedge								0	(4,000,000)	$ (3,000,000)
Interest rate contract | Fair value hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount								$ 0	$ 0

FINANCIAL INSTRUMENTS, DERIVA_5

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Gains and Losses on Derivative Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge and net investment hedge, gain (loss), before reclassification, tax	$ (34)	$ 32	$ (92)
Other comprehensive income (loss), reclassification adjustment from AOCI, cash flow hedges and net investment hedges, net of tax	4
Amount reclassified to earnings during the year		(12)	(8)
Gain (loss) recognized in income, fair value hedges		4	3
Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax	0
Other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, net investment hedge, before tax		0	0
Interest rate contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, fair value hedges	0	(4)	(3)
Foreign exchange contract | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, undesignated derivative instruments	(17)	0	(37)
Cash Flow Hedges | Interest rate contract
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax	(37)
Gain (loss) recognized in OCI		(3)	(3)
Cash Flow Hedges | Interest rate contract | Net Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	0
Gain (loss) reclassified from AOCI into income		0	0
Cash Flow Hedges | Foreign exchange contract
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax	(9)
Gain (loss) recognized in OCI		3	(24)
Cash Flow Hedges | Foreign exchange contract | Cost of Goods Sold
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	4
Gain (loss) reclassified from AOCI into income		(12)	(8)
Net investment hedge
Derivative Instruments, Gain (Loss) [Line Items]
Other comprehensive income (loss), net investment hedge, gain (loss), before reclassification and tax	$ 12
Other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, net investment hedge, before tax		$ 32	$ (65)

FINANCIAL INSTRUMENTS, DERIVA_6

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Net of Tax Activity in Accumulated Other Comprehensive Income Related to Cash Flow Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019	Jan. 01, 2018	Jan. 01, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss) balance at beginning of year	$ (3,823)
Adoption of new accounting standard				$ (161)	$ (3)
Amount reclassified to earnings during the year		$ 12	$ 8
Accumulated other comprehensive income (loss) balance at end of year	(3,710)	(3,823)
Deferred, net after-tax gains on derivative instruments	6
Continuing Operations
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive income (loss) balance at beginning of year	(1)	(10)	3
Adoption of new accounting standard				$ (1)	$ 0	$ 0
(Loss) gain in fair value of derivatives during the year	(36)	(1)	(18)
Amount reclassified to earnings during the year	(3)	10	5
Accumulated other comprehensive income (loss) balance at end of year	$ (41)	$ (1)	$ (10)

FINANCIAL INSTRUMENTS, DERIVA_7

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Classification and Fair Value Amounts of Derivative Instruments (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$ 21	$ 25
Derivative liability, fair value	54	6
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	20	23
Derivative liability, fair value	52	4
Designated as Hedging Instrument | Interest rate contract | Other Long-Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	10	0
Designated as Hedging Instrument | Interest rate contract | Other Long-term Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	52	3
Designated as Hedging Instrument | Foreign exchange contract | Other Long-Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	0	1
Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	10	22
Designated as Hedging Instrument | Foreign exchange contract | Other Long-term Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	0	0
Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	0	1
Not Designated as Hedging Instrument | Foreign exchange contract | Prepaid expenses and other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	1	2
Not Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 2	$ 2

FINANCIAL INSTRUMENTS, DERIVA_8

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Derivative Positions Presented On Net Basis (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross amounts recognized in the consolidated balance sheet, Asset	$ 21	$ 25
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset	(11)	(3)
Total, Asset	10	22
Gross amounts recognized in the consolidated balance sheet, Liability	54	6
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability	(11)	(3)
Total, Liability	$ 43	$ 3

FINANCIAL INSTRUMENTS, DERIVA_9

FINANCIAL INSTRUMENTS, DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Amounts Recorded on Condensed Consolidated Balance Sheet Related to Fair Value Hedges (Details) - Long-term Debt [Member] - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Carrying amount of hedged item	$ 103	$ 103
Cumulative amount of fair value hedging adjustment included in the carrying amount of the hedged item	$ 6	$ 7

FAIR VALUE MEASUREMENTS - Summa

FAIR VALUE MEASUREMENTS - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	$ 11	$ 25
Interest rate hedges, assets at fair value	10
Marketable equity securities	3	3
Total assets	24	28
Foreign exchange contracts	2	3
Interest rate contracts, liabilities at fair value	52	3
Contingent payments related to acquisitions	39	32
Total liabilities	93	38
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	0	0
Interest rate hedges, assets at fair value	0
Marketable equity securities	3	3
Total assets	3	3
Foreign exchange contracts	0	0
Interest rate contracts, liabilities at fair value	0	0
Contingent payments related to acquisitions	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	11	25
Interest rate hedges, assets at fair value	10
Marketable equity securities	0	0
Total assets	21	25
Foreign exchange contracts	2	3
Interest rate contracts, liabilities at fair value	52	3
Contingent payments related to acquisitions	0	0
Total liabilities	54	6
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange contracts	0	0
Interest rate hedges, assets at fair value	0
Marketable equity securities	0	0
Total assets	0	0
Foreign exchange contracts	0	0
Interest rate contracts, liabilities at fair value	0	0
Contingent payments related to acquisitions	39	32
Total liabilities	$ 39	$ 32

FAIR VALUE MEASUREMENTS - Finan

FAIR VALUE MEASUREMENTS - Financial Instruments and Related Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Financial Instruments and Fair Value [Line Items]
Cash and cash equivalents	$ 3,335	$ 2,934	$ 1,902	$ 1,838	$ 2,863	$ 2,858	$ 2,949
Other Assets
Financial Instruments and Fair Value [Line Items]
Other equity investments without readily determinable fair values	73			41
Fair Value, Inputs, Level 2
Financial Instruments and Fair Value [Line Items]
Cash and cash equivalents	3,300			1,800
Money market funds, at carrying value	$ 1,700			$ 169

FAIR VALUE MEASUREMENTS - Recon

FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Contingent payments, Fair value as of beginning of period	$ 32	$ 9
Contingent payments, additions	18	24
Contingent payments, net gains recognized in earnings	(4)	0
Contingent payments, payments	(7)	(1)
Contingent payments, Fair value as of end of period	$ 39	$ 32

FAIR VALUE MEASUREMENTS - Book

FAIR VALUE MEASUREMENTS - Book Values and Fair Values of Financial Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Book Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt	$ 226	$ 2
Current maturities of long-term debt and finance lease obligations	315	2
Long-term debt and finance lease obligations	4,809	3,481
Fair values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Short-term debt	226	2
Current maturities of long-term debt and finance lease obligations	315	2
Long-term debt and finance lease obligations	$ 5,156	$ 3,469

SEGMENT INFORMATION - Financial

SEGMENT INFORMATION - Financial Information of Segments (Details) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019USD ($)u_baxGeographical	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2019USD ($)u_baxGeographical	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Net sales	$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Total segment operating income			350	383	391		377	434	733	811	1,772	1,584	1,288
Depreciation											606	602	596
Capital Expenditures											686	692	606
Interest Income (Expense), Net			20	18	11		11	12	38	23	71	45	55
Other Nonoperating Income (Expense)			4	(21)	(33)		(38)	(6)	(17)	(44)	731	(78)	133
Income from continuing operations before income taxes			$ 326	$ 386	$ 413		$ 404	$ 428	$ 712	$ 832	$ 970	1,617	1,100
Number Geographical Segments | u_baxGeographical	3										3
Americas
Segment Reporting Information [Line Items]
Net sales											$ 6,094	5,951	5,718
EMEA
Segment Reporting Information [Line Items]
Net sales											2,968	2,946	2,752
APAC
Segment Reporting Information [Line Items]
Net sales											2,300	2,202	2,114
Operating Segments
Segment Reporting Information [Line Items]
Total segment operating income											3,575	3,609	3,310
Operating Segments | Americas
Segment Reporting Information [Line Items]
Total segment operating income											2,374	2,411	2,238
Depreciation											255	229	231
Capital Expenditures											325	296	269
Operating Segments | EMEA
Segment Reporting Information [Line Items]
Total segment operating income											652	666	562
Depreciation											149	158	149
Capital Expenditures											143	140	141
Operating Segments | APAC
Segment Reporting Information [Line Items]
Total segment operating income											549	532	510
Depreciation											85	95	84
Capital Expenditures											98	122	95
Corporate and Other
Segment Reporting Information [Line Items]
Total segment operating income											(1,803)	(2,025)	(2,022)
Depreciation											117	120	132
Capital Expenditures											$ 120	$ 134	$ 101

SEGMENT INFORMATION - Operating

SEGMENT INFORMATION - Operating Income to Income from Continuing Operations Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)	$ 350	$ 383	$ 391	$ 377	$ 434	$ 733	$ 811	$ 1,772	$ 1,584	$ 1,288
Interest expense, net	20	18	11	11	12	38	23	71	45	55
Other (income) expense, net	4	(21)	(33)	(38)	(6)	(17)	(44)	731	(78)	133
Income from continuing operations before income taxes	$ 326	$ 386	$ 413	$ 404	$ 428	$ 712	$ 832	970	1,617	1,100
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)								3,575	3,609	3,310
Corporate and Other
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)								$ (1,803)	$ (2,025)	$ (2,022)

SEGMENT REPORTING - Geographic

SEGMENT REPORTING - Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Consolidated PP&E and operating lease right-of-use assets, net	5,120				4,530						5,120	4,530
U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											4,826	4,723	4,510
Consolidated PP&E and operating lease right-of-use assets, net	1,889				1,786						1,889	1,786
Latin America and Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											1,268	1,228	1,208
Consolidated PP&E and operating lease right-of-use assets, net	825				648						825	648
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											6,094	5,951	5,718
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											2,968	2,946	2,752
Consolidated PP&E and operating lease right-of-use assets, net	1,447				1,204						1,447	1,204
APAC
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											2,300	2,202	2,114
Consolidated PP&E and operating lease right-of-use assets, net	$ 959				$ 892						959	892
APAC
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											2,300	2,202	2,114
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											2,968	2,946	2,752
Total Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales											$ 6,094	$ 5,951	$ 5,718

QUARTERLY FINANCIAL DATA (UNA_3

QUARTERLY FINANCIAL DATA (UNAUDITED) - Quarterly Financial Results (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended					3 Months Ended								6 Months Ended		12 Months Ended
	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Nov. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information [Line Items]
Net sales						$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Gross margin						1,298	1,230	1,153	1,080	1,183	1,232	1,223	1,121	2,233	$ 2,344	4,761	4,759	4,474
Less: Income from continuing operations attributable to noncontrolling interests										$ 311	$ 518	$ 341	$ 382			$ 1,001	$ 1,552	$ 609
Income (loss) from continuing operations per common share
Basic (in dollars per share)										$ 0.59	$ 0.97	$ 0.64	$ 0.71		$ 1.35	$ 1.97	$ 2.91	$ 1.12
Diluted (in dollars per share)										$ 0.58	$ 0.95	$ 0.62	$ 0.69		$ 1.32	$ 1.93	$ 2.84	$ 1.10
Loss from discontinued operations, net of tax										$ (6)	$ 0	$ 0	$ 0		$ 0	$ 0	$ (6)	$ (7)
(Loss) income from discontinued operations per common share
Basic (in dollars per share)										$ (0.01)	$ 0	$ 0	$ 0		$ 0	$ 0	$ (0.01)	$ (0.01)
Diluted (in dollars per share)										$ (0.01)	$ 0	$ 0	$ 0		$ 0	$ 0	$ (0.01)	$ (0.02)
Net income (loss)						$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Earnings per share
Basic (in dollars per share)						$ (0.05)	$ 0.72	$ 0.61	$ 0.67	$ 0.58	$ 0.97	$ 0.64	$ 0.71	$ 1.28	$ 1.35	$ 1.97	$ 2.90	$ 1.11
Diluted (in dollars per share)						(0.05)	0.71	0.60	0.66	0.57	0.95	0.62	0.69	$ 1.26	$ 1.32	1.93	2.83	1.08
Cash dividends declared per common share (in dollars per share)	$ 0.22	$ 0.22	$ 0.19	$ 0.19	$ 0.22	$ 0.220	0.220	0.220	0.190	0.190	0.190	0.190	0.160			$ 0.85	$ 0.73	$ 0.61
Market price per common share
Settlement charge						$ 755										$ (755)	$ (1)	$ (2)
Maximum
Market price per common share
High/Low market price per common share (in dollars per share)						$ 88.45	89.78	82.41	81.31	77.80	77.75	75.41	72.26			$ 89.78	$ 77.80
Minimum
Market price per common share
High/Low market price per common share (in dollars per share)						$ 76.70	$ 81.40	$ 73.44	$ 64.48	$ 61.45	$ 70.71	$ 63.43	$ 62.56			$ 64.48	$ 61.45

QUARTERLY FINANCIAL DATA (UNA_4

QUARTERLY FINANCIAL DATA (UNAUDITED) - Balance Sheets (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,335	$ 2,934	$ 1,902	$ 1,838	$ 2,863	$ 2,858	$ 2,949
Accounts receivable, net		1,897	1,801		1,837	1,789	1,818
Inventory, Net	1,653	1,756	1,743	1,667	1,716	1,616	1,578
Prepaid expenses and other current assets	619	642	614	614	615	621	610
Total current assets	7,503	7,229	6,060	5,959	7,031	6,884	6,955
Property, Plant and Equipment, Net	4,512	4,485	4,476	4,530	4,476	4,486	4,576
Goodwill	3,030	2,937	2,929	3,002	2,978	2,981	3,103	$ 3,102
Intangible Assets, Net (Excluding Goodwill)	1,471	1,363	1,440	1,410	1,400	1,424	1,505
Operating lease right-of-use assets	608	595	513
Other non-current assets	1,069	894	823	819	918	744	704
Total assets	18,193	17,503	16,241	15,720	16,803	16,519	16,843
Current liabilities:
Short-term debt	226	2	796	2
Current maturities of long-term debt and finance lease obligations	315	2	2	2	3	3	3
Accounts payable and accrued liabilities	2,689	2,553	2,478	2,810	2,660	2,583	2,598
Total current liabilities	3,230	2,557	3,276	2,814	2,663	2,586	2,601
Long-term debt and finance lease obligations	4,809	5,157	3,451	3,481	3,480	3,491	3,550
Operating lease liabilities	510	496	417
Other non-current liabilities	1,732	1,490	1,504	1,559	1,570	1,612	1,630
Total liabilities	10,281	9,700	8,648	7,854	7,713	7,689	7,781
Commitments and contingencies
Equity:
Common stock	683	683	683	683	683	683	683
Common stock in treasury, at cost	(10,764)	(10,322)	(10,284)	(9,989)	(8,639)	(8,485)	(8,354)
Additional contributed capital	5,955	5,906	5,839	5,898	5,931	5,916	5,912
Retained earnings	15,718	15,598	15,414	15,075	14,886	14,484	14,254
Accumulated other comprehensive (loss) income	(3,710)	(4,086)	(4,082)	(3,823)	(3,754)	(3,756)	(3,427)
Total Baxter stockholders’ equity	7,882	7,779	7,570	7,844	9,107	8,842	9,068
Noncontrolling interests	30	24	23	22	(17)	(12)	(6)
Total equity	7,912	7,803	7,593	7,866	9,090	8,830	9,062	9,109	$ 8,221
Total liabilities and equity	$ 18,193	$ 17,503	$ 16,241	$ 15,720	$ 16,803	$ 16,519	$ 16,843
Common stock, par value (in dollars per share)	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Common stock, authorized (in shares)	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000
Common stock, issued (in shares)	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944
Treasury stock, shares (in shares)	177,340,358	173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164
Other	$ 389			$ 404
Equipment Leased to Customers under Operating Leases
Current assets:
Other non-current assets		$ 11	$ 10	10
Current liabilities:
Other non-current liabilities				5
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Current assets:
Property, Plant and Equipment, Net		5
Equity:
Other				2
As previously reported
Current assets:
Cash and cash equivalents		2,925	1,908	1,832	$ 2,860	$ 2,857	$ 2,947
Accounts receivable, net		1,885	1,802	1,812	1,826	1,783	1,807
Inventory, Net		1,757	1,751	1,653	1,718	1,622	1,581
Prepaid expenses and other current assets		651	626	622	624	628	621
Total current assets		7,218	6,087	5,919	7,028	6,890	6,956
Property, Plant and Equipment, Net		4,541	4,539	4,542	4,520	4,531	4,614
Goodwill		2,938	2,930	2,958	2,980	2,984	3,107
Intangible Assets, Net (Excluding Goodwill)		1,364	1,441	1,398	1,402	1,427	1,507
Operating lease right-of-use assets		588	517
Other non-current assets		895	836	824	917	746	706
Total assets		17,544	16,350	15,641	16,847	16,578	16,890
Current liabilities:
Short-term debt		2	796	2
Current maturities of long-term debt and finance lease obligations		2	2	2	3	3	3
Accounts payable and accrued liabilities		2,593	2,529	2,832	2,701	2,626	2,639
Total current liabilities		2,597	3,327	2,836	2,704	2,629	2,642
Long-term debt and finance lease obligations		5,157	3,451	3,473	3,485	3,495	3,550
Operating lease liabilities		490	420
Other non-current liabilities		1,464	1,483	1,516	1,545	1,585	1,605
Total liabilities		9,708	8,681	7,825	7,734	7,709	7,797
Equity:
Common stock		683	683	683	683	683	683
Common stock in treasury, at cost		(10,322)	(10,284)	(9,989)	(8,639)	(8,485)	(8,354)
Additional contributed capital		5,906	5,839	5,898	5,931	5,916	5,912
Retained earnings		16,184	15,970	15,626	15,394	14,966	14,734
Accumulated other comprehensive (loss) income		(4,639)	(4,562)	(4,424)	(4,239)	(4,199)	(3,876)
Total Baxter stockholders’ equity		7,812	7,646	7,794	9,130	8,881	9,099
Noncontrolling interests		24	23	22	(17)	(12)	(6)
Total equity		7,836	7,669	7,816	9,113	8,869	9,093	9,116	8,280
Total liabilities and equity		17,544	16,350	15,641	16,847	16,578	16,890
Restatement impacts
Current assets:
Cash and cash equivalents		9	(6)	6	3	1	2
Accounts receivable, net		12	(1)	28	11	6	11
Inventory, Net		(1)	(8)	14	(2)	(6)	(3)
Prepaid expenses and other current assets		(9)	(12)	(8)	(9)	(7)	(11)
Total current assets		11	(27)	40	3	(6)	(1)
Property, Plant and Equipment, Net		(56)	(63)	(12)	(44)	(45)	(38)
Goodwill		(1)	(1)	44	(2)	(3)	(4)
Intangible Assets, Net (Excluding Goodwill)		(1)	(1)	12	(2)	(3)	(2)
Operating lease right-of-use assets		7	(4)
Other non-current assets		(1)	(13)	(5)	1	(2)	(2)
Total assets		(41)	(109)	79	(44)	(59)	(47)
Current liabilities:
Short-term debt		0	0	0
Current maturities of long-term debt and finance lease obligations		0	0	0	0	0	0
Accounts payable and accrued liabilities		(40)	(51)	(22)	(41)	(43)	(41)
Total current liabilities		(40)	(51)	(22)	(41)	(43)	(41)
Long-term debt and finance lease obligations		0	0	8	(5)	(4)	0
Operating lease liabilities		6	(3)
Other non-current liabilities		26	21	43	25	27	25
Total liabilities		(8)	(33)	29	(21)	(20)	(16)
Equity:
Common stock		0	0	0	0	0	0
Common stock in treasury, at cost		0	0	0	0	0	0
Additional contributed capital		0	0	0	0	0	0
Retained earnings		(586)	(556)	(551)	(508)	(482)	(480)
Accumulated other comprehensive (loss) income		553	480	601	485	443	449
Total Baxter stockholders’ equity		(33)	(76)	50	(23)	(39)	(31)
Noncontrolling interests		0	0	0	0	0	0
Total equity		(33)	(76)	50	(23)	(39)	(31)	$ (7)	$ (59)
Total liabilities and equity		(41)	(109)	79	(44)	(59)	(47)
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Current assets:
Prepaid expenses and other current assets					448
Other non-current assets		12	(9)	8	20	16	(20)
Current liabilities:
Other non-current liabilities		12	(13)	13	12	13	(14)
Equity:
Retained earnings		(514)	(491)	487		(425)	(426)
Accumulated other comprehensive (loss) income		514	487	482	456	428	432
Restatement impacts | Foreign Currency Derivative Contracts
Current assets:
Prepaid expenses and other current assets		2
Current liabilities:
Accounts payable and accrued liabilities		4
Equity:
Retained earnings		2
Restatement impacts | Foreign Currency Derivative Contracts | Foreign exchange contract
Current assets:
Prepaid expenses and other current assets			1	2	(3)	4	(1)
Current liabilities:
Accounts payable and accrued liabilities				1	(4)	(4)	(4)
Equity:
Retained earnings			1	1	(1)		3
Restatement impacts | Equipment Leased to Customers under Operating Leases
Current assets:
Property, Plant and Equipment, Net		(61)	(55)	53	(49)	(45)	(44)
Other non-current assets					(12)	11	11
Current liabilities:
Other non-current liabilities		6	5		(2)	(2)	(2)
Equity:
Retained earnings		(44)	(40)	38	(35)	(32)	(31)
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Current assets:
Cash and cash equivalents		9	(6)	6	3	1	2
Accounts receivable, net		6	(7)	22	5		5
Inventory, Net		4	(3)	19	3	(1)	2
Prepaid expenses and other current assets		1	(1)			1
Property, Plant and Equipment, Net			(8)	41	5		6
Goodwill		(1)	(1)	44	(2)	(3)	(4)
Intangible Assets, Net (Excluding Goodwill)				13	(1)	(2)	(1)
Operating lease right-of-use assets		7	(4)
Other non-current assets		5	(3)	6	(2)		(4)
Current liabilities:
Accounts payable and accrued liabilities		3	(4)	24	2		2
Long-term debt and finance lease obligations				8	(5)	(4)
Operating lease liabilities		6	(3)
Other non-current liabilities		4	(3)	19	(1)		(3)
Equity:
Retained earnings		(16)	(16)	17	(14)	(15)	(10)
Accumulated other comprehensive (loss) income		39	(7)	119	(29)	(15)	(17)
Restatement impacts | Other miscellaneous adjustments
Current assets:
Accounts receivable, net		6	6	6	6	6	6
Inventory, Net		(5)	(5)	5	(5)	(5)	(5)
Prepaid expenses and other current assets		(12)	(12)	12	(12)	(12)	(12)
Intangible Assets, Net (Excluding Goodwill)		(1)	(1)	1	(1)	(1)	(1)
Other non-current assets		(29)	(29)	29	(29)	(29)	(29)
Current liabilities:
Accounts payable and accrued liabilities		(47)	(47)	47	(47)	(47)	(47)
Other non-current liabilities		16	16	16	16	16	16
Equity:
Retained earnings		$ (10)	$ (10)	$ 10	$ (10)	$ (10)	$ (10)

QUARTERLY FINANCIAL DATA (UNA_5

QUARTERLY FINANCIAL DATA (UNAUDITED) - Income Statements (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Net sales	$ 3,039	$ 2,851	$ 2,834	$ 2,638	$ 2,833	$ 2,761	$ 2,813	$ 2,692	$ 5,472	$ 5,505	$ 11,362	$ 11,099	$ 10,584
Cost of sales			1,681	1,558	1,650		1,590	1,571	3,239	3,161	6,601	6,340	6,110
Gross margin	$ 1,298	$ 1,230	1,153	1,080	1,183	1,232	1,223	1,121	2,233	2,344	4,761	4,759	4,474
Selling, general and administrative expenses			641	601	627		676	633	1,242	1,309	2,535	2,620	2,627
Research and development expenses			166	129	175		172	141	295	313	595	654	615
Other (income) expense, net			(4)	(33)	(10)		(2)	(87)	(37)	(89)
Operating income			350	383	391		377	434	733	811	1,772	1,584	1,288
Interest expense, net			20	18	11		11	12	38	23	71	45	55
Other (income) expense, net			4	(21)	(33)		(38)	(6)	(17)	(44)	731	(78)	133
Income from continuing operations before income taxes			326	386	413		404	428	712	832	970	1,617	1,100
Income tax expense (benefit)			13	44	102		63	46	57	109	(41)	65	491
Income from continuing operations			313	342	311		341	382	655	723	1,011	1,552	609
Loss from discontinued operations, net of tax					(6)	$ 0	0	0		0	0	(6)	(7)
Net income			$ 313	$ 342	$ 305		$ 341	$ 382	$ 655	$ 723	$ 1,011	$ 1,546	$ 602
Earnings per share from continuing operations
Basic (in dollars per share)					$ 0.59	$ 0.97	$ 0.64	$ 0.71		$ 1.35	$ 1.97	$ 2.91	$ 1.12
Diluted (in dollars per share)					0.58	0.95	0.62	0.69		1.32	1.93	2.84	1.10
Loss per share from discontinued operations
Basic (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.01)
Diluted (in dollars per share)					(0.01)	0	0	0		0	0	(0.01)	(0.02)
Earnings per share
Basic (in dollars per share)	$ (0.05)	$ 0.72	$ 0.61	$ 0.67	0.58	0.97	0.64	0.71	$ 1.28	1.35	1.97	2.90	1.11
Diluted (in dollars per share)	$ (0.05)	$ 0.71	$ 0.60	$ 0.66	$ 0.57	$ 0.95	$ 0.62	$ 0.69	$ 1.26	$ 1.32	$ 1.93	$ 2.83	$ 1.08
Weighted-average number of shares outstanding
Basic (in shares)			510	512	528		535	539	511	537	509	534	543
Diluted (in shares)			519	522	538		547	551	520	549	519	546	555
Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses												$ 9	$ 56
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Net sales			$ 2,840	$ 2,632	$ 2,841		$ 2,842	$ 2,677	$ 5,472	$ 5,519		11,127	10,561
Cost of sales			1,681	1,552	1,649		1,603	1,563	3,233	3,166		6,346	6,091
Gross margin			1,159	1,080	1,192		1,239	1,114	2,239	2,353		4,781	4,470
Selling, general and administrative expenses			642	600	629		681	622	1,242	1,303		2,617	2,566
Research and development expenses			166	129	175		174	140	295	314		655	613
Other (income) expense, net			(4)	(33)	(10)		0	(80)	(37)	(80)
Operating income			355	384	398		384	432	739	816		1,599	1,291
Interest expense, net			20	18	11		11	12	38	23		45	55
Other (income) expense, net			(28)	(25)	(58)		(31)	(18)	(53)	(49)		(139)	19
Income from continuing operations before income taxes			363	391	445		404	438	754	842		1,693	1,217
Income tax expense (benefit)			20	44	91		61	49	64	110		63	493
Income from continuing operations			$ 343	$ 347	354		$ 343	$ 389	$ 690	$ 732		1,630	724
Loss from discontinued operations, net of tax					(6)							(6)	(7)
Net income					$ 348							$ 1,624	$ 717
Earnings per share from continuing operations
Basic (in dollars per share)					$ 0.67							$ 3.05	$ 1.33
Diluted (in dollars per share)					0.66							2.99	1.30
Loss per share from discontinued operations
Basic (in dollars per share)					(0.01)							(0.01)	(0.01)
Diluted (in dollars per share)					(0.01)							(0.02)	(0.01)
Earnings per share
Basic (in dollars per share)			$ 0.67	$ 0.68	0.66		$ 0.64	$ 0.72	$ 1.35	$ 1.36		3.04	1.32
Diluted (in dollars per share)			$ 0.66	$ 0.66	$ 0.65		$ 0.63	$ 0.71	$ 1.33	$ 1.33		$ 2.97	$ 1.29
Weighted-average number of shares outstanding
Basic (in shares)			510	512	528		535	539	511	537		534	543
Diluted (in shares)			519	522	538		547	551	520	549		546	555
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Net sales			$ (6)	$ 6	$ (8)		$ (29)	$ 15	$ 0	$ (14)		$ (28)	$ 23
Cost of sales			0	6	1		(13)	8	6	(5)		(6)	19
Gross margin			(6)	0	(9)		(16)	7	(6)	(9)		(22)	4
Selling, general and administrative expenses			(1)	1	(2)		(5)	11	0	6		3	61
Research and development expenses			0	0	0		(2)	1	0	(1)		(1)	2
Other (income) expense, net			0	0	0		(2)	(7)	0	(9)
Operating income			(5)	(1)	(7)		(7)	2	(6)	(5)		(15)	(3)
Interest expense, net			0	0	0		0	0	0	0		0	0
Other (income) expense, net			32	4	25		(7)	12	36	5		61	114
Income from continuing operations before income taxes			(37)	(5)	(32)		0	(10)	(42)	(10)		(76)	(117)
Income tax expense (benefit)			(7)	0	11		2	(3)	(7)	(1)		2	(2)
Income from continuing operations			$ (30)	$ (5)	(43)		$ (2)	$ (7)	$ (35)	$ (9)		(78)	(115)
Loss from discontinued operations, net of tax					0							0	0
Net income					$ (43)							$ (78)	$ (115)
Earnings per share from continuing operations
Basic (in dollars per share)					$ (0.08)							$ (0.14)	$ (0.21)
Diluted (in dollars per share)					(0.08)							(0.15)	(0.20)
Loss per share from discontinued operations
Basic (in dollars per share)					0							0	0
Diluted (in dollars per share)					0							0.01	(0.01)
Earnings per share
Basic (in dollars per share)			$ (0.06)	$ (0.01)	(0.08)		$ 0	$ (0.01)	$ (0.07)	$ (0.01)		(0.14)	(0.21)
Diluted (in dollars per share)			$ (0.06)	$ 0	$ (0.08)		$ (0.01)	$ (0.02)	$ (0.07)	$ (0.01)		$ (0.14)	$ (0.21)
Weighted-average number of shares outstanding
Basic (in shares)			0	0	0		0	0	0	0		0	0
Diluted (in shares)			0	0	0		0	0	0	0		0	0
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Error Corrections and Prior Period Adjustments Restatement
Other (income) expense, net			$ (26)	$ (5)	$ (26)			$ (9)	$ (31)	$ (9)		$ 64	$ 96
Income tax expense (benefit)			(5)		(5)			(3)	(4)	(3)
Restatement impacts | Equipment Leased to Customers under Operating Leases
Error Corrections and Prior Period Adjustments Restatement
Cost of sales			5	2	4		$ 2	1	7	3		11	8
Income tax expense (benefit)			(2)		(1)		(1)		(2)	(1)		(3)	3
Restatement impacts | Translation of the Financial Position and Results of Operations of our Foreign Operations into U.S. Dollars
Error Corrections and Prior Period Adjustments Restatement
Net sales			(6)	6	(8)		(29)	15		(14)		(28)	23
Cost of sales			(5)	4	(3)		(15)	7	$ (1)	(8)		(17)	11
Selling, general and administrative expenses			$ (1)	$ 1	(2)		(7)	4		(3)		(6)	5
Research and development expenses							(2)	1		(1)		(1)	2
Other (income) expense, net							(1)			(1)		(2)	(1)
Income tax expense (benefit)							(1)			(1)		(2)	1
Restatement impacts | Income Statement Classification Of Transition Services Income
Error Corrections and Prior Period Adjustments Restatement
Selling, general and administrative expenses							$ 2	$ 7		$ 9		$ 9	$ 56
Restatement impacts | Other Miscellaneous Adjustments to Statement of Income
Error Corrections and Prior Period Adjustments Restatement
Income tax expense (benefit)					$ 7

QUARTERLY FINANCIAL DATA (UNA_6

QUARTERLY FINANCIAL DATA (UNAUDITED) - Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Other comprehensive income (loss), net of tax:
Currency translation adjustments			2	(97)			(368)	63	(95)	(305)	(95)	(323)	599
Pension and other postretirement benefit plans			6	14			28	57	20	85	408	33	134
Hedging activities			(12)	(15)			11	(5)	(27)	6		9	(13)
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Comprehensive income			309	244			12	497	553	509	$ 1,285	1,265	1,324
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss), net of tax:
Currency translation adjustments			(78)	30			(363)	81	(48)	(282)		(461)	425
Pension and other postretirement benefit plans			13	8			29	52	21	81		32	141
Hedging activities			(12)	(15)			11	(5)	(27)	6		9	(13)
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
Comprehensive income			266	370			20	517	636	537		1,204	1,272
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss), net of tax:
Currency translation adjustments			80	(127)			(5)	(18)	(47)	(23)		138	174
Pension and other postretirement benefit plans			(7)	6			(1)	5	(1)	4		1	7
Hedging activities			0	0			0	0	0	0		0	0
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
Comprehensive income			43	(126)			(8)	(20)	(83)	(28)		61	52
Restatement impacts | Foreign Exchange Rate Used To Translate
Other comprehensive income (loss), net of tax:
Currency translation adjustments			(54)	132			$ 5	27	78	32		74	78
Restatement impacts | Offsetting Balance Sheet Impact Adjustments
Other comprehensive income (loss), net of tax:
Currency translation adjustments			$ (26)	$ 5				$ 9	$ (31)	$ 9		$ 64	$ 96

QUARTERLY FINANCIAL DATA (UNA_7

QUARTERLY FINANCIAL DATA (UNAUDITED) - Changes in Equity (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 7,803	$ 7,593	$ 7,866	$ 9,090	$ 8,830	$ 9,062	$ 9,109	$ 7,866	$ 9,109	$ 7,866	$ 9,109	$ 8,221
Common stock, issued (in shares)	683,494,944		683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944	683,494,944
Treasury stock, shares (in shares)	177,340,358		173,275,586	173,447,198	170,495,859	150,213,621	148,485,202	146,993,164	173,275,586	148,485,202	177,340,358	170,495,859
Adoption of new accounting standards				$ 0				$ (23)	$ 0	$ (23)	$ 0	$ (25)
Net income attributable to Baxter stockholders	$ (23)	369	$ 313	342	$ 305	$ 518	$ 341	382	655	723	1,001	1,546	602
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Purchases of common stock			(111)	(586)			(259)	(522)	(697)	(781)	$ (1,247)	$ (2,475)	$ (564)
Purchases of common stock (in shares)											16,500,000	35,800,000	9,200,000
Stock issued under employee benefit plans and other			123	166			123	85	289	208	$ 445	$ 354	$ 426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
Changes in noncontrolling interests			1	1			(6)	2	2	(4)	(2)	30	2
End of year	$ 7,912		7,803	7,593	7,866	9,090	8,830	9,062	7,803	8,830	7,912	7,866	9,109
As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,836	7,669	7,816	9,113	8,869	9,093	9,116	7,816	9,116	7,816	9,116	8,280
Adoption of new accounting standards				0				(19)	0	(19)		(21)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
Purchases of common stock			(111)	(586)			(259)	(522)	(697)	(781)		(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208		354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
Changes in noncontrolling interests			1	1			(6)	2	2	(4)		30	2
End of year			7,836	7,669	7,816	9,113	8,869	9,093	7,836	8,869		7,816	9,116
Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(33)	(76)	50	(23)	(39)	(31)	(7)	50	(7)	50	(7)	(59)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			(33)	(76)	$ 50	(23)	(39)	(31)	(33)	(39)		50	(7)
Common stock
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		683	$ 683	$ 683		683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683
Common stock, issued (in shares)	683,000,000		683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000	683,000,000
End of year	$ 683		$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683	$ 683	$ 683	$ 683
Common stock | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		683	$ 683	$ 683		683	$ 683	$ 683	$ 683	$ 683	683	$ 683	$ 683
Common stock, issued (in shares)			683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000	683,000,000		683,000,000	683,000,000	683,000,000
End of year			$ 683	$ 683	$ 683		$ 683	$ 683	$ 683	$ 683		$ 683	$ 683
Common stock | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		0	$ 0	$ 0		0	$ 0	$ 0	$ 0	$ 0	0	$ 0	$ 0
Common stock, issued (in shares)			0	0	0		0	0	0	0		0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0
Common stock in treasury
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(10,322)	$ (10,284)	$ (9,989)		(8,485)	$ (8,354)	$ (7,981)	$ (9,989)	$ (7,981)	$ (9,989)	$ (7,981)	$ (7,995)
Treasury stock, shares (in shares)	177,000,000		173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	173,000,000	148,000,000	177,000,000	170,000,000	142,000,000	144,000,000
Purchases of common stock			$ (157)	$ (586)			$ (259)	$ (522)	$ (743)	$ (781)	$ (1,293)	$ (2,415)	$ (564)
Purchases of common stock (in shares)			2,000,000	8,000,000			3,000,000	8,000,000	10,000,000	11,000,000	16,000,000	36,000,000	9,000,000
Stock issued under employee benefit plans and other			$ 119	$ 291			$ 128	$ 149	$ 410	$ 277	$ 518	$ 407	$ 578
Stock issued under employee benefit plans and other (in shares)			(2,000,000)	(5,000,000)			(2,000,000)	(3,000,000)	(7,000,000)	(5,000,000)	9,000,000	8,000,000	11,000,000
End of year	$ (10,764)		$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (10,322)	$ (8,485)	$ (10,764)	$ (9,989)	$ (7,981)
Common stock in treasury | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(10,322)	$ (10,284)	$ (9,989)		(8,485)	$ (8,354)	$ (7,981)	$ (9,989)	$ (7,981)	(9,989)	$ (7,981)	$ (7,995)
Treasury stock, shares (in shares)			173,000,000	173,000,000	170,000,000		148,000,000	147,000,000	173,000,000	148,000,000		170,000,000	142,000,000	144,000,000
Purchases of common stock			$ (157)	$ (586)			$ (259)	$ (522)	$ (743)	$ (781)		$ (2,415)	$ (564)
Purchases of common stock (in shares)			2,000,000	8,000,000			3,000,000	8,000,000	10,000,000	11,000,000		36,000,000	9,000,000
Stock issued under employee benefit plans and other			$ 119	$ 291			$ 128	$ 149	$ 410	$ 277		$ 407	$ 578
Stock issued under employee benefit plans and other (in shares)			(2,000,000)	(5,000,000)			(2,000,000)	(3,000,000)	(7,000,000)	(5,000,000)		(8,000,000)	(11,000,000)
End of year			$ (10,322)	$ (10,284)	$ (9,989)		$ (8,485)	$ (8,354)	$ (10,322)	$ (8,485)		$ (9,989)	$ (7,981)
Common stock in treasury | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		0	$ 0	$ 0		0	$ 0	$ 0	$ 0	$ 0	0	$ 0	$ 0
Treasury stock, shares (in shares)			0	0	0		0	0	0	0		0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0
Additional contributed capital
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		5,906	5,839	5,898		5,916	5,912	5,940	5,898	5,940	5,898	5,940	5,958
Purchases of common stock			46						46		46	(60)
Stock issued under employee benefit plans and other			21	(59)			4	(28)	(38)	(24)	11	18	(18)
End of year	5,955		5,906	5,839	5,898		5,916	5,912	5,906	5,916	5,955	5,898	5,940
Additional contributed capital | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		5,906	5,839	5,898		5,916	5,912	5,940	5,898	5,940	5,898	5,940	5,958
Purchases of common stock			46						46			(60)	0
Stock issued under employee benefit plans and other			21	(59)			4	(28)	(38)	(24)		18	(18)
End of year			5,906	5,839	5,898		5,916	5,912	5,906	5,916		5,898	5,940
Additional contributed capital | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		0	0	0		0	0	0	0	0	0	0	0
End of year			0	0	0		0	0	0	0		0	0
Retained earnings
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		15,598	15,414	15,075		14,484	14,254	14,014	15,075	14,014	15,075	14,014	13,846
Adoption of new accounting standards				161				(20)	161	(20)	161	(22)
Net income attributable to Baxter stockholders			313	342			341	382	655	723	1,001	1,546	602
Stock issued under employee benefit plans and other			(17)	(66)			(9)	(36)	(83)	(45)	(84)	(71)	(134)
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
End of year	15,718		15,598	15,414	15,075		14,484	14,254	15,598	14,484	15,718	15,075	14,014
Retained earnings | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		16,184	15,970	15,626		14,966	14,734	14,483	15,626	14,483	15,626	14,483	14,200
Adoption of new accounting standards				161				(16)	161	(16)		(18)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Stock issued under employee benefit plans and other			(17)	(66)			(9)	(36)	(83)	(45)		(71)	(134)
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
End of year			16,184	15,970	15,626		14,966	14,734	16,184	14,966		15,626	14,483
Retained earnings | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(586)	(556)	(551)		(482)	(480)	(469)	(551)	(469)	(551)	(469)	(354)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
End of year			(586)	(556)	(551)		(482)	(480)	(586)	(482)		(551)	(469)
Accumulated other comprehensive income (loss)
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(4,086)	(4,082)	(3,823)		(3,756)	(3,427)	(3,539)	(3,823)	(3,539)	(3,823)	(3,539)	(4,261)
Adoption of new accounting standards				(161)				(3)	(161)	(3)	(161)	(3)
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
End of year	(3,710)		(4,086)	(4,082)	(3,823)		(3,756)	(3,427)	(4,086)	(3,756)	(3,710)	(3,823)	(3,539)
Accumulated other comprehensive income (loss) | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(4,639)	(4,562)	(4,424)		(4,199)	(3,876)	(4,001)	(4,424)	(4,001)	(4,424)	(4,001)	(4,556)
Adoption of new accounting standards				(161)				(3)	(161)	(3)		(3)
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
End of year			(4,639)	(4,562)	(4,424)		(4,199)	(3,876)	(4,639)	(4,199)		(4,424)	(4,001)
Accumulated other comprehensive income (loss) | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		553	480	601		443	449	462	601	462	601	462	295
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			553	480	601		443	449	553	443		601	462
Total Baxter stockholders' equity
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,779	7,570	7,844		8,842	9,068	9,117	7,844	9,117	7,844	9,117	8,231
Adoption of new accounting standards								(23)		(23)		(25)
Net income attributable to Baxter stockholders			313	342			341	382	655	723	1,001	1,546	602
Other comprehensive income (loss)			(4)	(98)			(329)	115	(102)	(214)	274	(281)	722
Purchases of common stock			(111)	(586)			(259)	(522)	(697)	(781)	(1,247)	(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208	445	354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)	(435)	(392)	(334)
End of year	7,882		7,779	7,570	7,844		8,842	9,068	7,779	8,842	7,882	7,844	9,117
Total Baxter stockholders' equity | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		7,812	7,646	7,794		8,881	9,099	9,124	7,794	9,124	7,794	9,124	8,290
Adoption of new accounting standards								(19)		(19)		(21)
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Other comprehensive income (loss)			(77)	23			(323)	128	(54)	(195)		(420)	555
Purchases of common stock			(111)	(586)			(259)	(522)	(697)	(781)		(2,475)	(564)
Stock issued under employee benefit plans and other			123	166			123	85	289	208		354	426
Dividends declared on common stock			(112)	(98)			(102)	(86)	(210)	(188)		(392)	(334)
End of year			7,812	7,646	7,794		8,881	9,099	7,812	8,881		7,794	9,124
Total Baxter stockholders' equity | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		(33)	(76)	50		(39)	(31)	(7)	50	(7)	50	(7)	(59)
Adoption of new accounting standards								(4)		(4)		(4)
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Other comprehensive income (loss)			73	(121)			(6)	(13)	(48)	(19)		139	167
End of year			(33)	(76)	50		(39)	(31)	(33)	(39)		50	(7)
Noncontrolling interests
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		24	23	22		(12)	(6)	(8)	22	(8)	22	(8)	(10)
Net income attributable to Baxter stockholders											10
Changes in noncontrolling interests			1	1			(6)	2	2	(4)	(2)	30	2
End of year	$ 30		24	23	22		(12)	(6)	24	(12)	30	22	(8)
Noncontrolling interests | As previously reported
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		24	23	22		(12)	(6)	(8)	22	(8)	22	(8)	(10)
Changes in noncontrolling interests			1	1			(6)	2	2	(4)		30	2
End of year			24	23	22		(12)	(6)	24	(12)		22	(8)
Noncontrolling interests | Restatement impacts
Error Corrections and Prior Period Adjustments Restatement
Beginning of year		$ 0	0	0		$ 0	0	0	0	0	$ 0	0	0
End of year			$ 0	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0		$ 0	$ 0

QUARTERLY FINANCIAL DATA (UNA_8

QUARTERLY FINANCIAL DATA (UNAUDITED) - Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operations
Net income attributable to Baxter stockholders	$ (23)	$ 369	$ 313	$ 342	$ 305	$ 518	$ 341	$ 382	$ 655	$ 723	$ 1,001	$ 1,546	$ 602
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Depreciation and amortization				192				190	385	382	789	771	750
Deferred income taxes				(6)				(38)	(63)	(51)	(310)	(263)	211
Stock compensation				22				20	57	54	122	115	107
Net periodic pension benefit and other postretirement costs				3				10	7	21	22	39	123
Intangible asset impairment				0					31
Other				14				(1)	44	0	115	50	38
Changes in balance sheet items:
Accounts receivable, net				32				76	(60)	43	(65)	(12)	30
Inventories				(82)				(56)	(91)	(134)	4	(197)	76
Accounts payable and accrued liabilities				(335)				(119)	(299)	(124)	(212)	60	11
Other				(48)				(34)	(86)	(82)	(152)	(99)	(227)
Cash flows from operations – continuing operations				134					580		2,110	2,017	1,730
Cash flows from operations - discontinued operations				(6)					(6)		(6)	0	(16)
Cash flows from operations				128				430	574	832	2,104	2,017	1,714
Cash flows from investing activities
Capital expenditures				(193)				(152)	(338)	(303)	(696)	(659)	(616)
Acquisitions and investments, net of cash acquired				(109)				(219)	(111)	(228)	(418)	(268)	(686)
Other investing activities, net				1					1		14	11	10
Cash flows from investing activities				(301)				(371)	(448)	(531)	(1,100)	(916)	(1,292)
Cash flows from financing activities
Issuances of debt				0					1,661		1,661	0	665
Net increases in debt obligations with original maturities of three months or less				795					0
Cash dividends on common stock				(101)				(87)	(198)	(173)	(423)	(376)	(315)
Proceeds from stock issued under employee benefit plans				173				82	262	170			347
Purchases of treasury stock				(597)				(522)	(720)	(781)	(1,270)	(2,452)	(564)
Other financing activities, net				(32)				(18)	(37)	(24)	(48)	(33)	(40)
Cash flows from financing activities				238				(545)	968	(808)	498	(2,603)	93
Effect of foreign exchange rate changes on cash and cash equivalents				(1)				32	2	(38)	(5)	(63)	102
Increase (decrease) in cash and cash equivalents				64				(454)	1,096	(545)	1,497	(1,565)	617
Cash and cash equivalents at beginning of year		2,934	1,902	1,838		2,858	2,949	3,403	1,838	3,403	1,838	3,403	2,786
Cash and cash equivalents at end of year	$ 3,335		2,934	1,902	1,838		2,858	2,949	2,934	2,858	3,335	1,838	3,403
As previously reported
Cash flows from operations
Net income attributable to Baxter stockholders			343	347			343	389	690	732		1,624	717
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Depreciation and amortization				195				192	393	387		785	761
Deferred income taxes				(6)				(33)	(55)	(51)		(267)	211
Stock compensation				22				20	57	54		115	107
Net periodic pension benefit and other postretirement costs				3				10	7	21		39	123
Intangible asset impairment									31
Other				19				2	34	10		43	43
Changes in balance sheet items:
Accounts receivable, net				32				76	(60)	43		(12)	30
Inventories				(82)				(56)	(91)	(134)		(197)	76
Accounts payable and accrued liabilities				(333)				(120)	(303)	(126)		64	5
Other				(49)				(33)	(86)	(84)		(105)	(229)
Cash flows from operations – continuing operations				148					617				1,853
Cash flows from operations - discontinued operations				(6)					(6)				(16)
Cash flows from operations				142				447	611	852		2,096	1,837
Cash flows from investing activities
Capital expenditures				(198)				(155)	(352)	(311)		(681)	(634)
Acquisitions and investments, net of cash acquired				(109)				(219)	(111)	(228)		(268)	(686)
Other investing activities, net				1					1			11	10
Cash flows from investing activities				(306)				(374)	(462)	(539)		(938)	(1,310)
Cash flows from financing activities
Issuances of debt									1,661				633
Net increases in debt obligations with original maturities of three months or less				795
Cash dividends on common stock				(101)				(87)	(198)	(173)		(376)	(315)
Proceeds from stock issued under employee benefit plans				173				82	262	170			347
Purchases of treasury stock				(597)				(522)	(720)	(781)		(2,452)	(564)
Other financing activities, net				(32)				(18)	(37)	(24)		(33)	(40)
Cash flows from financing activities				238				(545)	968	(808)		(2,603)	61
Effect of foreign exchange rate changes on cash and cash equivalents				2				25	(24)	(42)		(117)	5
Increase (decrease) in cash and cash equivalents				76				(447)	1,093	(537)		(1,562)	593
Cash and cash equivalents at beginning of year		2,925	1,908	1,832		2,857	2,947	3,394	1,832	3,394	1,832	3,394	2,801
Cash and cash equivalents at end of year			2,925	1,908	1,832		2,857	2,947	2,925	2,857		1,832	3,394
Restatement impacts
Cash flows from operations
Net income attributable to Baxter stockholders			(30)	(5)			(2)	(7)	(35)	(9)		(78)	(115)
Adjustments to reconcile income from continuing operations to net cash from operating activities:
Depreciation and amortization				(3)				(2)	(8)	(5)		(14)	(11)
Deferred income taxes				0				(5)	(8)	0		4	0
Stock compensation				0				0	0	0		0	0
Net periodic pension benefit and other postretirement costs				0				0	0	0		0	0
Intangible asset impairment									0
Other				(5)				(3)	10	(10)		7	(5)
Changes in balance sheet items:
Accounts receivable, net				0				0	0	0		0	0
Inventories				0				0	0	0		0	0
Accounts payable and accrued liabilities				(2)				1	4	2		(4)	6
Other				1				(1)	0	2		6	2
Cash flows from operations – continuing operations				(14)					(37)				(123)
Cash flows from operations - discontinued operations				0					0				0
Cash flows from operations				(14)				(17)	(37)	(20)		(79)	(123)
Cash flows from investing activities
Capital expenditures				5				3	14	8		22	18
Acquisitions and investments, net of cash acquired				0				0	0	0		0	0
Other investing activities, net				0					0			0	0
Cash flows from investing activities				5				3	14	8		22	18
Cash flows from financing activities
Issuances of debt									0				32
Net increases in debt obligations with original maturities of three months or less				0
Cash dividends on common stock				0				0	0	0		0	0
Proceeds from stock issued under employee benefit plans				0				0	0	0			0
Purchases of treasury stock				0				0	0	0		0	0
Other financing activities, net				0				0	0	0		0	0
Cash flows from financing activities				0				0	0	0		0	32
Effect of foreign exchange rate changes on cash and cash equivalents				(3)				7	26	4		54	97
Increase (decrease) in cash and cash equivalents				(12)				(7)	3	(8)		(3)	24
Cash and cash equivalents at beginning of year		$ 9	(6)	6		$ 1	2	9	6	9	$ 6	9	(15)
Cash and cash equivalents at end of year			$ 9	(6)	$ 6		$ 1	2	9	1		6	9
Restatement impacts | Foreign Currency Denominated Monetary Assets and Liabilities
Cash flows from financing activities
Issuances of debt													32
Effect of foreign exchange rate changes on cash and cash equivalents				$ 4				$ 11	$ 33	$ 2		$ 64	$ 99

Qualifying And Valuation Accoun

Qualifying And Valuation Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 110	$ 120	$ 127
Additions Charged to costs and expenses	18	4	4
(Credited) charged to other accounts	(8)	(7)	8
Deductions	(8)	(7)	(19)
Balance at end of period	112	110	120
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	310	483	150
Additions Charged to costs and expenses	117	20	350
(Credited) charged to other accounts	0	(4)	0
Deductions	(7)	(189)	(17)
Balance at end of period	$ 420	$ 310	$ 483